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Short-Term Cooling Increases Plasma ANGPTL3 and ANGPTL8 in Young Healthy Lean Men
but Not in Middle-Aged Men with Overweight and Prediabetes
Reprinted from: J. Clin. Med. 2019, 8, 1214, doi:10.3390/jcm8081214 . . . . . . . . . . . . . . . . . 92
v
James P. Corsetti, Charles E. Sparks, Richard W. James, Stephan J. L. Bakker and Robin P. F.
Dullaart
Low Serum Paraoxonase-1 Activity Associates with Incident Cardiovascular Disease Risk
in Subjects with Concurrently High Levels of High-Density Lipoprotein Cholesterol and
C-Reactive Protein
Reprinted from: J. Clin. Med. 2019, 8, 1357, doi:10.3390/jcm8091357 . . . . . . . . . . . . . . . . . 103
Luca Liberale, Federico Carbone, Giovanni G. Camici and Fabrizio Montecucco
IL-1β and Statin Treatment in Patients with Myocardial Infarction and Diabetic 
Cardiomyopathy
Reprinted from: J. Clin. Med. 2019, 8, 1764, doi:10.3390/jcm8111764 . . . . . . . . . . . . . . . . . 115
Hanna Wessel, Ali Saeed, Janette Heegsma, Margery A. Connelly, Klaas Nico Faber and
Robin P. F. Dullaart
Plasma Levels of Retinol Binding Protein 4 Relate to Large VLDL and Small LDL Particles in
Subjects with and without Type 2 Diabetes
Reprinted from: J. Clin. Med. 2019, 8, 1792, doi:10.3390/jcm8111792 . . . . . . . . . . . . . . . . . 133
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Preface to ”Novel Aspects of Lipoprotein
Metabolism with Focus on Systemic Inflammation”
Twenty-three papers were submitted to this Special Issue of JCM. Two were considered not 
suitable for the topic of this Special Issue, one paper was withdrawn by the authors, and four papers 
were rejected. As a result, this Special Issue contains 16 outstanding papers with contributors from 
Europe and North America.
Four research papers studied the role of autoantibodies against apolipoprotein A-I (apo A-I)
in cardiovascular disease. Anti apoA-I autoantibodies i) were shown to predict a new adverse
atherosclerotic event in patients who had experienced a coronary event, ii) were observed to predict
cardiovascular mortality in renal transplant patients, iii) were positively related to macrophage
cholesterol content but were paradoxically also associated with ABCA1-mediated cholesterol efflux
capacity in vitro, and iv) were found to induce foam cell formation, but were unexpectedly associated
with lower LDL cholesterol in children with familial hypercholesterolemia.
The other original research papers dealt with a variety of topics. At a glance: A North European
population-based study on incident cardiovascular disease reported that low serum activity of
the antioxidative enzyme paraoxonase-1 predicts incident cardiovascular events in subjects with
concurrently high HDL cholesterol and hsCRP levels. Systemic oxidative stress, as inferred from
higher plasma levels of free thiols, was found to be unaltered in well-controlled non-smoking type
2 diabetic patients; higher free thiol levels were paradoxically associated with higher triglycerides
and greater numbers of large VLDL particles. In a multiethnic US cohort, higher plasma levels of
GlycA—a nuclear magnetic resonance-based glycoprotein marker of systemic inflammation—was
found to predict incident cardiovascular disease which was, in part, attributable to impaired
HDL-mediated cholesterol efflux capacity.
The topics of the four review papers dealt with i) the emerging role of oxidatively modified
lipoproteins and HDL in breast cancer development, ii) the importance of microvesicles, in concert
with oxidized LDL, on the onset and progression of atherothrombosis by promoting vascular
inflammation, iii) the dual role of statin treatment to ameliorate low-grade inflammation in addition
to its LDL cholesterol lowering effects, and the potential benefit of combining statin therapy with
canakinumab, an interleukin-1 inhibitor, and iv) the influence of the gut microbiome on bile acid
metabolism, short chain fatty acid signaling, and endocrine cell function via GLP-1/GLP-2,thereby
affecting an important pathway for postprandial lipid metabolism.
We hope that the items covered in this Special Issue of JCM are relevant for your future research.
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Abstract: Autoantibodies against apolipoprotein A-I (anti-apoA-I IgGs) are prevalent in
atherosclerosis-related conditions. It remains elusive whether they improve the prognostic accuracy
of the Global Registry of Acute Coronary Events (GRACE) score 2.0 (GS) in acute coronary syndromes
(ACS). In this prospective multicenter registry, 1713 ACS patients were included and followed for
1 year. The primary endpoint (major adverse cardiovascular events (MACE)) was defined as the
composite of myocardial infarction, stroke (including transient ischemic attack), or cardiovascular
(CV) death with individual events independently adjudicated. Plasma levels of anti-apoA-I IgGs
upon study inclusion were assessed using ELISA. The association between anti-apoA-I IgGs and
incident MACE was assessed using Cox models with splines and C-statistics. One-year MACE
incidence was 8.4% (144/1713). Anti-apoA-I IgG levels were associated with MACE with a non-linear
relationship (p = 0.01), which remained unchanged after adjusting for the GS (p = 0.04). The hazard
increased progressively across the two first anti-apoA-I IgG quartiles before decreasing thereafter.
Anti-apoA-I IgGs marginally improved the prognostic accuracy of the GS (c-statistics increased from
0.68 to 0.70). In this multicenter study, anti-apoA-I IgGs were predictive of incident MACE in ACS
J. Clin. Med. 2019, 8, 1002; doi:10.3390/jcm8071002 www.mdpi.com/journal/jcm1
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independently of the GS but in a nonlinear manner. The practical implications of these findings
remain to be defined.
Keywords: acute coronary syndrome; biomarkers; anti-apolipoprotein A-I autoantibodies; GRACE
score; C-statistics
1. Introduction
Over the last decades, the insight into the pathogenesis of atherosclerosis evolved from a
lipid-centered disease to a predominantly T-helper (Th)-1 driven immune response against various
antigens and auto-antigens within atherosclerotic plaques [1–3]. Among the latter, both cellular and
humoral autoimmune responses against different membrane proteins, native or modified lipoproteins
have been shown to modulate the course of atherogenesis either in a pro- or anti-atherogenic
manner [4,5]. Reflecting this intrinsic biological complexity, several autoantibodies have been detected
in sera of individuals and associated either with an increased or decreased cardiovascular (CV)
risk [6–10].
Among autoantibodies targeting lipoproteins potentially associated with increased CV risk,
those directed against apolipoprotein A-I (apoA-I), the major protein of high-density lipoprotein
(HDL), appear as appealing candidates. Indeed, most observational studies performed so far
indicate that antibodies against anti-apoA-I (anti-apoA-I IgGs) were an independent CV risk factor
predictive of poor prognosis, both in the general population and in different CV risk settings,
associated with a systemic pro-inflammatory profile and atherosclerotic plaque vulnerability [11–22].
Furthermore, in vitro and in vivo studies indicate that these autoantibodies can promote the loss of
HDL anti-oxidative function [15], induce sterile inflammation, atherogenesis, myocardial necrosis, and
death in experimental mouse models through activation of a specific innate immune receptor complex
consisting of Toll-like receptor (TLR)2, 4, and CD14 [23–25].
Nevertheless, it is unknown whether anti-apoA-I IgGs provide incremental prognostic value
over the Global Registry of Acute Coronary Events (GRACE) risk score 2.0 [26] after acute coronary
syndromes (ACS), and whether such an association could follow a nonlinear relationship with
the hazards, as recently shown for HDL-cholesterol regarding incident overall mortality [27].
Finally, we explored the associations between anti-apoA-I IgGs and other clinical and biological
variables available for this cohort [28,29], such as lipid profile, high sensitivity C-reactive protein
(hs-CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-cTnT),
trimethyl-amine-N-oxide (TMAO), red blood cells, white blood cells, and platelets counts.
2. Experimental Section
2.1. Study Population
These findings are derived from the prospective multicenter Swiss ACS Cohort [28,30,31], as part
of the Special Program University Medicine (SPUM), which enrolled patients referred for coronary
angiography with a primary diagnosis of ACS at one of the participating University Hospitals (Zurich,
Bern, Lausanne, Geneva; Clinical Trials Registration number: NCT01000701; www.spum-acs.ch)
between December 2009 and October 2012. Of 2168 included Biomarker Cohort 1 patients, 1713 ACS
patients had available anti-apoA-I IgG measurements in addition to the previously described clinical
and laboratory data and were included in this study.
Briefly, inclusion criteria were: (1) patients older than 18 years admitted within 5 days (preferably
within 72 h) after pain onset with the main diagnosis of S–T segment (ST)-elevation myocardial
infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), or unstable angina (UA);
(2) persistent ST-segment elevation or depression, T-inversion or dynamic Electrocardiogram (ECG)
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changes, or new left bundle branch block (LBBB); (3) evidence of positive troponin by local laboratory
reference values with a rise and/or fall in serial troponin levels; (4) known coronary artery disease,
specified as status after myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous
coronary intervention, or newly documented ≥50% stenosis of an epicardial coronary artery during
the initial catheterization. Exclusion criteria comprised of (1) severe physical disability; (2) inability
to comprehend study; (3) less than 1 year of life expectancy for non-cardiac reasons. Patients were
followed-up for 1 year. All subjects gave written informed consent according to the declaration of
Helsinki, and the study was approved by the respective institutional review boards.
2.2. Definitions of Study Outcomes
The primary outcome of this study consisted of major adverse CV events (MACE), defined as a
composite of myocardial infarction (MI), stroke (including transient ischemic attack), or CV death, as
described previously [28,30,31]. Participants were first followed up at 1-year post-ACS by telephone
by a trained study nurse to attend a clinical visit. If patients were unable to attend the clinic visit,
follow-up was performed in the following order: (1) phone call, (2) postal mail or email, (3) through
family members, or (4) via primary care physician or cardiologist. Reviews of medical records and
clinical visits were conducted for the 1-year outcomes. Clinical endpoints were adjudicated by a
panel of three independent certified senior cardiologists blinded to anti-apoA-1 IgG results using
standardized pre-specified adjudication forms.
2.3. Biochemical Analyses
Blood was drawn from the arterial sheath at coronary angiography and centrifuged at 2700 × g
for 10 min at room temperature to obtain serum, and then frozen and stored in aliquots at −80 ◦C.
Routine laboratory tests (including lipid profile, hs-CRP, NT-proBNP, hs-cTnT, TMAO, red blood cells,
white blood cells, and platelets count) were performed according to laboratories of each Institution,
and the corresponding detailed analytical aspects have been reported earlier [28,29]. Estimated
glomerular filtration rate (eGFR; in mL/min per 1.73 m2) was calculated for each cohort using the
modification of Diet in Renal Disease study (MDRD) equation.
Anti-Apolipoprotein A-I IgG Levels
Anti-apoA-I IgGs were measured as previously described [11–13,16,20–22], using frozen EDTA
plasma aliquots, stored at −80 ◦C until analyses. Maxisorp plates (NuncTM, Roskilde, Denmark)
were coated with purified, human-derived delipidated apolipoprotein A-I (20 μg/mL; 50 μL/well)
for 1 h at 37 ◦C. After being washed, all wells were blocked for 1 h with 2% bovine serum albumin
(BSA) in a phosphate buffer solution (PBS) at 37 ◦C. Participants’ samples were also added to a
non-coated well to assess individual non-specific binding. After six washing cycles, a 50 μL/well of
signal antibody (alkaline phosphatase-conjugated anti-human IgG; Sigma-Aldrich, St Louis, MO, USA),
diluted 1:1000 in a PBS/BSA 2% solution, was added and incubated for 1 h at 37 ◦C. After washing
six more times, phosphatase substrate p-nitrophenyl-phosphate-disodium (Sigma-Aldrich, St Louis,
MO, USA) dissolved in a diethanolamine buffer (pH 9.8) was added and incubated for 20 min at 37 ◦C
(Molecular DevicesTM Filter Max F3, Molecular Devices, San Jose, CA, USA). Optical density (OD) was
determined at 405 nm, and each sample was tested in duplicate. Corresponding non-specific binding
was subtracted from mean OD for each sample. The specificity of detection against lipid-free and
unmodified apoA-I has been determined previously by conventional saturation tests, Western blot,
and LC-MS analyses [12]. At an intermediate value of 0.6 OD, the interassay coefficient of variation
was 9% (n = 5), and the intra-assay CV was 5% (n = 5).
2.4. Statistical Methods
The data were expressed as medians ± interquartile ranges for continuous variables and as
numbers and percentages for categorical variables. The correlation between anti-apoA-I IgG and other
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biomarkers was evaluated by nonparametric approach (Spearman rank correlation). Given the fact that
anti-apoA-I IgG seropositivity cut-off has not been defined nor validated on EDTA plasma, continuous
anti-apoA-I IgG levels in OD were categorized according to quartiles and/or used as a continuous
variable to assess the association with clinical outcomes. Time-to-first event or composite events were
analyzed censoring patients at 365 days or last valid contact date. Univariate and adjusted (for GRACE
score 2.0) associations of anti-apoA-I IgG categories with study endpoint was evaluated using Cox
proportional hazards models and expressed with hazard ratios (HRs) and 95% CI. The predictive
value of anti-apoA-I IgG over and above a reference model was assessed by Harrell’s C-statistics
calculated from a Cox proportional hazards regression model based on a logistic model using the
GRACE risk score as a reference [26]. To identify a possible nonlinear relationship between MACE risk
and anti-ApoA-I IgG continuous values, we used a Cox regression model with splines (with a degree of
freedom 2) [32]. A two-sided p-value <0.05 was considered statistically significant. Statistical analyses
were performed using STATA software® (Version 15, STATA Corp., College Station, TX, USA).
3. Results
3.1. Baseline Demographic and Biological Characteristics
Baseline characteristics of patients and pertinent data are summarized in Table 1. During the
1-year follow-up, 144 patients (8.4%) met the composite endpoint of MACE. Among them, 57 had a
myocardial infarction, 26 had a stroke, and 68 died from CV causes.
3.2. Associations with Major Adverse Cardiovascular Events (MACE) at 1-Year of Follow-Up
Traditional CV risk factors, as well as the GRACE risk score 2.0, hs-CRP, hs-cTnT, NT-proBNP,
TMAO levels, and anti-apoA-I IgG, upon study inclusion, were found to be higher in individuals with
MACE at 1-year post-ACS than in those without (Table 1). As shown in Tables 2 and 3, most of the
traditional CV risk factors, history of MI, renal function, and conventional biomarkers were significantly
associated with MACE at 1 year in univariate analyses. Of note, HDL cholesterol was not associated
with the study endpoint. As previously reported in the SPUM-ACS cohort [33], lower low-density
lipoprotein (LDL) and total cholesterol levels were significantly associated with a decreased risk
of MACE.
Anti-apoA-I IgG levels were associated with MACE (Table 3). Cumulative incidence curves
are represented in Figure 1 by anti-apoA-I IgGs quartiles. The adjustment for the GRACE score
did not modify the association (Table 4). The relationship between the incidence of MACE and
anti-apoA-I IgG levels was not linear since the cumulative incidence and the hazard ratio did not
change progressively with the anti-apoA-I IgG level (Figure 1, Table 3). The non-adjusted relationship
between the one-year risk of MACE and anti-apoA-I IgGs is depicted in more detail in Figure 2a.
An inverted U-shaped reminiscent association was apparent for MACE, with a progressively increasing
risk up to an anti-apoA-I IgG level of 1.0 OD, before an apparent decrease, difficult to interpret due
to the broadness of the 95% confidence interval. In an additional Cox model accounting for this
nonlinearity and adjusted for the GRACE score, the relation between the hazard and MACE remained
identical (Figure 2b). With this model, the non-linearity of the relationship (p = 0.0110) and the
association between MACE and anti-apoA-I IgG level (p = 0.0068) were statistically significant. Of note,
anti-apoA-I IgG values spanning from 0 to 1.0 OD represented 77% of all anti-apoA-1 IgGs values,
whereas values above 1.0 represented 23% of all anti-apoA-I IgG values on this cohort. Secondary
analyses revealed that the main driver of anti-apoA-I IgG-related MACE risk in the composite first
endpoint was the recurrence of MI as anti-apoA-I IgG levels were not predictive of stroke or CV deaths
(Figure S1, Supplementary Material).
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Table 1. Baseline characteristics.
Patient Characteristics All Patients (n = 1713) MACE * (n = 144) No MACE * (n = 1569)
Age, years
Median (IQR) 64 (54–74) 76 (64–81) 63 (53–73)
BMI, kg/m2
Median (IQR) 26.5 (24.2–29.4) 26.0 (24.1–30.4) 26.5 (24.2–29.4)
Missing data 23 9 14
Female, n (%) 363/1713 (21.2%) 35/144 (24.3%) 328/1569 (20.9%)
Current smoker, n (%) 690/1680 (41.1%) 44/138 (31.9%) 646/1542 (41.9%)
Diabetes history, n (%) 310/1713 (18.1%) 47/144 (32.6%) 263/1569 (16.8%)
MI history, n (%) 246/1713 (14.4%) 31/144 (21.5%) 215/1569 (13.7%)
Hypertension history, n (%) 993/1713 (58.0%) 100/144 (69.4%) 893/1569 (56.9%)
Dyslipidemia history, n (%) 1031/1711 (60.3%) 82/143 (57.3%) 949/1568 (60.5%)
Valvular disease history, n (%) 33/1713 (1.9%) 10/144 (6.9%) 23/1569 (1.5%)
Statin use, n (%) 503/1702 (29.6%) 50/141 (35.5%) 453/1561 (29.0%)
Beta-blocker use, n (%) 410/1699 (24.1%) 54/141 (59.3%) 356/1558 (22.8%)
GRACE score 2.0
Median (IQR) 123 (106–142) 144 (120–165) 121 (104–140)
Hs-CRP, mg/l
Median (IQR) 3.0 (1.2–8.0) 5.8 (2.3–18.9) 2.7 (1.1–7.6)
Missing data 203 11 192
Hs-cTnT, pg/L
Median (IQR) 0.22 (0.07–0.75) 0.51 (0.13–1.92) 0.21 (0.06–0.70)
Missing data 194 10 184
TMAO, μmol/L
Median (IQR) 2.93 (1.99–4.97) 4.25 (2.12–7.35) 2.86 (1.98–4.85)
Missing data 360 38 322
Anti-ApoA-I IgGs, OD
Median (IQR) 0.66 (0.44–0.97) 0.76 (0.49–0.98) 0.65 (0.44–0.97)
HDL, mmol/L
Median (IQR) 1.13 (0.94–1.39) 1.15 (0.94–1.46) 1.12 (0.94–1.38)
missing data 65 8 57
LDL, mmol/L
Ledian (IQR) 3.08 (2.34–3.84) 2.72 (2.04–3.45) 3.11 (2.39–3.86)
Missing data 68 8 60
Total cholesterol, mmol/L
Median (IQR) 4.86 (4.10–5.70) 4.5 (3.7–5.2) 4.9 (4.1–5.8)
Missing data 49 7 42
Triglyceride, mmol/L
Median (IQR) 1.02 (0.69–1.60) 0.95 (0.65–1.33) 1.04 (0.70–1.60)
Missing data 58 7 51
Creatinine
Median (IQR) 76.0 (65.0–91.0) 89.0 (71.8–114.3) 75.0 (65.0–90.0)
eGFR
Median (IQR) 90.9 (73.5–108.8) 74.6 (55.8–92.3) 92.1 (75.4–109.6)
Missing data 5 0 5
Systolic blood pressure
Median (IQR) 129 (114–145) 129 (110–142) 129 (115–145)
Diastolic blood pressure
Median (IQR) 75.0 (65.0–84.0) 72.0 (61.0–80.3) 75.0 (65.0–84.0)
Missing data 17 0 17
Renal failure (eGFR < 60), n (%) 214/1708 (12.5%) 43/144 (29.8%) 171/1564 (9.0%)
* one-year follow-up; Abbreviations: BMI—body mass index; SBP—Systolic blood pressure; DBP—diastolic
blood pressure; MACE—major adverse cardiovascular events; IQR—interquartile range; MI—myocardial
infarction; GRACE—Global Registry of Acute Coronary Events; Hs-CRP—high sensitivity C-reactive protein;
Hs-cTnT—high-sensitivity troponin T; TMAO—trimethyl-amine-N-oxide; Anti-ApoA-I IgGs—autoantibodies
against apolipoprotein A-I; OD—optical density; HDL—high-density lipoprotein; LDL—low-density lipoprotein;
eGFR—estimated glomerular filtration rate.
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Table 2. One-year cumulative major adverse cardiovascular events (MACE) incidence according to
univariate analyses.
Predictors Levels N MACE/N Total
One-Year Cumulative Incidence of
MACE (95% CI)
p-Value *
Age 26–54 y 17/450 3.8 (2.0–5.6) <0.0001
55–64 y 22/443 5.0 (3.0–7.0)
65–74 y 32/418 7.7 (5.1–10.3)
≥75 y 73/402 18.4 (14.5–22.1)
BMI, kg/m2 20–24.9 49/554 9.0 (6.5–11.3) 0.1569
25–29.9 50/767 6.6 (4.8–8.4)
30–34.9 26/283 9.3 (5.8–12.6)
≥35 10/86 12.0 (4.7–18.8)
GRACE score ≤99 9/318 2.9 (1.0–4.7) <0.0001
100–119 25/453 5.6 (3.4–7.7)
120–139 29/456 6.4 (4.1–8.7)
140–159 37/303 12.3 (8.5–16.0)
≥160 44/183 24.3 (17.8–30.3)
Gender female 35/363 9.8 (6.6–12.8) 0.3095
male 109/1350 8.2 (6.7–9.6)
Diabetes history no 97/1403 7.0 (5.6–8.3) <0.0001
yes 47/310 15.5 (11.3–19.4)
MI history No 113/1467 7.8 (6.4–9.2) 0.0124
yes 31/246 12.9 (8.5–17.0)
Hypertension
history no 44/720 6.2 (4.4–7.9) 0.0041
yes 100/993 10.2 (8.3–12.1)
Dyslipidemia
history no 61/680 9.1 (6.9–7.9) 0.4057
yes 82/1031 8.0 (6.4–12.1)
Valvular history no 134/1680 8.1 (6.8–9.4) <0.0001
yes 10/33 30.3 (12.7–44.3)
Current smoker no 96/990 9.6 (7.7–11.4) 0.0251
yes 44/690 6.5 (4.6–8.3)
Hs-CRP, mg/L 0–0.99 12/299 4.1 (1.8–6.3) <0.0001
1–1.99 18/280 6.5 (3.5–9.3)
2–9.99 55/614 9.1 (6.8–11.4)
≥10 48/317 15.4 (11.3–19.4)
Hs-cTnT, ng/L 0–0.14 40/647 6.3 (4.4–8.1) 0.0001
0.15–0.52 29/379 7.8 (5.0–10.5)
>0.52 65/493 13.3 (10.3–16.3)
TMAO, μmol/L <2 25/340 7.4 (4.6–10.2) 0.0001
2–2.99 12/350 3.5 (1.5–5.4)
3–3.99 13/206 6.4 (3.0–9.7)
4–6.99 27/257 10.6 (6.7–14.3)
≥7 29/200 14.7 (9.6–19.4)
* Log-rank test. Abbreviations: BMI—body mass index; GRACE—Global Registry of Acute Coronary Events;
MI—myocardial infarction; Hs-CRP—high sensitivity C-reactive protein; Hs-cTnT—high-sensitivity troponin
T; TMAO—trimethyl-amine-N-oxide.
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Table 3. One-year cumulative major adverse cardiovascular events (MACE) incidence according to
univariate analyses.
Predictors Levels N MACE/N Total




OD ≤0.45 31/442 7.1 (4.7–9.5) 0.0323
0.46–0.65 24/396 6.1 (3.7–8.5)
0.66–0.95 48/425 11.5 (8.4–14.5)
>0.95 41/450 9.2 (6.5–11.9)
HDL, mmol/L <1 41/511 8.2 (5.7–10.5) 0.6210
1–1.3 48/626 7.8 (5.6–9.8)
>1.3 47/511 9.3 (6.7–11.8)
LDL, mmol/L <2.5 59/492 12.3 (9.3–15.1) 0.0005
2.5–3.5 46/580 8.0 (5.8–10.2)
>3.5 31/573 5.5 (3.6–7.3)
Total cholesterol,
mmol/L <4.5 98/606 11.4 (8.8–13.9) 0.0027
4.5–5.5 41/573 7.2 (5.1–9.3)
>5.5 28/485 5.9 (3.7–7.9)
Triglyceride,
mmol/L <0.80 46/527 8.8 (6.3–11.2) 0.0653
0.80–1.30 56/564 10.1 (7.6–12.6)
>1.30 35/564 6.3 (4.2–8.3)
Creatinine, μmol/L <70 31/606 5.2 (3.4–7.0) <0.0001
70–85 35/550 6.5 (4.4–8.5)
>85 78/557 14.2 (11.2–17.1)
NT-proBNP, ng/L <200 18/511 3.6 (1.9–5.2) <0.0001
200–1000 36/514 7.1 (4.8–9.3)
>1000 80/493 16.5 (13.1–19.7)
SBP, mmHg <120 47/561 8.4 (6.1–10.7) 0.5490
120–140 60/649 9.4 (7.1–11.6)
>140 37/503 7.5 (5.2–9.8)
DBP, mmHg <70 59/602 9.9 (7.5–12.3) 0.2120
70–80 49/565 8.8 (6.4–11.1)
>80 36/529 6.9 (4.7–9.0)
eGFR <60 mL/min no 101/1595 6.9 (5.6–8.1) <0.0001
yes 43/257 20.3 (14.7–25.6)
* Log-rank test. Abbreviations: MACE—major adverse cardiovascular events; Anti-ApoA-I IgGs—autoantibodies
against apolipoprotein A-I; OD—optical density; HDL—high-density lipoprotein; LDL—low-density lipoprotein;
NT-proBNP—N-terminal pro-brain natriuretic peptide; SBP—Systolic blood pressure; DBP—diastolic blood pressure;
eGFR—estimated glomerular filtration rate.
Figure 1. Cumulative incidence of major adverse cardiovascular events (MACE) (myocardial infarction,
stroke, TIA, or cardiovascular (CV) death) according to autoantibodies against apolipoprotein A-I
(anti-apoA-I IgG) optical density (OD) quartiles.
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Table 4. Autoantibodies against apolipoprotein A-I (Anti-apoA-I IgGs) and major adverse
cardiovascular events (MACE) (myocardial infarction, stroke, or cardiovascular (CV) death) risk
according to Cox-regression analyses.
Predictors Unadjusted HR (95% CI) p-Value Adjusted HR (95% CI) ** p-Value
Anti-ApoA-I IgGs OD
≤0.45, Q1 Reference group 0.0338 * Reference group 0.0496 *
0.46–0.65, Q2 0.85 (0.50–1.46) 0.5625 0.82 (0.48–1.40) 0.4682
0.66–0.95, Q3 1.64 (1.04–2.57) 0.0322 1.56 (0.99–2.44) 0.0558
>0.95, Q4 1.30 (0.82–2.08) 0.2657 1.23 (0.77–1.97) 0.3808
GRACE score 2.0
≤99 Reference group <0.0001 * Reference group <0.0001 *
100–119 1.96 (0.92–4.20) 0.0931 1.99 (0.93–4.26) 0.0772
120–139 2.27 (1.07–4.79) 0.0321 2.25 (1.07–4.76) 0.0332
140–159 4.44 (2.14–9.19) <0.0001 4.44 (2.14–9.20) <0.0001
≥160 9.44 (4.61–19.35) <0.0001 9.36 (4.57–19.18) <0.0001
* p-Value for the overall association between the factor (all levels) and risk of MACE; ** Adjusted for the GRACE score
2.0. Abbreviations: HR—hazard ratio; OD—optical density; GRACE—Global Registry of Acute Coronary Events.
Figure 2. (a) Cumulative incidence of major adverse cardiovascular events (MACE) at one year
according to autoantibodies against apolipoprotein A-I (anti-apoA-I IgG) levels (in optical density
(OD)) in univariate analyses (black line). (b) Hazard ratio for MACE according to anti-apoA-I IgG
levels (black line) adjusted for the categories of the Global Registry of Acute Coronary Events (GRACE)
score 2.0. The vertical black lines above the x-axis represent the distribution of anti-apoA-I IgG levels in
the study population: each vertical line represents the value of one participant. In both panels, the grey
lines represent the 95% confidence interval. The distribution of anti-apoA-I IgG values was as followed:
from 0 to 0.5 OD: n = 544 (31.8%); >0.5 and ≤1.0: n = 774 (45.2%); >1.0 and ≤1.5: n = 292 (17.0%); >1.5
and ≤2.0: n = 89 (5.2%); >2.0: n = 14 (0.8%).
C-statistics confirmed that anti-apoA-I IgG levels were a modest but significant predictor for
MACE. When added to the GRACE risk score for MACE prediction at one year, anti-apoA-I IgG
marginally improved the prognostic accuracy of the model: C-statistics changed from 0.680 for Cox
model with the categories of a GRACE risk score to 0.698 for Cox model combining the categories of
GRACE risk score and anti-apoA-I IgG levels in a continuous way.
3.3. Anti-apoA-I IgG Associations in Acute Coronary Syndrome (ACS)
To further explore the associations between anti-apoA-I IgGs and patients’ clinical and biological
characteristics in ACS, we analyzed the distribution of the latter according to anti-apoA-I IgG quartiles.
As shown in Tables 5 and 6, an inverse association was observed with the prevalence of diabetes that
decreased among the increasing anti-apoA-I IgG categories, and a trend toward increased representation
of valvular disease along anti-apoA-I IgG categories was noted. Furthermore, Spearman correlation
coefficients showed modest but statistically significant positive associations between anti-apoA-I IgG
levels and NT-proBNP and hemoglobin levels, while negative associations were retrieved between
anti-apoA-I IgG and neutrophil, eosinophil, and platelet counts (Table S1, Supplementary Material).
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Close to significant associations (p ≤0.1) were noted with age, hs-cTnT, hemoglobin, hematocrit,
leucocytes, creatinine, total cholesterol, and triglyceride levels. No other significant association was
retrieved, notably with TMAO levels (Table S1). None of these anti-apoA-I IgG associations would
have remained significant after the application of Bonferroni correction (significance threshold: 0.05/24:
p = 0.002).
Table 5. Exploring the factors associated with autoantibodies against apolipoprotein A-I (anti-apoA-I
IgG) levels.
Anti-apoA-I IgG Levels
All Patients ≤0.45 Q1 >0.45 and ≤0.65 Q2 >0.65 and ≤0.95 Q3 >0.95 Q4 P *
Age, years
median (IQR) 64 (54–74) 63 (53–74) 63 (54–74) 64 (54–72) 65 (55–75) 0.1787
26–54 y 450 (26.3%) 122 (27.6%) 111 (28.0%) 109 (25.6%) 108 (24.0%)
55–64 y 443 (25.9%) 121 (27.4%) 102 (25.8%) 114 (26.8%) 106 (23.6%)
65–74 y 418 (24.4%) 99 (22.4%) 92 (23.2%) 110 (25.9%) 117 (26.0%)
≥75 y 402 (23.5%) 100 (22.6%) 91 (23.0%) 92 (21.6%) 119 (26.4%)
BMI, kg/m2
median (IQR) 26.5 (24.2–29.4) 26.2 (24.2–29.3) 26.4 (24.2–29.3) 26.8 (24.3–29.7) 26.6 (24.2–29.4) 0.6434
20–24.9 554 (32.8%) 154 (35.2%) 128 (32.4%) 134 (32.2%) 138 (31.3%)
25–29.9 767 (45.4%) 189 (43.2%) 187 (47.3%) 182 (43.8%) 209 (47.4%)
30–34.9 283 (16.7%) 75 (17.1%) 62 (15.7%) 73 (17.5%) 73 (16.6%)
≥35 86 (5.1%) 20 (4.6%) 18 (4.6%) 27 (6.5%) 21 (4.8%)
missing data 23 4 1 9 9
Female, n (%) 363/1713 (21.2%) 102/442 (23.1%) 87/396 (22.0%) 93/425 (21.9%) 81/450 (18.0%) 0.2669
Current smoker, n (%) 690/1680 (41.1%) 174/436 (39.9%) 147/390 (37.7%) 183/419 (43.7%) 186/435 (42.8%) 0.2875
Diabetes history, n (%) 310/1713 (18.1%) 97/442 (21.9%) 66/396 (16.7%) 83/425 (19.5%) 64/450 (14.2%) 0.0177
Hypertension history,
n (%) 720/1713 (42.0%) 248/442 (56.1%) 234/396 (59.1%) 247/425 (58.1%) 264/450 (58.7%) 0.8191




(60.3%) 276/441 (62.6%) 247/395 (62.5%) 257/425 (60.5%) 251/450 (55.8%) 0.1311
Valvular history, n (%) 33/1713 (1.9%) 4/442 (0.9%) 6/396 (1.5%) 8/425 (1.9%) 15/450 (3.3%) 0.0572
GRACE score
median (IQR) 123 (106–142) 123 (106–142) 123 (106–140) 123 (104–144) 123 (106–143) 0.7916
≤99 318 (18.6%) 83 (18.8%) 74 (18.7%) 84 (19.8%) 77 (17.1%)
100–119 453 (26.4%) 121 (27.4%) 110 (27.8%) 100 (23.5%) 122 (27.1%)
120–139 456 (26.6%) 115 (26.0%) 103 (26.0%) 115 (27.1%) 123 (27.3%)
140–159 303 (17.7%) 84 (19.0%) 65 (16.4%) 76 (17.9%) 78 (17.3%)
≥160 183 (10.7%) 39 (8.8%) 44 (11.1%) 50 (11.8%) 50 (11.1%)
CRP, mg/L
median (IQR) 3.0 (1.2–8.0) 2.60 (1.10–7.70) 2.70 (1.00–6.40) 3.30 (1.40–8.25) 3.10 (1.30–9.20) 0.1704
0–0.99 299 (19.8%) 77 (20.2%) 80 (22.7%) 63 (16.6%) 79 (19.9%)
1–1.99 280 (18.5%) 76 (19.9%) 67 (19.0%) 71 (18.7%) 66 (16.6%)
2–9.99 614 (40.7%) 149 (39.1%) 141 (39.9%) 166 (43.8%) 158 (39.8%)
≥10 317 (21.0%) 79 (20.7%) 65 (18.4%) 79 (20.8%) 94 (23.7%)
missing data 203 61 43 46 53
Hs-cTnT, ng/L
median (IQR) 0.22 (0.07–0.75) 0.20 (0.06–0.67) 0.21 (0.06–0.66) 0.24 (0.07–0.87) 0.26 (0.07–0.83) 0.1947
0–0.14 647 (42.6%) 172 (45.0%) 155 (43.7%) 158 (41.1%) 162 (40.7%)
0.15–0.52 379 (25.0%) 98 (25.7%) 86 (24.2%) 93 (24.2%) 102 (25.6%)
>0.52 493 (32.5%) 112 (29.3%) 114 (32.1%) 133 (34.6%) 134 (33.7%)
missing data 194 60 41 41 52
TMAO
median (IQR) 2.93 (1.99–4.97) 2.85 (1.89–4.97) 2.96 (2.01–4.98) 2.93 (2.00–4.46) 3.05 (2.07–5.43) 0.4744
<2 340 (25.1%) 98 (28.3%) 74 (23.9%) 83 (25.1%) 85 (23.2%)
2–2.99 350 (25.9%) 87 (25.1%) 84 (27.2%) 86 (26.0%) 93 (25.3%)
3–3.99 206 (15.2%) 42 (12.1%) 51 (16.5%) 60 (18.1%) 53 (14.4%)
4–6.99 257 (19.0%) 66 (19.1%) 50 (16.2%) 63 (19.0%) 78 (21.3%)
≥7 200 (14.8%) 53 (15.3%) 50 (16.2%) 39 (11.8%) 58 (15.8%)
missing data 360 96 87 94 83
* Kruskal-Wallis or Chi-2 tests (Fisher exact test for liver history). Abbreviations: IQR—interquartile range;
BMI—body mass index; MI—myocardial infarction; GRACE—Global Registry of Acute Coronary Events;
CRP—C-reactive protein; hs-cTnT—high-sensitivity troponin T; TMAO—trimethyl-amine-N-oxide.
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Table 6. Exploring the factors associated with autoantibodies against apolipoprotein A-I (anti-apoA-I
IgG) levels.
Anti-apoA-I IgG Levels
All Patients ≤0.45 Q1 >0.45 and ≤0.65 Q2 >0.65 and ≤0.95 Q3 >0.95 Q4 P *
SBP, mmHg
Median (IQR) 129 (114–145) 129 (115–145) 129 (115–144) 128 (112–145) 130 (114–146) 0.9714
Missing data 0 0 0 0 0
DBP, mmHg
Median (IQR) 75 (65–84) 75 (66–84) 75 (65–84) 73 (65–84) 74 (63–84) 0.6476
Missing data 17 7 2 4 4
Hemoglobin, g/L
Median (IQR) 138 (127–149) 137 (124–149) 138 (126–148) 139 (129–148) 139 (128–150) 0.3715
Missing data 87 30 19 19 19
Hematocrit, %
Median (IQR) 41 (38–43.3) 41 (37–43) 40 (37–43) 41 (38–44) 41 (38–44) 0.2161
Missing data 76 26 14 18 18
Leucocytes, G/L
Median (IQR) 9.6 (7.4–12.1) 9.5 (7.3–12.0) 9.2 (7.1–12.0) 9.8 (7.9–12.1) 9.8 (7.6–12.3) 0.0340
Missing data 73 25 14 17 17
Erythrocytes, T/L
Median (IQR) 4.5 (4.1–4.8) 4.5 (4.1–4.9) 4.4 (4.1–4.8) 4.5 (4.2–4.8) 4.5 (4.1–4.8) 0.3240
Missing data 84 28 17 19 20
Lymphocytes, %
Median (IQR) 1.62 (1.16–2.35) 1.67 (1.20–2.55) 1.54 (1.09–2.31) 1.69 (1.19–2.34) 1.58 (1.11–2.22) 0.0526
Missing data 395 118 95 87 95
Neutrophils, G/L
Median (IQR) 7.3 (5.3 to 10.0) 7.0 (5.0 to 9.7) 7.2 (4.7 to 10.1) 7.4 (5.5 to 9.9) 7.6 (5.5 to 10.1) 0.1500
Missing data 412 122 97 93 100
Monocytes, %
Median (IQR) 0.62 (0.45 to 0.95) 0.63 (0.45 to 1.05) 0.56 (0.41 to 0.92) 0.64 (0.48 to 0.99) 0.61 (0.45 to 0.90) 0.1220
Missing data 398 118 96 88 96
Basophils, %
Median (IQR) 0.03 (0.01–0.07) 0.03 (0.02–0.08) 0.03 (0.01–0.07) 0.03 (0.01–0.07) 0.03 (0.01–0.06) 0.7491
Missing data 399 118 95 88 98
Eosinophils, %
Median (IQR) 0.08 (0.02–0.19) 0.10 (0.03–0.21) 0.08 80.03–0.20) 0.07 (0.02–0.17) 0.07 (0.02–0.16) 0.0237
Missing data 401 119 96 88 98
Thromboctyes, G/L
Median (IQR) 215 (183–257) 226 (188–272) 211 (179–250) 218 (185–253) 208 (176–255) 0.0026
Missing data 85 27 15 21 22
Total cholesterol, mmol/L
Median (IQR) 4.9 (4.1–5.7) 4.9 (4.1–5.8) 4.9 (4.0–5.8) 4.9 (4.1–5.7) 4.7 (4.0–5.6) 0.1602
Missing data 49 13 13 11 12
HDL, mmol/L
Median (IQR) 1.13 (0.69–1.60) 1.14 (0.93–1.40) 1.14 (0.96–1.40) 1.13 (0.94–1.40) 1.10 (0.93–1.33) 0.2852
Missing data 65 20 15 14 16
LDL, mmol/L
Median (IQR) 308 (2.34–3.84) 3.07 (2.32–3.94) 3.13 (2.40–3.82) 3.08 (2.37–3.81) 2.99 (2.26–3.81) 0.7418
Missing data 68 20 16 16 16
Triglyceride
Median (IQR) 1.02 (0.69–1.60) 1.08 (0.72–1.70) 1.05 (0.69–1.68) 1.00 (0.66–1.51) 0.99 (0.69–1.48) 0.2165
Missing data 58 17 15 13 13
Creatinine, μmol/L
Median (IQR) 76 (65–91) 75 (64–88) 76 (66–91) 76 (65–92) 77 (66–92) 0.3484
Missing data 0 0 0 0 0
NT-ProBNP, ng/L
Median (IQR) 414 (131–1436) 386 (118–1462) 355 (129–1196) 433 (132–1627) 544 (159–1633) 0.0390
Missing data 195 60 41 42 52
eGFR, mL/min
Median (IQR) 90.9 (73.5–108.8) 92.1 (75.8–110.9) 91.0 (73.5–107.2) 89.8 (73.5–108.3) 90.7 (70.5–108.6) 0.4791
Missing data 5 1 1 2 1
Renal failure (eGFR <60), n
(%) 214/1708 47/441 53/395 56/423 58/449 0.5828
* Kruskal-Wallis or Chi-2 tests (Fisher exact test for liver history). Abbreviations: Anti-apoA-I IgG—autoantibodies
against apolipoprotein A-I; SBP—systolic blood pressure; DBP—diastolic blood pressure; IQR—interquartile range;
HDL—high-density lipoprotein; LDL—low-density lipoprotein; NT-ProBNP—N-terminal pro-brain natriuretic
peptide; eGFR—estimated glomerular filtration rate.
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4. Discussion
The key finding of the present study is that anti-apoA-I IgG was predictive of incident MACE
independently of the GRACE score 2.0, one of the strongest prognostic stratification tools currently
validated in ACS. Furthermore, the prognostic accuracy of the GRACE score was slightly improved
(+2%) by adding anti-apoA-I IgGs to it, according to C-statistics. Because of the important controversy
regarding the reliability of C-statistics comparison and reclassification statistics (net reclassification
index and integrated discrimination index) in embedded models due to the important false positive
findings [34,35], we did not perform further statistical analyses to interpret this difference. Indeed, we
feel that a 2% increase in C-statistics is unlikely to be clinically meaningful or to change current clinical
practice in ACS. Nevertheless, these results strengthen the proof-of-principle that anti-apoA-I IgGs are
predictive of a poor CV prognosis, as suggested earlier in the general population and in different high
CV risk settings [11–17,20–22].
The second notable finding of this study is that the association between anti-apoA-I IgGs and
MACE was not linear over the full range of anti-apoA-I IgG values. Indeed, the relationship was linear
for the first 87% anti-apoA-I IgG values but started to decline for the remaining 23% highest anti-apoA-I
IgG values. According to Cox regression models with splines confirming the significant nature of
this non-linear relationship with MACE, we hypothesized that anti-apoA-I IgGs would mirror the
U-shaped relationship between HDL-cholesterol and outcomes reported lately [27]. Nevertheless,
there was no association between HDL-cholesterol and MACE or between HDL-cholesterol and
anti-apoA-I IgGs in this study. Furthermore, due to the small number of events in this last 23% portion
of anti-apoA-I IgG values, the confidence intervals of our regression model increased, preventing us
from concluding on a possibly inverted U-shape relationship with MACE or the occurrence of a plateau
at high anti-apoA-I IgG values. To the best of our knowledge, this is the first report of a non-linear
association between anti-apoA-I IgG levels and MACE. Whether this non-linear association is specific
for the ACS population is still elusive, but should be taken into account in future studies in order to
avoid possible false negative findings related to the classic assumption of a proportional risk increase
between anti-apoA-I IgG levels and hazards.
To further explore the possible associations between biological and clinical parameters with
anti-apoA-I IgG levels in ACS, our linear regression analyses of anti-apoA-I IgG quartiles did not
identify specific items markedly associated with anti-apoA-I IgG, and we did not reproduce the often
reported association with previous MI history [11,20–22]. Interestingly, a trend was observed with the
presence of valvular diseases, and an inverse relationship with the history of diabetes. This possible
association with the presence of valvular diseases is in line with the concept supporting a causal role
between humoral autoimmunity and different valvular diseases historically exemplified by rheumatic
heart disease [6]. Nevertheless, as anti-apoA-I IgGs have never been shown to be associated with
valvular diseases, these results open a new field of investigations, especially as we could not specify
more in detail with which specific valvular disease these autoantibodies were associated. Furthermore,
as anti-apoA-I IgGs were found to be higher in type 2 diabetic patients and associated with a CVD [17],
the inverse association reported here between the prevalence of diabetes across anti-apoA-I IgG
quartiles was unexpected and thus requires further confirmation. Of note, we did not retrieve any
association between anti-apoA-I IgG and hs-CRP levels, despite previous reports, notably in the general
population, where such association was retrieved [11]. Because anti-apoA-I IgG has been shown to
promote various inflammatory cytokines production [10], including interleukin-6 regulating CRP liver
production, this absence of association was unexpected. The reason for such difference is unknown
and may be explained by differences related to the acute phase the samples of ACS patients were taken
when compared to the stable situation of CoLaus individuals.
On the other hand, the inverse associations retrieved between these antibodies and lymphocyte
and platelet counts are similar to what has been retrieved in HIV patients [36], and the possible causal
nature of such associations is still under investigation. The inverse association between anti-apoA-I
IgGs and eosinophil counts has not been reported. Whether patients with high anti-apoA-I IgG levels
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could be less prone to develop an allergic coronary syndrome (known as the Kounis syndrome) [37]
should be further explored. The weak but significant positive anti-apoA-I IgG correlation with
NT-proBNP, one of the strongest prognostic biomarkers of mitigated prognosis, may be related to the
prognostic value previously ascribed to anti-apoA-I IgGs in different settings [11–17,20–22]. Because
experimental evidence indicates that these autoantibodies could per se promote atherogenesis and
atherothrombosis, as well as mitigate mouse survival by eliciting sterile inflammation through TLR2/4
and CD14 signaling [22–25], the present results reinforce the notion that anti-apoA-I IgGs could
represent a future therapeutic target rather than a mere innocent bystander. Nevertheless, due to the
non-linear relationship between these antibodies and MACE, knowing whether and how assessing
anti-apoA-I IgG levels could affect current medical practice remains to be demonstrated.
The major limitation of this study relies on the fact that we did not assess other auto-antibodies of
potential CV relevance, which is outside of the scope of the present work. The strength of the study
relies on the fact that so far, it represents the largest and best characterized ACS cohort studying the
prognostic value of anti-apoA-I IgGs in ACS.
5. Conclusions
In conclusion, anti-apoA-I IgGs are associated with incident MACE in ACS, independently of the
GRACE 2.0 score, and with a nonlinear relationship to the hazards. Whether anti-apoA-I IgGs could
provide incremental information over the existing risk stratification tool still needs to be determined.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/7/1002/s1,
Figure S1: Hazard ratio for the association between anti-apoA-I IgGs levels and specific endpoints of the composite
MACE outcome assessed with Cox models accounting for the potential non linearity (with splines) of the
relationship and adjusted for categories of the GRACE score, Table S1: Spearman Correlation coefficients between
anti-apoA-I IgG and other continuous variables of interest
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Abstract: Aims: To explore the associations between cholesterol efflux capacity (CEC), coronary
artery calcium (CAC) score, Framingham risk score (FRS), and antibodies against apolipoproteinA-1
(anti-apoA-1 IgG) in healthy and obese subjects (OS). Methods and Results: ABCA1-, ABCG1-, passive
diffusion (PD)-CEC and anti-apoA-1 IgG were measured in sera from 34 controls and 35 OS who
underwent CAC score determination by chest computed tomography. Anti-apoA-1 IgG ability to
modulate CEC and macrophage cholesterol content (MCC) was tested in vitro. Controls and OS
displayed similar ABCG1-, ABCA1-, PD-CEC, CAC and FRS scores. Logistic regression analyses
indicated that FRS was the only significant predictor of CAC lesion. Overall, anti-apoA-1 IgG were
significantly correlated with ABCA1-CEC (r = 0.48, p < 0.0001), PD-CEC (r = −0.33, p = 0.004), and the
CAC score (r= 0.37, p= 0.03). ABCA1-CEC was correlated with CAC score (r= 0.47, p= 0.004) and FRS
(r = 0.18, p = 0.29), while PD-CEC was inversely associated with the same parameters (CAC: r = −0.46,
p = 0.006; FRS: score r = −0.40, p = 0.01). None of these associations was replicated in healthy controls
or after excluding anti-apoA-1 IgG seropositive subjects. In vitro, anti-apoA-1 IgG inhibited PD-CEC
(p < 0.0001), increased ABCA1-CEC (p < 0.0001), and increased MCC (p < 0.0001). Conclusions:
We report a paradoxical positive association between ABCA1-CEC and the CAC score, with the latter
being inversely associated with PD in OS. Corroborating our clinical observations, anti-apoA-1 IgG
enhanced ABCA1 while repressing PD-CEC, leading to MCC increase in vitro. These results indicate
that anti-apoA-1 IgG have the potential to interfere with CEC and macrophage lipid metabolism, and
may underpin paradoxical associations between ABCA1-CEC and cardiovascular risk.
J. Clin. Med. 2019, 8, 1225; doi:10.3390/jcm8081225 www.mdpi.com/journal/jcm15
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1. Introduction
Lately, impaired high-density lipoprotein (HDL) cholesterol efflux capacity (CEC) from
macrophages, involving mainly the adenosine triphosphate (ATP)-binding cassette (ABC) transporter
A1 (ABCA1) pathway, has gained considerable interest as a promising biomarker of atherosclerosis
and cardiovascular (CV)-related risk, both in primary and secondary prevention settings [1–3], and
served as proof of concept that HDL functional measures may provide improved CV risk stratification
over standard lipid profile and other traditional CV risk factors [1–3]. Nevertheless, inverse and
paradoxical positive associations between CEC and incident CV events have been reported in high-risk
populations [4], and patients with metabolic syndrome have been shown to have an increased CEC,
possibly due to increase pre-β-HDL levels [5,6]. To further fuel this controversy, no associations were
retrieved between CEC and coronary artery calcium (CAC) score, either in the general population or in
rheumatoid arthritis patients [3,7]. These contrasting observations relating CEC with CV risk and CAC
score might be influenced by disease state or oxidative stress and immune-mediated inflammation.
Among factors influencing immune-mediated inflammation and related to lipid metabolism,
we and others focused our investigations on antibodies against apolipoprotein A-1 (anti-apoA-1 IgG),
the major protein fraction of HDL regulating ABCA1 activity, as a biomarker of poor general and CV
outcomes, both in primary and secondary prevention settings [8–13]. In parallel, in vitro and animal
studies have shown that anti-apoA-1 IgG could promote inflammation, atherogenesis, myocardial
necrosis, and mice death through interaction with the Toll-like receptor (TLR) 2, 4 and the cluster
of differentiation 14 (CD14) complex [14–18]. Accordingly, we demonstrated in obese but otherwise
healthy subjects that anti-apoA-1 IgG were independent predictors of coronary artery lesion upon chest
computed tomography [19]. Several groups have shown that these autoantibodies could also promote
atherogenesis by affecting HDL anti-oxidant properties [20–24], and recently anti-apoA-1 IgG against
the c-terminal part of the protein was found to be inversely associated with fibroblasts CEC [25].
In this pilot study, we explored whether specific pathways of HDL CEC (ABCG1-mediated,
ABCA1-mediated, passive diffusion) could be differentially associated with the CAC score in healthy
obese and non-obese participants, and whether anti-apoA-1 IgG are associated with a specific HDL
CEC pathway modification on macrophages.
2. Experimental Section
2.1. Study Population and Design
The current investigation follows as sub-analysis of a previous published study [19], including
48 non-obese subjects (BMI < 30 kg/m2) and 43 obese subjects (BMI ≥ 30 kg/m2), without known
traditional CV risk factors (such as arterial hypertension, smoking, and diabetes mellitus, anamnestic
notion of variant angina, family history of premature coronary artery disease), clinically patent
cardiovascular/systemic disease, or CV treatment (statins, any cardiac or vasoactive medication). From
these 91 Subjects, 14 samples were missing from non-obese participants and 8 samples were missing
from obese subjects, leaving 69 subjects available for HDL CEC determination. As reported earlier,
“before inclusion in the cardiac perfusion assessment test, study participants underwent a complete
visit, including a physical examination, electrocardiogram, blood pressure measurements, and blood
puncture in a fasting state. Following inclusion, each study participant underwent multidetector
computed tomography (MDCT) and CAC assessment. The study was approved by the University
Hospitals of Geneva Institutional Review Board (protocol number 07-183), and each participant
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signed the approved informed consent form. This study has been conducted in compliance with the
Declaration of Helsinki [19].
2.2. Study Endpoints
Two predetermined endpoints were considered for this pilot study. The primary endpoint
was to test the ability of CEC to predict the presence of any coronary artery calcification on chest
computed tomography (CT) scan, as described below. The secondary endpoint was to explore the
possible association between anti-apoA-1 IgG and CEC. All CT scan data were assessed by two senior
cardiologists blinded to the participants’ biochemical data.
2.3. Assessment of Coronary Artery Calcification by Chest CTscan
In the first step of the perfusion assessment, a 64-slice multidetector computed tomography (MDCT)
(64-sliceBiograph HiRez TruePoint Positron Emission Tomography/Computed Tomography (PET-CT)
scanner, Siemens, Erlangen, Germany) was performed to determine the CAC score. The scanner was
operated in the single slice mode with an image acquisition time of 100 ms and a Section thickness
of 3 mm. Prospective electrocardiogram (ECG) triggering was done at 55% of the R-R interval.
Contiguous slices to the apex of the heart were obtained. CAC was considered present if three or
more contiguous pixels with a signal intensity of >130 Hounsfield Unit were identified. The size of
the lesion was automatically calculated, and the CAC was scored using the Agatston algorithm. The
CAC was computed across all lesions denoted within the left main, left anterior descending (LAD), left
coronary circumflex (LCx), and right coronary artery (RCA), and the sum of all lesion scores yielded
the total CAC score [26]. As recommended, we used the CAC scoring system in a binary fashion (CAC
present or absent) [26,27]. Accordingly, any Agatston score above 0 was considered as a present CAC
lesion [26,27].
2.4. Biochemical Analyses
A conventional lipid profile and high-sensitive C-Reactive Protein (hsCRP) profile were performed
on routine autoanalyzers. Low-density lipoprotein (LDL) cholesterol levels were derived from the
conventional Friedwald equation. Anti-apoA-1 IgG serum levels were measured as previously
described [8,9,11–13]. Briefly, Maxi-Sorb plates (Nunc) were coated with purified, human-derived
delipidated apoA-1 (20 μg/mL; 50 μL/well) for 1 h at 37 ◦C. After 3 washes with phosphate buffered
saline (PBS)/2% bovine serum albumin (BSA; 100μL/well), all wells were blocked for 1 h with 2% BSA at
37 ◦C. Samples were diluted 1 to 50 in PBS/2% BSA and incubated for 60 min. Additional patient samples
at the same dilution were also added to an uncoated well to assess individual nonspecific binding.
After 6 further washes, 50 μL/well of signal antibody (alkaline phosphatase-conjugated anti-human
IgG; Sigma-Aldrich, Saint Louis, MO, USA) diluted 1:1000 in PBS/2% BSA solution were incubated for
1 h at 37 ◦C. After 6 more washes (150 μL/well) with PBS/2% BSA solution, the phosphatase substrate
p-nitrophenyl phosphate disodium (50 μL/well; Sigma-Aldrich) dissolved in diethanolamine buffer
(pH 9.8) was added. Each sample was tested in duplicate, and absorbance, determined as the optical
density at 405 nm (OD405 nm), was measured after 20 min of incubation at 37 ◦C (FilterMax, Molecular
Devices, San Jose, CA, USA). The corresponding nonspecific binding value was subtracted from the
mean absorbance value for each sample. Anti-apoA-1 IgG seropositivity cutoff was predefined as
previously validated and set at an optical density (OD) value of 0.6 and 37% of the positive control
value, as described earlier [8,9,11–13]. OD values ranged from 0 to 1.3, and corresponding index values
were between 0 and 84.9%.
Pre-β-HDL levels were measured using a quantitative enzyme-linked immunosorbent assay
(ELISA) kit for pre-β-HDL detection in human plasma [28], following the manufacturer’s instruction
(Sekisui Diagnostic, Darmstadt, Germany). The coefficient of variation was 3.1% to 5.3% for individual
analytical runs, and 4.9% to 9.1% between different analytical runs.
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2.5. Serum HDL Cholesterol Efflux Capacity (CEC)
All serum samples were stored at−80 ◦C. The aliquots were slowly defrosted in ice. Four cholesterol
efflux pathways were evaluated in cell cultures: total CEC (in J774 mouse macrophages treated with
0.3 mm cAMP for 18 h to up-regulate ABCA1 expression) [1]; passive diffusion (PD)-CEC (in J774 mouse
macrophages, basal conditions) [29]; ABCA1-CEC (as a difference between total efflux and PD) [30];
ABCG1-CEC (in hABCG1-expressing Chinese hamster ovary cells, CHO-K1, as efflux difference
between hABCG1-expressing and parent CHO-K1 control cells) [31]. In all determinations, cells
were labeled with [1,2-3H]-cholesterol in the presence of acyl CoA: cholesterol acyl tranferase (ACAT)
inhibitor (2 μg/mL, Sandoz 58035) for 24 h. The efflux was promoted for 4 h (6 h for ABCG1-CEC) to
2% (v/v) serum samples. Serum HDL CEC was expressed as a percentage of the radioactivity released
to the medium in 4 h (6 h for ABCG1-CEC) over the total radioactivity incorporated by cells. Control
samples were run to confirm the responsiveness of cells. Background efflux, evaluated in the absence
of acceptors, was subtracted from each samples value. Serum samples were determined in triplicate,
while a standard pool of human serum from our laboratory (SN1) permitted correction for inter-assay
variability and a second serum standard pool (SN2) was used to determine inter-assay variability [29].
2.6. Antibody Anti-apoA-1 Modulation of Cellular Cholesterol Efflux
The efflux process was evaluated in J774 cells as previously described. Following the ABCA1
upregulation with cyclic adenosine monophosphate (cAMP) we incubated cells, during the efflux time
(4 h), with 25 μg/mL of anti-apoA-1 IgG. The efflux was promoted to either 10 μg/mL of apo-A-1 or 2%
(v/v) of human serum standard [32].
2.7. Measurement of Intracellular Cholesterol Content
J774 cells were cultured in 10% fetal calf serum (FCS) in RPMI cell medium at 37 ◦C in 5% CO2.
To perform the experiments, cells were seeded in 24-well plates at a density of 2 × 105 cells/well for 24 h.
Cells were exposed for 24 h to either 10% (v/v) whole serum and control IgG or anti-apoA-1 IgG 40μg/mL.
Cellular cholesterol content before and after serum exposure was measured as previously described [33].
Briefly, at the end of the experiment, cell monolayers were washed with Phosphat-Buffered Salin
(PBS) and lysed in 0.5 mL of a 1% sodium cholate solution in water supplemented with 10 U/mL
DNase. Cholesterol was than measured fluorimetrically using the Amplex Red Cholesterol Assay Kit
(Molecular Probes, Eugene, OR, USA) as described by the manufacturer. The amount of cholesterol in
each well was measured by comparison with a cholesterol standard curve included in each experiment.
An aliquot of the cell lysates was also taken to measure cell protein by a modified Lowry method [34].
Cell cholesterol content after exposure of cells to serum and immunoglobulin G (IgG) was expressed as
μg of cholesterol /mg protein.
2.8. Antibody Anti-apoA-1 Modulation of Membrane Free Cholesterol: Assay of Cholesterol Oxidase
Cholesterol oxidase treatment was essentially as previously described [35]. Briefly, cells were
labelled with 3 μCi/mL [3H] cholesterol. Cholesterol oxidase (1 U/mL) was added, and cells were
incubated for 4 h. Lipid was extracted with isopropanol, and radioactive cholesterol and cholestenone
were separated using thin-layer chromatography and quantified.
2.9. Anti-apoA-1 IgG Modulation of Cellular Cholesterol Esterification: ACAT Activity
Cells were treated as previously described for the measurement of intracellular cholesterol content.
Cholesterol esterification was evaluated as the incorporation of radioactivity into cellular cholesteryl
esters after addition of [14C]-oleate-albumin complex [36]. At the end of incubation, cells were washed
with PBS and lipids were extracted with hexane/isopropanol (3:2). The extracted lipids were separated
by thin layer chromatography (TLC) (isoctane/diethyl ether/acetic acid, 75:25:2, v/v/v). Cholesterol
radioactivity in the spots was determined by counting liquid scintillation.
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2.10. Measurement of Free Cholesterol Content in Cell Supernatant
Free cholesterol in supernatant was measured using the fluorometric method Amplex® Red
Cholesterol Assay Kit (Molecular Probe, Eugene, OR, USA) following the manufacturer’s instruction.
The experiments were conducted without an ACAT inhibitor.
2.11. Statistical Analyses
Analyses were performed using Statistica software (StatSoft, Tulsa, OK, USA). Normally,
distributed clinical data are presented as mean ± standard deviation (SD), whereas data following a
non-normal distribution are presented as median and interquartile range (IQR). Accordingly, means
were compared using bilateral student T test, and medians were compared with the Mann-Whitney-test.
Proportions were compared using two-tailed exact Fischer test. Correlations between variables were
assessed using Spearman test. Due to the limited sample size, adjusted analyses were limited to the
different forms of cholesterol efflux analyzed and the 10-year Framingham risk score (FRS) for coronary
heart disease risk prediction [37] (allowing the aggregation of all traditional CV risk factors within a
single continuous variable). Cholesterol efflux and intracellular cholesterol data were expressed as
mean ± SD. Treatment groups were compared using an unpaired two tailed Student’s t-test. Because of
the explorative nature of this work with predefined endpoints, Bonferroni correction was not applied.
Logistic regression analyses were used to assess associations between the presence of any CAC lesion
and CEC, or anti-apoA-1 IgG as variables. In this model, the presence of any CAC lesion was set as the
dependent variable. Associations are presented as odds ratios (OR) and corresponding 95% confidence
intervals (95% CI). A p value below 0.05 was considered as statistically significant.
3. Results
3.1. Study Characteristics
Baseline demographic characteristics are presented in Table 1. As shown in this table, obese
participants had lower levels of HDL, but higher triglycerides, hsCRP, and pre-βHDL levels when
compared to non-obese subjects. No significant differences were found between control and obese
subjects in terms of CEC mediated by ABCG1, ABCA1, or PD pathways and total (ABCA1 + PD) CEC,
and no difference was observed between these two groups for the CAC score, the number of coronary
artery lesions, or the presence of any lesion identified in chest CT scans. On the other hand, obese
participants tended to have higher anti-apoA-1 IgG levels and a significantly higher anti-apoA-1 IgG
positivity rate. Interestingly, anti-apoA-1 IgG positive participants (n = 6) were only observed in the
obese subjects. No other significant association with any of the other parameters tested was retrieved
(Table 1).






(n = 34) * p Value
Age, mean (+/−SD) 44 (11.4) 44.6 (12.0) 43.5 (11.0) 0.61
Male Gender; n (%) 42 (60.8) 23 (65.7) 19 (55.8) 0.46
Weight in Kg, mean (+/−SD) 97.5 (26.37) 116 (19.3) 74.4 (12.5) <0.001
Height in cm, mean (+/−SD) 74 (9.3) 173 (9.4) 172.2 (9.5) 0.56









FRS > 10%; n (%) 7 (10.1) 6 (17) 1 (2.9) 0.10
Chest CT:
Total CAC score, mean (+/−SD) 4.9 (15.8) 4.65 (14.8) 5 (17) 0.75
Number of CAC lesions, mean (+/−SD) 0.28 (0.75) 0.28 (0.71) 0.26 (0.79) 0.74
Presence of any CAC lesion; n (%) 10 (14.4) 6 (17.1) 4 (11.7) 0.73
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(n = 34) * p Value
Lipid profile:
Total cholesterol in mg/dL, mean (+/−SD) 198.9 (36.4) 198.5 (41.4) 202.1 (31.5) 0.69
LDL cholesterol in mg/dL mean (+/−SD) 127.9 (32.2) 126.9 (36.9) 133.9 (26.7) 0.42
HDL cholesterol in mg/dL, mean (+/−SD) 47.1 (13.0) 42.1 (11.5) 50.4 (13.9) 0.04
Triglycerides in mg/dl, mean (+/−SD) 97.5 (73.2) 122.8 (70.8) 83.0 (67.0) <0.001
Pre-β-HDL in μg/mL 42.6 (16.62) 49.2 (17.26) 35.6 (12.8) <0.001
Cholesterol Efflux Capacity:
ABCG1-mediated, mean (+/−SD) 4.04 (1.2) 4.04 (0.89) 3.85 (1.49) 0.96
ABCA1-mediated, mean (+/−SD) 3.98 (1.49) 4.18 (1.34) 3.67 (1.61) 0.18
Total, mean (+/-SD) 13.73 (1.55) 13.5 (1.57) 13.80 (1.57) 0.64























Note: * p values were obtained by comparing obese versus non-obese subjects. For normally distributed parameters,
p values were computed according to student t-test and for non-parametric parameters U-Mann Whitney test was
used. Proportions were compared using two-tailed exact Fischer test. Abbreviations: SD = standard deviation; IQR
= interquartile range; BMI = Body mass index; FRS = Framingham Risk Score; CT = Computed tomography; CAC =
Coronary artery calcium; LDL = Low-density lipoprotein; HDL = High-density lipoprotein; ABCG1 = ATP-binding
cassette subfamily G member 1; ABCA1 = ATP-binding cassette transporter 1; OD = Optical density; hsCRP =
High-sensitivity C-reactive Protein.
3.2. Associations between CEC Pathways, CAC Score, Framingham Risk Score, Pre-Beta-HDL,
and hsCRP Levels
ABCG1 CEC was not found to be associated with CAC score or FRS, nor with pre-β-HDL levels
in any of the study groups (Table 2). ABCA1 CEC was found to be positively associated with CAC
score and the number of CAC lesions in overall subjects (r = 0.26, p = 0.02), and the strength of this
association seemed to increase in obese subjects (r = 0.47, p = 0.004), whereas it was lost in non-obese
participants (Table 2). The only significant association retrieved between CEC and pre-β-HDL levels
was between pre-β-HDL and PD-CEC (r = 0.39, p = 0.02), which was only observed in obese subjects.
Furthermore, FRS correlated positively with ABCA1-CEC in overall and control subjects, but not in
obese participants, whereas we observed an inverse correlation between PD-CEC, CAC score, and FRS
in overall and obese participants, but not in non-obese subjects (Table 2). HsCRP levels did not correlate
with any forms of CEC in any subgroups (Table 2), nor with the FRS (r = 0.09; p = 0.43), with CAC score
(r = −0.04; p = 0.75), or with the number of CAC lesions (r = −0.03; p = 0.77). This absence of correlation
between hsCRP, FRS, the CAC score, and the CAC lesion was unchanged in obese and non-obese
individuals (data not shown). Because of the significant correlation shown between CAC score and
anti-apoA-1 IgG [19], as well as between CAC score/lesions and ABCA1- and PD-CEC, we performed
a sensitivity analysis after excluding anti-apoA-1 IgG positive patients (n = 6) in the obese subgroup in
order to see if excluding high anti-apoA-1 IgG values could change the associations between different
forms of CEC with FRS, number of CAC lesions, and CAC score, as well as with pre-β-HDL. Due to
the non-significant aforementioned associations with hsCRP levels and any forms of CEC, hsCRP
was not considered in our sensitivity analyses. As shown in Table 2, after excluding anti-apoA-1
IgG seropositive subjects, the correlations between CAC score/lesion and ABCA1-CEC and PD-CEC
remained significant and of the same order of magnitude, whereas the significant association between
FRS and ABCA1 was lost. The correlation between FRS and PD-CEC was unchanged. This does
not point to anti-apoA-1 IgG as a key determinant of the associations retrieved between CAC score,
ABCA1-CEC, and PD-CEC. Finally, if logistic regression analyses indicated that ABCA1-CEC, PD-CEC,
and FRS were all significant predictors of CAC lesion in univariate analysis, the FRS was found to be
the only independent predictor of CAC lesion in the overall cohort (Table 3). Given the limited study
sample size, these analyses were not performed in the obese and non-obese subgroups separately.
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p Value R Value
(Spearman)




CAC score 0.02 0.84 −0.03 0.82 0.10 0.57
Nr of CAC lesions 0.02 0.86 −0.04 0.81 0.09 0.61
Framingham RS −0.01 0.90 0.06 0.70 −0.09 0.59
Pre-β-HDL −0.22 0.09 −0.19 0.27 −0.23 0.18
hsCRP 0.007 0.94 0.04 0.77 0.22 0.20
ABCA1-mediated CEC vs.:
CAC score 0.26 0.02 0.47 0.004 0.05 0.76
Nr of CAC lesions 0.26 0.02 0.47 0.004 0.04 0.80
Framingham RS 0.30 0.01 0.18 0.29 0.40 0.01
Pre-β-HDL −0.08 0.48 −0.15 0.38 −0.25 0.15
hsCRP 0.05 0.44 0.04 0.79 −0.12 0.47
Passive Diffusion vs.:
CAC score −0.30 0.01 −0.46 0.006 −0.10 0.53
Nr of CAC lesions −0.29 0.01 −0.45 0.006 −0.09 0.60
Framingham RS −0.33 0.006 −0.40 0.01 −0.22 0.21
Pre-β-HDL 0.15 0.20 0.39 0.02 0.06 0.72
hsCRP −0.01 0.90 0.06 0.63 0.17 0.35
Correlations after excluding anti-apoA-1 IgG seropositive individuals in obese participants (n = 29)
Correlations R Value (Spearman) p Value
ABCG1-mediated CEC vs.:
CAC score 0.01 0.72
Nr of CAC lesions 0.01 0.97
Framingham RS 0.06 0.72
Pre-β HDL −0.13 0.49
ABCA1-mediated CEC vs.:
CAC score 0.39 0.03
Nr of CAC lesions 0.39 0.03
Framingham RS 0.24 0.20
Pre-β HDL −0.14 0.48
Passive diffusion vs.:
CAC score −0.39 0.04
Nr of CAC lesions −0.39 0.04
Framingham RS −0.45 0.009
Pre-β-HDL 0.41 0.03
Table 3. Logistic regression analyses for CAC lesion prediction
Univariate Analyses Multivariate Analyses
Continuous Predictors Odds Ratio 95% CI p Odds Ratio 95% CI p
ABCG1 CEC 1.10 0.64–1.91 0.72 1.02 * 0.51–2.05 0.94
ABCA1 CEC 1.17 1.17–3.13 0.009 1.38 ** 0.67–2.86 0.38
Passive diffusion 0.56 0.32–0.97 0.03 0.78 *** 0.37–1.54 0.44
Framingham RS 1.31 1.13 0.004 1.27 **** 1.09–1.49 0.002
Note: * Adjusted for ABCA1 CEC, Passive diffusion and FRS; ** adjusted for ABCG1-CEC, passive diffusion, and FRS;
*** adjusted for ABCG1-CEC and ABCA1-CEC, and FRS; **** adjusted for ABCA1, ABCG1, and passive diffusion.
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3.3. Associations between Anti-apoA-1 IgGs, Specific CEC Pathways, Pre-β-HDL, and hsCRP Levels
Spearman correlations showed a positive association between ABCA1-CEC and anti-apoA-1
IgG (r = 0.48, p < 0.001) and a negative association between PD-CEC and these antibodies (r = −0.33;
p = 0.004; Table 4) on our overall participants samples. The anti-apoA-1 IgG association with
ABCA1-CEC remained significant for the obese and non-obese subgroups. Nevertheless, if the
association with PD-CEC was unchanged in non-obese subjects, it was lost in obese participants
(Table 4). No associations were retrieved between pre-β-HDL serum levels and anti-apoA-1 IgG,
nor between these antibodies and hsCRP (data not shown).








Correlations R value p value R value p value R value p value
Anti-apoA-1 IgG (OD) vs.:
CAC score 0.21 0.09 0.37 0.03 0.01 0.91
Nr of CAC lesions 0.21 0.09 0.37 0.03 0.02 0.88
Framingham Risk Score −0.03 0.81 −0.03 0.82 −0.11 0.51
ABCG1-mediated CEC −0.16 0.17 −0.23 0.18 −0.10 0.54
ABCA1-mediated CEC 0.48 0.00002 0.49 0.002 0.44 0.007
Passive diffusion −0.33 0.004 −0.29 0.09 −0.36 0.03
Pre-β-HDL 0.17 0.89 −0.04 0.81 −0.06 0.9
3.4. Anti-apoA-1 IgG-Mediated Modulation of Cellular Cholesterol Efflux
To further evaluate the possible impact of anti-apoA-1 IgG on CEC, we measured ABCA1-CEC
and PD-CEC using standard serum or apoA-1 in J774 macrophages without cAMP stimulation in
presence of anti-apoA-1 antibodies during the efflux time. As shown in Figure 1, cells incubated with
the antibody showed an increased ABCA1-mediated efflux to the acceptors (4.28 ± 0.29 vs. 6.45 ± 0.45
p < 0.0001 to apoA1 as acceptor; 1.16 ± 0.15 vs. 1.81 ± 0.19 p < 0.0001 to human serum as acceptor).
Conversely, the presence of the anti-apoA-1 IgG reduced the passive cellular efflux diffusion to both
apoA-1 and human serum (0.77 ± 0.10 vs. 0.48 ± 0.11 p < 0.0001; 6.49 ± 0.05 vs. 4.67 ± 0.66 p < 0.0001).
3.5. Modulation of Anti-apoA-1 IgGs on Intracellular and Membrane Cholesterol Content
To understand the net effect of such dual modification of anti-apoA-1 IgGs on cellular cholesterol
balance, we measured the impact of anti-apoA-1 IgGs on intracellular cholesterol content according to
a previously validated method. As shown in Figure 2, anti-apoA-1 IgGs induced a significant increase
in intracellular cholesterol content compared to control IgGs and baseline conditions.
To better investigate the possible anti-apoA-1 IgG-mediated passive diffusion inhibition, we look
at the free cholesterol content in the membrane of J774 cells after four hour anti-apoA-1 IgG stimulation.
As shown in Figure 3, anti-apoA-1 IgGs significantly reduced the free cholesterol membrane content
when compared to the control IgGs or to the untreated condition. In the same experimental conditions,
we observed a significant reduction of the free cholesterol content in the supernatant counterpart in the
presence of anti-apoA-1 IgGs (Figure 4). Since ACAT is the key enzyme for the cholesterol esterification
and its cellular redistribution, we measured the ACAT activity in the presence of anti-apoA-1 IgGs or
control antibodies. As shown in Figure 5, anti-apoA-1 IgGs (and not the control IgGs) significantly
increased ACAT activity.
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Figure 1. Cholesterol efflux from J774 to various acceptors in presence of anti-apoA-1 (AAA1) IgG. (a,b)
The cells were activated with cAMP to measure the specific efflux from ABCA1 to serum or apoA-1
as acceptors after 4 h incubation. Data are expressed as the mean ± SD of the measurements done in
triplicate and repeated four times (n = 4). Statistical differences were determined by one-way analysis
of variance (one-way ANOVA), with p ≤ 0.05 being considered significant. (c,d) The cells were not
activated in order to quantify the passive cellular efflux diffusion to both apoA-1 or human serum. The
percentage of cholesterol efflux is shown. Data are expressed as the mean ± SD of the measurements
done in triplicate and repeated four times (n = 4). Statistical differences were determined by one-way
analysis of variance (one-way ANOVA), with p ≤ 0.05 being considered significant.
 
Figure 2. Anti-apoA-1 IgG increase the intracellular cholesterol content. Cell cholesterol content after
exposure of cells to serum, anti-apoA-1 IgG, or control IgG, and was expressed as μg of cholesterol /mg
total protein. Data are expressed as the mean ± SD of the measurements done in triplicate and repeated
three times (n = 3). Statistical differences were determined by one-way analysis of variance (one-way
ANOVA), with p ≤ 0.05 being considered significant.
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Figure 3. Free cholesterol in membrane. Monolayers were labeled with 3 μCi/mL [3H] cholesterol
for 24 h in RPMI medium with 10% FCS, control IgGs or anti-apoA-1 IgGs 40 μg/mL. Cells were then
washed and incubated with 1 U/mL cholesterol oxidase enzyme in Dulbecco’s Phosphate Buffered
Saline (DPBS) for 4 h at 37 ◦C. Data are expressed as the mean ± SD of the measurements done in
triplicate and repeated three times (n = 3). Statistical differences were determined by one-way analysis
of variance (one-way ANOVA), with p ≤ 0.05 being considered significant.
 
Figure 4. Free cholesterol in the cell supernatant. Free cholesterol content in J774 supernatant after
exposure of cells to serum, anti-apoA-1 IgGs or control IgGs was expressed as μg of free cholesterol
per well. Data are expressed as the mean ± SD of the measurements done in triplicate and repeated
three times (n = 3). Statistical differences were determined by one-way analysis of variance (one-way
ANOVA), with p ≤ 0.05 being considered significant.
Taken together, these results indicate that the presence of anti-apoA-1 IgG on J774 macrophages
enhances ACAT activity leading to increased intracellular esterified cholesterol pools, and decreases
membrane free-cholesterol content. Such decrease in membrane free-cholesterol content reduce the
cholesterol gradient, leading to a decrease in passive diffusion PD followed by the reduction of
free-cholesterol content in cell supernatants. In this context, the increase in ABCA1-efflux in the
presence of anti-apoA-1 IgG can be interpreted as the consequence of increased intracellular lipid pools.
24
J. Clin. Med. 2019, 8, 1225
 
Figure 5. ACAT activity. Cells were incubated for 24 h in RPMI medium with 10% FCS, control IgG
or anti-apoA-1 IgG 40 μg/mL. Monolayers underwent a second incubation (4 h) in the presence of
[1-14C]-oleic acid albumin complex. Data are expressed as the mean ± SD of the measurements done in
triplicate and repeated three times (n = 3). Statistical differences were determined by one-way analysis
of variance (one-way ANOVA), with p ≤ 0.05 being considered significant.
4. Discussion
In this study, we extend previous findings by demonstrating that on top of being significantly
associated with higher CAC [19], anti-apoA-1 IgG levels are inversely associated with PD-CEC and
positively with ABCA1-CEC in healthy obese subjects, despite the absence of ABCA1-CEC, ABCG1-CEC,
and PD-CEC differences between obese and control participants. This apparently counterintuitive
clinical observation derived from this small case-control study prompted us to evaluate the possible
direct impact of anti-apoA-1 IgG on normal serum and apoA-1 CEC on macrophages, and on
macrophage cholesterol content.
Corroborating our clinical observations, these in vitro investigations indicated that, per se, these
autoantibodies could at the same time inhibit PD-CEC and potentiate ABCA1-CEC. PD efflux consists of
the simple diffusion of free/unesterified cholesterol molecules across the membrane through the aqueous
phase following their concentration gradient between the membrane and HDL/apoA-1, and accounts
for the majority of total macrophage efflux (up to 80%) in normocholesterolemic conditions [38,39].
On the other hand, ABCA1-mediated efflux is an active pathway facilitating the transfer of unesterified
cholesterol specifically to lipid-poor apoA-1, and represents up to 60% of total macrophage cholesterol
efflux when activated by increased intracellular cholesterol load [38–40]. For this reason, determining
the net effect of simultaneously blocking and activating these two important HDL CEC pathways at
the cellular level was the key to providing a sound interpretation of our clinical and functional in vitro
observations. As anti-apoA-1 IgG leads to increased intracellular cholesterol content in macrophages
after 24 h of stimulation, we currently postulate that the anti-apoA-1 IgG overdriving mechanism
consists of ACAT stimulation, leading to intracellular esterified cholesterol accumulation, decreasing
the amount of membrane free-cholesterol available, and thus diminishing the cholesterol gradient
requested for PD-CEC. In this context, the increase in ABCA1 efflux can be ascribed to a feedback loop
aiming at preventing cellular cholesterol accumulation. Nevertheless, other possibilities cannot be
formally excluded, and the exact mechanisms by which anti-apoA-1 IgG stimulates ACAT activity
are still elusive. Several non-exclusive hypotheses are discussed below. Firstly, one can postulate an
upstream mechanism, where anti-apoA-1 IgG could, per se, stimulate ACAT activity. With ACAT being
an endoplasmic reticulum intracellular protein, an indirect effect may be evoked. Indeed, as ACAT
deficiency has been shown to increase TLR4 expression and function in hepatocytes stellate cells [41],
we cannot exclude the fact that anti-apoA-1 IgG-mediated TLR2/TLR4 stimulation may interfere
with ACAT activity, although this hypothesis is currently devoid from of experimental evidence.
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Alternatively, as ACAT activation is known to occur in response to cholesterol overload [42], any factor
increasing either the intracellular cholesterol synthesis or uptake could be susceptible to increase
ACAT activity. Therefore, knowing whether anti-apoA-1 IgG could affect HGMCoA reductase or
LDL-receptor expression and function is currently under investigation.
Alternatively, we can consider the anti-apoA-1 IgG-mediated ACAT stimulation as a downstream
consequence of mechanisms related to PD-CEC inhibition. Given the complexity of PD-CEC, where
desorption of free cholesterol molecules from the cell plasma membrane into the surrounding aqueous
phase is the rate-limiting step [38–40], there are several possibilities, including those in direct relation
with apoA-1 [40]. Firstly, by stabilizing lecithin-cholesterol acyltransferase (LCAT) activity, apoA-1
maintains a favourable cholesterol gradient. One could hypothesize that anti-apoA-1 IgG may
decrease LCAT stability, attenuating the cholesterol gradient and followed by PD-CEC attenuation.
Secondly, as apoA-1 can also facilitate the maintenance of such gradient, either by acting as an
acceptor for cholesterol molecules diffusing away from the cell surface, or by mediating the process
of membrane microsolubilization, we can also envisage an antibody-mediated interference of one of
these acceptor-related processes [38]. Indeed, as c-terminal (c-ter) part of apoA-1 is known to mediate
membrane microsolubilization important for PD-CEC to occur [43], and because anti-apoA-1 IgG in
humans is biased against the c-ter part of apoA-1 [44], we cannot rule-out a direct and antagonistic
effect of anti-apoA-1 IgG on PD-CEC. Finally, as mentioned above, the increased ABCA1-CEC in
the presence of anti-apoA-1 IgG is likely to represent a homeostatic feedback loop. Nevertheless,
as ABCA1 activity is regulated by apoA-1′s interaction with an epitope on the c-terminal part of
apoA-1 [45], we cannot formally rule out a direct agonistic effect of these antibodies on ABCA1, or an
indirect effect mediated through the antibody-induced macrophage interleukin-6 (IL-6) production
known to increase ABCA1 efflux [46]. Despite these current mechanistic knowledge gaps requiring
further detailed investigations, these results indicate that anti-apoA-1 IgG-induced ACAT stimulation
followed by PD-CEC inhibition represent another mechanism by which these auto-antibodies can
promote atherogenesis.
The second notable finding of the present study is the observation that in obese participants,
macrophage ABCA1-CEC is positively associated with coronary atherosclerosis burden quantified by
the CAC score, whereas no such association was retrieved in healthy controls. Although somehow
contrasting with data published in primary and secondary prevention settings [1–3], these results are in
line with previous observations in metabolic syndrome and rheumatoid arthritis [4–6], and lend weight
to the notion that depending on disease-related systemic factors, the associations between macrophage
ABCA1-CEC and coronary atherosclerosis burden are not necessarily straightforward. As metabolic
syndrome patients share many pathophysiological similarities with obese patients, the existence of
such a paradoxical association was suspected, but still remained to be demonstrated. Furthermore,
providing PD-CEC results in parallel with ABCA1-CEC was found to be instrumental in facilitating
the interpretation of these results. Indeed, the inverse association between CAC score and macrophage
PD-CEC suggest that the lower the PD efflux, the higher the level of intracellular cholesterol, and
thus atherosclerosis burden. In this context, the anti-apoA-1 IgG-dependent ABCA1-CEC increase, in
fact, may not sufficiently compensate for the PD inhibition ascribed to anti-apoA-1 IgG. Furthermore,
as our in vitro data demonstrated a substantial influence of anti-apoA-1 IgG on PD-CEC through
ACAT stimulation, we performed a sensitivity analysis excluding anti-apoA-1 IgG seropositive subjects
in the obese subgroup, which yielded similar results overall. Taken together, these results indicate
that considering ABCA1-CEC without considering other concomitant functional effluxes may lead to
erroneous conclusions. These results also suggest that the presence of anti-apoA-1 IgG may represent
a new systemic factor susceptible to altering the usual association between ABCA1-CEC and CV risk.
This study has several limitations. The first one relates to the low number of subjects enrolled in
this study, raising possible power issues when it comes to the plausibility of non-significant findings.
Nevertheless, despite this power limitation, the significant findings derived from this cohort enabled
us to generate hypotheses that were tested and validated in vitro, providing valuable insights to
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correctly interpret counterintuitive associations. A second limitation of this study is that we were not
able to decipher the exact molecular mechanisms by which anti-apoA-1 IgG could stimulate ACAT
activity and inhibit PD-CEC, and we did not explore their possible ability to modulate key cholesterol
homeostasis regulating genes, which is currently under investigation (Pagano S. et al., under review).
A further limitation is the fact that due to limited human sample availability, we could not evaluate
the effects of human purified apoA-1 IgG in this study. Nevertheless, as we previously demonstrated
that the commercial anti-human apoA-1 IgGs used in this study were promoting the same effects as
human-purified IgG fraction containing high levels of these autoantibodies in vitro [13,18], and because
these autoantibodies have been consistently used in different validated and published animal and
in vitro studies [11–19], we expect similar impacts on in vitro lipid metabolism to occur by using human
purified anti-apoA-1 IgG, even if not formally demonstrated. Finally, being focused on atherogenesis
and foam cell formation, we did not evaluate whether the anti-apoA-1 IgG effects on lipid metabolism
could be reproduced by other cell types, such as hepatocytes, and did not measure the scavenger
B-I-related CEC.
5. Conclusions
In conclusions, the results of this study indicate that in healthy obese subjects there is a paradoxical
positive association between CAC score and ABCA1-CEC, and a negative association between PD-CEC
and CAC score. These associations could be partly explained by the propensity of anti-apoA-1 IgG to
inhibit PD-mediated cholesterol efflux through ACAT stimulation and promote foam cell formation,
notwithstanding an enhancing effect on ABCA1-mediated cholesterol efflux. Although preliminary,
these results highlight the importance of simultaneously considering the different CEC pathways and
using a translational approach for proper ABCA1-CEC interpretation.
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Abstract: Aims: Anti-Apolipoprotein A-1 autoantibodies (anti-ApoA-1 IgG) promote atherogenesis
via innate immune receptors, and may impair cellular cholesterol homeostasis (CH). We explored the
presence of anti-ApoA-1 IgG in children (5–15 years old) with or without familial hypercholesterolemia
(FH), analyzing their association with lipid profiles, and studied their in vitro effects on foam cell
formation, gene regulation, and their functional impact on cholesterol passive diffusion (PD). Methods:
Anti-ApoA-1 IgG and lipid profiles were measured on 29 FH and 25 healthy children. The impact
of anti-ApoA-1 IgG on key CH regulators (SREBP2, HMGCR, LDL-R, ABCA1, and miR-33a) and
foam cell formation detected by Oil Red O staining were assessed using human monocyte-derived
macrophages. PD experiments were performed using a validated THP-1 macrophage model. Results:
Prevalence of high anti-ApoA-1 IgG levels (seropositivity) was about 38% in both study groups.
FH children seropositive for anti-ApoA-1 IgG had significant lower total cholesterol LDL and
miR-33a levels than those who were seronegative. On macrophages, anti-ApoA-1 IgG induced
foam cell formation in a toll-like receptor (TLR) 2/4-dependent manner, accompanied by NF-kB- and
AP1-dependent increases of SREBP-2, LDL-R, and HMGCR. Despite increased ABCA1 and decreased
mature miR-33a expression, the increased ACAT activity decreased membrane free cholesterol,
functionally culminating to PD inhibition. Conclusions: Anti-ApoA-1 IgG seropositivity is frequent
in children, unrelated to FH, and paradoxically associated with a favorable lipid profile. In vitro,
anti-ApoA-1 IgG induced foam cell formation through a complex interplay between innate immune
receptors and key cholesterol homeostasis regulators, functionally impairing the PD cholesterol efflux
capacity of macrophages.
Keywords: anti-apolipoprotein A-1 IgG; familial hypercholesterolemia; cholesterol homeostasis;
foam cells; miR-33a; TLR2/4; passive diffusion
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1. Introduction
Humoral autoimmunity has recently been shown to represent a dual mediator of atherogenesis
and cardiovascular diseases (CVD) by modulating three main pathways, including inflammation,
coagulation, and foam cell formation [1,2]. Among autoantibodies of interest in CVD, the interest in
antibodies against apolipoprotein A-1 (anti-ApoA-1 IgG) appears to be gaining momentum. Indeed,
three recent studies derived from a large multicenter general population cohort demonstrated that
anti-ApoA-1 IgGs were an independent cardiovascular (CV) risk factor predictive of poor prognosis [3–5]
similarly to what had been reported previously and more recently in high CV risk populations [6–11].
In parallel, translational studies pointed to these autoantibodies as mediators of atherogenesis,
promoting atherosclerosis, myocardial necrosis, and mice death through toll-like receptors (TLR)
2,4 and CD14 signaling [12–14]. Interestingly, inverse associations were regularly noted between
anti-ApoA-1 IgG, total cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL)
levels [3,13,15,16], potentially suggesting that these antibodies could also interfere with cholesterol
metabolism in addition to their established pro-inflammatory and pro-thrombotic properties [13,14,17].
Such a hypothesis has been further supported by two recent observations. The first showed that
antibodies directed against the c-terminal part of ApoA-1 in type 2 diabetes were associated with
decreased cholesterol efflux capacity (CEC) of fibroblasts [18]. The second reported that anti-ApoA-1
IgG levels were inversely associated with PD- and positively associated with ABCA1-CEC in healthy
obese subjects, with the capacity, to enhance ABCA1-CEC in vitro while repressing PD-CEC, leading
to foam cell formation [19], the hallmark of atherosclerosis [20]. Nevertheless, the exact molecular
mechanisms underlying these drastic cellular phenotype modifications induced by anti-apoA-1 IgG
are still elusive, and likely to imply major changes in the gene and protein expression levels of key
regulators of cellular cholesterol homeostasis; whether such effect could be reproduced in human
macrophages is currently unknown [20–23].
Among these, 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) and low-density lipoprotein
receptor (LDL-R) are known as key cholesterol homeostasis regulatory elements leading to the
developments of statins, the most efficient and commonly used pharmacological molecules available
to prevent atherosclerosis-related complications [21]. HMGCR and LDLR are controlled by the sterol
regulatory element binding protein 2 (SREBP2) encoded by SREBF2 gene, which contains microRNAs
33a (miR-33a) in its intronic sequence and reduces cholesterol efflux via repression of the adenosine
triphosphate (ATP)-binding cassette transporter A1 (ABCA1), impairing HDL biogenesis [22,23].
Upon SREBF2 gene activation, both LDLR and HMGCR are upregulated by SREBP2, enhancing LDL
uptake and increasing intracellular cholesterol synthesis. In response to SREBF2 gene transcription,
miR-33a expression will increase, inhibiting ABCA-1 cholesterol efflux [22,23]. Therefore, miR-33a
and SREBP2 act synergistically to efficiently increase cellular cholesterol levels by inhibiting cellular
cholesterol efflux and increasing lipid uptake and intracellular synthesis, respectively. While previous
studies suggested that miR-33 may represent therapeutic target for the treatment of cardiovascular
disease [24,25], a recent work showed that miR-33 deletion in mice results in dyslipidemia, obesity,
and insulin resistance [26], assigning a role for miR-33 that is much more complex than what has been
considered so far. Such complexity has also been illustrated in humans by the fact that miR-33 levels
are surprisingly elevated in pediatric patients affected by familial hypercholesterolemia (FH) [27].
Since foam cells can be generated by the uncontrolled uptake of unmodified LDL via LDL-R [28,29],
any factor influencing LDLR, HMGCR, or miR-33a expression will efficiently modulate lipid uptake,
cellular cholesterol synthesis, and cholesterol efflux, and therefore affect atherogenesis.
Taken together, these observations suggest that anti-ApoA-1 IgG may reorient the lipids from the
plasmatic compartment toward the intracellular lipid pools, potentially explaining the paradoxical
associations frequently retrieved between anti-apoA-1 IgG and lipid profile despite an increased
32
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CV risk. If so, such a hypothesis would imply modulation of key regulators of cellular cholesterol
homeostasis and foam cell formation, including miR-33.
Therefore, in this translational study, we explored the associations between anti-ApoA-1 IgG,
lipid profile, and miR-33a levels in FH children as an extreme and optimal human dyslipidemia
phenotype to perform such explorations and compared whether such associations could be retrieved
in age- and gender-matched controls. Fueled by these clinical observations, we then dissected the
in vitro mechanisms by which anti-ApoA-1 IgG could lead to foam cell formation. Our results showed
that associations between anti-ApoA-1 IgG, lipid profile, and miR-33 levels were only retrieved in FH
children. Furthermore, our in vitro studies using human macrophages provided the first molecular
insights on how these antibodies could act as novel endogenous cholesterol homeostasis disruptors.
2. Experimental Section
2.1. Patients
In this study, we considered 29 children (14 males and 15 females) aged 5–15 affected by FH and
referred to the Center of Clinical Lipid Research, Department of Pediatrics, Sapienza University of
Rome [27]. Children were classified as FH on the basis of the presence of a first-degree relative with
hypercholesterolemia (total cholesterol (TC) >95th age and sex-specific percentile) according to the
MEDPED criteria [30]. In the same center, a control group of 25 healthy children (11 males, 14 female)
was recruited with a BMI (body mass index) appropriate for their age and gender, as matched for age
with the FH group.
Exclusion criteria consisted of acute or chronic disease or infection (connective tissue disease,
hypothyroidism, renal disease, malignancy, clinical evidence of CVD, diabetes mellitus, hypertension
or metabolic syndrome), autoimmune disease, or the use of medication potentially affecting
growth and development, associated with a history of alcohol consumption and smoking (when
appropriate), immunosuppressive drugs, non-steroidal, anti-inflammatory, lipid-lowering drugs,
and/or vitamin supplements.
At first visit, anthropometric data were measured (body weight and waist, hip, and arm
circumferences). Weight was measured using an electronic scale (Soehnle, Murrhardt, Germany) and
standing height was measured with the Harpenden Stadiometer (Holtain, Crymych, UK). Systolic and
diastolic blood pressure was measured using a random zero sphygmomanometer (Hawksley & Sons
Ltd., Lancing, UK); the mean of three measurements was used in the analysis. BMI was calculated as
weight/height2 (kg/m2).
Informed written consent was obtained from all the participants. The study was in conformity
with the ethical guidelines of the Declaration of Helsinki, and was reviewed and cleared by the Ethical
Committee of Sapienza University of Rome.
2.2. Plasma Samples and Blood Analyses
Venous blood samples (10 mL) were collected in EDTA-containing tubes from 12 h fasted subjects.
Blood was then centrifuged (1200g for 10 min at 4 ◦C). Supernatant was then collected and centrifuged
(2000g for 10 min at 4 ◦C). Plasma samples were stored at −80 ◦C and were thawed on ice before use.
Plasma concentrations of lipoprotein and apolipoproteins were determined as previously described [27].
LDL cholesterol was calculated using Friedewald’s equation.
2.3. Assessment of Anti-ApoA-1 IgG Levels
Anti-ApoA-1 IgG were measured as previously described [7,9,13,14,17]. Briefly, MaxiSorp
plates (NuncTM, city, Roskilde, Denmark) were coated with purified, human-derived delipidated
apolipoprotein A-1 (20 μg/mL; 50 μL/well) for 1 h at 37 ◦C. After being washed, all wells were
blocked for 1 h with 2% bovine serum albumin (BSA) in a phosphate-buffered solution (PBS) at 37 ◦C.
FH samples were also added to a non-coated well in order to assess individual non-specific binding.
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After six washing cycles, 50 μL/well of the alkaline phosphatase-conjugated anti-human IgG was
added (Sigma-Aldrich, St Louis, MO, USA), it was diluted at 1:1000 in a PBS/BSA 2% solution, and this
was added and incubated for 1 h at 37 ◦C. After washing six more times, phosphatase substrate
p-nitrophanylphosphate disodium (Sigma-Aldrich) dissolved in a diethanolamine buffer (pH 9.8) was
added and incubated for 30 min at 37 ◦C. Optical density (OD) was determined at 405 nm (Filtermax 3,
Molecular DevicesTM, San Jose, CA, USA). and each sample was tested in duplicate. Corresponding
non-specific binding was subtracted from mean OD for each sample. The specificity of detection was
assessed using conventional saturation tests by Western blot analysis.
As previously described, elevated levels of anti-ApoA-1 IgG (seropositivity) were defined by an
OD cutoff of OD > 0.64 corresponding to the 97.5th percentile of a reference population. In order to
limit the impact of interassay variation, we further calculated an index consisting of the ratio between
sample net absorbance and the positive control net absorbance × 100. The index value corresponding
to the 97.5th percentile of the normal distribution was 37. Accordingly, to be considered as positive
(presenting elevated anti-apoA-1 IgG levels), samples had to display both an absorbance value of
OD > 0.64 and an index value ≥37%. [7,9,13,14,17].
2.4. Reagents
RPMI-1640 medium, fetal bovine serum (FBS), PBS free of Ca2+ and Mg2+, L-glutamine,
penicillin, and streptomycin were obtained from Gibco BRL-Life Technologies (Rockville, MD, USA).
Interferon-gamma (IFN-γ) was from Roche (Mannheim, Germany).
Affinity purified goat polyclonal anti-human ApoA-1 IgG (ref. 11AG2) was obtained from
Academy Bio-Medical Company (Houston, TX, USA) and goat control IgG were from Meridian Life
Science (ref. A66200H) (Saco, ME, USA). Ultrapure lipopolysaccharide (LPS) from Escherichia coli was
purchased from Alexis Enzo Life Sciences (Lausen, Switzerland). Blocking anti-human TLR4 (clone
HTA 125) antibody, anti-human TLR2 antibody (clone TL2.1), and matched isotype control antibodies
were from Biolegend (San Diego, CA, USA). Blocking anti-human TLR2 (clone TL2.5) and blocking
anti-human CD14 antibodies were from InvivoGen (San Diego, CA, USA). SP600125 (c-Jun N-terminal
kinase (JNK) inhibitor and BAY11-7082 (IkB-α inhibitor) were from InvivoGen. San Diego, CA, USA)
2.5. Human Monocyte-Derived Macrophage Preparation
Human monocytes were isolated from buffy coats obtained from healthy donors in the Geneva
Hospital Blood Transfusion Center (Geneva, Switzerland) and differentiated into macrophages
by 24 hours incubation with IFN-γ (500 U/mL) in a complete RPMI-1640 culture medium (10%
heat-inactivated FCS, 50 μg/mL streptomycin, 50 U/mL penicillin, 2 mM L-glutamine) as previously
described [14,17]. Macrophage preparation consisted of >90% CD68+ cells as assessed by flow
cytometry.
When indicated, anti-TLR4, anti-TLR2 (TL2.5/2.1), and anti-CD14 blocking antibodies, as well as
isotype-matched control mAb (10 μg/mL) and specific pharmacological inhibitors, were added 30 min
before stimulation with IgG [14,17].
2.6. Protein Purification and Western Blot Analysis
Macrophages (2 × 106) were lysed at 4 ◦C for 20 min with radioimmunoprecipitation assay
(RIPA) lysis buffer with added protease inhibitors (Complete tablets, mini, Roche diagnostics,
Mannheim, Germany) and phosphatase inhibitors (Halt Protease and Phosphatase Inhibitor Cocktail,
Thermo Scientific, Waltham, MA, USA) and then samples were centrifuged at 14,000 rpm at 4 ◦C
for 15 min. Protein concentration was determined by Bradford protein assay (Biorad, Hercules, CA,
USA). To increase protein concentration, samples were loaded onto Amicon Ultra-0.5 centrifugal
filter devices 3K (Merck Millipore, Darmstadt, Germany) following the manufacturer’s instructions.
Forty micrograms of total protein extract were resolved by 8% or 10% polyacrylamide gel electrophoresis
under reducing conditions, and transferred to a polyvinylidene difluoride (PVDF) membrane
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(Immobilon, Millipore IPVH 00010). Membranes were incubated with the following antibodies:
anti-SREBP2 (rabbit polyclonal, ref. 10007663, Cayman chemical, Ann Arbor, MI, Stati Uniti), anti-LDL
Receptor (rabbit monoclonal, ref. ab52818, Abcam, Cambridge, UK), anti-HMGCR (rabbit monoclonal,
ref. ab174830, Abcam), anti-SCAP (Rabbit polyclonal, ref. ab125186 Abcam), anti-ABCA1 (rabbit
polyclonal, ref. NB400-105, Novus Biologicals, Centennial, CO, USA), anti-β-actin (mouse monoclonal,
ref. ab8226, Abcam). Horseradish peroxidase-conjugated antisera from Dako (Glostrup, Denmark),
were used to reveal primary antibody binding, with detection by BM Chemiluminescence Blotting
Substrate (POD) from Roche Diagnostics (Mannheim, Germany). Relative protein levels were measured
using densitometric analysis with ImageJ software (1.48v, Java 1.5.0_20, 64-bit). Results are expressed
in arbitrary units.
2.7. Lipid Uptake by Oil Red O Staining
Monocytes (3 × 105) were plated onto Lab-Tek chamber slide system (Nunc, Roskilde, Denmark)
and IFN-γ (500 U/mL) was added to RPMI supplemented with 10% FCS for 24 h at 37 ◦C. After that
time, cells were washed once with PBS and exposed, or not, for 24 h to 20 μg/mL LDL from Academy
Bio-Medical Company (Houston, TX, USA). One hour before adding LDL, cells were incubated with
40 μg/mL of goat polyclonal anti-human apolipoprotein A-1 or control IgG, shown to be the optimal
dose to elicit a pro-inflammatory response [7,9,13,14,17]. Cells were examined for lipid inclusion by
Oil Red O staining. Briefly, cells were incubated with 10% formalin (Sigma-Aldrich, St Louis, MO,
USA) for 30 min at room temperature, incubated with Oil Red O solution (Sigma- Aldrich, St Louis,
MO, USA) for 15 min, and cells were then counterstained with hematoxylin (Sigma- Aldrich, St Louis,
MO, USA). Aquatex (Merck Millipore, Darmstadt, Germany) was used as mounting media. Images
were acquired with a microscope Zeiss Axioskop 2 plus. We used a 40× objective (Plan-Neofluar 40×
/0.75 Ph2) for all images. The images were collected using the AxioVision 4.8.1.0 softwares (Zeiss,
Oberkochen, Germania). Quantification of the lipid content (Oil Red O staining) per cell, identified
by hematoxylin blue nuclear staining, was performed using Definiens Developer XD2 (Cambridge,
MA, USA). Results are expressed as mean granule area in arbitrary units.
2.8. RNA Extraction
Macrophage cells (1 × 106) were subjected to RNA extraction using a total RNA purification
RNeasy Micro kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. RNA from
plasma (200 μL) was extracted using a Total RNA Purification Plus kit (Norgen Biotek, Thorold, ON,
Canada) and RNA from macrophage supernatant (200 μL) was extracted using TRIzol LS (Ambion,
Life-Technologies, Austin, TX, USA) as an internal control, with 10 fmol cel-miR-39a (Qiagen, Hilden,
Germany) spiked into each plasma and supernatant sample after adding lysis buffer or TRIzol LS. We
then followed the manufacturer’s protocol for RNA extraction. RNA was quantified using NanoDrop
2000 software (NanoDrop Products, Thermo Fisher Scientific, Wilmington, DE, USA.).
2.9. miRNA Quantitative PCR
miRNA quantification was done using a TaqMan®MicroRNA Reverse Trancription Kit (Applied
Biosystems) for reverse transcription reactions, according to the manufacturer’s instructions. TaqMan
Universal PCR master mix (Life Technologies, Carlsbad, CA, USA) was used to quantify miRNA levels
in plasma, macrophage cells, and in the supernatant counterpart with a 7900HT SDS Fast System
instrument (Applied Biosystems, Foster City, CA, USA). Primers for miR-33a, cel-miR-39a were obtained
from Applied Biosystems (Foster City, CA, USA). miR-33a level in plasma and in cell supernatant
were normalized to the spiked cel-miR-39a whereas miR-33a expression levels in each sample from
macrophage cells were normalized to RNU6B, miR-16, Z30 controls (Applied Biosystems, Foster City,
CA, USA). geNorm was used to determine the most stable genes from the set of control tested genes
since geNorm calculates the gene expression stability measure (M value) for a control gene as the
average pairwise variation for that gene with all other tested control genes [31]. Data were analyzed
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with the 7900HT SDS Software v2.3 (Applied Biosystems, Foster City, CA, USA). Relative expressions
of miR-33a were calculated using the comparative threshold cycle values (CT) method (2−ΔΔCt) [32].
2.10. Quantitative PCR
For mRNA quantification, cDNA was synthesized using the High Capacity RNA to cDNA kit
(Life Technologies, Carlsbad, CA, USA). Quantitative re al-time PCR was performed in duplicate
using TaqMan Universal Master mix II, no UNG on the StepOne Plus Real-Time PCR System (Thermo
Fisher Scientific, Waltham, MA, USA). The mRNA levels were normalized to Gapdh (hs99999905_m1)
as a housekeeping gene. The following primers were used: pri-miR-33a (hs03293451), Abca1
(hs01059137_m1), and Srebf-2 (hs01081784_m1). All primers were obtained from (Applied Biosystems,
Foster City, CA, USA). Data were analyzed with the 7900HT SDS Software v2.3 (Applied Biosystems,
Foster City, CA, USA). Relative expression of mRNA was calculated using the comparative threshold
cycles values (CT) method (2−ΔΔCt) [32].
2.11. Anti-ApoA-1 IgG Modulation of Membrane Free Cholesterol. Assay of Cholesterol Oxidase
Cholesterol oxidase treatment was essentially as previously described [33]. Briefly, cells were
labeled with 3 μCi/mL [3 H] cholesterol. Cholesterol oxidase (1 U/mL) was added, and cells were
incubated for 4 hours. Lipid was extracted with isopropanol, and radioactive cholesterol and
cholestenone were separated using thin-layer chromatography and quantified.
2.12. ACAT Activity Assessment
Cholesterol esterification was evaluated as the incorporation of radioactivity into cellular
cholesteryl esters after addition of [14C]-oleate-albumin complex [34]. At the end of incubation,
cells were washed with PBS and lipids were extracted with hexane/isopropanol (3:2). The extracted
lipids were separated by TLC (isooctane/diethyl ether/acetic acid, 75:25:2 (v/v/v)). Cholesterol
radioactivity in the spots was determined by liquid scintillation counting.
2.13. Measurement of Free Cholesterol Content in Cell Supernatant
Free cholesterol in supernatant was measured using the fluorometric method using the Cholesterol
Quantitation Assay Kit by Abcam (ab65359, Cambridge, UK) following the manufacturer’s instruction.
The experiments were conducted without ACAT inhibitors.
2.14. Passive Diffusion Analysis
We used a validated model of THP-1 monocytes cultured in RPMI 1640 medium supplemented
with 10% FBS at 37 ◦C in 5% CO2 [35]. To perform the experiments for passive diffusion, cells
were seeded in 24-well plates at a density of 5 × 105 cells/well in the presence of 100 ng/mL PMA
for 72 h to allow differentiation into macrophages. Cells were labeled with (1,2-3H)-cholesterol in
the presence of an ACAT inhibitor (2 μg/mL, Sandoz 58035 by Sandoz, Holzkirchen, Germany) for
24 h. In order to measure passive diffusion, the key cholesterol efflux regulator in non-dyslipidemic
macrophages [36], the experiment was performed in the absence of 10% whole serum, but cells were
supplemented with 0.2% albumin to avoid any active ABCA1- or ABCG1-mediated cholesterol efflux.
Cholesterol measurement was expressed as a percentage of the radioactivity released to the medium
in 4 h over the total radioactivity incorporated by cells. Control samples were run to confirm the
responsiveness of cells. Background efflux, evaluated in the absence of acceptors, was subtracted from
each samples value.
2.15. Statistics
Continuous variables were expressed as median (interquartile range (IQR)) and comparisons
between two groups were performed using a non-parametric Mann–Whitney U test, unless stated
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otherwise. Correlation analysis was carried out using a Spearman test. Analyses were performed with
Statistica package (version13.5.0.17, TIBCO Software inc., Palo Alto, CA, USA). Statistical significance
was defined at p < 0.05. For the in vitro results, statistical analysis was performed using the parametric
unpaired Student’s t-test using GraphPad Prism (version 7.0., GraphPad SoftwareSan Diego, CA, USA).
Statistical significance was defined as p < 0.05.
3. Results
3.1. Anti-ApoA-1 IgG Associations with Lipid Profile in FH Children
Baseline, clinical, and biological characteristics of FH and healthy children are described in Table 1.
As expected, FH children had higher levels of total cholesterol, LDL cholesterol, apoB particles, HDL
cholesterol, and miR-33a than their age-matched controls. No other differences in baseline clinical
characteristics were observed between these two groups. Median anti-ApoA-1 IgG were similar in
these two groups and a similar prevalence of high anti-ApoA-1 IgG levels was retrieved in both groups
(38.8% and 37.9%, respectively).
In FH children, there were no significant differences between anti-ApoA-1 IgG positive and
anti-ApoA-1 IgG negative children in terms of age, gender, and overweight-associated features, with the
possible exception of BMI and waist circumference, which tended to be higher in ApoA-1 IgG positive
FH children than seronegative ones. Anti-ApoA-1 IgG positive subjects showed significantly lower
median levels of LDL cholesterol, total cholesterol, and miR-33a, with a marginal trend for apoB
particles when compared to anti-ApoA1 IgG negative subjects (Table 2). Significant correlations were
only observed between anti-ApoA-1 IgG and miR-33a levels (r = 0.42, p = 0.02).
In age-matched healthy children, the aforementioned differences between anti-ApoA-1 IgG
seropositive and seronegative individuals related to lipid profile and miR-33a levels were not observed
(Table 3). In contrasting to the observation in FH children, we observed that BMI, waist, and arm
circumference in healthy children were lower in subjects positive for anti-ApoA-1 IgG when compared
to seronegative children.
Table 1. Baseline demographic and biological characteristics of subjects according to familial
hypercholesterolemia (FH) status.
Characteristic Healthy Children (n = 25) FH Children (n = 29) * p-Value
Age, year (IQR) 8.5 (7–11) 9 (6–11) 0.89
Sex (male %) 45 48.2 0.88
BMI (kg/m2) 19 (16.6–20.2) 17.8 (15.6–20) 0.55
Systolic BP *, mmHg (IQR) 105 (95–110) 110 (100–120) 0.14
Diastolic BP, mmHg (IQR) 60 (60–70) 60 (60–70) 0.75
Waist circumference, cm (IQR) 61.5 (53–69) 60 (53–68) 0.94
Hip circumference, cm (IQR) 66 (61–76) 64 (57–73) 0.85
Arm circumference, cm (IQR) 20 (18–22) 20 (17–23) 0.83
Total cholesterol (mg/dL) 152.5 (138–167.5) 231 (213–280) <0.0001
LDL cholesterol (mg/dL) 91.4 (79.5–103) 156 (137.6–211.6) <0.0001
HDL cholesterol (mg/dL) 52 (43.5–58.5) 57 (51–66.5) 0.02
Triglycerides (mg/dL) 56.5 (45.5–63) 64 (47–75) 0.17
Apolipoprotein B (mg/dL) 65 (49–81.5) 93 (86–134) <0.0001
Anti-ApoA-1 IgG (OD value) 0.53 (0.4–0.77) 0.55 (0.5–0.68) 1
Anti-ApoA-1 IgG positivity (%) 38.8 37.9 0.9
miR-33a (2ˆ-ΔCt) 0.05 (0.03–0.2) 0.4 (0.19–1) <0.0001
* p-values were obtained by comparing FH positive versus FH negative subjects, p-values were calculated using the
Mann–Whitney U test. BMI, body mass index. BP, blood pressure. IQR: interquartile range.
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Negative (n = 15)
Anti-ApoA-1
Positive (n = 10) * p-Value
Age, year (IQR) 8.5 (7–11) 10 (7–11) 7 (7–9) 0.08
Sex (male %) 45 42.8 50 0.28
BMI (kg/m2) 19 (16.6–20.2) 19.2 (17–20.2) 17.2 (15.4–19.5) 0.02
Systolic BP *, mmHg (IQR) 105 (95–110) 100 (90–105) 110 (100–120) 0.7
Diastolic BP, mmHg (IQR) 60 (60–70) 60 (60–75) 62.5 (60–70) 0.53
Waist circumference, cm (IQR) 61.5 (53–69) 66 (51–69) 61 (54–64) 0.03
Hip circumference, cm (IQR) 66 (61–76) 70 (61–76) 66 (61–67) 0.09
Arm circumference, cm (IQR) 20 (18–22) 20 (17–22) 19.5 (18–21) 0.01
Total cholesterol (mg/dL) 151 (138.5–167.5) 147 (135–167) 163 (148–168) 0.27
LDL cholesterol (mg/dL) 91.4 (79.5–103) 89.4 (72–95) 101.8 (87–108) 0.11
HDL cholesterol (mg/dL) 52 (43.5–58.5) 50.5 (39–55) 56 (47–62) 0.12
Triglycerides (mg/dL) 56.5 (45.5–63) 58.5 (47–70) 55 (41–58) 0.97
Apolipoprotein B (mg/dL) 65 (49–81.5) 53.5 (40–66) 79.5 (69–85) 0.19
miR-33a (2ˆ-ΔCt) 0.05 (0.03–0.25) 0.1 (0.03–0.26) 0.05 (0.04–0.1) 0.4
* p-values were obtained by comparing anti-ApoA-1 IgG positive versus anti-ApoA-1 IgG negative subjects, p-values
were calculated using the Mann–Whitney U test. IQR: interquartile range.






Negative (n = 18)
Anti-ApoA-1
Positive (n = 11) * p-Value
Age, year (IQR) 9 (6–11) 8 (7–10) 10 (6–13) 0.45
Sex (male %) 48 54.5 72.7 0.08
BMI (kg/m2) 17.8 (15.6–20) 16.8 (15.3–18.2) 19.3 (17.4–21.9) 0.05
Systolic BP*, mmHg (IQR) 110 (100–120) 110 (100–115) 110 (100–125) 0.39
Diastolic BP, mmHg (IQR) 60 (60–70) 62.5 (60–70) 60 (60–70) 0.58
Waist circumference, cm (IQR) 60 (53–68) 56.5 (53–63) 66 (61–70) 0.05
Hip circumference, cm (IQR) 64 (57–73) 72 (64–80) 62.5 (57–71) 0.10
Arm circumference, cm (IQR) 20 (17–23) 22 (22–23) 19 (17–22) 0.14
Total cholesterol (mg/dL) 213 (213–280) 263 (219–305) 209 (188–240) 0.04
LDL cholesterol (mg/dL) 156.6 (137.6–211.6) 191.2 (144.6–228) 124.4 (113.8–168.8) 0.04
HDL cholesterol (mg/dL) 57 (51–66.5) 61 (55–67) 55 (50–58) 0.24
Triglycerides mg/dL) 64 (47–75) 60 (47–66) 66 (35–78) 0.35
Apolipoprotein B (mg/dL) 93 (86–134) 109 (91–143) 86 (76–103) 0.05
miR-33a (2ˆ-Ct) 0.41(0.19–1.03) 0.85 (0.36–1.2) 0.28 (0.14–0.5) 0.04
* p-values were obtained by comparing anti-ApoA-1 IgG positive versus anti-ApoA-1 IgG negative subjects, p-values
were calculated using the Mann–Whitney U test. IQR: interquartile range.
3.2. Lower Level of miR-33a in Anti-ApoA-1 IgG-Treated Human Macrophages
To further explore a possible causal link between the presence of anti-ApoA-1 antibodies, lower
miR-33a levels, and a more favorable lipid profile in FH children, we first tested the ability of
polyclonal anti-ApoA-1 IgG or control IgG to modulate the in vitro miR-33a production in human
monocyte-derived macrophages (HMDM).
After a time course of 4, 8, 16, and 24 h of antibody exposure, miR-33a levels were detected by
quantitative PCR, as shown in Figure 1a. Anti-ApoA-1 IgG, and not control IgG, was found to decrease
the miR-33a production in vitro on HMDM. As shown in Figure 1a, when compared to baseline
conditions and control IgG, anti-ApoA-1 IgG (40 μg/mL) induced a slight but consistent decrease
of cellular miR-33a levels during each time point, with the exception of 4 h stimulation, and was
statistically significant at 24 hours (p < 0.01). As shown in Figure 1b, this anti-ApoA-1 IgG-induced
miR-33a downregulation was associated with a decreased miR-33a level at 24 h in the cell supernatant.
Up to now, most of the anti-ApoA-1 IgG pro-atherogenic effects have been shown to be mediated
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by TLR2/TLR4/CD14 complex engagement followed by nuclear factor (NF)-kB and activator protein
(AP)-1 pathway activation [4,14,17], and we examined the role TLR2/4, CD14, NF-kB, and AP-1 in the
anti-ApoA-1 IgG-mediated downregulation of miR-33a. Accordingly, we pretreated these cells with
blocking antibodies against TLR2, TLR4, and the co-receptor CD14, and added chemical inhibitors
BAY11-7082 (5 μM) or SP600125 (20 μM), specific to NF-kB and AP-1, respectively, 30 minutes before
treatment with polyclonal anti-ApoA-1 IgG for 24 h. As shown in Figure 1c, none of the used inhibitors
modulated the anti-ApoA-1 IgG effect on miR-33a, suggesting that the anti-ApoA-1 IgG-dependent
miR-33a regulation was independent of TLR2/4/CD14 complex signaling.
We then looked at the primary miR-33a (pri-miR-33a) precursor transcript that, after complex
processing, gives the mature miR-33a, as well as at the SREBP2 mRNA, since miR-33a is located in the
intronic region of SREBP2 gene [23,37] and we checked whether they would follow the same regulation
as for miR-33a. Surprisingly, HMDM exposure to anti-ApoA-1 IgG for 24 hours significantly increased
pri-miR-33a levels as well as SREBP2 mRNA (Figure 2a,b).
These results suggest that despite the fact that the levels of primary miR-33a transcript are
increased by anti-ApoA-1 IgG, the mature intracellular miR-33a form is nevertheless decreased by
anti-ApoA-1 IgG exposure. Current ongoing investigations to dissect the exact mechanisms underlying
this discrepancy indicate that miR-33a stability issues rather than maturation or nuclear export defects
may be involved, but no clear-cut mechanisms have been identified so far.
 
Figure 1. Lower levels of intracellular and extracellular miR-33a in anti-ApoA-1 IgG-treated human
macrophage. Cells were treated with anti-ApoA-1 IgG or control antibodies for 4, 8, 16, and 24 h and
RT-PCR was performed to determine (a) intracellular miR-33a levels as well as (b) miR-33a in the
supernatant counterpart after 24 h anti-ApoA-1 IgG or control IgG treatment. (c) Blocking antibodies
againstTLR2/4 were used as well as inhibitors of NF-kB and AP-1 to investigate the anti-ApoA-1 IgG
mediated miR-33a downregulation. In (a,b), data are expressed as fold change expression of the mean
± SD of miR-33a calculated by ΔΔCT method of five independent experiments (n = 5) and values were
normalized to untreated condition, while in panel (c), data are expressed as miR-33a quantity (2−ΔΔCt).
p-values were calculated using Student’s t-test. Panel a, * p = 0.015, ** p = 0.0012. Panel b, the difference
is not statistically significant, anti-ApoA-1 IgG vs. untreated p = 0.11, anti-ApoA-1 IgG vs. ctl control
IgG p = 0.28. (c), ** p = 0.0017.
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Figure 2. Primary miR-33a and SREBP2 mRNA are upregulated by anti-ApoA-1 IgG. Cells were
treated with anti-ApoA-1 IgG or control antibodies for 24 h and RT-PCR was performed to determine
pri-miR-33a and SREBP2 mRNA levels (a,b). Data are expressed as fold change expression of the mean
± SD of pri-miR-33a or SREBP2 mRNA calculated by ΔΔCT method of five independent experiments
(n = 5) and values were normalized to untreated condition. p-values were calculated using the Student’s
t-test. (a), * p = 0.032, ** p = 0.0031; (b), * p = 0.043, ** p = 0.007.
3.3. Anti-ApoA-1 IgGs Modulate Cholesterol-Regulating Proteins in Macrophages
We further investigated the possible modulation, by anti-ApoA1 IgG, of SREBP2 transcription
factor known to bind and activate LDL-R and HMGCR gene transcription [37–39] involved in cholesterol
uptake and biosynthesis respectively. After 24 h of stimulation, anti-ApoA-1 IgG treatment increased
the levels of SREBP2, HMGCR, and LDL-R protein when compared to the control IgG (Figure 3).
As shown in Figure 3, only anti-ApoA-1 IgGs and not the control IgGs were found to increase the
expression of the SCAP protein (SREBP cleavage-activating protein), responsible for cleaving and
activating SREBP2 [40].
 
Figure 3. Anti-apoA-1 IgGs interfere with key regulators of cholesterol metabolism in macrophages.
Anti-ApoA-1 IgGs induced the expression of the key regulators of the cholesterol pathway after 24 h as
evidenced by Western blot. One of four representative Western blot is shown (n = 4).
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3.4. The Impact of Anti-ApoA-1 IgG on Cholesterol-Regulating Proteins Is Mediated by TLR2 and TLR4
Furthermore, we examined the role of TLR members as well as CD14, NF-kB, and AP-1 in the
anti-ApoA-1 IgG-mediated upregulation of SREBP-2, LDL-R, and HMGCR on HMDM. Blocking both
TLR2 and TLR4, NF-kB, and AP-1, as previously described, induced a significant reduction in the
SREBP-2, LDL-R, and HMGCR protein expression (Figure 4b–d), while only blocking AP-1 significantly
decreased anti-ApoA-1 IgG-induced HMGCR protein expression (Figure 4d).
 
Figure 4. The impact of anti-ApoA-1 IgG on cholesterol metabolism is mediated by TLR2, TLR4, Nf-KB,
and AP-1 transcription factors. Western blot-derived results showed that anti-ApoA-1 IgG-mediated
upregulation of SREBP2, LDL-R, and HMGCR on human monocyte-derived macrophages (HMDM) is
significantly reduced by blocking TLR2 and TLR4 with specific blocking antibodies. Blocking NF-kB
and AP-1 using the specific inhibitors BAY117082 and SP600125 respectively provided similar results.
(a) One of five representative Western blots is shown. (b–d) Data are expressed as mean ± SD of
band intensity volume/actin intensity volume from five different experiments (n = 5). p-values were
calculated using the Student’s t-test: * p < 0.05, ** p < 0.01.
3.5. Anti-ApoA-1 IgGs Promote LDL Uptake and Foam Cell Formation
The complexity underlined by the previous observations indicating that i) anti-ApoA-1 IgG are
associated with a more favorable lipid profile in FH children but lower miR-33a levels and ii) that these
antibodies could increase both pro-atherogenic (HMGCR increase) and anti-atherogenic pathways
(SREBP-2, LDLR) in vitro prompted us to evaluate the global result of exposing human macrophages
to anti-ApoA-1 IgG in terms of foam cell formation. For this purpose, HMDM were treated with or
without LDL (20 μg/mL) in the presence or absence of anti-ApoA-1 IgG (40 μg/mL) or control IgG (40
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μg/mL) for 24 hours and followed by Oil Red O staining of HMDM. As shown in Figure 5, anti-ApoA-1
IgG exposure without LDL induced a modest but significant increase in cellular lipid content when
compared to control IgG (Figure 5b). Furthermore, in the presence of LDL, the effect of anti-ApoA-1 IgG
was enhanced (Figure 5a,b). In presence of LDL, the anti-ApoA-1 IgG effect on foam cell formation was
abrogated by all the inhibitors used, with the exception of AP-1 inhibitor, which nevertheless provided
a close to significant inhibition (Figure 5b). Taken together, these results indicate that anti-ApoA-1 IgG
promotes foam cell formation through partly TLR2/4-dependent pathways. Of note, this anti-ApoA-1
IgG-induced foam cell formation was specifically enhanced by native LDL because in presence of
oxidized LDL, anti-ApoA-1 IgG increases foam cell formation to the same extent as anti-ApoA-1 IgG
alone (Supplemental Figure S1).
Importantly, given the fact that LDL per se substantially induced foam cell formation regardless
of the concomitant presence of anti-ApoA-1 IgG, the rest of our experimental procedures were carried
out without LDL in order to assess the effects specifically ascribed to anti-ApoA-1 IgGs.
 
Figure 5. Anti-ApoA-1 IgG promote LDL uptake and foam cell formation mediated by TLR2/4, NF-kB,
and AP1. (a) HMDM were treated for 24 h with anti-ApoA-1 IgG or ctl IgG in the presence or absence
of native LDL (20 μg/mL). Cells were stained with Oil Red O to highlight the lipid uptake. (b) Blocking
antibodies to TLR2/4 were used as well as inhibitors to NF-kB and AP-1 to try to inhibit the anti-ApoA-1
IgG mediated LDL uptake as evidenced by Oil Red O staining quantification as the mean granule
area per cell. Oil Red O was quantified as indicated in the method section. Results are expressed in
arbitrary units as mean ± SD of four independent experiments (n = 4), p-values were calculated using
the Student’s t-test: ** p < 0.01, *** p < 0.001, **** p < 0.0001.
3.6. Anti-ApoA-1 IgGs Upregulate ABCA1
Because ABCA1 is a known target of miR-33a [23], we expected that the anti-ApoA-1 IgG-induced
downregulation of miR-33a would increase ABCA1 expression. As shown in Figure 6, anti-ApoA-1
IgG increased both the mRNA (Figure 6a) and protein levels of ABCA1 (Figure 6b) in HMDM.
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Figure 6. Anti-ApoA-1 IgGs upregulate ABCA1. ABCA1 was increased after 16 and 24 h of anti-ApoA-1
IgG exposure to HMDM at the mRNA level as revealed by RT-PCR (a) as well as at the protein level
after 24 h anti-apoA-1 IgG stimulation, as revealed by Western blot analysis (b). In panel a, data are
expressed as fold change expression of the mean ± SD of ABCA1 calculated by ΔΔCT method of six
independent experiments (n = 6) and values were normalized to untreated condition. p-values were
calculated using the Student’s t-test: * p < 0.05, ** p < 0.01, **** p < 0.0001. (b) One of four representative
Western blots is shown. Data are the mean ± SD of band intensity volume/actin intensity volume of
four independent experiments (n = 4). p-values were calculated using the Student’s t-test: * p = 0.02,
** p = 0.005.
3.7. ACAT Activity and Cellular Cholesterol Distribution in Macrophages Following Anti-ApoA1 IgG
Treatment
Because ABCA1 levels are known to be upregulated as part of a homeostatic feedback loop in
presence of intracellular lipid overload [36], the previous experiments did not allow us to conclude
whether there was a direct or indirect effect of anti-ApoA-1 IgG on ABCA1 levels. Nevertheless, as the
net effect of anti-ApoA-1 IgGs was an increase in foam cell formation (which is usually associated with
lower ABCA1 levels), we primarily suspected that the ABCA1 increase in response to anti-ApoA-1 IgG
was part of a negative feedback mechanism. In that case, the exposure of anti-ApoA-1 IgG on HMDM
should primarily reorient the free cholesterol present in the plasmatic membrane toward esterified
cholesterol intracellular pools, which is mediated by the acyl coenzyme A: cholesterol acyltransferase
(ACAT) [41]. To validate this hypothesis, we assessed the impact of anti-ApoA-1 IgGs on the ACAT
activity and protein levels on HMDM. As shown in Figure 7a, anti-ApoA-1 IgGs increased ACAT
activity, while the protein levels remained unchanged (Supplemental Figure S2).
As shown in Figure 7b, this anti-ApoA-1 IgG- induced ACAT activation was accompanied by a
significant reduction of free cholesterol content in membrane and a non-significant reduction of the
free cholesterol content in the cell supernatant counterpart (Figure 7c).
43
J. Clin. Med. 2019, 8, 2035
 
Figure 7. Effect of anti-ApoA-1 IgG on cholesterol distribution. (a) Cells were incubated for 24 hours
in RPMI medium with 10% FCS, control IgGs, or anti-ApoA-1 IgG. Monolayers underwent a second
incubation (4 h) in the presence of [1-14C]-oleic acid albumin complex. Data are expressed as the mean
± SD of the measurements done in triplicate and repeated on three HMDM donors (n = 3). Statistical
differences were determined by Student’s t-test: ** p ≤ 0.0036. (b) HMDM were labelled with 3 μCi/mL
[3H] cholesterol for 24 h in RPMI medium with 10% FCS, control IgGs or anti-ApoA-1 IgGs. Cells were
then washed and incubated with 1 U/mL cholesterol oxidase enzyme in DPBS for 4 hours at 37 ◦C. Data
are expressed as the mean ± SD of the measurements done in triplicate and repeated on three HMDM
donors (n = 3), p-values were calculated using the Student’s t-test: * p < 0.05. (c) Free cholesterol content
in HMDM supernatant after exposure of cells to anti-ApoA-1 IgGs or control IgGs was expressed as μg
of free cholesterol per well. Data are expressed as the mean ± SD of the measurements done on five
HMDM donors (n = 6). The differences between groups were not statistically significant, anti-ApoA-1
IgG vs. untreated p = 0.12; anti-ApoA-1 IgG vs. ctl IgG p = 0.14.
3.8. Anti-ApoA-1 IgG Impact on Cholesterol Passive Diffusion
Cholesterol passive diffusion (also known as aqueous diffusion) represents the free cholesterol
exchange occurring between cells membranes and plasma by a passive process driven by free
cholesterol concentration gradients towards HDL/ApoA-1, independently of any efflux pumps [36] In
normocholesterolemic conditions, passive diffusion has been shown to account for up to 80% total
cholesterol macrophage efflux [42]. Given the decrease in membrane free cholesterol induced by
anti-ApoA-1 IgG in response to the ACAT redistribution within intracellular pools, we expected these
antibodies to decrease passive diffusion due to the decrease in the free cholesterol gradient. For this
purpose, we used a validated model of human macrophage derived from THP-1 monocytic cell line [35]
as our human primary macrophage model was not validated for such kind of experiments. Cells were
treated for 24 h with anti-ApoA 1 IgGs or control IgGs in the absence of serum but in presence of 0.2%
albumin to avoid any active ABCA1-, ABCG1- or SR-B1-mediated cholesterol efflux. As shown in
Figure 8, anti-ApoA-1 IgGs significantly decreased the passive diffusion.
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Figure 8. Anti-ApoA-1 IgGs inhibit passive diffusion. THP-1 cells were treated for 24 h with anti-ApoA-1
IgGs or ctl IgGs and passive diffusion was analyzed and expressed as percentage of the radioactivity
released to the medium in 4 h over the total radioactivity incorporated by cells. p-values were calculated
using the Student’s t-test: ** p = 0.010, *** p < 0.001.
4. Discussion
In this study, we report, for the first time, that the prevalence of high anti-ApoA-1 IgG levels in
children devoid of any concomitant autoimmune diseases is substantial, reaching 38%, and seemed
unrelated to familial hypercholesterolemia. Such a prevalence is similar to what has been reported
in adults in secondary prevention or equivalent CV risk-associated conditions [4,7,43], and close to
double of what has been observed in a general adult population [3], where these antibodies were
shown to be associated with a worse overall and CV prognosis [3,5].
The second notable finding of this study is that FH positive children with high anti-ApoA-1 IgG
levels displayed a more favorable lipid profile consisting of lower total and LDL cholesterol levels,
when compared to children who tested negative for these autoantibodies. These results complement
previous observations [3,13,15,16] showing that high anti-ApoA-1 IgG levels were associated with
lower total, LDL, and miR-33a levels, despite being associated with increased CVD risk, according to
previous reports [3,13,15,16]. This clinical observation derived from a limited number of pediatric FH
patients (and not retrieved on age and gender matched controls), prompted us to evaluate the ability of
anti-ApoA-1 IgG to promote in vitro foam cell development on human primary macrophages, and to
determine the molecular mechanisms involved, which led to the following new mechanistic findings.
If the role of the TLR2/4/CD14 complex has been well documented accounting for the cytokine-
dependent pro-inflammatory, pro-thrombotic, and pro-arrythmogenic biological properties ascribed
to anti-ApoA-1 IgG [9,14,17], this is the first demonstration that these antibodies promote foam cell
formation on human macrophages by the same innate immune receptors. Our results demonstrate that
anti-ApoA-1 IgGs upregulate the expression of key cholesterol homeostasis-related proteins, such as
SREBP2, LDL-R, and HMGCR in a TLR2/4 complex-dependent manner, leading to both increased LDL
uptake and intracellular cholesterol synthesis, independently of oxidized LDL uptake. We considered
this cellular cholesterol overload as the key driver of ACAT stimulation [44] leading to the esterification
of free cholesterol excess into intracellular cholesterol pools (lipid droplet accumulation) and decreased
the amount of plasma membrane free cholesterol, diminishing the free cholesterol gradient requested
for passive diffusion, a key macrophage cholesterol efflux regulator in normolipidemic conditions [36].
Our observations are in line with previous observations demonstrating that TLR4 and TLR2 agonists can
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upregulate SREBP2, HMGCR, and LDL-R expression and promote foam cell formation independently
of oxidized-LDL uptake [29,45,46].
In this context, the anti-ApoA-1 IgG-induced increase of the anti-atherogenic ABCA1 protein
expression, and decrease in pro-atherogenic miR-33a has to be understood as the reflection of the
activation of a compensatory but insufficient homeostatic feedback loop to limit intracellular cholesterol
overload for two main reasons. First of all, our results indicate that miR-33a expression is independent
of TLR2/TLR4 signaling, whereas TLR2 and 4 ligands have been reported to downregulate miR-33a in
the case of direct signaling [47]. Secondly, any increase in intracellular cholesterol accumulation is
known to downregulate miR-33a expression which, in turn, will alleviate miR-33a-mediated ABCA1
inhibition, leading to an increase in ABCA1 protein expression and ABCA1 efflux independently of
TLR stimulation [23,48]. Taken together, these results indicate that in our experimental context, changes
in miR-33a and ABCA1 expression have to be considered as the effectors of a negative feedback loop
aimed at limiting anti-ApoA-1 IgG-induced intracellular lipid accumulation without being able to fully
prevent it, as a common feature of negative feedback loops [49]. Nevertheless, our results indicate that
in presence of anti-ApoA-1 IgG, the usual negative feedback mechanism activated by high intracellular
cholesterol levels to reduce LDLR seems to be blunted [49]. The exact mechanisms underlying this
observation are currently unknown and warrant further investigations.
Despite these remaining questions, to the best of our knowledge, this is the first thorough
experimental demonstration unravelling the detailed mechanisms by which anti-ApoA-1 IgGs could
promote atherogenesis by acting as disruptors of macrophage cholesterol homeostasis by increasing
both LDL uptake and intracellular cholesterol synthesis independently of oxidized LDL. As such,
our results show that anti-ApoA-1 IgGs have at least two antagonist mechanisms of action to those
of statins in the sense that the former act as HMGCR and ACAT activators, whereas statins act as
HMGCR and ACAT inhibitors [50] Although, concordant with our clinical data, knowing whether
these mechanisms could explain the clinical associations retrieved between anti-ApoA-1 IgG and lipid
profile remains to be determined. Our current understanding of these possible pathophysiological
mechanism is summarized in Supplemental Figure S3.
This study has several limitations. It is worth mentioning the very limited size of our FH
pediatric sample used in this translational study, due to the low prevalence of FH [51] and the issues
related to pediatric blood sampling. Despite this power limitation, the significant associations derived
from this cohort were instrumental in providing guidance for the in vitro experiments which, in
turn, provided results that could explain the reported clinical associations, albeit not providing a
formal demonstration. Another limitation resides in the unresolved paradox raised by the fact that
anti-ApoA-1 IgG can decrease mature miR-33a levels despite increasing levels of miR-33a precursor.
The reason underlying such an observation is under active investigation, as we currently suspect a
possible effect of anti-ApoA-1 IgG on miRNA decay that we did not investigate due to highly elusive
mechanisms underlying miRNA stability [52,53], which could not be resolved within the scope of the
present work. The third limitation is that we did not consider ABCA1 efflux in this work because all
our experiments related to protein regulation were done in normocholesterolemic conditions without
additional LDL, where passive diffusion is believed the main functional driver of the cholesterol efflux
in macrophages [36]. Nevertheless, as ABCA1 levels were increased in response to anti-ApoA-1 IgG as
part of the negative feedback loop (see above), we expect ABCA1 cholesterol efflux to be concomitantly
increased, but not sufficiently to inhibit anti-ApoA-1 IgG-induced foam cell formation. Lastly, due to
limited human sample availability, we could not evaluate the effect of human purified anti-ApoA-1 IgG
in this study. Nevertheless, as we previously demonstrated that the commercial anti-human ApoA-1
IgG used in this study promoted the same effects as the human-purified IgG fraction containing high
levels of these autoantibodies in vitro [9,17], and because these autoantibodies have been consistently
used in different validated and published animal and in vitro studies [9,12–14,17], we expect a similar
impact on in vitro lipid metabolism to occur by using human purified anti-ApoA-1 IgG, even if not
formally demonstrated.
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In conclusion, the results of this hypothesis-generating translational study show that the prevalence
of ApoA-1 IgG seropositivity is frequent in children, unrelated to FH, and surprisingly associated
with a favorable lipid profile in FH but not in controls. Furthermore, anti-ApoA-1 IgG were found to
induce foam cell formation in vitro through a complex interplay between innate immune receptors
and key cholesterol homeostasis regulators, functionally impairing the cholesterol efflux capacity of
macrophages. The clinical implications of these findings are unclear, but may suggest that the presence
of circulating anti-ApoA-1 IgG could not only interfere with some beneficial effects of lipid-lowering
drugs in humans, but could also potentially decrease the contribution of the lipid profile to the
individual’s CV risk in current CV risk stratification tools. If so, these antibodies may be considered
as an additional CV risk enhancer to the list of the factors already considered as such in the latest
dyslipidemia management guidelines [54]. These hypotheses are currently devoid of any experimental
evidence and await further investigations.
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Abstract: Renal transplant recipients (RTRs) are known to have a high cardio-vascular disease (CVD)
burden only partly explained by traditional CVD risk factors. The aim of this paper was therefore to
determine: i) the prognostic value of autoantibodies against apoA-1 (anti-apoA-1 IgG) for incidence
of CVD mortality, all-cause mortality and graft failure in RTR. Four hundred and sixty two (462)
prospectively included RTRs were followed for 7.0 years. Baseline anti-apoA-1 IgG were determined
and associations with incidence of CVD mortality (n = 48), all-cause mortality (n = 92) and graft
failure (n = 39) were tested. Kaplan–Meier analyses demonstrated significant associations between
tertiles of anti-apoA-1 IgG and CVD mortality (log rank test: p = 0.048). Adjusted Cox regression
analysis showed a 54% increase in risk for CVD mortality for each anti-apoA-1 IgG levels standard
deviation increase (hazard ratio [HR]: 1.54, 95% Confidence Interval [95%CI]: 1.14–2.05, p = 0.005),
and a 33% increase for all-cause mortality (HR: 1.33; 95%CI: 1.06–1.67, p = 0.01), independent of CVD
risk factors, renal function and HDL function. The association with all-cause mortality disappeared
after excluding cases of CVD specific mortality. The sensitivity, specificity, positive predictive value,
and negative predictive value of anti-apoA-1 positivity for CVD mortality were 18.0%, 89.3%, 17.0%,
and 90.0%, respectively. HDL functionality was not associated with anti-apoA-1 IgG levels. This
prospective study demonstrates that in RTR, anti-apoA-1 IgG are independent predictors of CVD
mortality and are not associated with HDL functionality.
J. Clin. Med. 2019, 8, 948; doi:10.3390/jcm8070948 www.mdpi.com/journal/jcm51
J. Clin. Med. 2019, 8, 948
Keywords: biomarker; anti-apolipoprotein A-1 antibodies; renal transplant recipient; HDL function;
prognosis; cholesterol
1. Introduction
Impaired kidney function is a major risk factor for cardiovascular diseases (CVD) through all
stages of renal dysfunction, amounting to a substantial 40-fold increased risk of CVD mortality in
end-stage renal disease (ESRD) patients [1,2]. Even after renal transplantation the CVD risk remains
four to six times higher in age-adjusted analyses, with half of all deaths of renal transplant recipients
(RTRs) being attributable to a CVD origin [3]. Traditional CVD risk factors, such as the ones aggregated
in the Framingham risk score (FRS), are known to be of little use in CVD risk prediction in RTRs [4,5].
Thus, accurate CVD risk stratification in RTRs represents an unmet clinical need in this constantly
increasing patient population.
Autoantibodies against apoA-1 (anti-apoA-1 IgG) represent a recently identified biomarker with
a high potential to predict increased CVD risk. Increased levels of these antibodies are associated
with a pro-atherogenic lipid profile, a systemic pro-inflammatory state [6–8], as well as high-density
lipoprotein (HDL) dysfunction [9,10], and were shown to be associated with increased CVD risk
and poorer prognosis in high-risk patients, as well as in the general population [7,11–14]. When
administered to mouse models of atherosclerosis, anti-apoA-1 IgG enhanced atherogenesis, myocardial
necrosis and premature death indicating that anti-apoA-1 IgG have the potential to serve as a causative
biomarker for CVD [15–17]. A previous study showed that ESRD patients have a high prevalence
of elevated anti-apoA-1 IgG levels, which was associated with dialysis vintage, and was a major
determinant of cardiovascular outcomes in these patients [18]. The reasons underpinning such
association in ESRD are still elusive, but may suggest that a prolonged exposure to the uremic milieu,
characterized by increased oxidative stress and inflammation, could increase apoA-1 immunogenicity
leading to an anti-apoA-1 IgG response. Accordingly, as RTR are exposed to a uremic milieu prior
to transplantation, they could also constitute a particularly risk-prone group to such a humoral
autoimmunity phenomenon, despite receiving immunosuppressive treatment.
The aim of our present study was to determine: i) the prognostic value of anti-apoA-1 IgG for
incidence of CVD specific mortality, overall mortality and graft failure in RTR and ii) to delineate the
relationship of anti-apoA-1 IgG with apoA-1 levels and HDL functionality.
2. Experimental Section
2.1. Study Design and Study Population
This study included all adult RTR who visited the University Medical Centre Groningen (UMCG)
outpatient clinic between August 2001 and July 2003 with a functioning renal graft for at least 1 year.
Of 847 eligible patients, 606 consented to participate in the overall study. Exclusion criteria consisted
of congestive heart failure, malignant disease other than cured skin cancer, as well as endocrine
abnormalities other than diabetes, or suspected acute infection upon inclusion, indicated by a CRP
value above 15 mg/L. This way 477 patients were initially included in the present study; serum was
available from 462 RTRs, in which subsequently anti-apoA-1 IgG levels were measured. All relevant
patient characteristics were obtained from the “Groningen Renal Transplant Database”. Patients were
followed for a period of 7 years, and no patients were lost during follow-up. More detailed definitions
of the characteristics of the database patients’ baseline characteristics, as well as the routine laboratory
methods used have been previously described [19,20]. The study was approved by the local Medical
Ethics Committee (METc2001/039), and is in accordance with the Declaration of Helsinki and Principles
of the Declaration of Istanbul as outlined in the ’Declaration of Istanbul on Organ Trafficking and
Transplant Tourism’.
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2.2. Outcome Measures
The main outcome measure in this study is the level of anti-apoA-1 IgG. The primary endpoints
consisted in CVD mortality, all-cause mortality and graft failure. As previously reported [21,22]. graft
failure was defined as return to dialysis or re-transplantation. Cause of death was obtained by linking
the number on the death certificate to the primary cause of death, as coded by a physician from the
Central Bureau of Statistics. CVD mortality was defined as deaths in which the principal cause of death
was cardiovascular in nature, using ICD-9 codes 410–447. The secondary endpoint was a possible
association between anti-apoA-1 IgG levels and apoA-1 levels, as well as a key HDL functionality,
namely macrophage cholesterol efflux capacity (CEC).
2.3. Sensitivity Analyses
Sensitivity analyses were performed, in which the association of anti-apoA-1 IgG with non
CVD-mortality was assessed, in order to assess the specificity of anti-apoA-1 with CVD.
2.4. Determination of Anti-apoA-1 IgG
Anti-apoA-1 IgG were measured using RTR serum aliquots stored at −80 ◦C, as previously
described [6–8,11–13]. The experiments demonstrating the specificity of our assay against the native
and unmodified form of apoA-1 are available in the Table 1.
Table 1. Baseline characteristics according to gender stratified tertiles of anti-apoA-1 IgG.
Characteristic
Gender Stratified Tertiles of Anti-apoA-1 Levels p-Value
First (n = 154) Second (n = 154) Third (n = 154)
Recipient demographics
Anti-apoA-1 IgG, AU (OD405 nm) 0.15 (0.11–0.19) 0.31 (0.26–0.36) 0.64 (0.52–0.82) <0.001
Recipient demographics
Age, years 50.5 (41.6–59.4) 53.4 (44.7–61.1) 52.1 (44.0–60.8) 0.12
Male gender, n (%) 84 (55) 84 (55) 84 (55) 1.00
Current smoking, n (%) 28 (18) 33 (21) 22 (14) 0.26
Previous smoking, n (%) 70 (46) 67 (44) 72 (47) 0.85
Metabolic syndrome, n (%) 83 (57) 94 (65) 84 (60) 0.34
Body composition
BMI, kg/m2 26.1 ± 4.3 26.1 ± 4.2 25.9 ± 4.2 0.86
Lipid Profile
Total cholesterol, mmol/L 5.6 ± 1.0 5.7 ± 0.9 5.7 ± 1.3 0.49
LDL cholesterol, mmol/L 3.5 ± 1.0 3.6 ± 0.8 3.6 ± 1.2 0.82
HDL cholesterol, mmol/L 1.1 ± 0.3 1.3 ± 0.3 1.1 ± 0.3 0.55
Apolipoprotein A-I, g/L 1.6 ± 0.3 1.6 ± 0.3 1.6 ± 0.3 0.75
Triglycerides, mmol/L 2.1 (1.3–2.7) 2.1 (1.4–2.5) 2.2 (1.4–2.7) 0.22
Cholesterol efflux percentage 7.3 (6.2–8.4) 7.5 (6.3–8.3) 7.6 (6.5–8.9) 0.11
Use of statins, n (%) 79 (51) 88 (57) 74 (48) 0.27
Cardiovascular disease history
History of MI, n (%) 12 (7) 8 (5) 20 (13) 0.047
TIA/CVA, n (%) 5 (3) 8 (5) 9 (6) 0.54
Blood pressure
Systolic blood pressure, mmHg 152.2 ± 23.9 151.0 ± 21.4 154.1 ± 22.0 0.47
Diastolic blood pressure, mmHg 89.8 (± 9.8) 89.0 (± 9.5) 90.1 (± 10.0) 0.59
Use of ACE inhibitors, n (%) 55 (36) 49 (32) 58 (38) 0.55
Use of β–blockers, n (%) 90 (58) 93 (60) 95 (61) 0.84
Use of diuretics, n (%) 59 (38) 75 (49) 63 (41) 0.16
Number of antihypertensive drugs, n (%) 2 (1–3) 2 (1–3) 2 (1–3) 0.16
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Table 1. Cont.
Characteristic
Gender Stratified Tertiles of Anti-apoA-1 Levels p-Value
First (n = 154) Second (n = 154) Third (n = 154)
Glucose homeostasis
Glucose, mmol/L 4.9 (4.1–5.0) 4.8 (4.1–5.0) 4.8 (4.1–5.1) 0.69
Insulin, μmol/L 11.3 (8.7–16.5) 10.6 [7.8–14.8) 11.4 (7.6–15.4) 0.16
HbA1c, % 6.3 (5.8–6.9) 6.3 (5.8–7.0) 6.4 (5.7–7.1) 0.47
HOMA-IR 3.1 (1.7–3.6) 2.7 (1.5–3.4) 2.8 (1.5–3.4) 0.21
Post-Tx diabetes mellitus, n (%) 24 (15) 29 (19) 29 (19) 0.69
Use of anti-diabetic drugs, n (%) 17 (11) 25 (16) 21 (14) 0.41
Use of insulin, n (%) 7 (5) 9 (6) 13 (8) 0.36
Inflammation
hsCRP, mg/L 3.4 (0.7–4.4) 3.3 (0.9–4.1) 3.3 (1.0–4.2) 0.43
Framingham risk score 17.2 (7.6–27.3) 20.8 (9.6–32.9) 20.7 (8.6–31.3) 0.28
Donor demographics
Age, years 37.6 (23.0–50.0) 37.2 (23.8–50.0) 37.1 (23.0–51.3) 0.76
Male gender, n (%) 76 (49) 90 (59) 85 (56) 0.24
Living kidney donor, n (%) 28 (18) 17 (11) 15 (10) 0.06
(Pre)transplant history
Dialysis time, months 34.8 (12.0–48.3) 37.0 (14.8–51.0) 33.6 (12.8–45.0) 0.44
Primary renal disease
Primary glomerular disease, n (%) 35 (23) 40 (26) 52 (34) 0.08
Glomerulonephritis, n (%) 11 (7) 6 (4) 12 (8) 0.32
Tubulo-interstitial disease, n (%) 33 (21) 24 (16) 17 (11) 0.05
Polycystic renal disease, n (%) 26 (17) 31 (20) 24 (16) 0.56
Dysplasia and hypoplasia, n (%) 7 (5) 8 (5) 2 (1) 0.15
Renovascular disease, n (%) 11 (7) 12 (8) 6 (4) 0.32
Diabetic nephropathy, n (%) 3 (2) 2 (1) 9 (6) 0.04
Other or unknown cause, n (%) 28 (18) 31 (20) 32 (21) 0.84
Immunosuppressive medication
Daily prednisolone dose, mg 9.2 (7.5–10.0) 9.1 (7.5–10.0) 9.1 (7.5–10.0) 0.33
Calcineurin inhibitors, n (%) 120 (78) 126 (82) 124 (81) 0.68
Proliferation inhibitors, n (%) 124 (81) 109 (71) 108 (70) 0.07
Renal allograft function
Creatinine clearance, mL/min 47.3 ± 14.6 48.2 ± 15.9 46.5 ± 16.1 0.62
Urinary protein excretion, g/24 h 0.3 (0.0–0.3) 0.2 (0.1–0.2) 0.4 (0.1–0.4) 0.07
Normally distributed continuous variables are presented as mean ± SD. Continuous variables with a skewed
distribution are presented as median [25th to 75th percentile]. Categorical data are summarized by n (%), and
differences were tested by chi-squared test. MI, myocardial infarction; TIA, transient ischemic attack; CVA,
cerebrovascular accident; ACE, angiotensin-converting enzyme; Tx, transplantation.
2.5. Determination of HDL Function
To determine HDL-mediated CEC, a previously published method was used [21,22]. For further
details see the Table 1.
2.6. Statistical Analysis
In order to eliminate bias due to gender specific differences in levels of anti-apoA-1 IgG renal
transplant recipients were divided into gender-stratified tertiles based on levels of anti-apoA-1 IgG.
This was done by first dividing the group into males and females, then computing tertiles based on the
levels of anti-apoA-1 IgG, and subsequently merging the groups back together. Differences between
baseline characteristics were tested. For continuous variables with a skewed distribution differences
were tested by Kruskal–Wallis test. Differences for normally distributed continuous variables were
tested by one-way analysis of variance followed by Bonferroni post-hoc test. Differences in categorical
data were tested by chi-squared test.
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Thereafter, multivariable linear regression analysis was performed to evaluate which variables
predict levels of anti-apoA-1. Baseline characteristics with a p-value of ≤0.2 between tertiles of
anti-apoA-1 IgG were first fitted into a univariate linear regression. Variables that had a significant
association with anti-apoA-1 IgG in a univariate analysis were then entered into a multivariate
linear regression.
The association of anti-apoA-1 IgG levels with the primary endpoints was assessed by the log-rank
test and by Cox proportional hazards regression. Kaplan-Meier curve analyses were performed across
anti-apoA-1 IgG tertiles and according to anti-apoA-1 IgG seropositivity, based upon a predefined and
validated anti-apoA-1 IgG cut-off value (an OD value >0.64 and a percentage of the positive control
above 37%) [7,8,11–14,18]. Differences were assessed using a log-rank test. Cox regression analyses
were used to calculate hazard ratios (HR) and reported with their 95% confidence intervals (95%CI).
Univariate and multivariate Cox regression analyses were performed per standard deviation (SD,
0.316) increase of anti-apoA-1 IgG levels, and according to anti-apoA-1 IgG seropositivity. Multivariate
analyses were performed using different models, taking into account traditional CV risk factors, renal
function, HDL functionality, and all the variables that had significant association with anti-apoA-1 levels
in linear regression. Schoenfeld residuals test was used to test the proportional hazard assumption for
the outcomes of CVD mortality, all-cause mortality and graft failure for analysis per standard deviation
increase (p = 0.18, p = 0.20 and p = 0.69 respectively) and for analysis with seropositivity (p = 0.38, p =
0.09 and p = 0.77 respectively), and was found not to be violated. Sensitivity (SN), specificity (SP),
positive predictive and negative predictive values (PPV and NPV, respectively) for anti-apoA-1 IgG
seropositivity were computed. p-values <0.05 were considered statistically significant. All statistical
analyses were performed using the Statistical Package for the Social Sciences version 24 (IBM SPSS,
IBM Corporation, Armonk, NY, USA) and GraphPad Prism version 6.0 (GraphPad Software, San Diego,
CA, USA).
3. Results
3.1. Baseline Demographic Characteristics
In this longitudinal follow-up study the levels of anti-apoA-1 IgG were measured in 462 RTR. Of
these patients, 92 (20%) died within the follow-up of 7 years, 48 of these from a confirmed CVD cause,
as determined by ICD-9 codes 410–447 (10% of included patients, 52% of all recorded deaths). A total
of 39 (8%) patients experienced graft failure. Overall, the prevalence of high levels of anti-apoA-1 IgG
(anti-apoA-1 IgG seropositivity according to a previously defined cut-off value based on data from
the general population) was 11.5 % (53/462). [7,11–13,18] In order to better explore the architecture
of anti-apoA-1 IgG in RTR, patients were divided into gender-stratified tertiles of anti-apoA-1 IgG,
with median values of 0.15 (range 0–0.24), 0.31 (range 0.24–0.49), and 0.64 (range 0.50–2.09) for the
first, second and third tertile, respectively (Table 1). Analyses between tertiles showed a significant
difference for the history of myocardial infarction (MI), which was most common in patients with
the highest levels of anti-apoA-1 IgG (p = 0.047), as well as for diabetic nephropathy (p = 0.04) as the
primary renal disease. A trend was also observed for tubulo-interstitial disease (p = 0.05), which is
characterised by acute or chronic inflammation of the renal tubules and interstitium, and primary
glomerular disease (p = 0.08), which covers a group of conditions in which there is primary injury in
the glomerulus [23].
When participating RTR were stratified according to anti-apoA-1 IgG seropositivity, there was
again a significant association with a higher prevalence of previous MI (p = 0.02), glomerular disease (p
= 0.03) and tubulo-interstitial disease (p = 0.03) as the primary renal disease (Table 1). Furthermore,
anti-apoA-1 IgG seropositive patients tended to have received grafts from older donors (p = 0.05)
and showed a higher urinary protein excretion (p = 0.04, Supplementary Table S1). Importantly,
cholesterol efflux capacity as central HDL function metric did not differ between patients seropositive
for anti-apoA-1 IgG and those seronegative for these antibodies (Supplementary Table S1).
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Subsequently, univariate and thereafter multivariate linear regression was performed to deduce
which variables are independently associated with levels of anti-apoA-1 IgG (Table 2). A positive,
independent association was seen between anti-apoA-1 IgG and a history of myocardial infarction
(β = 0.103, p = 0.026) and primary glomerular disease (β = 0.116, p = 0.016). A negative association
was seen with tubule-interstitial disease (β = −0.106, p = 0.028). No significant relationship between
anti-apoA-1 IgG and the metric of HDL function, CEC, was discernible, nor with concentrations
of HDL-C or with apoA-1. There was also no association with immunosuppressive drugs, either
individually or combined.
Table 2. Multivariate linear regression for baseline characteristics that are significantly associated with








Primary glomerular disease 0.086 0.016–0.156 0.116 0.016
History of MI 0.121 0.015–0.227 0.103 0.026
Tubulo-interstitial disease −0.0.96 −0.182–−0.010 −0.106 0.028
Variables are listed in decreasing order of strength of association. R2 = 0.043 (Cox & Snell). Model x2: 49.8; p < 0.001.
3.2. Association with Incidence of CVD Mortality, All-Cause Mortality, and Graft Failure
As shown in Figure 1, Kaplan Meier curves showed a significant association of tertiles of
anti-apoA-1 IgG with CVD mortality (p = 0.048), but not with all-cause mortality (p = 0.22) or graft
failure (p = 0.13).
Figure 1. Higher levels of anti-apoA-1 IgG are associated with an increased incidence of cardiovascular
mortality and all-cause mortality in renal transplant recipients. Kaplan-Meier curves depicting (A)
cardiovascular mortality, (B) all-cause mortality, and (C) graft failure according to tertiles of anti-apoA-1
IgG. The corresponding P value was obtained from log-rank tests.
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When Kaplan Meier curves were generated comparing anti-apoA-1 IgG seropositive versus
anti-apoA-1 IgG seronegative RTR (Supplementary Figure S1), the same associations were retrieved,
namely significance for CVD mortality (p = 0.035), but not for all-cause mortality or for incident
graft failure.
At the pre-specified cut-off for anti-apoA-1 IgG positivity, sensitivity was 18.0% (95% CI: 9–32),
specificity 89.3% (95% CI: 86–92), positive predictive value 17.0% (95% CI: 9–30) and negative predictive
value 90.0% (95% CI: 87–92) for CVD-related deaths.
Finally, as shown in Table 3 Cox regression analyses showed that anti-apoA-1 IgG levels were
significantly associated with CVD mortality in a model adjusted for age and gender (model 1, HR: 1.56,
p = 0.002). This association remained significant, independent of adjustment either for the Framingham
risk score (FRS, model 2, HR: 1.56, p = 0.002), eGFR (model 3, HR: 1.54, p = 0.004) or both parameters
combined (model 4, HR: 1.54, p = 0.004), HDL CEC (model 5, HR: 1.54, p = 0.003), history of MI
(model 6, HR: 1.45, p = 0.0013), primary renal disease (model 7, HR: 1.53, p = 0.005) and time between
transplantation and baseline (model 8, HR: 1.56, p =0.002). Importantly, FRS itself was not associated
with CVD mortality in our RTR cohort (unadjusted HR: 1.00 [0.99–1.02], p = 0.51; age and gender
adjusted HR: 1.00 [0.98–1.03], p =0.95). For all-cause mortality, the same associations were retrieved
(models 3 and 4; Table 3). On the other hand, no significant associations were detected between
anti-apoA-1 IgG levels and incident graft failure (Table 3). In our sensitivity analyses there was no
association between anti-apoA-1 IgG levels and non-CVD mortality, further supporting the specificity
of the relationship between anti-apoA-1 IgG and CVD mortality (Table 3).
Table 3. Hazard ratios for cardiovascular mortality, all-cause mortality, and graft failure per one
standard deviation increase of anti-apoA-1 IgG.





p HR [95%CI] per
1–SD Increase
p HR [95%CI] per
1–SD Increase
p HR [95%CI] per
1–SD Increase
p
Model 1 1.56 [1.17–2.07] 0.002 1.36 [1.09–1.70] 0.007 1.17 [0.93–1.48] 0.18 1.41 [0.95–2.09] 0.09
Model 2 1.56 [1.17–2.08] 0.002 1.36 [1.09–1.70] 0.007 1.18 [0.94–1.49] 0.16 1.41 [0.94–2.11] 0.09
Model 3 1.54 [1.15–2.06] 0.004 1.32 [1.05–1.67] 0.017 1.14 [0.91–1.42] 0.26 1.39 [0.92–2.08] 0.11
Model 4 1.54 [1.15–2.07] 0.004 1.32 [1.04–1.66] 0.020 1.15 [0.92–1.44] 0.22 1.39 [0.92–2.10] 0.12
Model 5 1.54 [1.16–2.05] 0.003 1.36 [1.09–1.71] 0.007 1.19 [0.94–1–50] 0.15 1.44 [0.98–2.11] 0.06
Model 6 1.45 [1.08–1.94] 0.013 1.32 [1.05–1.66] 0.016 1.14 [0.90–1.45] 0.27 1.39 [0.90–2.14] 0.14
Model 7 1.53 [1.14–2.05] 0.005 1.33 [1.06–1.67] 0.016 1.17 [0.93–1.48] 0.18 1.45 [0.96–2.20] 0.08
Model 8 1.56 [1.18–2.09] 0.002 1.37 [1.09–1.17] 0.07 1.17 [0.93–1.48] 0.18 1.47 [0.98–2.23] 0.07
Model 1: adjustment for recipient age and gender; model 2: model 1 + adjustment for FRS; model 3: model 1
+ adjustment for eGFR; model 4: model 1 + adjustment for FRS and eGFR; model 5: model 1 + adjustment for
cholesterol efflux capacity; model 6: model 1 + adjustment for history of MI; model 7: model 1 + adjustment for
primary renal disease; model 8: model 1 + adjustment for time between transplantation and baseline. In sensitivity
analysis non-CVD deaths were used as endpoint. One standard deviation is equivalent to 0.316. HR: Hazard ratios;
FRS: Framingham risk score.
When Cox regression analyses were performed according to anti-apoA-1 IgG seropositivity ,
the aforementioned associations remained unchanged, at the exception of all-cause mortality which
remained significant after adjusting for renal function, and for which the association became close to
significance after adjusting for previous MI on top of age and gender (Supplementary Table S2). Again,
no association between anti-apoA-1 IgG levels and graft failure could be observed (Supplementary
Table S2).
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4. Discussion
The novel finding of this prospective study is that anti-apoA-1 IgGs are an independent predictor
of CVD mortality in a RTR cohort with a follow-up of 7 years. Our observations indicate that traditional
CVD risk factors were presently not associated with CVD mortality. Furthermore, no association
was observed between anti-apoA-1 IgG and non-CVD mortality in the preformed sensitivity analysis.
This reinforces both the possible clinical relevance and the CVD specificity of the present findings.
Indeed, to the best of our knowledge and at the exception of renal function markers [3–5,21,22], no
specific biomarkers of CVD outcome independent of renal function have been identified so far in RTR.
Considering the absence of currently validated tools for CVD risk prediction in RTR, a rule-out test with
a 90% NPV could conceivably be of clinical interest as a first step in the field of CV risk stratification in
these patients. In this context, we hypothesize that a simple standard follow-up could be particularly
well adapted to RTR patients with low anti-apoA-1 IgG values. Further validation studies are now
required to challenge this hypothesis before any clinical recommendations can be made.
The second notable finding of this study is that anti-apoA-1 IgG were not associated with graft
failure, nor with HDL CEC. Although further reinforcing the specificity between anti-apoA-1 IgG
and CV outcomes, these results were somehow unexpected, as anti-apoA-1 IgG have been previously
shown to be associated with impaired HDL CEC [9,10], lately reported as being an independent
predictor of incident graft failure [21]. The reasons for such differences are still elusive, most
likely numerous, and possibly related to pathophysiological differences between CVD and graft
atherosclerosis. Indeed, rupture of vulnerable atherosclerotic plaques is known to underlie most
cases of acute CVD events, while this is not thought to play an important role in chronic transplant
vasculopathy-induced graft failure, where progressive arteriolar luminal narrowing due to the intimal
accumulation of degenerating smooth muscle-like cells and adventitial fibrosis represent the major
pathogenic processes [23]. Furthermore, another explanation could lie in the fact that RTR represent a
unique patient population in terms of oxidative stress exposure and persistent loss of HDL function,
when compared to e.g. systemic lupus erythematosus patients [10] or dyslipidaemic subjects with
preserved renal function [9]. Finally due to the heterogeneity of methodological protocols underlying
the numerous unstandardized HDL functional assays, we cannot exclude that an analytical difference
between our HDL assay and those from other groups could undermine the present observation [24–26].
Therefore, further studies are warranted to determine if this absence of correlation between anti-apoA-1
IgG and HDL functionality in RTR is intrinsically disease-specific.
Thirdly, this study strengthens previous observations and provides the first insights of the
anti-apoA-1 IG architecture in RTR. Indeed, the association between these antibodies with previous MI
has been consistently reported across different populations with preserved renal function [7,8,11,13].
Reproducing this association reinforces the notion that a previous acute coronary event is an important
acquired factor, that could, together with niacin therapy [9] and genetic determinants [27], contribute
to better understand the reasons underlying the existence of anti-apoA-1 IgG in individuals without
overt signs of clinical autoimmunity. In this context, we report for the first time specific associations
with primary glomerular disease and tubulo-interstitial disease as primary renal diseases possibly
associated to the existence of anti-apoA-1 IgG.
Lastly, the somewhat lower than expected prevalence of anti-apoA-1 IgG seropositivity retrieved
presently (11.5%) when compared to maintenance hemodialysis patients and the general population
(20%) [8,18], is worth a comment, as we would have expected an increased prevalence as previously
reported in all other clinical situations with a high CV risk [7,8,10,12–14,18]. A conceivable explanation
for this observation might be that RTRs are under chronic immunosuppressive medication, known to
improve features of autoimmunity and thus decrease autoantibody levels. The trend toward a decrease
in the prevalence of proliferation inhibitors along the increasing anti-apoA-1 IgG tertiles may lend
weight to this hypothesis and warrants further investigations.
Although the results of the present study lend further weight to the growing body of
evidence indicating that humoral autoimmunity contributes to CVD, we could not explore the
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mechanisms by which anti-apoA-1 IgG levels may associate with CVD in RTR. So far, previous
animal and in-vitro studies showed that anti-apoA-1 IgG could be active mediators of atherogenesis,
inducing myocardial necrosis and death in mice through toll-like receptors (TLR) [2,4] and CD14
heterodimer signaling [6,7,11,15–17,28]. Since these deleterious effects could potentially be amended
by immunomodulation therapies, either using a specific apoA-1 mimetic peptide or intravenous
immunoglobulins, anti-apoA-1 IgGs have been proposed as emergent therapeutic targets [11,29].
In accordance with these in vitro and animal experiments, a functional CD14 polymorphism was
recently shown to be a strong modulator of anti-apoA-1 IgG-related CVD risk prediction in the general
population [12]. As CD14 expressing monocytes display higher TLR2 and 4 expression in RTR [30],
knowing whether CD14 and/or TLR2/4 polymorphisms together with the presence of anti-apoA-1 IgG
could further improve prognosis assessment in RTR remains to be investigated. Given the important
pathophysiological differences between atherogenesis and transplant vasculopathy [23], knowing
whether the aforementioned molecular mechanisms could also explain the increased CV risk ascribed to
these antibodies in RTR remains unknown and constitutes an important limitation of the present study.
Further, despite the relatively large number of included RTR in this adequately powered study, the
number of events was still somewhat low, leading to restricted possibilities with regards to statistical
analysis. Since this investigation was also carried out in a single center, further validation of our
findings in a larger multicentre cohort appears desirable. In addition, it would be interesting to analyse
whether RTR with high anti-apoA-1 IgG titers show a differential response to an intervention with
cardiovascular treatment strategies. A further limitation resides in the fact that we did not measure
other autoantibodies of possible CV relevance, such as auto-antibodies to β2 glycoprotein I domain I
and IV, cardiolipin, heat-shock protein 60, and to phosphorylcholine. Because anti-apoA-1 IgG were
shown to display the strongest and independent prognostic accuracy for major adverse cardiovascular
events in non-autoimmune settings when compared to the aforementioned auto-antibodies [31], we
focused our work specifically on this class of antibodies. Knowing whether the present association
could be reproduced with other auto-antibodies remains to be shown. Also, before utilizing anti-apoA-1
IgGs as clinical biomarker, it would be interesting to screen kidney graft donors to learn, whether
intra-individual variability in titers has a potential impact on outcomes after transplantation.
In conclusion, we report anti-apoA-1 IgG as a novel prognostic biomarker for CVD mortality in
RTR, independent of traditional CVD risk factors and HDL functionality. These data indicate that
anti-apoA-1 IgG holds potential as a clinical biomarker for CVD risk stratification in RTR patients, a
high CVD risk population with altered functionality of the immune system. Further investigations to
define the potential usefulness of anti-apoA-1 IgG assessments in clinical decision making are required,
as well as studies to delineate the intrinsic pathophysiological pathways that these antibodies activate
to subsequently result in an increased CVD risk in RTR.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/2077-0383/8/7/948/s1.
Table S1: Baseline characteristics according to seropositivity of anti-apoA-1 IgG, Table S2: Hazard ratios for
cardiovascular disease mortality, all-cause mortality, and graft failure by seropositivity of anti-apoA1 IgG,
Figure S1: Seropositivity of anti-apoA-1 IgG is associated with increased cardiovascular mortality in renal
transplant recipients.
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Abstract: Background: The increased cardiovascular morbidity and mortality observed in chronic
kidney disease (CKD) patients can be partly explained by the presence of carbamoylated lipoproteins.
Lipid profiles can be determined with infrared spectroscopy. In this paper, the effects of carbamoylation
on spectral changes of non-high-density lipoproteins (non-HDL) were studied. Methods: In the
present study, fasting serum samples were obtained from 84 CKD patients (CKD stage 3–5: n = 37 and
CKD stage 5d (hemodialysis): n = 47) and from 45 healthy subjects. In vitro carbamoylation of serum
lipoproteins from healthy subjects was performed using increasing concentrations of potassium
cyanate. Lipoprotein-containing pellets were isolated by precipitation of non-HDL. The amount of
carbamoylated serum non-HDL was estimated using attenuated total reflectance-Fourier transform
infrared (ATR-FTIR) spectroscopy, followed by soft independent modelling by class analogy analysis.
Results: Carbamoylation resulted in a small increase of the amide I band (1714–1589 cm−1) of the
infrared spectroscopy (IR) spectrum. A significant difference in the amide II/amide I area under the
curves (AUC) ratio was observed between healthy subjects and CKD patients, as well as between the
two CKD groups (non-dialysis versus hemodialysis patients). Conclusions: ATR-FTIR spectroscopy
can be considered as a novel method to detect non-HDL carbamoylation.
Keywords: carbamoylation; chronic kidney disease; lipoproteins; infrared spectroscopy
1. Introduction
Carbamoylation is a post-translational modification, playing a role in chronic kidney disease
(CKD), comparable to the role of glycation in diabetes mellitus [1,2]. This non-enzymatic reaction is
characterized by a covalent binding of isocyanic acid to the amino group (either the epsilon amino
group of lysine residus or the N-terminal amino group) of amino acids, polypetides, and (lipo)proteins.
This post-translational molecular modification contributes to the molecular ageing of proteins. Isocyanic
acid is formed continuously in an equilibrium reaction with urea or by myeloperoxidase (MPO). MPO is
an enzyme (present in e.g., neutrophils, monocytes, and some tissue macrophages) that catalyzes the
oxidation of thiocyanate in the presence of hydrogen peroxide, producing isocyanate at inflammation
sites (e.g., atherosclerotic plaques) [3]. Plasma isocyanic acid concentrations increase with a declining
kidney function [4].
An increased cardiovascular morbidity and mortality (10–30 times higher than in the general
population) has been reported in the end-stage renal disease (ESRD) population [5], which can be
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partly attributed to the influence of carbamoylated lipoproteins [6]. In renal failure, dyslipidemia
contributes to a worsening kidney function. Proteinuria is accompanied by a marked elevation of
low-density lipoproteins (LDL) [7]. Due to its carbamoylation, LDL can exert its prothrombotic [8] and
atherosclerosis-prone effects by stimulating an increased adhesion of monocytes to endothelial cells [9],
by inducing endothelial dysfunction [6] and endothelial mitotic cell death [10], and by promoting
smooth muscle proliferation [11]. Carbamoylated LDL (cLDL) has been identified as the most abundant
modified LDL isoform in human blood, which is also present in healthy individuals [12]. It is generated
by carbamoylation of apolipoprotein B, the protein component of the LDL particle [13]. CKD is also
associated with decreased serum high-density lipoprotein (HDL) concentrations. Carbamoylation
of HDL leads to a loss of the atheroprotective function of HDL, illustrated by an impaired ability to
promote cholesterol efflux from macrophages [14].
As carbamoylation is of major clinical importance, practical biomarkers for assessing
carbamoylation and lipoprotein carbamoylation, in particular, are needed. In the present study,
we explored the possibilities of infrared (IR) spectroscopy to assess non-HDL carbamoylation.
The advantages of IR spectroscopy to determine lipid profiles were already applied in the past [15].
In this paper, the effects of in vitro carbamoylation on spectral changes of non-HDL were studied.
Furthermore, non-HDL carbamoylation was investigated in healthy subjects, in non-dialysis (CKD
stage 3–5) as well as in hemodialysis patients (CKD stage 5d).
2. Materials and Methods
2.1. Study Participants
The control group consisted of 45 healthy subjects (median age: 28 years, interquartile range (IQR):
24–33 years), whereas the patient group consisted of 84 CKD patients (CKD stage 3–5: n = 37, median
age: 70 years, IQR: 56–75 years, and CKD stage 5d (hemodialysis): n = 47, median age: 67 years,
IQR: 56–75 years) of the Department of Nephrology, Ghent University Hospital. The approval of this
study was granted by the Ethical committee of the Ghent University Hospital (EC/2015/0932).
2.2. In Vitro Carbamoylation of Lipids
In vitro carbamoylation of lipids was achieved by adding increasing volumes of 0.5 mol/L
potassium cyanate (KOCN) solution (Sigma–Aldrich, St. Louis, MO, USA) in a phosphate buffered salt
(PBS) solution (0.1 mol/L, pH 8.0) (Sigma–Aldrich, MO, USA) to 1000 μL serum of healthy subjects.
Serum samples were carbamoylated using increasing concentrations of KOCN: 0 mmol/L, 20 mmol/L,
50 mmol/L, 80 mmol/L and 100 mmol/L. In vitro carbamoylation was carried out for 48 h at 37 ◦C (these
reaction conditions warrant a completeness of the reaction). Proof of carbamoylation was obtained by
verifying the electrophoretic mobility of lipoprotein fractions on a lipoprotein agarose electrophosis
(Hydragel 7, Sebia, Lisses, France) using a semi-automated HYDRASYS instrument (Sebia, Lisses,
France). The separated lipoproteins were stained with a lipid-specific Sudan black stain. The excess of
stain was removed with an alcoholic solution. The resulting electropherogram was evaluated visually.
2.3. In Vitro Oxidation
Oxidative stress is involved in the exacerbation of disease burden in CKD patients. In vitro
oxidation of serum was performed to reveal potential influences on the infrared spectrum. Ten samples
from the serum pool at the laboratory of clinical biology of the University Hospital in Ghent were
randomly selected. One milliliter of each sample was pooled. Before the oxidation process, non-HDL
were precipitated 5 times. According to a modified version of the method used by Coffey et al. [16],
oxidized non-HDLs were prepared by dialyzing 4 mL of the serum pool against 400 mL isotonic saline
(0.15 mol/L NaCl (VWR International, Haasrode, Belgium) dissolved in distilled water) containing
60 μmol/L CuSO4 (copper(II)sulphate pentahydrate, Merck Eurolab, Leuven, Belgium) during one
hour. The dialysate was then changed to isotonic saline containing 0.5 mmol/L EDTA (BDH Chemicals,
63
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Poole, England) and dialysis continued during one hour with changes of dialysate every 15 min.
After the oxidation process, non-HDL were precipitated 5 times from the oxidized serum pool.
2.4. Precipitation Procedure
All serum samples were centrifugated during 10 min at 3000× g. A precipitation reaction
was performed, in which non-HDL fats very-low-density lipoprotein (VLDL), intermediate-density
lipoprotein (IDL), lipoprotein(a), LDL and chylomicrons) were precipitated. 20 μL of a 13 mmol/L
sodium phosphotungstate hydrate solution (Sigma Aldrich St Louis, MO, USA) and 5 μL of 2 mol/L
MgCl2 (E. Merck KG, Darmstadt, Germany) were added to 200 μL serum. After vortexing, the samples
were centrifuged (10 min, 6000× g) (centrifuge 54515 D, Eppendorf, Hamburg, Germany) [17]. The
precipitate was subsequently dried for 48 h in an incubator. Completeness of the precipitation
reaction was assessed by lipid electrophoresis of the serum pre- and post-precipitation (5 samples
were precipitated in triplicate). The formed pellet was ground prior to analysis with attenuated total
reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy.
2.5. ATR-FTIR Analysis
All spectra were obtained by a Perkin Elmer Two ATR-FTIR spectrometer with the ATR accesory
and spectrum 10 software (Perkin Elmer, Waltham, MA, USA). Before and after each analysis, the 50 mm
ZnSE crystal was thoroughly cleaned with an alcoholic solution (Dax alcoliquid, Dialex biomedica,
Sweden). A background scan was taken after the complete evaporation of the alcoholic solution.
The lipoprotein powder was placed in contact with the surface of the crystal until complete covering.
The pressure applied to the sample was standardised at 100 gauche to obtain a good contact between
the sample and the crystal.
Three peaks were investigated: the carbonyl peak, the peak of the amide I band and the peak
of the amide II band. Within-run coefficients of variation (CV) and between-run CV were calculated.
The area under the curves (AUC) of the amide I and amide II bands were obtained by auto-labeling of
the peaks in the Perkin Elmer 10 software.
Spectra were analyzed using the software program SIMCA version 14.1 (Umetrics, Sartorius
Stedim Biotech, Umeå, Sweden). SIMCA (soft independent modeling of class analogy) was used to
identify the spectral changes due to carbamoylation of lipoproteins. By applying various spectral
filters, the noise was eliminated and the region of interest was selected. Data were normalized
using the standard normal variate (SNV) method and were converted to their second derivative.
The Savitsky-Golay algorithm allowed smoothing of the spectrum.
2.6. Routine Laboratory Measurements
After overnight fasting, blood samples were collected and centrifuged (10 min, 3000× g).
Urea, creatinine, albumin, triglycerides, total and HDL-cholesterol concentrations were assayed
using commercial reagents on a Cobas 8000 analyzer (Roche, Mannheim, Germany) [18]. The serum
concentration of apolipoprotein B was determined by immunonephelometry on a Behring BN II
nephelometer (Siemens, Marburg, Germany) [19]. The LDL-cholesterol concentration was estimated
using the Friedewald-formula [20]. The estimated glomerular filtration rate (eGFR) was calculated
with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [21].
2.7. Statistics
Statistical analyses were performed using MedCalc (MedCalc, Mariakerke, Belgium). Normality
of distributions was tested using the D’Agostino Pearson test. Data are expressed as median ± IQR
or mean ± standard deviation (SD). Differences between patient groups were assessed using the
Student’s t-test and the Kruskall–Wallis test. The effect of the biological parameters on the spectrum
was evaluated using a multiple linear regression model. A p-value < 0.05 was considered a priori to be
statistically significant.
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3. Results
3.1. In Vitro Carbamoylation
In vitro carbamoylation of lipoproteins in serum of healthy subjects was demonstrated by agarose
gel electrophoresis, which showed a progressive increase in electrophoretic mobility of lipoproteins
with increasing KOCN concentrations. The effectiveness of the precipitation reaction was illustrated by
the disappearance of the LDL and VLDL fraction on agarose gel electrophoresis. Serum samples with
the highest concentrations of KOCN showed a less efficient precipitation, probably due to an altered
protein structure, which could interfere with the precipitation process.
Carbamoylation was further investigated with ATR-FTIR spectroscopy. Figure 1 presents the
different IR spectra of the pellet of precipitated lipoproteins, urea, and KOCN. The visual spectrum of
urea and KOCN did not interfere with the IR spectra of the precipitated lipoproteins. The between-run
and within-run CVs for the detection of the carbonyl band (4.5% and 4.9%), the amide I band (4.9%
and 8.4%) and the amide II band (5.8% and 8.1%) were low.
 
Figure 1. Infrared spectra of precipitated lipoproteins (green), urea (blue) and potassium cyanate (red).
Using the software package SIMCA 14.1, it was possible to differentiate non-carbamoylated from
in vitro carbamoylated non-HDL. The data set was centered, normalized and fitted, and a loading
line was formed from the cleaned data. We focused on the fingerprint region (1500–600 cm−1) and
the amide I and amide II region (1700–1500 cm−1). Carbamoylation resulted in a small increase in
the amide I band (1714–1589 cm−1) of the spectrum (Figure 2). The data set was reduced to the
amide I band, normalized and the second derivative was taken before fitting. Moreover, the in vitro
experiments showed a diminishing amide II band/amide I area under the curve (AUC) ratio with
increasing KOCN concentrations.
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Figure 2. Absorbance spectra of in vitro carbamoylated lipids, adding increasing concentrations of
potassium cyanate (0 mmol/L, 20 mmol/L, 50 mmol/L and 100 mmol/L) to serum of healthy subjects.
In vitro oxidation revealed an increased absorption in the amide I and amide II band (p < 0.01).
However, the amide II/amide I ratio remained the same before and after in vitro oxidation (ratio 0.55).
3.2. In Vivo Samples
Table 1 describes the general characteristics of the healthy subjects and the CKD patients. In the
in vivo part of the study, the findings of the in vitro study were compared with the CKD patients’
samples. The same spectral filters were applied and the amide I band was selected. There was a clear
distinction between the various groups (healthy subjects, patients with CKD stage 3–5 and CKD
5d patients).
Table 1. General characteristics of the healthy subjects and the chronic kidney disease patients.
Healthy Subjects CKD Stage 3, 4 or 5 CKD Stage 5d p
N 45 37 47
Median age (years) 28 (24–33) 70 (56–75) 67 (56–75) <0.0001
% diabetes mellitus 0 30 32
Urea (mmol/L) 8.9 (7.8–9.9) 25.0 (18.7–37.5) 32.8 (28.5–40.1) <0.0001
Creatinine (μmol/L) 72.5 (62.8–80.0) 160.9 (138.6–243.8) 627.6 (474.7–774.4) <0.0001
eGFR (mL/min/1.73 m2) >90 31.0 ± 13.6 <15 <0.0001
Albumin (g/L) 47.3 (45.0–50.0) 42.2 (40.3–44.5) 40.0 (36.2–42.9) <0.0001
Total cholesterol (mmol/L) 4.8 (4.3–5.5) 4.7 (3.7–5.5) 4.3 (3.7–5.8) NS
HDL cholesterol (mmol/L) 1.6 (1.3–2.0) 1.3 (1.0–1.6) 1.1 (0.9–1.5) <0.0001
LDL cholesterol (mmol/L) 2.7 (2.3–3.1) 2.3 (1.8–3.1) 2.4 (1.7–3.2) NS
Triglycerides (mmol/L) 1.0 (0.8–1.3) 1.7 (1.1–2.3) 1.4 (1.1–2.4) =0.0002
Apolipoprotein B (g/L) 0.8 (0.7–1.0) 0.8 (0.7–1.0) 0.8 (0.7–0.9) NS
NS = not significant.
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In addition, a significant difference in the amide II/amide I AUC ratio was observed between the
healthy subjects and the CKD groups (p < 0.0001) (Figure 3), as well as between the two CKD groups
(non-dialysis versus hemodialysis patients). A negative correlation was observed between the amide
II/amide I AUC ratio and the serum urea concentration (r = −0.63, p < 0.0001).
 
Figure 3. Amide II/amide I AUC ratio among the different study groups.
Multiple regression analysis with the amide II/amide I AUC ratio as a dependent variable revealed
that the serum urea concentration and the serum apolipoprotein B concentration were the main
predictors (Table 2).
Table 2. Multiple regression model with the amide II/amide I area under the curves (AUC) ratio as
dependent variable.
Variable β (Standard Error) p
Amide II/amide I AUC
ratio, r2 = 0.54, p < 0.001
Triglycerides (mmol/L) −0.001819 (0.001367) 0.1858
Apolipoprotein B (g/L) −0.0306 (0.006277) <0.0001
Creatinine (μmol/L) −0.00001067 (0.000006989) 0.1293
Urea (mmol/L) −0.0006622 (0.0001436) <0.0001
Age (years) −0.0002128 (0.00008219) 0.0108
4. Discussion
In the present study, we have demonstrated for the first time the detection of carbamoylated
non-HDL using ATR-FTIR spectroscopy. More specifically, in vitro carbamoylation of non-HDL
induced structural changes, which were clearly visible in the mid-IR spectrum of the lipid pellets.
The amide I band, containing mainly C=O stretching vibrations of protein peptide bonds was identified
as the relevant region. In the clinical part of this study, significant differences at the amide I band were
observed between healthy subjects, patients with CKD stage 3–5 and hemodialysis patients (CKD stage
5d). The amide I band depends on the secondary structure of the backbone and is, therefore, the amide
vibration, which is most commonly used for secondary structure analysis [22]. The amide II mode is
the out-of-phase combination of the N−H in plane bend and the C≡N stretching vibration with smaller
contributions from the C=O in plane bend and the C≡C and N≡C stretching vibrations. Although the
protein secondary structure and frequency correlate less straightforward than for the amide I vibration,
the amide II band provides valuable structural information [23]. Previous studies have attributed
the amide I band to apolipoproteins [24,25]. The change in the amide I band can be expected as the
carbamoylation process alters the protein component of LDL, namely apolipoprotein B [13].
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Building on the in vitro model of carbamoylation, we showed that increasing serum KOCN
concentrations resulted in a reduced amide II/amide I AUC ratio. These amide bands in the IR
spectrum take part in the adding of the carbamoyl group on the amino group of the epsilon-amino
group of lysine and the terminal amino groups. The amide II/amide I AUC ratio reflects the observed
spectral changes due to carbamoylation. Significant differences of the amide II/amide I AUC ratio were
observed between healthy subjects, patients with advanced stages of CKD and hemodialysis patients.
As expected, this ratio showed a negative correlation with the serum urea concentration. This result
is supported by earlier findings, showing a similar regression coefficient between % carbamoylated
albumin and blood urea concentrations in ESRD subjects [26].
As demonstrated in the multiple regression model, age was identified as a minor predictor of
the amide II/amide I AUC ratio in comparison with apolipoprotein B and urea. Tissue accumulation
of carbamoylated proteins may be considered as a general hallmark of ageing, linking cumulative
metabolic alterations and age-related complications. In addition to the association with carbamoylation,
many other nonenzymatic posttranslational modifications occur during the biological life of proteins,
leading to protein molecular ageing [27].
A limitation of the present study is the fact that we did not perform liquid chromatography
tandem-mass spectrometry (LC-MS/MS) to objectify the amount of carbamoylation. This technique has
already been used for the detection of carbamoylated albumin [26], but not for carbamoylated non-HDL.
However, the relationship between the amide II/amide I AUC ratio and the KOCN concentration,
as well as its relationship with the serum urea concentration are very suggestive for the carbamoylation
process of non-HDL. A potential confounder could be the effect of diabetes mellitus, as the lysine
residues are susceptible to both carbamoylation and glycation by glucose [28]. However, previous
work of our research group showed no significant changes in the amide I and amide II band after
in vitro glycation of keratins in nail powder. After incubation of nail powders with respectively 1 mL
of 0.9% sodium chloride solution, 5% glucose solution and 10% glucose solution, a clear difference
in the area under the infrared peak was observed at wavenumber 1047 cm−2, a region characterized
by a characteristic carbohydrate absorption. This band was used for measuring the degree of keratin
glycation. No influence of glycation products was observed on the amide I and amide II bands [29].
In the CKD stage 3-5 group and in the CKD 5d group, there were respectively 29.7% and 31.3% diabetics
as compared to 0% in the group of healthy subjects. In addition, also oxidation may modify lipoproteins
in a similar way as it has been demonstrated by amino acid analysis that modification of lysine residues
occurs during LDL oxidation [30]. However as demonstrated in our in vitro experiments, oxidation
had no important influence on the reported results.
5. Conclusions
Carbamoylation is involved in the pathogenesis of various diseases (atherosclerosis, kidney
diseases, autoimmune diseases, infections, and thrombus formation) and has been identified as an
important risk factor for mortality in dialysis patients or in those with accelerated atherogenesis.
The development of novel tools to determine the degree of post-translational modification-derived
products is a demanding task. At this moment, the majority of potential carbamoylation biomarkers
can only be assessed by rather complex analytical methods, hampering their use in clinical practice [2].
In the present study, we have demonstrated that ATR-FTIR spectroscopy is an easy-to-use,
reagent-free, and cost-effective method. It is a non-destructive technique, consuming only a small
amount of sample [31]. Spectral changes of non-HDL were observed depending on a declining kidney
function. So, ATR-FTIR can be regarded as a new method for identification of carbamoylated non-HDL
in CKD patients.
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Abstract: Breast cancer is the most prevalent cancer and primary cause of cancer-related mortality
in women. The identification of risk factors can improve prevention of cancer, and obesity and
hypercholesterolemia represent potentially modifiable breast cancer risk factors. In the present work,
we review the progress to date in research on the potential role of the main cholesterol transporters,
low-density and high-density lipoproteins (LDL and HDL), on breast cancer development. Although
some studies have failed to find associations between lipoproteins and breast cancer, some large clinical
studies have demonstrated a direct association between LDL cholesterol levels and breast cancer
risk and an inverse association between HDL cholesterol and breast cancer risk. Research in breast
cancer cells and experimental mouse models of breast cancer have demonstrated an important role for
cholesterol and its transporters in breast cancer development. Instead of cholesterol, the cholesterol
metabolite 27-hydroxycholesterol induces the proliferation of estrogen receptor-positive breast cancer
cells and facilitates metastasis. Oxidative modification of the lipoproteins and HDL glycation activate
different inflammation-related pathways, thereby enhancing cell proliferation and migration and
inhibiting apoptosis. Cholesterol-lowering drugs and apolipoprotein A-I mimetics have emerged as
potential therapeutic agents to prevent the deleterious effects of high cholesterol in breast cancer.
Keywords: Breast cancer; cholesterol; 27-hydroxycholesterol; HDL; LDL; cholesterol-lowering therapies
1. Introduction
Breast cancer is the third most common cancer overall, with an estimated incidence of 1.7 million
cases in 2016 and a 29% increase in incident cases between 2006 and 2016. Moreover, breast cancer
was the fifth leading cause of cancer deaths for both sexes in 2016 and the primary cause of death for
women [1]. A substantial proportion of the worldwide burden of cancer could be prevented; however,
improved primary prevention of cancer requires identification of risk markers [2]. Reproductive,
hormonal factors, and unhealthy lifestyles that trigger obesity are considered significant risk factors
for breast cancer [3]. Obesity represents a potentially modifiable risk factor that could increase the risk
of breast cancer in women [4,5]. The biological association between obesity and disease risk, at least in
part, may be related to circulating lipid levels and tissue lipid metabolism [6].
J. Clin. Med. 2019, 8, 853; doi:10.3390/jcm8060853 www.mdpi.com/journal/jcm71
J. Clin. Med. 2019, 8, 853
Cancer cells show specific alterations in different aspects of lipid metabolism, which can affect
the availability of structural lipids for the synthesis of membranes, contribution of lipids to energy
homeostasis, and lipid signaling functions, including the activation of inflammation-related pathways.
All these changes are related to important cellular processes, including cell growth, proliferation,
differentiation, and motility [7]. The interplay among cholesterol, lipoproteins, proinflammatory
signaling pathways, and tumor development has mainly been studied in breast cancer cells and
experimental models in vivo. Furthermore, in humans, both benign and malignant proliferation of
breast tissue were associated with changes in plasma lipid and lipoprotein levels [8], despite that
epidemiological data on the association between lipoproteins and breast cancer showed inconclusive
results [9–11]. This article reviews the progress to date in research on the role of cholesterol and its
main lipoprotein transporters, the low-density and high-density lipoproteins (LDL and HDL), on
breast cancer development, mainly focusing on recent findings in human trials and those obtained in
experimental models of breast cancer. PubMed was searched comprehensively with combinations of
the keyword Breast Cancer and the rest of keywords related with cholesterol and lipoproteins.
2. Association of Cholesterol in Breast Cancer Risk: Clinical and Epidemiological Studies
Study of the relationship between serum cholesterol levels and risk of cancer is of special interest
and has sparked debate, especially with the expansion of lipid-modifying therapies and more aggressive
cholesterol goals to reduce the risk of cardiovascular events [12]. However, different studies have
produced divergent results. Indeed, one study found that total cholesterol was associated with the risk
of breast cancer [13], but others failed in finding such an association [14–18], or they even found that
total cholesterol was inversely associated with the risk of breast cancer [19].
Since cholesterol is mainly transported by LDL and HDL, several clinical trials have associated
them with breast cancer. A clinical study in which the lipid profile was assessed in women with breast
cancer showed that LDL cholesterol (LDL-C) levels at diagnosis was a prognostic factor of breast tumor
progression. A systemic LDL-C level above 117 mg dL−1 was found to be a predictive factor of tumor
stage, and it was positively associated with worse prognosis because of a higher histological grade,
higher proliferative rate, and more advanced clinical stage [20] (Table 1). Moreover, patients with
LDL-C above 144 mg dL−1 were also prone to have lymph node metastasis [20]. More importantly,
a Mendelian randomization study found that genetically raised LDL-C was associated with a higher
risk of breast cancer [11]. However, other meta-analyses and prospective studies found no association
between LDL-C and breast cancer risk [9,10,16,21]; some trials even found that LDL-C or non-HDL
were inversely associated with the risk of breast cancer [14,22] (Table 1).
Concerning HDL-C, discordant results were also found. One prospective study with a follow-up
time of 11.5 years found an inverse association between HDL-C and breast cancer risk [19],
and retrospectively collected clinical data showed that decreased HDL-C levels had a significant
association with worse overall survival in breast cancer patients [23] (Table 1). In contrast, a Mendelian
randomization study showed that raised HDL-C increased the risk of estrogen receptor (ER)-positive
breast cancer [11] (Table 1). It should also be noted that other studies failed to find any association
between HDL-C and breast cancer risk [10,21,24] or survival [24]. Moreover, controversy also exists
when considering the menopausal status of patients (Table 1). Some studies have found that low
HDL-C among premenopausal women increased breast cancer risk [9,25,26], while others found that
low HDL-C was associated with an increased postmenopausal risk of breast cancer [16,27].
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Table 1. Clinical and epidemiological studies linking low-density lipoprotein cholesterol (LDL-C) and
high-density lipoprotein cholesterol (HDL-C) levels to breast cancer risk.
Reference Year Study Design Participants Main Findings
Nowak et al. [11] 2018 Mendelianrandomization >400,000
Raised LDL-C increased the risk of breast cancer
(OR = 1.09 (1.02–1.18)) and ER-positive breast cancer
(OR = 1.14 (1.05–1.24)).
Raised HDL-C increased the risk of ER-positive breast
cancer (OR = 1.13 (1.01–1.26)).
Ni et al. [16] 2015 Meta-analysis 1,189,635
Inverse association between HDL-C and breast cancer
risk among postmenopausal women (RR = 0.45
(0.64–0.93)). No association in premenopausal women.
No association between LDL-C and breast cancer risk.
Touvier et al. [9] 2015 Meta-analysis 1,489,484
Inverse association between HDL-C and breast cancer
risk among premenopausal women (HR = 0.77
(0.31–0.67)). No association in postmenopausal women.
No association between LDL-C and breast cancer risk.
Borgquist et al. [21] 2016 Prospective 5281 No evident associations between LDL-C or HDL-Cand breast cancer incidence.
Chandler et al. [10] 2016 Prospective 15,602 No association between LDL-C or HDL-C and breastcancer risk.
His et al. [19] 2014 Prospective 7557 HDL-C was inversely associated with breast cancerrisk (HR 1 mmol L−1 increment = 0.48 (0.28–0.83)).
Rodrigues dos
Santos et al. [20] 2014 Prospective 244
Systemic levels of LDL-C correlated positively with
tumor size (Spearman’s r = 0.199, p = 0.002).
Kucharska-Newton
et al. [25] 2008 Prospective 7575
Modest association of low HDL-C (<50 mg dL−1) with
breast cancer among premenopausal women
(HR = 1.67 (1.06–2.63)). No association in
postmenopausal women.
Furberg et al. [27] 2004 Prospective 30,546
The risk of postmenopausal breast cancer was reduced
in women in the highest quartile of HDL-C
(>1.64 mmol L−1) compared with women in the lowest
quartile (<1.20 mmol L−1; RR = 0.73 (0.55–0.95)).
No association was found in premenopausal women.
Li et al. [23] 2017 Retrospective 1044
Decreased HDL-C levels showed significant
association with worse overall survival
(HR = 0.528 (0.302–0.923)).




The levels of LDL-C and HDL-C were lower in breast
cancer patients than controls (p < 0.001).




No association between LDL-C or HDL-C and breast
cancer risk or survival.




HDL-C was positively associated (75th vs. 25th
percentile: 23% higher, p = 0.05) and non-HDL-C was
negatively associated (75th vs. 25th percentile: 19%
lower, p = 0.03) with breast cancer risk.




Increasing levels of LDL-C were inversely associated
with breast cancer risk (OR = 0.41 (0.21–0.81)).
Lower levels of HDL-C were associated with a
significant increase in breast cancer risk
(OR = 1.99 (1.06–3.74)).




Postmenopausal breast cancer patients had higher
LDL-C levels (p < 0.001) and lower HDL-C levels
(p = 0.025) than controls. No significant changes in
premenopausal women.




Protective effect of HDL-C on breast cancer was only
observed among premenopausal women (OR = 0.49
(0.33–0.72) for HDL-C ≥ 60 vs. <50 mg dL−1 (p < 0.01)).
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Table 1. Cont.
Reference Year Study Design Participants Main Findings




Increased LDL-C levels in postmenopausal breast
cancer patients vs. controls (p < 0.05). No significant
changes in premenopausal women.







A decrease in HDL-cholesterol was observed in
patients with breast cancer vs. controls (p < 0.05).
LDL-C = low-density lipoprotein cholesterol, HDL-C = high-density lipoprotein cholesterol, ER = estrogen receptor,
OR = odds ratio, RR = risk ratio, and HR = hazard ratio. Between brackets, 95% confidence interval.
In summary, although some studies failed to find associations between lipoproteins and breast
cancer, the results of some large clinical trials seem to point to a direct association between LDL-C
and breast cancer risk as well as an inverse association between HDL-C and breast cancer risk. It is
important to note that clinical or methodological differences in the design of the studies, including
variation in geographic regions, menopausal status, number of cases, or follow-up length, could
explain the discrepancies found in these studies (summarized in Table 1). For this reason, basic
scientific research can contribute to determining potential underlying mechanisms that may explain
these associations [12].
3. Hypercholesterolemia and Breast Cancer
Diet and obesity are important risk factors for breast cancer development [5,32]. High cholesterol
intake was found to be positively associated with the risk of breast cancer, mainly among postmenopausal
women [33,34]. To address interactions between body weight and dietary fat intake on subsequent
mammary tumor development, a study was performed in which female murine mammary tumor
virus (MMTV)-transforming growth factor α (TGFα) mice consumed a moderately high-fat diet [35].
The MMTV promoter specifically directs expression to the mammary epithelium [36], obtaining a
model that recapitulates human breast cancer progression from early hyperplasia to malignant breast
carcinoma [37]. These mice exhibited mammary tumor latency inversely related to their body fat,
suggesting that body fat may be the mediating factor of the effect of a high-fat diet on mammary
tumor development [35]. Moreover, the expression of a number of proteins associated with leptin and
apoptosis signaling pathways were also affected by diet in the mammary tumors of these animals [38].
Some studies have specifically addressed the role of dietary cholesterol in the regulation of tumor
progression in different experimental mouse models of breast cancer. Llaverias et al. studied the
role of a high-fat/high-cholesterol (HFHC) diet administration in MMTV polyoma middle T (PyMT)
oncogene transgenic mice and found that the HFHC diet accelerated and enhanced tumor progression
in these mice [39]. Plasma cholesterol levels were reduced during tumor development but not prior to
its initiation, providing new evidence for an increased utilization of cholesterol by tumors and for its
role in tumor formation [39]. Another group administered an HFHC diet to female immunodeficient
mice implanted orthotopically with MDA-MB-231 cells and found that diet induced angiogenesis and
accelerated breast tumor growth in this model of breast cancer [40].
The role of dyslipidemia in breast cancer growth and metastasis was also explored in
hypercholesterolemic apolipoprotein E knockout mice (apoE–/–) fed an HFHC diet and injected
with non-metastatic Met-1 and metastatic Mvt-1 mammary cancer cells derived from PyMT mice and
c-Myc/vegf tumor explants, respectively [41]. The apoE glycoprotein is a structural component of all
lipoprotein particles other than LDL, and it acts as a ligand of lipoprotein receptors and participates
in the uptake of lipids into cells. The absence of apoE leads to the accumulation of cholesterol and
triglycerides in plasma [42]. ApoE–/– mice exhibited increased tumor growth and displayed a greater
number of spontaneous metastases to the lungs. The results in tumor growth were only observed
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when an HFHC diet was administered to the mice, not when they were fed a standard chow diet [41].
Therefore, although the uptake of cholesterol via apoE was blocked, other adipocyte apoE-independent
receptors, such as LDL receptor (LDLR) [43], may be involved in the cholesterol uptake by cancer
cells. Moreover, the phosphoinositide 3-kinase (PI3K)/Akt pathway, involved in proinflammatory
and cell proliferation signals, was found to be one mediator of the tumor-promoting activity of
hypercholesterolemia [41].
Whereas the selection of HFHC diets for these studies reflects current dietary trends, this approach
has not allowed an evaluation of the specific effect of cholesterol on tumor biology [44]. To directly
address this question, PyMT mice were administered a high-cholesterol diet from weaning and
developed palpable tumors earlier than mice on a control chow diet were [45]. High-cholesterol diet
administration to mice injected with different breast cancer cell lines (human breast cancer HTB20
and MDA-MB-231, and the mouse breast cancer cell line 4 T1) also promoted breast tumor growth.
Tumors of animals in the high-cholesterol diet group showed a higher proliferative ratio than those
from chow-fed mice, and lung metastasis was increased [46].
4. 27-Hydroxycholesterol and Breast Cancer
Estrogen receptor α-induced signal transduction controls the growth of most breast cancers [47].
27-hydroxycholesterol (27-HC), one of the most prevalent oxysterols, was identified as an endogenous
selective ER modulator (SERM) and liver X receptor (LXR) agonist [48]. This oxysterol is generated
enzymatically from cholesterol by the P450 enzyme sterol 27-hydroxylase CYP27A1. CYP27A1 is
abundant in the liver, but it is also expressed in the intestine, vasculature, brain, and macrophages.
27-HC is mainly transported in association with HDL and LDL, primarily in the esterified form [49].
Regarding its catabolism, 27-HC is hydroxylated by oxysterol 7α-hydroxylase CYP7B1, which is also
abundant in the liver [50].
The first evidence for 27-HC’s role in breast cancer began with studies that found that it stimulated
the growth of ER-positive MCF-7 cells but not that of ER-negative MCF-10 cells. The effect of a
concentration of 1–2 μM of 27-HC was similar to that of 1–2 nM of 17β-estradiol [51]. The proliferative
role of 27-HC in vitro on MCF-7 cells was also confirmed by others, who also reported that 27-HC
increased tumor growth in vivo in PyMT mice and in murine or human cancer cell xenografts [45,52].
27-HC was also found to hasten metastasis to the lungs, an effect that implicated LXR activation [45].
27-HC also hastened myeloid immune cell functions, as it was found that this oxysterol increased the
number of polymorphonuclear neutrophils and γδ T cells as well as decreased cytotoxic CD8+ T cells
within tumors and metastatic lesions [53].
In human breast cancer tissue, 27-HC concentration was found to increase because of decreased
catabolism, since CYP7B1 gene expression was downregulated, whereas CYP27A1 remained unchanged.
Moreover, increased CYP7B1 mRNA was correlated with better survival [52]. Consistently, Nelson
et al. found increased CYP27A1 protein expression in higher grade tumors [45]. Nevertheless, the first
prospective epidemiological study on prediagnosis of circulating 27-HC and breast cancer risk showed
an inverse association between blood 27-HC and breast cancer risk among postmenopausal women.
The authors hypothesized that 27-HC-associated inhibition of estradiol–ER binding outweighed
27-HC’s agonistic effect in human breast cancer [54].
Unlike humans, mice do not normally become severely hypercholesterolemic when fed an HFHC
diet [44]. To circumvent this limitation, breast cancer cells were implanted in mice in which the mouse
Apoe gene was replaced with the human APOE3 allele, which codes for the most frequent human
isoform. The animals on an HFHC diet exhibited both increased cholesterol and 27-HC in plasma as
well as promotion of larger tumors, effects that were partially reversed by treatment with the CYP27A1
inhibitor GW273297X [45].
Several studies investigated the potential mechanisms involved in 27-HC-induced breast cancer
development. First, 27-HC inhibited p53 protein and activity in MCF-7 cells via ER. The oxysterol
increased p53 regulator mouse double minute 2 (MDM2) levels and enhanced interaction between
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p53 and MDM2, suggesting that 27-HC proliferation depended on MDM2-mediated p53 degradation.
Interestingly, estradiol, the main physiological endogenous ligand for ER, which had similar
effects to 27-HC on cell proliferation, had no effect on p53 activity; this demonstrates that 27-HC
may contribute to ER-positive breast cancer progression via different mechanisms compared with
known estrogens [55]. Another study found that 27-HC increased Myc protein stability (a critical
oncogene that can promote proliferation, migration, and invasion of cancer cells) by reducing its
dephosphorylation and ubiquitination for proteasomal degradation [56]. Signal transducer and
activator of transcription (STAT)-3 is an important transcription factor that can target c-Myc, vascular
endothelial growth factor (VEGF), cyclin D1, matrix metalloproteinase (MMP) 2, and MMP9 to promote
the development of cancer involving tumor proliferation, invasion, metastasis, and angiogenesis [57].
27-hydroxycholesterol induced activation of STAT-3, which promoted the angiogenesis of breast cancer
cells via proinflammatory-related reactive oxygen species (ROS)/STAT-3/VEGF signaling [58]. Moreover,
it induced the epithelial–mesenchymal transition (EMT) [59], a mechanism that promotes migration and
invasion, via STAT-3/MMP9 and STAT-3/EMT [60], in both ER-positive and ER-negative breast cancer
cells. Furthermore, 27-HC causes greater macrophage infiltration and exacerbation of inflammation in
the setting of hypercholesterolemia [61], thereby providing a link between inflammation and cancer
development. Collectively, mechanisms involved in 27-HC-promoted progression of breast cancer are
complex. Therefore, seeking effective measures to prevent 27-HC-caused pathogenicity is difficult,
and further studies should be carried out with an emphasis on deeply investigating the potential
mechanisms involved in 27-HC breast cancer promotion [58].
The discovery of 27-HC as an endogenous ER ligand that promotes ER-positive breast tumor
growth could help explain why some breast cancer patients are resistant to aromatase inhibitors [62].
In this way, 27-HC may act as an alternate estrogenic ligand in a low-estrogen environment [63].
Assessments of 27-HC or their metabolic enzymes’ abundance in tumors could aid in personalizing
hormone-based therapy [64].
5. Low-Density Lipoprotein and Breast Cancer
Proliferating cancer cells have an increased cholesterol need. Increased LDLR expression was
demonstrated in breast cancer tissue to increase the uptake of LDL-C from the bloodstream [65]. In vitro,
LDLR gene and protein expression was found increased in ER-negative MDA-MB-231 cells in contrast
to ER-positive MCF-7 cells [66,67]. Accordingly, LDL-C mainly promoted proliferation [68–70] and
migration [46,71] in ER-negative cells, but this was not evident in ER-positive cell lines. This difference
between the two cell types corresponded to a greater ability of ER-negative cells to take up,
store, and utilize exogenous cholesterol because of the increased activity of acyl-CoA:cholesterol
acyltransferase 1 (ACAT1) [68]. The Women’s Intervention Nutrition Study (WINS) found that a
low-fat diet mainly extended relapse-free survival in women with ER-negative breast cancer [72].
At least in part, that ER-negative breast cancer cells differentially uptake and store cholesterol may
explain the differential effect of a low-fat diet on human breast cancer recurrence [68]. Another study
found that LDL-C also induced proliferation in ER-positive BT-474 breast cancer cells [46]. This
discrepancy could be because BT-474 cells usually express the Her2 (ErbB2) receptor [73]; furthermore,
high plasma LDL-C levels were found to be associated with Her2-positive breast cells [20]. It
is noteworthy that the Her2-positive and triple-negative subtypes are the most aggressive breast
cancers [74].
Beyond in vitro studies, tumors from breast cancer cells with high LDLR expression
(murine MCNeuA (Her2-positive) and human MDA-MB-231 (triple-negative), respectively) have
been incrementally grown in immunocompetent (LDLR–/– and apoE–/–) and immunodeficient
(Rag1–/–/LDLR–/– and Rag1–/–/apoE–/–) mouse models of hyperlipidemia with increasing serum LDL
concentrations. Importantly, silencing LDLR in the tumor cells reduced tumor growth [67].
Finally, in human samples, LDLR and ACAT1 were also found to be increased in Her2-positive and
triple-negative tumors compared with luminal A tumors. Her2-positive and triple-negative tumors
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were more cholesteryl ester-rich and had higher histological grades, Ki-67 expression, and tumor
necrosis. Therefore, cholesteryl ester accumulation due to increased LDL-C internalization and
esterification was associated with breast cancer proliferation [75]. In line with these findings, higher
LDLR expression was found to be associated with a worse prognosis in patients who underwent
systemic therapy [67]. Overall, elevated circulating LDL and breast cancer expression of LDLR
have roles, at least in Her2-positive and triple-negative breast cancers, in disease progression and
disease-free survival.
Oxidized Low-Density Lipoprotein and Breast Cancer
Lipid peroxidation is associated with carcinogenesis [76]. Lipid peroxidation metabolites cause
structural alterations in DNA and decrease DNA repair capacity through their direct interaction with
repair enzymes [77]. The oxidation of LDL affects both protein and lipid contents, resulting in the
formation of peroxidation metabolites. Patients with breast cancer exhibited elevated serum levels
of oxidized LDL (oxLDL) [78]. Moreover, serum oxLDL levels were associated with increased breast
cancer risk [78]. Oxidized LDL was also reported to trigger pro-oncogenic signaling in MCF10A cells;
concretely, cells treated with oxLDL showed a dose-dependent stimulation of proliferation mediated by
stimulation of the microRNA miR-21, which, in turn, activated the related proinflammatory PI3K/Akt
signaling pathways [79].
OxLDL lecithin-like receptor 1 (OLR1) is the main receptor for internalization of oxLDL. It is
overexpressed in human breast cancer and positively correlates to tumor stage and grade [80].
A microarray analysis of hearts of Olr1 KO mice compared with wild-type mice showed a reduction in
the expression of nuclear factor κB (NF-κB) target genes involved in cellular transformation (regulation
of apoptosis, proliferation, wound healing, defense response, immune response, and cell migration)
as well as an inhibition of key enzymes involved in lipogenesis. The human breast cancer cell line
HCC1143 showed increased OLR1 expression compared with the normal mammary epithelial cell line
MCF10A [81]. Forced overexpression of OLR1 in both cell lines resulted in upregulation of NF-κB
and its target pro-oncogenes involved in the inhibition of apoptosis (BCL2, BCL2A1, and TNFAIP3)
and regulation of the cell cycle (CCND2) in HCC1143 cells. Moreover, upregulation of OLR1 in breast
cancer cell lines enhanced cell migration [81,82]. In line with these findings, OLR1 depletion by
siRNAs, or ORL1 inhibition by antibodies or a recombinant OLR1 protein, significantly suppressed
the invasion and migration of breast cancer cells [81–83]. TBC1D3 is a hominoid-specific oncogene
that also regulates migration of human breast cancer cells. TBC1D3 was found to stimulate the
expression of OLR1, and this TBC1D3-induced OLR1 expression was regulated by tumor necrosis
factor α (TNFα)/NF-κB signaling [84]. Therefore, OLR1 may function in special situations, such as
obesity and chronic inflammation, to increase breast cancer susceptibility.
6. High-Density Lipoprotein and Breast Cancer
Controversy exists about the association between HDL-C levels and breast cancer risk, as detailed
in Section 2. In the present section, experimental data evaluating the role of HDL in breast cancer
development are reviewed. In vitro analyses have shown that HDL stimulated proliferation in both
ER-positive [69,85] and ER-negative breast cancer cell lines [69] in a dose-dependent manner, but
ER-negative cells showed a higher response [69]. Human HDL3 also induced migration and activated
Akt and extracellular signal-regulated kinases (ERK)1/2 signal transduction pathways in both MCF7
and MDA-MB-231 cells [86].
The scavenger receptor class B type I (SR-BI) acts as an HDL receptor and mediates its cholesterol
uptake in breast cancer cells [87]. The receptor SR-BI is abundantly expressed in human breast
cancer tissue compared with adjacent normal tissue [88]. Moreover, high SR-BI expression was
found related to tumor aggressiveness and poor prognosis in breast cancer [75,89,90], whereas
knockdown of SR-BI in vitro attenuated Akt activation and inhibited breast cancer cell proliferation
and migration [86]. Moreover, HDL-induced proliferation was blocked in transfected MCF-7 cells with
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a mutant, nonfunctional SR-BI [88]. Beyond in vitro studies, mice injected with SR-BI-knockdown
breast cancer cells showed a decreased tumor burden, accompanied with reduced Akt and ERK1/2
activation, reduced angiogenesis, and increased apoptosis [86]. Therefore, cholesteryl ester entry via
HDL-SR-BI and Akt signaling seems to play a critical role in the regulation of cellular proliferation
and migration and tumor growth. SR-BI was also found to increase concomitantly with an increased
number and size of tumors in PyMT mice fed an HFHC diet compared with those fed a chow diet.
However, cholesterol was not found accumulated in the mammary tumors, suggesting that even if
tumor cholesterol uptake was increased, cholesterol was probably metabolized to sustain a high level
of proliferation [39].
Serum HDL particles contain either a single copy or multiple copies of apolipoprotein A-I
(apoA-I), the most abundant HDL apolipoprotein [91]. Apolipoprotein A-I plays a role in promoting
cholesterol release from cells; possesses anti-inflammatory, antioxidant, and antiapoptotic properties;
and influences innate immunity [92]. The levels of apoA-I have normally been found to be inversely
associated with breast cancer risk [19,93,94], although one study found that apoA-I was positively
associated with breast cancer [21]. Our group showed that human apoA-I-containing HDL could not
hinder breast tumor development in PyMT mice. While overexpression of human apoA-I reduced the
levels of oxLDL, 27-HC levels were increased, which could promote tumor growth [95]. Concerning
apoA-II, the second major protein constituent of HDL [96], our research group showed that human
apoA-II-containing HDL increased the breast tumor burden in PyMT mice (Figure 1A) (unpublished
results). These results may be related with the apoA-II-mediated alteration in HDL remodeling,
decreased capacity to protect against LDL oxidative modification and its proinflammatory actions,
and postprandial hyperlipidemia (Figure 1B) [97,98].
Figure 1. Effects of human apolipoprotein A-II (hApoA-II) overexpression on tumor development
in polyoma middle T (PyMT) mice. PyMT mice were backcrossed with hApoA-II transgenic (TG)
mice on a C57BL/6 background. The mice were maintained on a regular chow diet until 19 weeks of
age, when they were euthanized, and the mammary glands were excised and weighed. Serum lipids
were determined after an overnight fasting period and 3 h after a 0.15 mL dose of olive oil by oral
gavage. A) Mammary gland weight. B) Serum lipid levels in fasting and postprandial conditions
(TG = triglycerides, and HDL-C = high-density lipoprotein cholesterol). Values shown represent the
mean ± SEM. A t-test was performed to determine the statistical significance between groups. * p < 0.05
vs. PyMT mice.
Dysfunctional High-Density Lipoprotein and Breast Cancer
Under conditions of oxidative stress, HDL can be oxidatively modified, and these modifications
may have an effect on HDL function. Hypochlorite-oxidized HDL was found to stimulate cell
proliferation, migration, invasion, and adhesion in vitro, involving the protein kinase C (PKC) pathway,
which regulates numerous cellular responses including cell proliferation and the inflammatory response.
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This modified HDL promoted breast cancer cell pulmonary and hepatic metastasis compared with
normal HDL in vivo. Interestingly, in this study, normal HDL reduced the metastasis of MCF7 cells in
the liver compared with control animals in which HDL was not injected [99].
In patients with type 2 diabetes mellitus (T2DM), HDL can be modified into dysfunctional glycated
HDL and oxidized HDL [100]. Indeed, T2DM patients have a 20% increased risk of breast cancer
compared with nondiabetic subjects [101]. In this context, diabetic HDL was found to have a stronger
capability to promote cell proliferation, migration, and invasion of breast cancer cells through the Akt,
ERK, and p38 mitogen-activated protein kinase (MAPK) pathways. These observations were also found
in glycated and oxidized HDL produced in vitro, compared with normal HDL [102]. Pretreatment
with diabetic, glycated, and oxidized HDL also promoted the metastasis capacity of breast cancer
cells in vivo, and it increased their capacity of adhesion to human umbilical vein endothelial cells
(HUVECs) and attachment to the extracellular matrix in vitro, compared with normal HDL. These
effects mainly were due to elevated PCK activity, which, in turn, could stimulate secretion of integrins,
which are important in promoting breast cancer metastasis [103]. Similarly, HDL isolated from patients
with breast cancer complicated with T2DM promoted an increase in breast cancer cell adhesion to
HUVECs and stimulated higher intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion
molecule 1 (VCAM-1) expression on the cell surfaces of breast cancer cells and HUVECs, along with
the activation of PKC, compared with HDL isolated from breast cancer patients. However, in breast
cancer patients complicated with T2DM, a lower expression of ICAM-I and VCAM-I was found in their
tumor tissue, which may contribute to the metastasis of tumor cells [104]. Collectively, associations
between T2DM and breast cancer could be attributed, in part, to alterations in HDL structure and
composition and their proinflammatory actions.
7. Effects of Cholesterol-Lowering Therapies on Breast Cancer
The studies reviewed indicate that cholesterol and its main metabolite, 27-HC, may increase breast
cancer development and metastasis. To address this, cholesterol-lowering drugs have emerged as
potential therapies to reverse the deleterious effects of impaired cholesterol metabolism in breast cancer.
7.1. Statins
Statins are inhibitors of the enzyme hydroxy-methyl-glutaryl-coenzyme A reductase (HMGCR),
which catalyzes the conversion of HMG-CoA to mevalonate, the rate-limiting step of cholesterol
synthesis [105]. In humans, the effect of statins in cancer prevention and treatment remains controversial
(Table 2). The use of lipid-lowering drugs, and more concretely, statins, was found to be associated
with a reduced risk of breast cancer in older women [106]. Specifically, the use of lipophilic statins but
not hydrophilic statins were found to significantly reduce the risk of breast cancer in Thai women [107].
Conversely, other studies, including a large Mendelian randomization study, failed to find a protective
effect of statins against breast cancer risk [108–113], or they even found a positive association between
long-term use of statins and increased risk of breast cancer [114]. In contrast, treatment with statins
seems to have a more important effect in protecting against breast cancer recurrence and death [115–122].
Considering the type of statin, lipophilic statins were mainly found to be associated with a reduced
risk of breast cancer recurrence or mortality [123–125], although hydrophilic statin use was also found
to be associated with improved progression-free survival compared with no statin use in inflammatory
breast cancer patients [126]. Taken together, HMGCR inhibitors do not seem to protect against breast
cancer development, but statins, and more concretely, lipophilic statins, could be a good strategy for
protecting against breast cancer recurrence and death.
Statins also exert antiproliferative and cytotoxic effects on breast cancer cells in vitro by increasing
apoptosis, autophagy, and cell cycle arrest [127,128]. However, only lipophilic statins show anticancer
activity [129], and the ER-negative phenotype seems to be more sensitive than those that overexpress
ER [129,130]. ER-positive cell resistance to statin treatment is associated with high expression of
cholesterol biosynthesis genes [131].
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In vivo studies have also reported controversial results. Atorvastatin was able to reduce the level
of circulating cholesterol, and it attenuated enhanced tumor growth and lung metastasis associated
with an HFHC diet in a transgenic model in which the murine Apoe gene was replaced with the human
APOE3 allele and injected with ER-positive E0771 murine mammary cancer cells [45,53]. Moreover,
simvastatin and fluvastatin treatments were found to inhibit tumor growth in mice inoculated with
breast cancer cells [129,132], and fluvastatin was also found to reduce the metastatic burden in a
murine breast cancer metastasis model [133]. The mechanisms of action of simvastatin included
the inhibition of NF-κB transcription factor, which attenuated expression of antiapoptotic BclXL
and derepressed expression of the antiproliferative/proapoptotic tumor suppressor PTEN, which
reduced the phosphorylation of Akt, resulting in decreased cancer cell proliferation and survival [132].
In contrast, statin treatment failed to reduce plasma cholesterol levels or tumor growth in mice injected
with breast cancer cells on an HFHC diet [46] or other models of breast cancer in mice and rats [134].
An explanation for these negative results could be that mice are generally unresponsive to statins [135].
Finally, an interesting study investigated the biological effect of short-term lipophilic fluvastatin
exposure on in situ and invasive breast cancer through paired tissue, blood, and imaging-based
biomarkers in women with a diagnosis of ductal carcinoma in situ or stage 1 breast cancer. Fluvastatin
exposure showed reduced tumor proliferation and increased apoptotic activity in high-grade breast
cancer, concomitant with a reduction of cholesterol levels [136]. An upregulation of HMGCR was
observed in breast cancer patients after two weeks of atorvastatin treatment, which was interpreted
as activation of the negative feedback loop controlling cholesterol synthesis. Moreover, in tumors
expressing HMGCR before treatment with atorvastatin, the proliferation marker Ki67 was found to be
downregulated. In summary, these results suggested that HMGCR was targeted by statins in breast
cancer cells in vivo, and that statins could have antiproliferative effects, mostly in HMGCR-positive
breast cancers [137]. Importantly, atorvastatin was also found to decrease serum 27-HC and CYP27A1
expression in tumors of breast cancer patients [138].
Table 2. Clinical and epidemiological studies linking statin treatment to breast cancer risk.
Reference Year Study Design Participants Main Findings
Ference et al. [113] 2019 Mendelianrandomization 654,783
Genetic inhibition of HMGCR did not affect breast
cancer risk.
Islam et al. [109] 2017 Meta-analysis 121,399 There was no association between statin use and breastcancer risk.
Liu et al. [123] 2017 Meta-analysis 197,048
Significant protective effects of lipophilic statin use,
but not hydrophilic statins, against cancer-specific
mortality (HR = 0.57 (0.46–0.70)).
Mansourian et al.
[116] 2016 Meta-analysis 124,669
Significant reduction in breast cancer recurrence
(OR = 0.792 (0.735–0.853)) and death (OR = 0.849
(0.827–0.870)) among statin users.
Manthravadi et al.
[124] 2016 Meta-analysis 75,684
Lipophilic statin use was associated with improved
recurrence-free survival (HR = 0.72 (0.59–0.89)).
Wu et al. [119] 2015 Meta-analysis 144,830
There was a significantly negative association between
prediagnosis statin use and breast cancer mortality
(for overall survival: HR = 0.68 (0.54–0.84), and for
disease-specific survival (HR = 0.72 (0.53–0.99)). There
was also a significant inverse association between
postdiagnosis statin use and breast cancer
disease-specific survival (HR = 0.65 (0.43–0.98)).
No significant association was detected between statin
use and breast cancer risk.
Undela et al. [111] 2012 Meta-analysis >2.4 million Statin use and long-term statin use did notsignificantly affect breast cancer risk.
Bonovas et al. [108] 2005 Meta-analysis 327,238 Statin use did not significantly affect breast cancer risk.
Dale et al. [112] 2005 Meta-analysis 86,936 Statins did not reduce the incidence of breast cancer.
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Table 2. Cont.
Reference Year Study Design Participants Main Findings
Borgquist et al.
[115] 2017 Prospective 8010
Initiation of cholesterol-lowering medication in
postmenopausal women with early stage, hormone
receptor-positive invasive breast cancer during
endocrine therapy was related to improved
disease-free survival (HR = 0.79 (0.66–0.95)), breast
cancer-free interval (HR = 0.76 (0.60–0.97)), and distant
recurrence-free interval (HR = 0.74 (0.56–0.97)).
Murtola et al. [122] 2014 Prospective 31,236
Both postdiagnostic and prediagnostic statin uses were
associatedwith a lowered risk of breast cancer death
(HR = 0.46 (0.38–0.55) and
HR = 0.54 (0.44–0.67), respectively).
Brewer et al. [126] 2013 Prospective 723
Hydrophilic statins were associated with significantly
improved progression-free survival compared with no
statin (HR = 0.49 (0.28–0.84)) in inflammatory breast
cancer patients.
Ahern et al. [125] 2011 Prospective 18,769
Significant reduction in breast cancer recurrence
among patients using simvastatin after 10 y of follow
up (adjusted HR = 0.70 (0.57–0.86)).
Cauley et al. [106] 2003 Prospective 7528
Older women who used statins had a reduced risk of
breast cancer (RR = 0.28 (0.09–0.86), adjusted for age
and body weight) compared with nonusers.
Shaitelman et al.
[120] 2017 Retrospective 869
Statin use was significantly associated with overall
survival (HR = 0.10 (0.01–0.76)) in triple-negative
breast cancer.
Smith et al. [121] 2017 Retrospective 6314
Prediagnostic statin use was associated with breast
cancer-specific mortality (HR = 0.81 (0.68–0.96)). This
reduction was greatest in statin users with ER-positive
tumors (HR = 0.69 (0.55–0.85)).
Anothaisintawee
et al. [107] 2016 Retrospective 15,718
Using lipophilic statins, but not hydrophilic statins,
could significantly reduce the risk of breast cancer
(risk difference = –0.0034
(–0.006,–0.001) lipophilic statin users vs. nonusers).
Mc Menamin et al.
[139] 2016 Retrospective 15,140
There was no evidence of an association between statin
use and breast cancer-specific death.
Sakellaki et al.
[117] 2016 Retrospective 610
Statins may be linked to a favorable outcome in early
breast cancer patients,
especially in younger age groups
(HR = 0.58 (0.36–0.94)).
Chae et al. [118] 2011 Retrospective 703
Significant reduction in breast cancer recurrence
among patients who used statins (HR = 0.43
(0.26–0.70)). No association was found regarding
overall survival.








Cases: 916 IDC +
1068 ILC
Controls: 902
Current users of statins for ≥10 y had increased risk of
IDC (OR = 1.83 (1.14–2.93)) and ILC (OR = 1.97
(1.25–3.12)) compared with never users of statins.
OR = odds ratio, RR = risk ratio, HR = hazard ratio, y = years, IDC = invasive ductal carcinoma; and ILC = invasive
lobular carcinoma. Between brackets, 95% confidence interval.
7.2. Ezetimibe
Ezetimibe is a drug that specifically targets intestinal Niemann-Pick C1-Like 1 (NPC1L1) and
mediates the inhibition of intestinal sterol absorption [140]. Few studies have explored the effects of
ezetimibe on breast cancer. However, considering that statins may have little effect on plasma cholesterol
in mice [135], ezetimibe’s action on breast cancer development is of interest. A study by Pelton et al.
investigated the effects of ezetimibe administered in an HFHC diet on breast cancer development in an
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orthotopic breast tumor model, in which mice were implanted with MDA-MB-231 cells. Ezetimibe was
able to reduce tumor volume, proliferation, and angiogenesis and increase apoptosis compared with
the HFHC-fed mice, achieving similar results to those in mice fed a low-fat/low cholesterol (LFLC) diet.
These results were accompanied with a reduction in circulating cholesterol levels, but intratumoral
cholesterol levels remained unchanged [40].
To our knowledge, the effects of ezetimibe treatment on breast cancer risk or mortality have
not been studied. Only Kobberø Lauridsen et al. explored the effects of genetic variants of NPC1L1
(–133A>G and V1296V T>C), mimicking treatment with ezetimibe, on breast cancer risk. These
researchers found that NPC1L1 variants were not associated with the risk of breast cancer [141].
7.3. Phytosterols
Plant sterols, or phytosterols, lower serum LDL-C levels by reducing intestinal cholesterol
absorption [142]. Several in vivo studies have tested the efficacy of dietary phytosterol in breast
cancer development. Female severe combined immunodeficiency (SCID) mice supplemented with
2% phytosterols and injected with MDA-MB-231 cells exhibited a reduction in serum cholesterol,
accompanied with a reduction in tumor size and metastasis to lymph nodes and lungs [143].
In ovariectomized athymic mice injected with MCF-7 cells, supplementation with β-sitosterol,
the most common phytosterol, was also able to reduce tumor size [144]. Furthermore, phytosterol
supplementation could decrease both the development of mammary hyperplastic lesions and tumor
burden in PyMT mice fed an HFHC diet. This protective effect was not observed in mice fed an LFLC
diet. A potential mechanism of action of phytosterol was the prevention of lipoprotein oxidation [145].
Numerous experimental in vitro studies showed that phytosterols functioned as anticancer
compounds acting on host systems to affect tumor surveillance or on tumors to affect tumor cell
biology. Mechanisms affecting the tumors include slowing of cell cycle progression, induction of
apoptosis, inhibition of tumor metastasis, altered signal transduction, and activation of angiogenesis.
Host influences comprise enhancing immune recognition of cancer, influencing hormonal-dependent
growth of endocrine tumors, and altering cholesterol metabolism (reviewed in [146,147]).
7.4. Other Therapies
Fibrates are agonists of the peroxisome proliferator-activated receptor α (PPARα), which stimulate
the expression of genes involved in fatty acid and lipoprotein metabolism, resulting in a shift
from hepatic fat synthesis to fat oxidation. Fibrates are used as therapeutic agents for treating
dyslipidemia [148]. A meta-analysis of 17 long-term, randomized, placebo-controlled trials found that
fibrates had a neutral effect on breast cancer and other cancer outcomes [149].
The levels of HDL-C and apoA-I are inversely related to cardiovascular risk [150]. The beneficial
effects of HDL have largely been attributed to apoA-I, and researchers have sought apoA-I mimetic
peptides as therapeutic agents based on physical–chemical and biological properties [151]. To our
knowledge, a study from our group was the only one to analyze the effects of apoA-I mimetics on
breast cancer. In that study, the apoA-I mimetic peptide D-4F was administered to PyMT female mice,
and the treatment significantly increased tumor latency and inhibited the development of tumors.
D-4F was unable to reduce the levels of 27-HC in the tumors, but it decreased the plasma levels of
oxLDL and prevented the oxLDL-mediated proliferative response in MCF-7 cells, suggesting that D-4F
inhibited breast cancer by protecting against LDL oxidative modifications [95].
8. Concluding Remarks
Results of some large clinical studies indicate a direct association for LDL-C and an inverse
association for HDL-C and breast cancer risk; however, these findings have not been reproduced in all
epidemiological studies and are still debated. Basic research studies have determined the important
role of cholesterol, especially the 27-HC metabolite, and its transporters in breast cancer development.
Both LDL and HDL, and their modified forms (oxLDL and oxidized and glycated HDL), may promote
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breast cancer via several mechanisms. Investigations in breast cancer cells and experimental models
in vivo have demonstrated an interplay among modified lipoproteins, proinflammatory signaling
pathways, and breast cancer tumorigenic processes (summarized in Figure 2). Cholesterol can be
esterified or metabolized to 27-HC, which has been hypothesized to be responsible for stimulating the
proliferation of ER-positive breast cancer cells rather than cholesterol (Figure 2). Oxidized LDL as well
as oxidized and glycated HDL induce different OLR1 and SR-BI downstream inflammation-related
pathways, thereby inhibiting apoptosis and enhancing cell proliferation and migration. Therefore,
considering the important role of cholesterol in breast cancer development, cholesterol-lowering drugs
and apoA-I mimetics, which possess antioxidant and anti-inflammatory properties, could emerge as
potential therapies for preventing the deleterious effects of high cholesterol in breast cancer. Lipophilic
statins seem a good strategy for protecting against breast cancer recurrence and death. However, more
studies in humans are necessary to evaluate the role of other therapies, such as ezetimibe, phytosterols
or fibrates, on breast cancer risk and prognosis.
Figure 2. Mechanisms by which low-density lipoprotein (LDL), high-density lipoprotein (HDL),
and their modified forms induce proliferation and migration and reduce apoptosis in breast cancer
cells. OLR1 = OxLDL lecithin-like receptor 1, LDLR = LDL receptor, SR-BI = scavenger receptor class B
type I, HMGCR = hydroxy-methyl-glutaryl-coenzyme A reductase, ACAT1 = acyl-CoA:cholesterol
acyltransferase 1, 27-HC = 27-hydroxycholesterol, ERK1/2 = extracellular signal-regulated kinases 12 ,
NFκB = nuclear factor κB, and ER/LXR = estrogen receptor/liver X receptor.
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Abstract: Angiopoietin-like proteins (ANGPTLs) regulate triglyceride (TG)-rich lipoprotein
distribution via inhibiting TG hydrolysis by lipoprotein lipase in metabolic tissues. Brown adipose
tissue combusts TG-derived fatty acids to enhance thermogenesis during cold exposure. It has
been shown that cold exposure regulates ANGPTL4, but its effects on ANGPTL3 and ANGPTL8
in humans have not been elucidated. We therefore investigated the effect of short-term cooling on
plasma ANGPTL3 and ANGPTL8, besides ANGPTL4. Twenty-four young, healthy, lean men and
20 middle-aged men with overweight and prediabetes were subjected to 2 h of mild cooling just
above their individual shivering threshold. Before and after short-term cooling, plasma ANGPTL3,
ANGPTL4, and ANGPTL8 were determined by ELISA. In young, healthy, lean men, short-term
cooling increased plasma ANGPTL3 (+16%, p < 0.05), ANGPTL4 (+15%, p < 0.05), and ANGPTL8
levels (+28%, p < 0.001). In middle-aged men with overweight and prediabetes, short-term cooling
only significantly increased plasma ANGPTL4 levels (+15%, p < 0.05), but not ANGPTL3 (230 ± 9
vs. 251 ± 13 ng/mL, p = 0.051) or ANGPTL8 (2.2 ± 0.5 vs. 2.3 ± 0.5 μg/mL, p = 0.46). We show that
short-term cooling increases plasma ANGPTL4 levels in men, regardless of age and metabolic status,
but only overtly increases ANGPTL3 and ANGPTL8 levels in young, healthy, lean men.
Keywords: adipose tissue; ANGPTL3; ANGPTL4; ANGPTL8; lipid metabolism
1. Introduction
Increased plasma triacylglycerol (TG) levels are an independent risk factor for cardiovascular
disease [1]. TG is either derived from dietary lipids or synthesized by the liver and white adipose
tissue (WAT) from glucose and carried in the circulation within TG-rich lipoproteins (TRLs). TRLs can
be hydrolysed by lipoprotein lipase (LPL) on endothelial cells to provide underlying oxidative tissues
with fatty acids (FA) as fuel during increased energy demands (fasting or exercise) or to increase lipid
storage in WAT during nutrient excess [2].
As energy needs can rapidly change, the LPL-mediated clearance of TRL-derived TG is under
strict regulation of several factors including lipoprotein-associated apolipoproteins (e.g., APOC2 and
APOC3) and angiopoietin-like proteins (ANGPTLs) [3]. ANGPTLs consist of a family of multifunctional
glycoproteins, of which ANGPTL3, ANGPTL4, and ANGPTL8 inhibit LPL activity and work in concert
to regulate lipoprotein metabolism [4]. Loss-of-function mutations in either one of these proteins
are associated with a favourable lipid profile including lower TG levels in humans [5–8]. Moreover,
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deficiency for either one of these proteins in mouse models results in lower plasma TG levels, whereas
overexpression leads to hypertriglyceridemia [9–13].
A recently identified novel player in TG metabolism is brown adipose tissue (BAT). Mouse studies
have shown that activating BAT reduces plasma TG [14], mainly via LPL-mediated processing of
TRLs [15] and alleviates dyslipidemia and atherosclerosis [16]. Therefore, BAT activation is currently
widely investigated as potential treatment strategy aiming to improve cardiometabolic diseases in
humans [17]. The main function of BAT is to generate heat by combustion of intracellular lipids to
maintain core body temperature, and the LPL-dependent FA influx into activated brown adipocytes is
required to replenish these intracellular lipid stores. The most potent physiological stimulus of BAT
activation is cold exposure, which results in sympathetic activation of β-adrenergic receptors on brown
adipocytes [18].
Cold exposure was previously shown to affect ANGPTL4 expression in adipose tissue in mice
and to increase circulating ANGPTL4 levels in men [19,20]. The effects of cold exposure on ANGPTL3
and ANGPTL8 in humans have not been established as yet. We, therefore, investigated the effect of
short-term cooling on plasma ANGPTL3 and ANGPTL8, in comparison with ANGPTL4, in relation to
changes in lipid metabolism in young, healthy, lean men as well as middle-aged men with overweight
and prediabetes.
2. Experimental Section
2.1. Study Design and Participants
In this study, blood samples of two clinical trials were used; one consisting of a cohort of young,
healthy, lean men [21] (Dutch Trial Register 2473) and one consisting of a cohort of middle-aged men
with overweight and prediabetes [22] (Clinicaltrials.gov NCT02291458). Both studies were approved
by the Medical Ethical Committee of the LUMC and conducted in accordance with the principles of
the revised Declaration of Helsinki (2013) and the Medical Research Involving Human Subjects Act
(WMO). All subjects signed written informed consent prior to participation.
The study setup of the young, healthy, lean cohort was described in detail elsewhere [21]. In short,
the study investigated the effect of cold exposure on brown adipose tissue and energy metabolism in
24 healthy, lean (BMI < 25 kg/m2) men, aged 18–28 years, of white Caucasian (n = 12) and South Asian
(n = 12) descent. Subjects were included between March 2013 and June 2013. After an overnight fast,
body fat percentage was measured by dual-energy X-ray absorptiometry (iDXA, GE Healthcare, UK).
A blood sample was collected at thermoneutrality and at the end of an individualized water-cooling
protocol, and here analyzed for plasma ANGPTL3, ANGPTL4, ANGPTL8, and serum lipids. The
individualized cooling protocol consisted of approximately 2 h mild cooling between 2 water-perfused
blankets; 1 above and 1 beneath the study subject (Blanketrol III, Cincinnati Sub-Zero Products,
Cincinnati, OH, USA). The individualized cooling protocol started at 32 ◦C and the water temperature
was gradually decreased until shivering occurred, after which the temperature was increased by 3–4
◦C to stop shivering. Hereafter, an [18F]FDG-PET/CT scan was performed to quantify BAT volume and
glucose uptake.
An elaborate description of the study setup of the middle-aged overweight prediabetic cohort can
be found elsewhere [22]. Briefly, 20 middle-aged (40–55 years) white Caucasian (n = 10) and South
Asian (n = 10) men with overweight or obesity (BMI 25–35 kg/m2) and prediabetes were included in a
randomized double-blind cross-over study, evaluating the effect of L-arginine on brown adipose tissue
and energy metabolism. Subjects were included between October 2014 and June 2015. Prediabetes
was defined according to ADA criteria as having either fasting plasma glucose levels between 5.6–6.9
mmol/L or plasma glucose levels 2 h after an oral glucose tolerance test between 7.8–11.1 mmol/L [23].
Two South Asian subjects used simvastatin 40 mg once daily. While subjects received either L-arginine
or placebo for 6 weeks, in the current study only data after ingestion of the placebo were used.
Placebo tablets consisted of a mixture of pregelatinized maize starch, microcrystalline cellulose, and
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magnesium stearate. Placebo supplements were divided over 3 gifts: after breakfast, lunch, and dinner.
On the following day after placebo intake, after 4 h of fasting in the morning, a blood sample was
collected under thermoneutral conditions. Hereafter, an individualized mild cooling protocol lasting
approximately 2 h was initiated, after which another blood sample was collected. The individualized
cooling protocol consisted of gradually lowering the water temperature until just above the shivering
point of the subjects, here being wrapped in a water-perfused suit (ThermaWrap Universal 3166,
MTRE Advanced Technologies, Yavne, Israel). In the current study, we assessed these blood samples
for serum lipids and plasma ANGPTL3, ANGPTL4, and ANGPTL8 as well as plasma glucose and
insulin. The following day after the cooling experiment, body fat percentage was determined with
DXA (Discovery A, Hologic, Bedford, MA, USA).
In both the young, healthy, lean cohort and middle-aged overweight prediabetic cohort, subjects
were instructed not to exercise more than 3 times per week and to refrain from exercise prior to the
experimental day. In both study cohorts, subjects were also instructed to not change their dietary
habits and to consume a standardized evening meal prior to the experimental day.
2.2. Serum and Plasma Analyses
Plasma samples of both the young, healthy, and lean and middle-aged overweight prediabetic
cohorts were analysed for ANGPTL3 [24] and ANGPTL8 [25] by in-house developed ELISAs. For the
ANGPTL8 ELISA, in brief, antibodies against multiple synthesized ANGPTL8 peptides were chosen
from different parts of the ANGPTL8 protein molecule. Rabbit R355 antibodies against the ANGPTL8
amino acid region 54–68 were combined with the horseradish peroxidase-labelled capture antibody
against the ANGPTL8 peptide region 182–196 (rabbit R360) [25]. Plasma samples were also analysed
for ANGPTL4 with a commercial ELISA assay (R&D Systems, Minneapolis, MN, USA). The intra-
and inter-assay coefficients of variation for ANGPTL3 and ANGPTL4 were <15% [24]. Precision or
intra- and inter-assay CVs for ANGPTL8 were approximately 10%. Serum TG and free fatty acid
(FFA) concentrations were determined with enzymatic kits in both the young, healthy, lean cohort
(Roche Diagnostics, Woerden, the Netherlands and Wako Chemicals, Neuss, Germany, respectively)
and the middle-aged overweight prediabetic cohort (ABX Pentra 400 autoanalyzer, HORIBA Medical,
Montpellier, France). In the middle-aged overweight prediabetic cohort, plasma glucose was also
measured with an enzymatic kit (ABX Pentra 400 autoanalyzer, HORIBA Medical, Montpellier, France)
and plasma insulin via a commercially available radioimmunoassay kit (Human Insulin-specific
Radioimmunoassay, Millipore Corporation, Burlington, MA, USA). Four young, healthy, lean subjects
and 1 middle-aged subject with overweight and prediabetes were excluded from this study due to
absent plasma samples.
2.3. Statistical Analysis
Statistical analyses were performed with SPSS Statistics version 25 for Windows (IBM, Armonk,
NY, USA). Baseline characteristics were compared between cohorts and ethnicities with a two-tailed
unpaired student’s t-test, and with a two-way mixed-effect ANOVA in case temperature was an
additional factor. A linear mixed-model analysis was performed with cohort, ethnicity, and temperature
modelled as fixed effects, to investigate the effect of cold exposure on ANGPTLs both within and
between cohorts and ethnicities. Temperature was additionally modelled as a random effect with
intercepts and an unstructured covariance type. Correlations between changes in plasma ANGPTLs
and serum lipids were performed using linear regression analysis and were assessed for interaction of
ethnicity. Data are presented as mean ± SEM, unless stated otherwise. A p-value < 0.05 was considered
statistically significant. No correction for multiple testing was applied.
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3. Results
3.1. Clinical Characteristics
Clinical characteristics of the healthy lean cohort as well as effects of short-term cooling on serum
lipids and other metabolic parameters have been described elsewhere [21]. In brief, subjects were 24
± 1 years of age, had a BMI of 21.9 ± 0.4 kg/m2, and a body fat percentage of 21.4 ± 1.2% (Table 1).
Short-term cooling increased both serum TG (+0.22 ± 0.06 mmol/L, p < 0.01) and FFA levels (+0.19
± 0.05 mmol/L, p < 0.001; Table 1). Similar observations were made when taking into account South
Asian and white Caucasian ethnicities separately (Table S1).
Clinical characteristics for the middle-aged men with overweight and prediabetes have also
been described in detail elsewhere [22]. Compared with the young, healthy, lean men, middle-aged
overweight prediabetic subjects were older (47 ± 2 vs. 24 ± 1 years, p < 0.001), had a higher BMI (30.6
± 0.8 vs. 21.9 ± 0.4 kg/m2, p < 0.001) and a higher body fat percentage (30.9 ± 0.9 vs. 21.4 ± 1.2%, p <
0.001) (Table 1). In addition, compared with the young, healthy, lean men, FFA levels were lower (0.54
± 0.04 vs. 0.84 ± 0.08 mmol/L, p < 0.01) and TG levels higher (1.56 ± 0.14 vs. 0.87 ± 0.10 mmol/L, p <
0.001) in middle-aged overweight prediabetic subjects (Table 1). Short-term cooling increased serum
TG (+0.18 ± 0.04 mmol/L, p < 0.001) but not FFA levels (+0.06 ± 0.04 mmol/L, p = 0.11) in middle-aged
men with overweight and prediabetes. Similar observations were made when taking into account
South Asian and white Caucasian ethnicities separately (Table S1).
Table 1. Clinical characteristics. Data are mean ± SEM. *** p < 0.001, ** p < 0.01 middle-aged overweight
prediabetic men vs. young, healthy, lean men. BMI = body mass index, FFA = free fatty acids, TG
= triglycerides. Four healthy, young, lean subjects and one middle-aged overweight subject were
excluded from the original cohorts due to absent plasma samples.
Clinical Characteristics Young Healthy Lean Men
(n = 20)
Middle-Aged Overweight
Prediabetic Men (n = 19)
Age (years) 24 ± 1 47 ± 2 ***
Height (m) 1.79 ± 0.02 1.78 ± 0.01
Weight (kg) 70.6 ± 2.1 96.9 ± 2.9 ***
BMI (kg/m2) 21.9 ± 0.4 30.6 ± 0.8 ***
Body fat percentage 21.4 ± 1.2 30.9 ± 0.9 ***
Thermoneutral TG (mmol/L) 0.87 ± 0.10 1.56 ± 0.14 ***
Cold-induced change TG (mmol/L) +0.22 ± 0.06 +0.18 ± 0.04
Thermoneutral FFA (mmol/L) 0.84 ± 0.08 0.54 ± 0.04 **
Cold-induced change FFA (mmol/L) +0.19 ± 0.05 +0.06 ± 0.04 p = 0.053
3.2. Short-Term Cooling Increases Plasma ANGPTL3 and ANGPTL8 in Young, Healthy, Lean Men but Not in
Middle-Aged Men with Overweight and Prediabetes
In young, healthy, lean men, short-term cooling increased ANGPTL3 (142 ± 9 vs. 164 ± 11 ng/mL,
+16%, p < 0.05; Figure 1A), ANGPTL4 (165 ± 19 vs. 190 ± 19 ng/mL, +15%, p < 0.05; Figure 1B), and
ANGPTL8 levels (1.8 ± 0.3 vs. 2.3 ± 0.3 μg/mL, +28%, p < 0.001; Figure 1C).
In middle-aged men with overweight and prediabetes, short-term cooling also increased ANGPTL4
levels (193 ± 27 vs. 234 ± 31 ng/mL, +15%, p < 0.001; Figure 1E). In contrary to the young, healthy, lean
men, short-term cooling did not overtly increase ANGPTL3 (230 ± 9 vs. 251 ± 13 ng/mL, p = 0.051;
Figure 1D) or ANGPTL8 levels (2.2 ± 0.5 vs. 2.3 ± 0.5 μg/mL, p = 0.46; Figure 1F). The effect of cold on
plasma ANGPTL8 levels was significantly different between the young, healthy, lean men and the
middle-aged men with overweight and prediabetes (+28% vs. +3%, p < 0.01). Similar trends were
observed for cold-induced ANGPTL4 and ANGPTL8 levels in both cohorts when taking into account
South Asian and white Caucasian men separately. However, in case of ANGPTL3, plasma levels
increased in white Caucasian but not South Asian middle-aged men with overweight and prediabetes
(Figure S1).
95
J. Clin. Med. 2019, 8, 1214
Figure 1. Effect of cold exposure on plasma ANGPTL3, ANGPTL4, and ANGPTL8 levels in young,
healthy, lean men (A–C) and middle-aged men with overweight and prediabetes (D–F). Data are mean
± SEM. *** p < 0.001, * p < 0.05 cold vs. thermoneutrality (TN).
3.3. The Change in Plasma ANGPTL4 Negatively Correlates with the Change in Triglycerides after Short-Term
Cooling in Young, Healthy, Lean Men
To further investigate whether the change in ANGPTLs during short-term cooling was related to
the increase in serum lipids, we performed correlation analyses between the changes in the ANGPTLs
and TG and FFA levels in both study cohorts.
Data of both ethnicities were pooled, as ethnic origin did not show interaction with any of the
correlation analyses. We did not observe a correlation between the cold-induced response in either one
of the ANGPTLs and FFA levels in the young, healthy, lean men or middle-aged men with overweight
and prediabetes. In the young, healthy, lean men, the cold-induced response in ANGPTL4 negatively
correlated with the cold-induced response in TG (R2 = 0.39, p < 0.01; Figure 2B), whereas no correlations
were observed for ANGPTL3 (Figure 2A) or ANGPTL8 (Figure 2C) levels. In addition, no correlations
between the cold-induced response in ANGPTL3, ANGPTL4, and ANGPTL8 and TG levels were
observed in the middle-aged men with overweight and prediabetes (Figure 2D–F). Of note, body fat
percentage did not correlate with cold-induced changes in levels of either of the ANGPTLs (Figure S2).
Moreover, body fat percentage did not affect any of the correlation analyses between cold-induced
changes in ANGPTLs and TG or FFA levels.
Figure 2. Correlation between cold-induced changes in serum triglyceride (TG) and plasma ANGPTL3,
ANGPTL4, and ANGPTL8 levels in young, healthy, lean men (A–C) and middle-aged men with
overweight and prediabetes (D–F). Dotted lines represent 95% confidence interval. TG = triglycerides.
Black circles are South Asians (SA), white circles are white Caucasians (WC).
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3.4. Changes in ANGPTLs are not Overtly Correlated to [18F]FDG Uptake by BAT or Plasma Glucose or
Insulin Levels after Short-Term Cooling
Short-term cooling not only increases TRL-derived FA uptake, but also glucose uptake to stimulate
thermogenesis by BAT, the latter likely to enhance de novo lipogenesis [26]. ANGPTLs have a
well-established role in TRL-derived FA uptake by metabolic tissues, but their interplay with glucose
metabolism is more controversial [27]. We therefore evaluated cold-induced changes in levels of
ANGPTLs in relation to [18F]FDG uptake by BAT on PET/CT scan in both young, healthy, lean men and
middle-aged men with overweight and prediabetes. We additionally assessed cold-induced changes
in ANGPTL levels in relation to delta glucose, delta insulin levels, as well as HOMA-IR under insulin
resistant conditions (i.e., in the cohort of middle-aged men with overweight and prediabetes).
Data of both ethnicities were pooled, as ethnic origin did not show interaction with any of the
correlation analyses aside from ANGPTL8. We did not observe correlations between the cold-induced
response in either one of the ANGPTLs and BAT volume, SUVmean, or BAT metabolic activity (BAT
volume multiplied by SUVmean) in the young, healthy, lean men (Figure S3). In the middle-aged men
with overweight and prediabetes, we only observed a negative correlation between the cold-induced
change in ANGPTL4 levels and BAT volume, but no correlations between other ANGPTLs and BAT
parameters (Figure S4). In addition, we did not observe correlations between the cold-induced response
in either one of the ANGPTLs and delta glucose, delta insulin levels, or HOMA-IR in the middle-aged
men with overweight and prediabetes (Figure S5).
4. Discussion
ANGPTLs are inhibitors of LPL activity and function in modulating TRLs that traffic between
tissues depending on specific situational energy demands. During cold exposure, LPL-mediated
hydrolysis of TRL-TG by BAT is enhanced to meet the increased FA demand to facilitate
thermogenesis [15]. Here, we confirmed that short-term cooling increases plasma ANGPTL4 levels in
both young, healthy, lean men and middle-aged men with overweight and prediabetes. In addition, we
now show that cooling increases plasma ANGPTL3 and ANGPTL8 levels, but only in young, healthy,
lean men. We propose that the elevated circulating ANGPTL3 and ANGPTL8 levels during short-term
cooling represent a compensatory response aimed at preventing an ANGPTL4-promoted excessive
lipid accumulation in oxidative tissues in young, healthy, lean men.
First, we show that short-term cooling increased plasma ANGPTL4 levels in both young, healthy,
lean men and middle-aged men with overweight and prediabetes. We previously obtained serum
ANGPTL4 levels in this same young, healthy, lean cohort, and these findings are in line albeit measured
with a different ELISA [20]. Plasma ANGPTL4 levels also increased after 48 h of continuous mild
cold exposure (16 ◦C) in young obese males [19]. In addition to cold exposure, both fasting and
exercise increased circulating ANGPTL4 levels in humans [28–30]. Regulation of Angptl4 expression is
tissue-specific, as fasting upregulated Angptl4 expression and impaired LPL activity in WAT in mice,
thereby facilitating the uptake of TG-derived FA by tissues with an increased energy demand [28,31].
In line with this, in mice, cold exposure upregulated Angptl4 expression and limited TRL-derived FA
uptake in WAT, whereas Angptl4 expression was downregulated and, as a consequence, TG-derived FA
uptake was increased in BAT [19,31]. We previously hypothesized that during short-term cooling in
humans, FAs derived from intracellular lipolysis bind to peroxisome proliferator-activated receptor-γ
to stimulate ANGPTL4 expression in WAT, thereby increasing circulating ANGPTL4 levels [32]. This
may subsequently limit TG-derived FA uptake by WAT and redirect TRLs towards active BAT for
hydrolysis of TG [20]. In the current study, we also observed a negative correlation between the
cold-induced changes in ANGPTL4 levels and TG levels in young, healthy, lean men. According
to our hypothesis, a higher increase in plasma ANGPTL4 levels during short-term cooling possibly
indicates more shuttling of TRLs away from WAT towards active BAT, which might be accompanied
by enhanced TRL-TG hydrolysis by BAT that subsequently results in a less pronounced cold-induced
increase in serum TG.
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In addition to ANGPTL4, we now show that short-term cooling increased plasma ANGPTL3
levels in young, healthy, lean men. ANGPTL3 in humans is nearly exclusively expressed in the liver
and inhibits LPL activity in metabolic tissues in an endocrine fashion [33,34]. In contrast to ANGPTL4,
ANGPTL3 inhibits LPL activity and TG-derived FA uptake by oxidative tissues after (re)feeding,
thereby promoting lipid storage in WAT. This was demonstrated by a study showing that Angptl3-/- mice
are unable to suppress LPL activity specifically in oxidative tissues in a fed state, thereby increasing
very-low density-lipoprotein (VLDL)-TG-derived FA uptake by oxidative tissues (skeletal muscle,
heart, and BAT) and reducing VLDL-TG-derived FA uptake by WAT. As a consequence, plasma TG
levels were markedly lower in Angptl3-/- mice compared with wild-type mice [35]. In addition to TG
levels, plasma FFA and glycerol levels were lower in Angptl3-/- mice, likely due to impaired inhibition of
lipolysis [36]. Lowering circulating TG levels via ANGPTL3 inactivation by antisense oligonucleotides
or monoclonal antibodies is a promising treatment strategy to target dyslipidemia and cardiovascular
disease, as this reduced atherosclerosis progression in mice and significantly improved lipid profile in
subjects with dyslipidemia in phase I trials [7,37]. However, the effect of pharmacologically targeting
ANGPTL3 on risk factors for cardiovascular disease in specific metabolically challenged subjects
remains to be elucidated in future studies.
We also show that short-term cooling increases plasma ANGPTL8 levels in young, healthy, lean
men. This is in line with mouse studies showing that cold exposure enhances expression of Angptl8 in
liver, BAT, and WAT, although circulating ANGPTL8 levels were not reported in these studies [31,38].
The expression of ANGPTL8 is enriched in liver and present to a lesser extent in WAT and BAT and is
highly upregulated in both tissues after (re)feeding [12,39]. Similar to ANGPTL3, ANGPTL8 likely
inhibits LPL activity and TG-derived FA uptake by oxidative tissues after feeding to promote lipid
storage in WAT. This was evident from a study showing that Angptl8-/- mice have increased LPL activity
only in oxidative tissues (heart and skeletal muscle) and not in WAT upon (re)feeding [11]. Moreover,
Wang et al. [13] showed that Angptl8-/- mice have impaired uptake of VLDL-TG-derived FA by WAT in
a fed state.
ANGPTL3 and ANGPTL8 share sequence homology, form a protein–protein complex, and need
each other’s presence to sufficiently regulate circulating lipid levels [12]. Zhang et al. [40] proposed
the idea of an ANGPTL3-4-8 axis that ensures adequate distribution of TRL-TG to energy-demanding
tissues in different nutritional states. In this model, during fasting, ANGPTL4 negatively regulates LPL
activity in WAT to redirect TRL-TG towards other energy requiring tissues for hydrolysis, whereas
upon feeding, ANGPTL3 and ANGPTL8 negatively regulate LPL activity in oxidative tissues to make
TG-derived FA available for storage by WAT. In this context, we hypothesize that the increase in plasma
ANGPTL4 during short-term cooling indicates inhibition of LPL activity in WAT to shuttle TRLs
towards active BAT for uptake of TG-derived FA, whereas ANGPTL3 and ANGPTL8 redirect TRLs
towards WAT to prevent the accumulation of excess lipids in active BAT in young, healthy, lean men.
It is tempting to speculate about the underlying mechanisms that increase plasma ANGPTL3 and
ANGPTL8 during short-term cooling in young, healthy, lean men. Both ANGPTL3 and ANGPTL8
are regulated by the liver X receptor (LXR) [41–43]. Oxysterols are metabolites of cholesterol and are
endogenous ligands of the LXR. As mouse studies have shown that cold exposure rapidly generates
TRL-derived cholesterol-enriched remnants that are cleared by the liver [16], this might provide a
source of cholesterol that enhances oxysterol formation and thereby stimulates LXR-induced expression
of ANGPTL3 and ANGPTL8. Possibly, reduced formation of oxysterols as a consequence of decreased
hepatic clearance of cholesterol-enriched remnants under insulin resistant conditions is involved in the
absent response of ANGPTL3 and ANGPTL8 during short-term cooling in our cohort of middle-aged
men with overweight and prediabetes [44]. Besides activation of the LXR, ANGPTL8 expression is
upregulated in both hepatocytes and adipocytes by insulin [34,39,45]. As insulin release is stimulated
during cold exposure [46], we speculate that insulin might contribute to the increased plasma ANGPTL8
levels during short-term cooling. Similar to other metabolic tissues, BAT becomes less sensitive to
insulin during (pre)diabetes [47]. Therefore, we speculate that the absent cold-induced changes in
98
J. Clin. Med. 2019, 8, 1214
ANGPTL3 and ANGPTL8 in middle-aged men with overweight and prediabetes might reflect an
attempt of the body to overcome impaired glucose uptake by insulin-resistant BAT. It should be noted
that we did not observe correlations between cold-induced changes in ANGPTL3 or ANGPTL8 and
changes in glucose or insulin levels to support these hypotheses. However, circulating levels of insulin
may not reflect local signaling function in metabolic tissues, including its effects on ANGPTL8 secretion.
We also did not observe overt correlations between cold-induced changes in ANGPTLs and [18F]FDG
uptake by BAT measured with PET/CT scan. However, this only reflects the uptake of glucose by
BAT. Taking into account the LPL-inhibitory function of ANGPTLs, it would be highly interesting to
specifically investigate cold-induced changes in ANGPTLs in relation to the uptake of (TRL-derived)
FA by BAT in future studies. Of note, we observed an increase in FFA levels upon short-term cooling in
the young, healthy, lean cohort but not in the middle-aged overweight prediabetic cohort. Interestingly,
an increased fat mass is associated with an impaired FFA release from subcutaneous WAT [48]. This
likely reflects impaired lipolysis, which may be mediated in part via catecholamine-resistance during
obesity (reviewed in [49]). We therefore propose that reduced activity of the sympathetic nervous
system in our cohort of overweight and obese men contributed to their unchanged FFA levels upon
short-term cooling.
A strong aspect of our study is that we evaluated the effects of short-term cooling on ANGPTLs in
both a cohort of healthy and metabolically challenged men. However, this study also had its limitations.
For example, its cross-sectional design, as it would be interesting to investigate whether differences in
cold-induced ANGPTL levels arise during metabolic changes within individuals over time. In addition,
the study designs of both cohorts, although comparable to a certain extent, are not identical with
respect to timing and fasting duration (which may explain lower baseline FFA levels in the middle-aged
vs. young cohort). As the applied cooling protocols are also slightly different, we cannot exclude
that variability in temperatures using individualized cooling protocols affected ANGPTL and lipid
levels. Additionally, it is likely that a fasting state, maintained during the short-term cooling, partly
contributed to an increase in circulating lipids and ANGPTL4, whereas this might have abolished
the increase in ANGPTL3 and ANGPTL8. Importantly, we cannot exclude possible confounding in
our analyses by a difference in age between both study cohorts, nor an effect of the placebo in the
middle-aged overweight prediabetic cohort. Lastly, as the sample size of both studies is small, larger
studies are warranted to confirm these observations.
5. Conclusions
In conclusion, we show that short-term cooling not only increases plasma ANGPTL4, but also
plasma ANGPTL3 and ANGPTL8 levels in young, healthy, lean men. We propose that these ANGPTLs
act in concert to facilitate TG partitioning between tissues in response to cold. While ANGPTL4 likely
functions to shuttle TRLs away from WAT towards active thermogenic tissues during cold exposure,
we suggest that ANGPTL3 and ANGPTL8 redirect TRLs away from thermogenic tissues to prevent
excessive lipid accumulation. Whether these increases in circulating ANGPTLs reflect their ability
to locally inhibit LPL-mediated TG hydrolysis and subsequent TG-derived FA uptake by metabolic
tissues, remains to be elucidated.
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Abstract: Paroxonase-1 (PON1) is a key enzyme that inhibits low-density lipoprotein oxidation and
consequently atherogenesis. Here, we assessed whether low serum PON1 activity associates with
incident cardiovascular disease (CVD) in subjects with high levels of high-density cholesterol (HDL-C)
and C-reactive protein (CRP), a marker of low-grade systemic inflammation. Cox proportional-hazards
modeling of incident CVD risk (11 years mean follow-up) adjusted for relevant clinical and biomarker
covariates was performed on a population-based study (N = 7766) stratified into three groups: low
CRP—(LR; event rate 4.9%); low HDL-C/high CRP—(HR1; event rate 14.4%); and high HDL-C/high
CRP—(HR2; event rate 7.6%). Modeling results for PON1 activity in HR2 were significant and robust
(hazard ratio/SD unit—0.68, 95% CI 0.55–0.83, p = 0.0003), but not so for LR and HR1. Analyses in
HR2 of the interaction of PON1 with HDL-C, apoA-I, apoA-II, and apoE levels were significant only
for PON1 with apoE (hazard ratio—1.77, 95% CI 1.29–2.41, p = 0.0003). Subsequent subgroup analysis
revealed inverse risk dependence for apoE at low PON1 levels. In conclusion, in a population-based
study of subjects with concurrently high HDL-C and CRP levels, low serum PON1 activity associates
with incident CVD risk with risk accentuated at low apoE levels.
Keywords: cardiovascular disease; C-reactive protein; HDL; paraoxonase-1
1. Introduction
Paraoxonases make up a family of three enzymes (PON1, PON2, and PON3) with predominantly
lactonase activity, each of which has been shown to manifest anti-atherogenic properties. This presumably
relates to hydrolytic activity against lactone-like structures elaborated by oxidized polyunsaturated
fatty acids on lipoproteins [1,2]. PON2 is an intracellular enzyme. After synthesis in the liver, PON1
and PON3 enter the circulation and become predominantly associated with high-density lipoprotein
(HDL) particles. Anti-atherogenic action of PON1 has been demonstrated to derive in large part from
the interaction of HDL-associated PON1 with low-density lipoprotein (LDL) particles. Such interaction
leads to inhibition of oxidative modification of LDL through PON1-mediated hydrolysis of oxidized fatty
acid species derived from oxidative stress-induced generation of hydroperoxides from phospholipids,
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cholesteryl esters, and triglycerides [2–6]. Likewise for HDL, studies have also demonstrated similar
anti-oxidative activity by PON1 on lipid peroxidation products generated on HDL in oxidative stress
environments [7–10]. The putative anti-atherogenic properties of PON1 stem from meta-analyses
of human population studies that consistently show decreased PON1 activity to be associated with
cardiovascular disease (CVD) risk [11–13]. It should also be noted that in addition to CVD, low PON1
activity has been reported in other disease states having a significant inflammatory component including
diabetes mellitus, obesity, metabolic syndrome, cancer, and various rheumatic, renal, hepatic, and
neurologic diseases [3,14].
Accumulating evidence demonstrates that the established anti-atherogenic actions of HDL
become dysfunctional and potentially pro-atherogenic in chronic inflammatory and oxidative stress
environments as a result of ensuing alterations in the HDL proteome and lipidome [15–17]. To elucidate
the role of dysfunctional HDL in CVD risk, investigations of HDL-associated risk have been undertaken
in populations with various inflammatory disorders. Notably, results from such studies demonstrate
that high levels of HDL cholesterol (HDL-C) associate with increased CVD risk rather than with
protective effects [18]. In our case, we have studied incident as well as recurrent coronary events in
subjects with high HDL-C and concurrently high levels of C-reactive protein (CRP) as a marker of
low-grade chronic inflammation. Compared to the controls, the results demonstrated significantly
higher CVD risk in these patient groups [19,20]. Furthermore, within these populations, additional
studies demonstrated risk associations for levels of apolipoprotein E (apoE) [21] and apolipoprotein
A-II (apoA-II) [22]; and, in studies of single nucleotide polymorphisms, risk associations were found for
genes associated with various aspects of HDL function including reverse cholesterol transport [19,23],
thrombogenesis [24], oxidative stress [25], and fibrinolysis [26].
In light of the key role of PON1 in inhibiting oxidative changes in the HDL lipidome that acts to
preserve anti-atherogenic functionality of HDL as described above, we hypothesized that low PON1
levels in subjects with high levels of HDL-C in the setting of chronic low-level inflammation would
be at increased risk for CVD. To test this hypothesis, we studied risk of incident CVD in subjects
having concurrently high HDL-C and CRP levels as an indicator of chronic low grade inflammation
in comparison to two other subject groups, one with low HDL-C and high CRP levels and the other
with “normal” HDL-C and low CRP levels. The present study was carried out in the frame of the
prospective Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort study.
2. Experimental Section
2.1. Study Population
PREVEND, a large general population-based prospective cohort study begun in 1997 that aimed to
explore the role of albuminuria in cardiovascular and renal disease, served as the basis of the current
study population [27]. Briefly for PREVEND recruitment, all inhabitants of the city of Groningen, the
Netherlands, aged 28–75 years (N = 85,421), were sent a questionnaire requesting an early morning urine
specimen. The response rate was 48% (N = 40,856). Of these, 9966 subjects had urine albumin levels
≥10 mg/L while 30,890 subjects had urine albumin <10 mg/L. Exclusions included pregnancy, type 1
diabetic individuals, and type 2 diabetic individuals using insulin. This resulted in 7768 subjects having
urine albumin ≥10 mg/L. This group was combined with 3395 randomly chosen subjects with urine
albumin <10 mg/L. Of this resultant group, 8592 individuals completed an additional screening program,
thus establishing the PREVEND study cohort. For the present work, the only further exclusion from
the PREVEND study cohort was for subjects with serum CRP levels ≥10 mg/L. This formed the study
population of the current work (N = 7766). The PREVEND study was approved by the Medical Ethics
Committee of the University of Groningen, the Netherlands. Informed written consent was obtained
from all participants. The study adhered to the ethical principles set by the Declaration of Helsinki.
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2.2. Clinical Parameters and Biomarkers
Questionnaires were used to ascertain cardiac history (hospitalization for myocardial infarction,
revascularization procedures, or obstructive coronary artery disease). Diabetes was established either
as fasting plasma glucose ≥7.0 mmol/L, self-report of physician diagnosis, or use of anti-diabetic
medications. Medication use was retrieved via Groningen pharmacy dispensing data [28]. Smoking
status was either current smoker or not; ethanol use was either one or less drinks per day or more than
one drink per day (with one drink assumed to contain 10 g of alcohol). Body mass index (BMI) was
calculated as weight divided by height squared (kg/m2). Blood pressure was measured for 10 min at
1-min intervals using automatic instrumentation (Dinamap XL Model 9300; Johnson-Johnson Medical,
Tampa, FL, USA) in the supine position; means of the last two recordings were the reported values [29].
The mean of two 24 h collections over two consecutive days at study entry was determined and
used as the reported UAE value. Nephelometry (BNII, Dade Behring, Marburg, Germany) was used to
measure urinary albumin concentration. Blood biomarker levels at study initiation were performed
on overnight-fasted plasma and sera. Blood levels of creatinine, HDL-C, apoA-I, apoA-II, apoE, total
cholesterol, triglycerides, apoB, glucose, and CRP were determined by standard techniques [20,21,30].
Estimated glomerular filtration rate (eGFR) was determined using the Chronic Kidney Disease
Epidemiology Collaboration (CDK-EPI) equation [31]. NonHDL-C was calculated as the difference
between total cholesterol and HDL-C. The Friedewald equation was used to estimate LDL-C levels.
Serum PON1activity was measured in terms of arylesterase activity (rate of phenyl acetate hydrolysis
to phenol) as described previously with inter-assay and intra-assay coefficients of variation of 8% and
6%, respectively [32].
2.3. Outcomes
CVD-related mortality and hospitalizations including acute MI (myocardial infarction), acute and
subacute ischaemic heart disease, coronary artery bypass grafting, and percutaneous transluminal
coronary angioplasty constituted incident cardiovascular events. Outcome events were followed over
time (11 years of follow-up). Survival time was taken as date of initial urine collection (1997–1998)
to date of first CVD event or to December 31, 2011. For subjects lost to follow-up (396 of the overall
cohort of 8592 participants), censoring date was date of removal from the municipal registry. Record
linkage with the Dutch Central Bureau of Statistics was used to acquire data on mortality and causes of
death. PRISMANT, the Dutch national registry of hospital discharge diagnoses was used to obtain
CVD morbidity data.
2.4. Data Analysis
Graphical and statistical analyses were performed using Statistica 13.3 (StatSoft, Inc., Tulsa, OK,
USA). Graphical analyses portraying CVD risk over a bivariate parameter risk domain was performed
using outcome event mapping as described previously [20]. Results are reported as means ± SD
for normally distributed variables and as medians (interquartile range) for non-normally distributed
variables. Differences among groups were assessed by ANOVA for continuous variables using Bonferroni
correction for multiple comparisons and chi-square testing for categorical variables. Non-normal
variables were log-transformed for analyses. Multivariable Cox proportional hazards modeling was
used to follow cardiovascular outcomes over time. Continuous independent variables were standardized
by transformation to distributions with means of zero and standard deviations of one for Cox analyses.
Hazard ratios (HR) are per SD unit. Inclusion of multiplicative interaction terms into base models
was used to assess interactions between risk variables. Two-sided p-values < 0.05 were considered
statistically significant. The proportional hazards assumption was verified by correlation analysis of
survival time with scaled Schoenfeld residuals.
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3. Results
3.1. Study Population
During follow-up (11 years), a total of 643 events were recorded. The surface plot of Figure 1A
demonstrates the estimated CVD outcome event rate as a function of HDL-C rank and CRP rank for the
resultant total study population. The figure shows two peaks indicative of higher-risk populations:
one at low HDL-C and high CRP rank and one at high HDL-C and high CRP rank. The corresponding
contour plot of Figure 1B demonstrates the delineation of three populations based upon dichotomizations
about median values of HDL-C and CRP ranks. The three resulting populations were designated as
follows: low CRP—low risk (LR; N = 3889; 192 events; 4.9% event rate); low HDL-C/high CRP—high
risk 1 (HR1; N = 2294; 331 events; event rate 14.4%); and high HDL-C/high CRP—high-risk 2 (HR2;
N = 1583; 120 events; event rate 7.6%). Clinical and blood biomarker characterizations for the total, LR,
HR1, and HR2 populations are given in Table 1. Results of chi square testing, unadjusted ANOVA, and
ANOVA adjusted for gender and age revealed significant differences among the LR, HR1, and HR2
groups for all variables except ethanol use. Subsequent post-hoc testing revealed pair-wise significant
differences between LR, HR1, and HR2 for all continuous variables except for: nonHDL-C (LR versus
HR2, p = 0.078), triglycerides (LR versus HR2, p = 0.90), and UAE (LR versus HR2, p = 0.55).
Figure 1. Cardiovascular event rates as a function of high-density lipoprotein (HDL) rank and C-reactive
protein (CRP) rank given: (A) as a surface plot and (B) as a contour plot. The contour plot demarcates a
low risk population (LR) characterized by lower CRP, a high-risk population (HR1) characterized by low
HDL and high CRP, and another high-risk population (HR2) characterized by high HDL and high CRP.
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3.2. Correlation of PON1 Activity with Blood Biomarker Levels
To provide further characterization of the study populations focusing on PON1 activity, Table 2
gives Spearman correlation coefficients for PON1 activity levels with blood biomarkers for the total,
LR, HR1, and HR2 populations. The table shows that although many of the correlations are statistically
significant, magnitudes of the coefficients are generally small except for HDL-C, apoA-I, and apoA-II
(highest at 0.28). Thus, PON1 activity did not appear to be highly correlated with any of the blood
biomarkers in any of the populations which may be indicative potentially of a relatively independent
role of PON1 activity in CVD risk.
Table 2. Spearman correlation coefficients of PON1 with biomarker levels for total, LR, HR1, and HR2
populations.
Parameter Total Population Low Risk High-Risk 1 High-Risk 2
HDL-C 0.20 *** 0.19 *** 0.11 *** 0.15 ***
CRP −0.05 *** −0.02 −0.06 ** 0.02
ApoA-I 0.19 *** 0.17 *** 0.10 *** 0.15 ***
ApoA-II 0.28 *** 0.26 *** 0.23 *** 0.26 ***
ApoA-I/HDL-C −0.12 *** −0.11 *** −0.04 0.01
ApoA-II/HDL-C (μmol/mmol) −0.04 *** −0.03 0.08 *** 0.13 ***
Cholesterol 0.08 *** 0.13 *** 0.09 *** 0.01
NonHDL-C 0.01 0.05 ** 0.07 ** −0.03
LDL-C 0.00 0.04 * 0.04 −0.06 *
Triglycerides 0.03 * 0.03 * 0.09 *** 0.13 ***
ApoB 0.00 0.03 0.05 * −0.02
Glucose −0.09 *** −0.09 *** −0.05 * −0.07 **
Creatinine −0.03 ** 0.01 −0.04 −0.02
UAE −0.02 0.02 −0.01 0.01
eGFR 0.02 * −0.01 0.05 * 0.03
ApoE 0.00 0.04 * 0.04 −0.07 **
* p < 0.05; ** p < 0.01; *** p < 0.001.
3.3. PON1 Activity as a Marker of CVD Risk in LR, HR1, and HR2 Populations
To assess PON1 activity as a marker of CVD risk, Table 3 gives results of Cox multivariable
proportional hazards modeling in the three populations. For the LR population, PON1 activity was
significant (protective) in an unadjusted model, but lost significance upon adjustment for gender and
age. For HR1, PON1 activity, even in an unadjusted model, did not achieve significance. For HR2,
PON1 activity was highly significant (protective) in an unadjusted model (p = 10−6); continued to be
highly significant in a collection of models adjusted for gender, age, and a set of covariates added
one-at-time; and finally remained significant (p = 0.0003) in a model adjusted simultaneously for all
covariates of the dataset (gender, age, UAE, past CVD, DM, apoB, use of statins, anti-hypertensives,
smoking, ethanol use, and eGFR). Thus, PON1 activity appears to have a robust inverse relationship
with CVD risk in the HR2 population.
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Table 3. Cox multivariable proportional hazards modeling results for PON1 level giving hazard ratio
(HR), 95% confidence interval (95% CI), and p-value. The first column lists the population examined (LR,
HR1, or HR2) along with parameters adjusted in models. Hazard ratios are per SD unit. For regression
calculations, PON1 levels were transformed to a distribution with mean of zero and SD of one.




LR unadjusted 0.86 0.75–0.98 0.024
LR gender, age 0.95 0.82–1.09 0.46
HR1 unadjusted 0.93 0.83–1.04 0.22
HR1 gender, age 1.02 0.91–1.14 0.72
HR2 unadjusted 0.62 0.000001 0.000001
HR2 gender, age 0.72 0.59–0.87 0.0007
HR2 gender, age, UAE 0.70 0.58–0.86 0.0004
HR2 gender, age, UAE, apoB 0.70 0.57–0.85 0.0003
HR2 gender, age, UAE, past CVD 0.71 0.58–0.86 0.0005
HR2 gender, age, UAE, DM 0.71 0.58–0.86 0.0006
HR2 gender, age, UAE, statins 0.69 0.57–0.83 0.0002
HR2 gender, age, UAE, anti-hypertensives 0.68 0.56–0.83 0.0001
HR2 gender, age, UAE, SBP 0.70 0.58–0.85 0.0004
HR2 gender, age, UAE, DBP 0.70 0.58–0.85 0.0004
HR2 gender, age, UAE, smoking 0.70 0.58–0.85 0.0004
HR2 gender, age, UAE, ethanol use 0.69 0.57–0.84 0.0003
HR2 gender, age, UAE, eGFR 0.72 0.59–0.87 0.0009
HR2 gender, age, UAE, past CVD, DM, 0.68 0.55–0.83 0.0003
apoB, statins, anti-hypertensives
smoking, ethanol use, eGFR, SBP, DBP
3.4. HDL Particle Constituents in Addition to PON1 as Markers of CVD Risk in HR2
To assess HDL-associated markers of risk in HR2 beyond PON1, we determined proportional
hazards modeling in HR2 as a function of PON1 activity along with additional single entry of
HDL-associated parameters (apoA-I, apoA-II, apoA-I/HDL-C, apoA-II/HDL-C, and apoE levels) (Table 4).
Models also included evaluation of the potential interaction of PON1 activity with each of the
HDL-associated parameters. Again, all models were adjusted for gender, age, UAE, past CVD, DM,
apoB, use of statins, anti-hypertensives, smoking, ethanol use, eGFR, SBP, and DBP. The results from
Table 4 indicate that, in each case for models without interaction, an independent significant protective
association continued for PON1. For HDL-associated parameters, an independent protective association
was demonstrated for apoA-I/HDL-C. In models assessing interactions, only apoE levels were found to
exhibit a statistically significant interaction with PON1 activity (HR–1.77, 95% CI 1.29–2.41, p = 0.0003).
To explore the nature of the PON1/apoE interaction in HR2, subgroup analysis using the
proportional hazards model adjusted as before was performed on subjects of HR2 but this time with
dichotomization about median PON1 levels giving low- and high-PON1 groups. Results indicated a
trend in continued risk association with low PON1 levels both in the low PON1 group (HR—0.74, 95%
CI 0.53−1.05, p = 0.089) and the high PON1 group (HR—0.60, 95% CI 0.26−1.40, p = 0.24). Regarding
apoE and risk, while results for the high PON1 group demonstrated the generally expected trend
in risk associated with high apoE levels (HR—1.41, 95% CI 0.91−2.18, p = 0.13), results for the low
PON1 group revealed significant risk in association with low apoE levels (HR—0.69, 95% CI 0.50−0.96,
p = 0.029). To illustrate the interaction, a contour plot of estimated CVD risk as a function of PON1
rank and apoE rank was generated (Figure 2). Consistent with the modeling results, the plot shows a
high-risk population at concurrently low levels of both PON1 and apoE; while by contrast, at high
PON1 levels, there is little indication of risk in association with low apoE levels. Hence in HR2, it would
appear that the PON1/apoE interaction manifests as intensification of the usual CVD risk association
for low PON1 activity but particularly in the setting of low apoE levels.
109
J. Clin. Med. 2019, 8, 1357
Table 4. Interaction of PON1 with HDL-related parameters for the HR2 population as assessed by Cox
proportional hazards models of cardiovascular event occurrence adjusted for gender, age, UAE, past
CVD history, diabetes, apoB, statin use, anti-hypertensive use, smoking, ethanol use, eGFR, SBP, and
DBP. Hazard ratios are per SD unit. For regression calculations, continuous variables were transformed
to distributions with means of zero and SDs of one.
Models without Interaction Models with Interaction
Parameters HR 95% CI p HR 95% CI p
PON1 0.67 0.54−0.83 0.0003 0.76 0.57−1.01 0.059
HDL-C 1.04 0.75−1.45 0.82 1.01 0.72−1.40 0.98
interaction 0.81 0.057−1.16 0.25
PON1 0.69 0.56−0.86 0.0007 0.69 0.54−0.89 0.0036
ApoA-I 0.76 0.58−1.00 0.051 0.76 0.58−1.00 0.054
interaction 0.99 0.77−1.29 0.96
PON1 0.70 0.57−0.88 0.002 0.70 0.57−0.87 0.001
ApoA-II 0.78 0.60−1.02 0.070 0.79 0.61−1.02 0.070
interaction 1.09 0.90−1.31 0.39
PON1 0.66 0.54−0.82 0.0001 0.71 0.55−0.92 0.008
ApoA-I/HDL-C 0.56 0.37−0.85 0.0057 0.59 0.39−0.89 0.013
interaction 1.17 0.87−1.57 0.30
PON1 0.68 0.55–0.84 0.0004 0.81 0.60−1.08 0.15
ApoA-II/HDL-C 0.63 0.40−1.00 0.051 0.65 0.41−1.03 0.065
interaction 1.30 0.94−1.80 0.12
PON1 0.66 0.53−0.82 0.0002 0.64 0.51−0.80 0.0001
ApoE 0.82 0.60−1.12 0.21 0.85 0.62−1.16 0.30
interaction 1.77 1.29−2.41 0.0003
Figure 2. Contour plot of the estimated cardiac event rate as a function of PON1 rank and apoE rank in
the high HDL/high CRP population (HR2).
4. Discussion
Results of the current study of incident CVD show a highly significant association of low serum
PON1 activity with risk in subjects with high levels of HDL-C in the setting of chronic low-grade
inflammation, as indicated by high CRP levels. Furthermore, interaction analysis demonstrated such
risk to be accentuated in those subjects with low levels of serum apoE; no corresponding effect was
observed for apoA-I, apoA-II, or HDL-C levels within the high HDL-C/high CRP group. These results
from multivariable proportional hazards modeling were robust with regard to adjustment for relevant
clinical and blood biomarkers including gender, age, past CVD event, diabetes, apoB, statin use,
anti-hypertensive use, smoking, ethanol use, and eGFR. It should be noted that corresponding analyses
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performed both on subjects with low HDL-C and high CRP and on subjects with low CRP did not
demonstrate in either case statistically significant associations for PON1 activity with CVD. Our results
suggest that the putative anti-oxidative effects of serum PON1 are most evidently exhibited in subjects
with high PON1 and high HDL-C levels in the setting of chronic inflammation that is signaled by
higher CRP levels.
Results of a recent meta-analysis addressing the role of PON1 activity on incident CVD risk
demonstrated an inverse relationship between PON1 activity and risk in general population settings [13].
It was also noted in this study that the inverse relationship became less robust when adjustments for
established risk factors including HDL-C were included—a finding that could potentially be relevant to
our results regarding PON1 activity in the high HDL-C/high CRP group. However, this does not appear
to be the case as results of risk models including PON1 activity and HDL-C levels were not significant
for HDL-C (p = 0.82); nor was interaction between the two significant (p = 0.25). It should also be
noted that corresponding analyses of PON1 activity with apoA-I and apoA-II were also non-significant.
Accordingly, although study results show a significant inverse relationship for PON1 activity with risk,
this is not the case for other HDL parameters including levels of HDL-C, apoA-I, and apoA-II. These
findings underscore the key role of low PON1 activity in establishment of CVD risk in this subject group,
which likely derives from inhibition of oxidative modification of the HDL lipidome, thus helping to
maintain HDL anti-atherogenic functionality. Consistent with our results regarding low PON1 activity
in the high HDL-C/high CRP subgroup, as noted previously, many other disease states associated with
low-grade chronic inflammation also manifest low PON1 activity [3,14]. In the case of CVD risk, in the
current study we have identified a group of subjects where PON1 action is particularly relevant.
Further results from our study did not show association of PON1 activity with risk both in the low
risk subject group (low CRP levels) and in a subject group with low HDL-C/high CRP levels. In the
first case, we speculate that the lower CRP levels provide an environment not conducive to oxidative
modification of HDL, thus preserving HDL functionality and consequently limiting the relevance of
PON1 activity in this group. In the second case, we speculate that higher PON1 was not protective in
HR1 stemming in one way or another from the inadequacy of PON1 to significantly inhibit oxidation
of the presumably heavier load of small dense LDL particles very likely present in this population
enriched with Metabolic Syndrome subjects (Table 1; HR1—51.3%, HR2—9.7%, p < 0.001). Inadequacy
of PON1 in this setting is likely attributable to multiple factors. First, the load of LDL-C in HR1 was
significantly higher than in HR2 (Table 1; 4.04 mM U/L versus 3.58 mM U/L, p < 0.001); and thus,
the concentration of potentially atherogenic dense LDL particles would be higher in HR1 given their
well-established smaller size. Second, from the very defining characteristics of HR1, the level of HDL-C
was less than in HR2 (Table 1; 1.01 mM versus 1.62 mM, p < 0.001). Thus, the amount of PON1, known
to be predominantly carried by HDL, should be and was observed to be smaller in HR1 (Table 1;
50.8 U/L versus 56.1 U/L, p < 0.001). Third, the carriage ability of HDL particles for PON1 might
be less in HR1 versus HR2 subjects. Thus, using the apoA-I/HDL-C ratio as a crude measure of the
number of apoA-I molecules per HDL particle, the observed higher apoA-I/HDL-C ratio in HR1 versus
HR2 (Table 1, 43.2 μM/mM versus 34.1 μM/mM, p < 0.001) would tend to limit carriage of additional
molecules like PON1 on HDL particles (the situation was similar for the apoA-II/HDL-C ratio).
Additional results in the high HDL-C/high CRP group of our study using interaction analysis
showed accentuation of CVD risk at concurrently low levels of PON1 and apoE. This is consistent with
in vitro studies of PON1 associations with reconstituted HDL particles carrying apoE that show such
binding to stabilize and stimulate PON1 lactonase activity as well as to stimulate PON1 anti-atherogenic
potential in a manner similar to apoA-I but with lower capacity [33]. Presumably then, lower apoE
levels would work to decrease PON1 anti-atherogenic action. Furthermore, results of a clinical
study of metabolic syndrome (MetS) showed that although subjects without MetS demonstrated a
positive correlation of PON1 activity with serum apoE levels, suggestive of enhancement of PON1
anti-atherogenic action with increased apoE levels; the relationship was abrogated in subjects with
MetS, a condition associated with inflammation and oxidative stress [34].
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There were strengths and limitations in our study. Strengths included the availability of a large
well-characterized population-based study cohort followed prospectively for CVD outcomes for an
average of 11 years and availability of extensive corresponding clinical and laboratory parameters
including serum apoA-I, apoA-II, and apoE levels. The study was limited in a number of ways. In terms
of the study population, there were exclusions for pregnancy, and type 1 diabetes mellitus and for
subjects with serum CRP ≥10 mg/L (to minimize confounding effects by acute inflammation, rheumatic
or other disease conditions manifesting high levels of inflammation); while it should also be noted that
the study cohort was almost exclusively comprised of subjects of white European origin thus potentially
limiting relevance of study findings to other populations. Additionally, the study population was
enriched with albuminuric subjects; however, risk modeling results included adjustments for UAE and
eGFR to account for this. In terms of clinical and laboratory parameters, values were determined only at
study initiation, thus limiting the effects of parameter value variation over time. Regarding PON1 action,
arylesterase activity as a measure was chosen because of good assay precision and good correlation with
PON1 mass assays [35]. Lastly, there was no experimental evidence to verify that the HDL lipidome was
actually preserved from oxidative dysfunctional transformation by high PON1 activity as speculated in
our study. Poor performance of the technically difficult characterization of lipoprotein lipidomics might
determine the effect of PON1 on the risk of functional genetic polymorphisms.
In summary, the results of our current work show that low serum PON1 activity is associated with
increased CVD risk in a group of subjects from a population-based study having concurrently high
levels of HDL-C and CRP indicative of a chronic low-grade inflammatory environment. We believe
that high serum PON1 activity in this group serves to facilitate inhibition of oxidative modification of
the HDL lipidome, thus tending to preserve anti-atherogenic functionality of HDL particles including
the curtailing of LDL oxidation. As such, these findings serve to underscore the presumptive efficacy
of PON1 activity in the inhibition of lipoprotein oxidative modification.
5. Conclusion
Individuals having high HDL-C levels in the setting of chronic systemic inflammation have
increased risk for incident cardiovascular disease. Furthermore, in such individuals, low serum PON1
levels associate with risk with risk accentuated at low apoE levels.”
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Abstract: Statins are effective lipid-lowering drugs with a good safety profile that have become, over
the years, the first-line therapy for patients with dyslipidemia and a real cornerstone of cardiovascular
(CV) preventive therapy. Thanks to both cholesterol-related and “pleiotropic” effects, statins have
a beneficial impact against CV diseases. In particular, by reducing lipids and inflammation statins,
they can influence the pathogenesis of both myocardial infarction and diabetic cardiomyopathy.
Among inflammatory mediators involved in these diseases, interleukin (IL)-1β is a pro-inflammatory
cytokine that recently been shown to be an effective target in secondary prevention of CV events.
Statins are largely prescribed to patients with myocardial infarction and diabetes, but their effects on
IL-1β synthesis and release remain to be fully characterized. Of interest, preliminary studies even
report IL-1β secretion to rise after treatment with statins, with a potential impact on the inflammatory
microenvironment and glycemic control. Here, we will summarize evidence of the role of statins in
the prevention and treatment of myocardial infarction and diabetic cardiomyopathy. In accordance
with the dual lipid-lowering and anti-inflammatory effect of these drugs and in light of the important
results achieved by IL-1β inhibition through canakinumab in CV secondary prevention, we will
dissect the current evidence linking statins with IL-1β and outline the possible benefits of a potential
double treatment with statins and canakinumab.
Keywords: cardiovascular disease; myocardial infarction; diabetic cardiomyopathy; cytokines;
interleukin 1β; inflammation; CANTOS; canakinumab
1. Introduction
Statin discovery dates back to 1976, when mevastatin was isolated from cultures of Penicillium
citrinum and proven to inhibit the production of cholesterol molecules [1]. Further experiments
showed that statins occupy a portion of the rate-controlling enzyme of cholesterol synthesis
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (HMGR) by binding its active site with
very high affinity, thus displacing the natural substrate, HMG-CoA, and inhibiting its function [2].
Furthermore, the statin-related reduction of circulatory lipoprotein induces the hepatic expression
of low-density lipoprotein (LDL) receptor (LDLR) and LDL clearance from the bloodstream, thus
accounting for a further decrease in circulating cholesterol levels [3]. Thanks to this dual mechanism
of action and a good safety profile, both natural and synthetic statins became, over the years, the
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first-line therapy for dyslipidemia patients and a real cornerstone of cardiovascular (CV) preventive
therapy. Soon after first trials with statins were published, evidence suggested that those compounds
might have putative, non-lipid-related effects. Both Cholesterol and Recurrent Events (CARE) and
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trials showed that their overall
cardiovascular benefit was disproportionate to the magnitude of lipid reduction [4,5]. In addition,
the speed by which statins exercised their protective role was faster than that obtained with other
lipid-lowering interventions such as ileal bypass [6]. These “pleiotropic” effects have been related to
statins’ inhibitory effect on the activation of different intracellular signaling mediators downstream
the mevalonate pathways (i.e., Rho, Ras, and Rac proteins) alongside direct stimulatory effects on
peroxisome proliferator-activated (PPAR)-α and -β [7].
Lipids and inflammation are closely interconnected and contribute to the pathogenesis of most
CV disease [8,9]. Among those, myocardial infarction constantly rates among the most important
causes of morbidity and mortality worldwide, while diabetic cardiomyopathy is an emerging disease
whose incidence is set to rise in the next years following the increased prevalence of the diabetic
population. Although the role of circulating lipoproteins in the determination of the individual CV
risk have been appreciated since a long time ago, recently, clinical and experimental observations
support a role for systemic inflammation [10]. Inflammatory cells and cytokines have been identified
in human atherosclerotic vessels, and their dynamic regulation plays an important role in cardiac
remodeling [11,12]. Observational studies reported a reduced CV risk in patients being treated with
anti-inflammatory agents for immunological disease (e.g., rheumatoid arthritis), supporting the concept
of inflammation as a valuable target for CV prevention [13]. However, not all anti-inflammatory
drugs provided efficacy in reducing CV risk as different trials designed to test this hypothesis gave
negative results (i.e., Cardiovascular Inflammation Reduction Trial [CIRT] testing methotrexate), and
non-steroidal anti-inflammatory agents are even associated with an increased CV morbidity [14,15].
Of importance, in 2017, the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
trial showed the efficacy of IL-1β neutralization in patients with established coronary heart disease,
highlighting this cytokine and its pathway as effective targets, as well as suggesting that specific
interaction with inflammatory mediators might be a better strategy than providing anti-inflammation
in a global fashion [16,17].
In this review article, we aim to summarize evidence of the role of statin treatment in myocardial
infarction and prevention of myocardial remodeling in patients with diabetes mellitus. In accordance
with the dual lipid-lowering and anti-inflammatory effect of these drugs and in light of the important
results achieved by CANTOS in CV secondary prevention, we dissect the current evidence linking
statins with IL-1β and outline possible benefits of double treatment with canakinumab.
2. Statins in Myocardial Infarction and Diabetic Cardiomyopathy
2.1. Myocardial Infarction
Coronary atherosclerotic heart disease is the major cause of CV events including stable and
angina, non-ST-segment elevation myocardial infarction (NSTEMI), ST-segment elevation myocardial
infarction (STEMI), and sudden coronary death [18]. Ample evidence demonstrated the key role of
dyslipidemia and, in particular, of elevated LDL levels in the development of coronary heart disease
and thus CV risk. As such, statins have become the first-line therapy for hyperlipidemia and reduction
of CV risk in patients at high and very high risk [19]. With clinical guidelines becoming increasingly
stringent with respect to cholesterol levels [20–22], the prescription and utilization of statins in the last
30 years has increased considerably, with most of the patients taking these drugs for primary prevention
of CV events [23]. To date, several randomized clinical trials (RCTs) and systematic reviews have
investigated the role of statins in this setting, reaching different conclusions [24–27]. These apparent
discrepancies might be explained by different factors: (i) the population in primary prevention is highly
heterogeneous, including patients with low CV risk and those with chronic kidney disease or diabetes
116
J. Clin. Med. 2019, 8, 1764
mellitus with organ damage, who are usually considered as risk-equivalent to CV patients; (ii) most
published systematic reviews, although focusing on primary prevention, included trials in which
a proportion of patients had a history of CV disease. A very recent overview of systematic reviews
tried to overcome these limitations by including exclusively primary prevention trials or individual
patient data of trial participants using only data from patients without established CVD [28]. Here, the
authors report a trend towards reduction of all-cause mortality in all systematic reviews, although
this reached statistical significance only in one study out of three [28]. Furthermore, when patients
where stratified for baseline risk, the effect of statin treatment lost statistical significance in almost all
categories [28]. Similar inconclusive results were reported also when considering different outcomes
such as vascular or non-vascular deaths or composite ones; here, again, stratification for baseline risk
deeply impacted the magnitude of the results. The authors concluded that despite the high number of
patients under statins treatment for primary CV prevention, the evidence for their prescription in this
setting is very limited and should be substantiated by a careful individual assessment of baseline risk,
absolute risk reduction, and potential harm [28].
On the other hand, the role of high-intensity statin treatment as a secondary prevention measure
to reduce the recurrence of CV and cerebrovascular events is well established and highlighted by all
international guidelines [20–22]. In patients with previous myocardial infarction and stroke, statins
blunt the rate of recurrent CV events as well as the need for revascularization procedures. In addition,
mortality is considerably reduced: In the five years after myocardial infarction, treatment of only
30 patients with statin is already able to prevent one cardiovascular death [29]. The pioneering
Scandinavian Simvastatin Survival Study (4S) trial compared simvastatin treatment vs. placebo
in n = 4444 patients with angina pectoris or previous myocardial infarction and found statin to
greatly reduce the risk of death (both cardiovascular and non-cardiovascular ones) as well as that
of undergoing revascularization procedures [29]. More recently, the Pravastatin or Atorvastatin
Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22 (PROVE-IT TIMI 22) trial
compared high-intensity (atorvastatin 80 mg/day) vs. moderate-intensity (pravastatin 40 mg/day) statin
treatment early after ACS and found the strongest intervention to bring an additional 16% reduction
of cardiovascular events as compared to pravastatin 40 mg/day, in 4162 patients [30]. Of interest,
the benefit was already evident within 30 days and became statistical significant throughout the
2.5 years of follow-up [30]. After this, several other trials tested different statins at different dosages,
and results have been summarized in numerous meta-analyses. Among them, in 2010 the Cholesterol
Treatment Trialists (CTT) Collaboration analyzed five randomized trials comparing more intensive
vs. less intensive statin regimens in n = 39612 patients with ACS or stable coronary disease [30]. As a
result, the intensive statin treatment showed a greater reduction in major CV events compared to
the less intensive one. Moreover, this research highlighted that statin benefit is maintained among
patients with and without hypercholesterolemia, and no threshold was found under which LDL
lowering was ineffective [30]. Recently, a specific analysis investigated specific population such as
elderly people and the benefit of statin treatment in secondary prevention remained valid, although
some warnings have been raised for specific high-dose regimens [31,32]. Importantly, the prognostic
role of LDL reduction and the importance of an early start to high-dose statin treatment after ACS
was consistently shown among the majority of clinical trials. This aspect has been taken further by
the recent secondary prevention trials investigating the use of non-statin lipid-lowering agents in
association with the maximally tolerated statin dose in ACS patients, confirming the concept of “the
lower, the better” [33]. Accordingly, the very recent guidelines on dyslipidemia by the European
Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) have adopted a more aggressive
approach with never-seen-before very low targets for LDL levels in high-risk categories (such as
individuals with previous CV events) [20]. Indeed, the LDL target for patients at very high risk is
now set at 1.4 mmol/L (<55 mg/dL), while in patients at very high-risk with multiple recent events,
the target reaches 1.0 mmol/L (<40 mg/dL) [20].
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2.2. Diabetic Cardiomyopathy
Diabetic patients are at increased risk of developing heart failure. The Framingham Heart Study
clearly indicated that diabetes and heart failure are associated, independently of the presence of coronary
artery disease and hypertension [34]. As such, hyperglycemia can cause cardiac insufficiency not only
by increasing the risk of heart failure determinants but also by directly affecting cardiac structure
and function. Diabetes is associated with cardiac oxidative stress, intracellular ion abnormalities,
inflammation, and mitochondrial dysfunction, with metabolic turbulences directly causing the
development of heart failure, and particularly, heart failure with preserved ejection fraction, by altering
specific signaling pathways [35]. Although debated [36], diabetes is also thought to be associated
with systolic heart failure, as previous work showed that indexes of systolic function may be slightly
reduced in diabetic patients without overt coronary disease [37,38]. In this case, the chronic alteration
of glucose levels may cause a reduction of myocardial flow reserve due to microvascular alterations
and lead to subendocardial ischemia and systolic dysfunction [39]. Although the molecular signaling
deranged by the chronic exposure to high glucose levels is very diverse and several pathways have
been involved in the pathophysiology of diabetic cardiomyopathy, in general, they all converge
towards the activation of the transcription factor NF-kB, which then leads to upregulation of cytokines,
chemokines, and adhesion molecules [40]. Indeed, genetic or pharmacologic inhibition of this
nuclear factor mitigates cardiac inflammation and oxidative stress in animal models of diabetes, thus
preventing the development of diabetic cardiomyopathy [41,42]. Glycemia-oriented therapy does
not effectively prevent cardiac complications of long-term type 2 diabetes mellitus [43], thus other
drugs have been tested to reduce cardiac damage. Statins have been hypothesized to hold a protective
role in the setting of diabetic cardiomyopathy thanks to their anti-inflammatory role. Furthermore,
hyperlipidemia is associated with intracardiac accumulation of fatty acids and dysfunction due to
lipotoxicity in the diabetic myocardium [44]. Pre-clinical evidence strongly supports this hypothesis;
atorvastatin could improve left ventricular function by reducing cardiac intramyocardial inflammation
and myocardial fibrosis in an experimental model of diabetic cardiomyopathy [45]. In addition,
atorvastatin could reduce β-adrenergic dysfunction in rats with diabetic cardiomyopathy via increasing
nitric oxide (NO) availability [46]. Rosuvastatin also exhibited protective properties in this setting
by reducing NLRP3 inflammasome and IL-1β activation via suppression of MAPK pathways [47].
Finally, simvastatin could reduce cardiac dysfunction in streptozotocin-induced diabetic rats by
attenuating hyperglycemia-induced cardiac oxidative stress, inflammation, and apoptosis. In the
clinical setting, intensive lipid control with statins and other drugs is associated with an important
decrease of cardiovascular risk in diabetic patients [48–50]. Accordingly, statins together with other
lipid-modifying agents (i.e., peroxisome proliferator-activated receptor (PPAR) agonists) are suggested
by diabetes guidelines for both primary and secondary CV prevention [51]. This being said, statins
failed to effectively modify the course of diabetic cardiomyopathy, and they may even facilitate the
onset of diabetes by impacting peripheral insulin sensitivity and β-cell function [52]. Nevertheless,
discontinuing statin therapy in diabetic patients is not recommended [53].
3. Statins, Inflammation, and IL-1β
The effectiveness of statin anti-inflammatory properties in the CV setting has been definitively
proven in clinical trials. The Justification for the Use of Statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin (JUPITER) trial enrolled apparently healthy persons without hyperlipidemia
but with elevated hs-CRP and demonstrated that treatment with rosuvastatin significantly reduced the
incidence of major CV events [54]. Similarly, the Pravastatin Or Atorvastatin Evaluation and Infection
Therapy (PROVE-IT), Aggrastat to Zocor (AtoZ), and Improved Reduction of Outcomes: Vytorin
Efficacy International Trial (IMPROVE-IT) trials also reported the clinical relevance of statin-related
hs-CRP reduction [30,55,56]. Statins exert these anti-inflammatory effects by blunting the downstream
synthesis of molecules in the mevalonate pathway through the inhibition of small GTPase prenylation
and isoprenoid production [57–59]. Of note, small GTPases regulate different signaling pathways
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and thus cellular processes dependent on isoprenylation and involved in the development of CV
diseases [60,61]. Rho and Rac cooperate in the surge of oxidative stress and inflammatory mediators
that characterize different pathologic processes [62,63]. Furthermore, Ras is thought to play a central
role in the regulation of cellular growth and proliferation [64]. The inhibition of those pathways is
associated with a number of protective immunomodulatory effects in inflammatory cells and vascular
and myocardial tissue [65,66]. In vascular cells, statins can enhance the availability of protective
nitric oxide (NO) by increasing its synthesis and reducing its degradation [67,68]. This accompanies
a sensible reduction of endothelial oxidative stress and modulation of redox-sensitive transcription
factors such as NF-kβ and activator protein 1 (AP-1), key enzymes involved in the regulation of several
pro-inflammatory genes [69]. As a result, treatment with statins is associated with blunted expression
of pro-thrombotic factors as well as different adhesion molecules such as vascular cell adhesion
molecule 1 (VCAM-1), platelet endothelial adhesion molecule 1 (PECAM-1), intercellular cell adhesion
molecule-1 (ICAM-1), and P-selectin [70–72]. Moreover, statin treatment reduces monocyte, endothelial,
and vascular smooth cell production of different pro-inflammatory cytokines including monocyte
chemoattractant protein-1 (MCP-1), regulated on activation, normal T cell expressed and secreted
(RANTES), and interleukin (IL)-6 and IL-8 [70,73,74]. Statins also exert their immunomodulatory effects
by reducing monocyte expression of CD11β (an integrin with a key role in monocyte–endothelium
interaction), suppressing the expression of major histocompatibility complex (MHC) class II protein,
as well as reducing the proliferation and differentiation of activated T- and B-lymphocytes [75–77].
Dyslipidemia, altered glucose metabolism, and inflammation share several cardiac signaling
pathways and are closely interconnected (Figure 1). Although the anti-inflammatory role of statins is
widely accepted, different studies demonstrated that those molecules could paradoxically increase the
production of IL-1β—among the most important pro-inflammatory cytokines—as a result of reduced
protein prenylation in immune cells [78]. Mature, active IL-1β derives from the cleavage of its pro-form
by the NOD-like receptor family, pyrin-domain-containing (NLRP) 3 inflammasome [79]. The NLRP3
inflammasome complex is formed by the sensor molecule NLRP3, the adaptor protein ASC, and
pro-caspase-1. This multimeric protein complex regulates the release of cytokines IL-1β and IL-18,
alongside initiating an inflammatory form of cell death known as pyroptosis [80]. Inflammasome
activation is a two-step process that requires adequate priming of NLRP3 followed by a signal
triggering the assembling [80]. The priming step occurs via different inflammatory stimuli such as
TLR4 agonists, resulting in activation of NF-kB and transcription of NLRP3 and pro-IL-1β [81–83].
Furthermore, NLRP3 priming also associates with post-translational modifications of NLRP3 (such
as phosphorylation and ubiquitination), further regulating its activation [84,85]. The second step is
provided by the recognition of damage-associated molecular patterns (DAMPs) causing the perturbation
of cellular metabolism with the production of reactive oxygen species, ion disturbances, and lysosomal
disruption [86–89]. Due to its pro-inflammatory role, the NLRP3 inflammasome has progressively
become an important molecular target to cope with different chronic diseases, including myocardial
infarction and diabetes [90]. To date, five specific NLRP3 inhibitors have been validated in vivo or
in vitro and entered clinical testing at different phases [91]. On the other hand, many drugs able to
modify cellular metabolism and homeostasis have been shown to activate the inflammasome [92].
Although some controversies still exist due to possible differences between different molecules, statins
are acknowledged among NLRP3 activators and thus IL-1β inducers. Of note, this characteristic
is thought to account for their association with diabetes onset [78,93,94]. Various statins have been
shown to increase IL-1β secretion from macrophages through NLRP3 activation, but none of them
were able to act as a priming agent on the inflammasome as they all need bacterial liposaccharide to
induce caspase-1-dependent cleavage of pro-IL1β into its active form [95,96]. In a report from 2014,
Henriksbo and colleagues showed that long-term treatment of obese mice with fluvastatin promoted
insulin resistance in adipose tissue and increased caspase-1 activity and IL-1β production in adipose
tissue explants in the presence of LPS [95]. Of interest, this effect was not observed in NLRP3−/−
explants and was reversed by glyburide, a known inflammasome inhibitor and antidiabetic drug [95].
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Similarly, fluvastatin could increase the secretion of 1L-1β and IL-18 in peripheral blood mononuclear
cells stimulated by Mycobacterium tuberculosis [97]. In additon, lovastatin increases reactive oxygen
species (ROS) and synergizes with LPS to trigger IL-1β release in macrophages and monocytes [98].
Of interest, these pro-inflammatory effects have been shown to relate with statin-related disturbances
on protein prenylation as addition of mevalonate or GGPP—an intermediate in the mevalonate
pathway—could prevent IL-1β release [96,99]. Recently, this aspect has been further dissected by
showing that, differently from LDL lowering, statin-related reduction of isoprenoids was required
for NLRP3/caspase-1 inflammasome activation and IL-1β-dependent insulin resistance in adipose
tissue [100]. Furthermore, supplementation of geranylgeranyl isoprenoids or caspase-1 inhibition
could prevent statin-induced alteration of insulin signaling [100]. Moreover, IL-1β, but not IL-18,
is necessary to induce insulin resistance in adipose tissue treated with atorvastatin [100]. Summarizing,
inflammasome activation and IL-1β secretion likely link statins with impaired glucose metabolism.
Thus, inflammasome might be an effective molecular target to reduce statin-related diabetes onset.
On the other hand, targeting the inflammasome and IL-1β might reduce the effectiveness of statin
treatment on CV prevention, as the importance of this interleukin has been recently highlighted in the
CANTOS trial.
4. Perspective
Human coronary plaques are inflammatory lesions in which immune cells and inflammatory
molecules are detectable at a high level and play pivotal roles [101–104]. Recently, the CANTOS trial
confirmed the inflammatory theory of atherosclerosis and shed new light on the role of IL-1β in CV
risk determination [16]. A total of 10,061 patients with a previous myocardial infarction and showing
inflammatory residual risk (CRP > 2 mg/L) under optimal CV-protective therapy were enrolled in
this randomized, double-blind trial to receive canakinumab, a IL-1β inhibitory monoclonal antibody,
or a placebo every 3 months. Levels of lipids remained unaltered upon treatment with canakinumab,
while a significant decrease in CRP levels was observed already after the first administration of
the anti-inflammatory drug. The primary endpoint composed of cardiovascular death, non-fatal
myocardial infarction, and non-fatal stroke was successfully met by the intermediate doses of the
drugs (100 and 150 mg/administration) [16]. Of interest, those patients with CRP levels reduced to
<2 mg/L after the first administration benefitted the most from the long-term treatment as this was
associated with a 31% reduction in CV mortality, a 31% reduction in all-cause mortality, and a 25%
reduction in major adverse CV events [105]. Conversely, in patients with on-treatment high-sensitivity
CRP ≥ 2 mg/L, the treatment effects were non-significant [105]. Of interest, canakinumab was also
effective in reducing rates of non-cardiovascular inflammatory disease, such as lung cancer, arthritis,
and gout. As expected, patients treated with IL-1β inhibitory antibody had a higher rate of fatal
infections as well as of neutropenia or thrombocytopenia [16]. The CANTOS trial not only provided
solid proof of the effectiveness of IL-1β inhibition in secondary CV prevention; it also allowed
a deepening of the complex relationship between lipids and inflammation. Indeed, cholesterol crystals
can induce IL-1β activation via canonical (i.e., NLRP3-mediated) and non-canonical pathways, then
IL-1β establishes a vicious circle that ends up in further pro-IL1β cleavage [106–108]. Then, blocking
this pathway via canakinumab could reduce the effect of lipids on atherosclerotic inflammation. On the
other hand, substantial evidence exists demonstrating a role for inflammation on the induction of
dyslipidemia [109,110]. Differently from other anti-inflammatory drugs, in CANTOS, canakinumab
did not affect cholesterol levels, while it slightly increased triglycerides [16]; thus, the cardiovascular
preventive effects did not depend on any lipid effects related to IL-1β.
120
J. Clin. Med. 2019, 8, 1764
Figure 1. Altered lipid and glucose metabolisms share common molecular pathways in the
pathophysiology of cardiac remodeling, relying on the release of pro-inflammatory interleukin (IL)-1β.
The increased levels of different deleterious mediators (such as AGE, AngII, DAMP, and modified
lipoproteins) are sensed by promiscuous receptors on cell surfaces and trigger secondary signaling
pathways leading to activation of NF-κβ and AP-1, two transcription factors involved in the regulation
of NLRP3 inflammasome activity. The activated inflammasome then leads to the activation and release
of IL-1β, which fuel the sterile inflammation associated with cardiac remodeling. AGE: advanced
glycation end-product; AngII: angiotensin II; AP-1: activator protein 1; DAMPs: damage-associated
molecular patterns; ERK: extracellular signal-regulated kinases; HMGB1: high mobility group box
1; IL-1β: interleukin 1β; JNK: Janus kinases; NF-κβ: nuclear factor kappa-light-chain-enhancer of
activated B cells; NLRP3: NACHT-, LRR-, and PYD-domain-containing protein 3; NOX: NADPH
oxidase; PKC: protein kinase C; TLR: Toll-like receptor; RAGE: receptor of AGE; ROS: reactive oxygen
species; oxLDL: oxidized low-density lipoproteins.
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Canakinumab is effective and relatively safe for secondary prevention of CV events; whether
this might also be the case for primary CV prevention or for the treatment of myocardial infarction
sequelae such as cardiac remodeling remains to be investigated. Cardiac repair after myocardial
infarction depends on the tight regulation of sterile inflammation, which serves to clear damaged cells
and promote the formation of a functional scar; alterations of the inflammatory balance associate with
deleterious myocardial remodeling, resulting in cardiac dysfunction and heart failure [111]. Being a key
regulator of inflammation, IL-1β plays an important role in orchestrating the inflammatory response in
an ischemic/reperfused myocardium [112]. In this setting, IL-1β can activate downstream mediators
which further amplify inflammation via MAPK and NF-κB signaling. Furthermore, it allows for the
spatial extension of inflammation by activating local parenchymal and infiltrating cells that express its
receptor and facilitates leukocytes recruitment via increasing the expression of adhesion molecules and
chemoattractant in the damaged myocardium [111]. In line with this evidence, previous experimental
studies reported a role of IL-1 blockade in preventing adverse cardiac remodeling (Table 1).
Table 1. Experimental studies investigating the effect of IL-1 inhibition in preventing cardiac remodeling
after myocardial infarction.
Author Year Drug(dose) Schedule Results





delayed (24 h after
ischemia) and then
daily for 6 days.
Anakinra-treated mice showed signs of
more favorable ventricular remodeling.
Van Tassell et al.
[114] 2010
IL-1 Trap (1, 5
or 30 mg/kg)
Every 48 h after
surgery.
Mice treated with 5 or 30 mg/kg of IL-1
Trap had more favorable cardiac
remodeling and echocardiographic




either 30 min or 4 h
prior to surgery
Irrespective of dose, treated mice
showed marked cardio-protection in
terms of LVEF and the reduction of the
infarct size.
Toldo et al.





When compared with control vehicle,
anti-IL-1β Ab limit left ventricular




[117] 2014 Anti-IL-1β Ab




After 10 weeks, anti-IL-1β Ab prevents
reduction of LVEF, impairment in the
myocardial performance index. and
contractile reserve.




Daily, starting 24 h
after surgery
Anakinra improved conduction velocity
and reduced action potential duration
dispersion, thus determining a









At 24 h, IL-1α blockade significantly
reduced inflammasome formation and
infarct size, thus preserving LVFS.
Herouki et al.





Immediate, but not delayed,
administration of anti-IL-1β Ab reduces
ischemia/reperfusion-related infarct
size, left ventricular remodeling, and
heart-failure-related coronary
dysfunction.
IL: interleukin; rhIL-1Ra: recombinant human interleukin-1 receptor antagonist; LVEF: left ventricular ejection
fraction; LVFS: left ventricular fractional shortening.
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Unfortunately, the few randomized clinical trials and observational and cohort studies that have
evaluated the effect of IL-1β inhibition in relation to the development of post-MI cardiac remodeling
have provided conflicting results [121–124] (Table 2). Of interest, most of them were based on the
unspecific blockage of IL-1 receptor, which recognizes both IL-1α and β isoforms; whether a more
specific targeting of the IL-1β pathway via canakinumab might provide additional beneficial effects
on top of statins in the context of post-myocardial remodeling remains to be fully determined.
Recently, a sub-analysis of the previously mentioned CANTOS trial suggested post-MI treatment
with canakinumab to dose-dependently reduce hospitalization for heart failure and the composite
of hospitalization for heart failure or heart-failure-related mortality as compared to a placebo [125].
In this regard, it is important to take into consideration that the CV-protective role of canakinumab
has been demonstrated only in patients with residual inflammatory risk, while that of statins is not
restricted to this group. Furthermore, lipid-lowering therapies hold a very competitive risk/benefit
balance even when very low LDL levels are reached [126], while this is not the case for IL-1β blockade,
which is associated with a higher risk of sepsis and fatal infections.
Similarly, given the relevance of inflammatory mediators, and particularly IL-1β, in the
pathophysiology of diabetes and diabetic cardiomyopathy [127], targeting the NLRP3/IL1β pathway
could effectively reduce the burden of this disease. Given the high number of diabetic individuals
under cardio-protective treatment with statins and the possible deleterious effect of these drugs on
Il-1β activation and thus glycemic control, adding IL-1β inhibition on top of statin treatment might
give additional benefit in terms of CV protection. In this sense, it will be very important to understand
whether the inflammasome could be safely targeted without altering the general anti-inflammatory
effect of statins. How statins could be generally anti-inflammatory and thus protective in the CV
setting while increasing the risk of diabetes remains to be fully explained. In other words, on which
pathophysiological aspect of the two diseases does the mechanism of action of statins differ? Different
investigators have previously tried to address this question, with different hypotheses being made [78].
Statins might have different effects on different cells with different roles in the diseases. In this sense,
the effect of statins on endothelial cells should drive the protective CV effects, while their roles on
adipocytes, pancreatic islet cells, or myocytes could be of more relevance in diabetes onset and diabetic
cardiomyopathy [78]. In addition, the cholesterol-lowering effect might play a more important role in
the prevention of CV disease as compared to that played in diabetes development. The connection
between statins, NLRP3/IL-1β, and insulin resistance remains to be characterized in depth, and many
mechanistic questions are still unsolved; understanding these aspects might pave the way for new
therapeutic strategies, including a combination of statins and IL-1β inhibition.
Table 2. Clinical studies investigating the effect of IL-1 inhibition in preventing cardiac remodeling
after myocardial infarction.










In this pilot double blind RCT,
treatment with anakinra showed to
be safe and to reduce left ventricular
remodeling (assessed by both
echocardiography and cardiac





2015 Anakinra 100 mg/daily scfor 14 days
NSTEMI
(n = 182)
In this proof-of-principle double
blind RCT, patients treated with
anakinra showed reduced levels of
hsCRP and IL-6 as compared to
those receiving a placebo.
123
J. Clin. Med. 2019, 8, 1764
Table 2. Cont.










In this pilot double blind RCT,
treatment with anakinra could
reduce hsCRP levels as compared to
a placebo. Anakinra-treated
patients also showed a numerically
lower incidence of heart failure,
although this was not statistically
significant.
Ridker et al.






In this double blind RCT, treatment
with canakinumab after STEMI was
shown to dose-dependently reduce
hospitalization for heart failure and
the composite of hospitalization for
heart failure or heart-failure-related
mortality as compared to a placebo.
Van Tassell et al.
VCU-ART3 [130] 2019 Anakinra





Preliminary results of this double
blind RCT were presented at the
2019 Congress of the European
Society of Cardiology. Patients
treated with anakinra showed
significant improvement in cardiac
systolic function after STEMI, as
compared to a placebo.
CANTOS: Canakinumab Anti-Inflammatory Thrombosis Outcomes Study; hsCRP: high-sensitivity C-reactive
protein; IL-6: interleukin-6; NSTEMI: non-ST-elevation myocardial infarction; RCT: randomized clinical trial; STEMI:
ST-elevation myocardial infarction; VCU-ART: Virginia Commonwealth University Anakinra Remodeling Trial.
5. Conclusions
Firstly introduced to reduce circulating LDL, statins soon became pillars of prevention and
treatment of CV diseases. Aside from their lipid-lowering actions, statins hold different pleiotropic
effects that are thought to deeply contribute to their CV-protective effect and involve the modulation
of the inflammatory response. Statins are recommended for prevention of myocardial infarction in
patients with dyslipidemia, high, or very high cardiovascular risk. In diabetic subjects, statins have been
hypothesized to reduce the development of diabetic cardiomyopathy thanks to their anti-inflammatory
effect. Despite the encouraging results of the pre-clinical tests, statins failed to effectively modify the
course of heart failure in diabetic patients and may even facilitate the onset of diabetes in patients
without previous glucose disturbances. Thanks to the CANTOS trial involving the IL-1β inhibitory
antibody canakinumab, this pro-inflammatory cytokine has recently emerged as an effective and
relatively safe target for secondary CV prevention in patients with residual inflammatory risk. Although
generally seen as anti-inflammatory drugs, statins may have different effects on IL-1β synthesis in
different cells, with some studies even demonstrating a paradoxical increase. In consideration of the
detrimental role of IL-1β in the pathophysiology of myocardial infarction and diabetic cardiomyopathy,
adding canakinumab on top of statins in these patients might then provide a stronger inhibition of
the IL-1β-mediated inflammatory response, with additional beneficial effects on the pathophysiology
of these diseases. In addition, in patients treated with statins, canakinumab might even be able to
reduce statin-induced insulin resistance as this is thought to depend on the activation of the NLRP3
inflammasome/IL-1β pathway. Further specific investigations will be needed to test this hypothesis in
order to reduce the very high global burden of myocardial infarction and diabetic cardiomyopathy.
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Abstract: Background: Retinol binding protein 4 (RBP4) carries retinol in plasma, but is also considered
an adipokine, as it is implicated in insulin resistance in mice. Plasma RBP4 correlates with total
cholesterol, low density lipoprotein (LDL)-cholesterol and triglycerides, and may confer increased
cardiovascular risk. However, controversy exists about circulating RPB4 levels in type 2 diabetes
mellitus (T2DM) and obesity. Here, we analyzed the relationships of RBP4 and retinol with lipoprotein
subfractions in subjects with and without T2DM. Methods: Fasting plasma RBP4 (enzyme-linked
immunosorbent assay) and retinol (high performance liquid chromatography) were assayed in 41
T2DM subjects and 37 non-diabetic subjects. Lipoprotein subfractions (NMR spectroscopy) were
measured in 36 T2DM subjects and 27 non-diabetic subjects. Physical interaction of RBP4 with
lipoproteins was assessed by fast protein liquid chromatography (FPLC). Results: Plasma RBP4 and
retinol were strongly correlated (r = 0.881, p < 0.001). RBP4, retinol and the RBP4/retinol ratio were
not different between T2DM and non-diabetic subjects (all p > 0.12), and were unrelated to body
mass index. Notably, RBP4 and retinol were elevated in subjects with metabolic syndrome (p < 0.05),
which was attributable to an association with elevated triglycerides (p = 0.013). Large VLDL, total
LDL and small LDL were increased in T2DM subjects (p = 0.035 to 0.003). Taking all subjects together,
RBP4 correlated with total cholesterol, non-HDL cholesterol, LDL cholesterol, triglycerides and
apolipoprotein B in univariate analysis (p < 0.001 for each). Age-, sex- and diabetes status-adjusted
multivariable linear regression analysis revealed that RBP4 was independently associated with large
VLDL (β = 0.444, p = 0.005) and small LDL particles (β = 0.539, p < 0.001). Its relationship with
large VLDL remained after further adjustment for retinol. RBP4 did not co-elute with VLDL nor LDL
particles in FPLC analyses. Conclusions: Plasma RBP4 levels are related to but do not physically
interact with large VLDL and small LDL particles. Elevated RBP4 may contribute to a proatherogenic
plasma lipoprotein profile.
Keywords: retinol binding protein 4; retinol; lipoprotein subfractions; large VLDL; small LDL; Type
2 diabetes mellitus; metabolic syndrome; nuclear magnetic resonance spectroscopy
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1. Introduction
The incidence of the metabolic syndrome (MetS) and Type 2 diabetes mellitus (T2DM) has rapidly
increased in the past few years [1]. Both MetS and T2DM are associated with an increased risk of
cardiovascular disease and reduced life span [2]. Impaired insulin action is a main determinant
responsible for the development of T2DM [3]. Hence, continued attention is being paid to the
pathogenic mechanisms underlying insulin resistance.
Retinol-binding protein 4 (RBP4) is produced by the liver and adipose tissue and transports
retinol (vitamin A) via the circulation to peripheral tissues. However, RBP4 is also considered to
be an adipokine, as it has been implicated in the pathogenesis of insulin resistance [4]. In rodent
studies, Rbp4 overexpression was convincingly shown to enhance insulin resistance, impair insulin
signaling in muscle and induce pathways involved in hepatic gluconeogenesis [4]. Conversely, genetic
deletion of Rbp4 in mice was found to enhance insulin sensitivity [4]. Nonetheless, studies in humans
with obesity, impaired glucose tolerance and T2DM have shown inconsistent results regarding the
associations of these pathologies with circulating RBP4. Initial studies documented that RBP4 levels
were elevated in patients with obesity, impaired glucose tolerance and T2DM, and were correlated with
HbA1c, fasting glucose and insulin [5]. Enhanced RBP4 levels were also observed in obese children,
and (pronounced) weight loss was shown to reduce RBP4 levels in some but not in all studies [6–8].
Likewise, studies reporting potential associations between RBP4 and T2DM were also inconsistent.
Initial studies observed elevated RBP4 levels in T2DM patients [9–11], whereas more recent reports
either detected no abnormalities in RBP4 [12] or even found a negative correlation of RBP4 with
diabetes status [13]. RBP4 is the major carrier of retinol in plasma although not all RBP4 may be
“loaded” with retinol. The RBP4/retinol ratio was found to be elevated in T2DM despite lower RBP4
levels as such [13], and similar observations were made in obese children [14]. The RBP4/retinol ratio
has therefore been advocated to better reflect alterations in obesity and T2DM [13,14].
In contrast to the equivocally reported relationships of circulating RBP4 with obesity,
dysglycemia and insulin resistance, positive relationships of RBP4 with total cholesterol, low
density lipoprotein (LDL) cholesterol and triglycerides have repeatedly and almost invariably been
demonstrated [6,7,12,13,15–17]. Quantification of specific lipoprotein subfractions is increasingly used
to better delineate dyslipidemia in pathological conditions, such as obesity and (pre)diabetes [18–21].
Interestingly, RBP4 associates with small dense LDL particles and oxidized LDL [17,22]. No
data are currently available regarding the relationship of RBP4 with nuclear magnetic resonance
(NMR)-quantified lipoprotein subfractions in adult subjects with and without T2DM, the latter condition
being expected to be characterized by elevated large VLDL and small-sized LDL particles [18,20]. Given
that an increasing number of human studies suggest that elevated plasma RBP4 levels may confer
(subclinical) cardiovascular disease (CVD) risk [15,23–26], it is clinically relevant to more precisely
delineate the association of RBP4 with various lipoprotein subfractions.
Therefore, the present study aimed to determine whether plasma levels of RBP4 and/or retinol
relate to VLDL and LDL subfractions in adults with and without T2DM.
2. Experimental Section
2.1. Subjects
The study protocol was approved by the medical ethics committee of the University Medical
Center Groningen. All participants provided written informed consent and were aged > 18 years. They
were recruited by advertisement in local newspapers. T2DM was diagnosed by primary care physicians
based on fasting plasma glucose ≥ 7.0 mmol/L and/or a non-fasting plasma glucose ≥ 11.1 mmol/L.
Diabetic patients using metformin, sulfonylurea and antihypertensives were included. Insulin use
was an exclusion criterion. A positive history of cardiovascular disease, chronic kidney disease
(estimated glomerular filtration rate < 60 mL/min/1.73 m2 and/or proteinuria), abnormal liver function
tests (transaminases > 3 times the upper reference limit) or thyroid dysfunction (thyroid stimulating
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hormone > 10 or < 0.40 mU/L or use of thyroid function influencing medication), as well as current
smoking and use of lipid lowering drugs was also an exclusion criterion. Blood pressure was measured
after 15 min of rest in the left arm in sitting position using a sphygmomanometer. Body mass index
(BMI in kg/m2) was calculated as weight divided by height squared. Waist circumference was measured
on bare skin between the 10th rib and the iliac crest. The participants were studied after an overnight
fast. Metabolic syndrome (MetS) was defined according to NCEP-ATP III criteria [27]. Three or more
of the following criteria were required for categorization of subjects with MetS: waist circumference
> 102 cm for men and > 88 cm for women; hypertension (blood pressure ≥ 130⁄85 mmHg or use of
antihypertensive drugs); fasting plasma triglycerides ≥ 1.70 mmol/L; HDL cholesterol <1.00 mmol/L
for men and <1.30 mmol/L for women; fasting glucose ≥ 5.60 mmol/l. Insulin sensitivity was estimated
by homeostasis model assessment of insulin resistance (HOMA-IR) applying the following equation:
fasting plasma insulin (mU/L) × glucose (mmol/L)/22.5.
2.2. Laboratory Analysis
Serum and EDTA-anticoagulated plasma samples were stored at −80 °C until analysis. Plasma
glucose was measured shortly after blood collection with an APEC glucose analyzer (APEC Inc., Danvers,
MA, USA). Plasma total cholesterol and triglycerides were measured by routine enzymatic methods
(Roche/Hitachi cat. nos 11,875,540 and 1,187,602, respectively; Roche Diagnostics GmBH, Mannheim,
Germany). HDL cholesterol was assayed by a homogeneous enzymatic colorimetric test (Roche/Hitachi,
cat.no 04713214). Non-HDL cholesterol was calculated as the difference between total cholesterol
and HDL cholesterol. LDL cholesterol was calculated by the Friedewald formula if triglycerides
were <4.5 mmol/L. Apolipoprotein A-I (apoA-I) and apolipoprotein B (apoB) were measured
by immunoturbidimetry (Roche/Cobas Integra Tinaquant cat no. 03032566, Roche Diagnostics).
HbA1c was measured by high-performance liquid chromatography (HPLC; Bio-Rad, Veenendaal,
the Netherlands; normal range: 27–43 mmol/mol).
Plasma RBP4 was assayed by enzyme-linked immunosorbent assay (ELISA; R&D Systems; Catalog
Number DRB400). In brief, 96-well plates precoated with anti-human RBP4 monoclonal antibody were
stored at 4 ◦C. After adding 200 μL of 2 vials (11 mL/vial) of a buffered protein solution to each well, 20
μL of sample material was added to each well and left for 1 h at room temperature on a horizontal
orbital microplate shaker (0.12” orbit) set at 500 rpm. This procedure was followed by aspiration and
washing of each well with 400 μL buffered surfactant, repeating the process three times for a total
of four washes. 200 μL of monoclonal antibody specific for human RBP4 conjugated to horseradish
peroxidase were added to each well and incubated for 1 h at room temperature under gentle agitation.
After repeating aspiration/wash as described, 200 μL of Substrate Solution consisting of stabilized
hydrogen peroxide and stabilized chromogen (tetramethylbenzidine) were added to each well and
incubated for 30 min at room temperature under protection from light. The reaction was then stopped
by adding 50 μL of 2 N sulfuric acid; the absorbance was measured at 450 nm, 540 nm and 570 nm.
Plasma retinol levels were analyzed by reverse phase high performance liquid chromatography
(HPLC) as described [28]. Briefly, 50 μL plasma samples were added in antioxidant solutions (2.8 mL)
and vortexed thoroughly for 1 min. Retinol was extracted and deproteinized twice with n-hexane in
the presence of retinol acetate (100 μL, concentration 4 μmol/L) as external standard to assess the level
of recovery after the extraction procedure. Standard curves created from a range of concentrations
of retinol were used to determine absolute serum retinol concentrations. Additionally, two negative
controls (only containing internal standard) and two positive controls (low and high concentrations of
retinol plus internal standard) were included in each series of extractions. Samples were evaporated
under N2 and diluted in 300 μL 100% ultrapure ethanol. Then, 50 μL were injected in HPLC (Waters
2795 Alliance HT Separations Module, Connecticut, USA) for phase separation on a C18 column
(Waters Symmetry C18, dimension 150 × 3.0 mm, particle size 5 μm, Waters Corporation, Milford, MA,
USA) (UV-VIS, dual wavelength, UV-4075 Jasco, Tokyo, Japan). Retinoids in samples were identified by
applying exact retention time of known standards in ultraviolet absorption at 325 nm by HPLC. Finally,
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retinol concentrations were calculated and normalized to final volume. The intra-assay coefficients of
variation (CV) of RBP4 and retinol amount to 5.7–8.1% and 3.6%, respectively.
Lipoprotein separation was performed by fast protein liquid chromatography (FPLC) as described
before [29]. One mL of plasma of four control individuals were subjected to size exclusion gel FPLC
filtration using a Superose 6 column (GE Healthcare, Uppsala, Sweden) at a flow rate of 0.5 mL/min.
Fractions of 500 μL each were collected. Total protein (Bradford), total cholesterol, triglycerides
and RBP4 were determined in the respective lipoprotein fractions by ELISA as detailed above. One
representative FPLC profile is presented.
Lipoprotein particle profiles were determined by nuclear magnetic resonance (NMR) spectroscopy
with the LP3 algorithm (LipoScience, now LabCorp, Morrisville, NC, USA) [30,31]. Very low density
lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) particle classes
and subfractions were quantified from the amplitudes of their spectroscopically distinct lipid methyl
group NMR signals. Diameter range estimates were for VLDL (including chylomicrons if present):
>60 nm to 29 nm, for LDL: 29 nm to 18 nm, and for HDL: 14 nm to 7.3 nm. The VLDL, LDL and HDL
particle concentrations (VLDL-P, LDL-P and HDL-P, respectively) were calculated as the weighted
average of the respective lipoprotein subclasses. The intra-assay CVs for the lipoprotein parameters
are: VLDL-P (11.0%), LDL-P (4.1%), HDL-P (2.0%) and amount to 6.6–27.9%. for the various VLDL,
LDL and HDL subfractions.
2.3. Statistical Analysis
IBM SPSS software (SPSS, version 24.0, SPSS Inc. Chicago, IL, USA) was used for data
analysis. Continuous variables were expressed in means ± SD or medians (interquartile ranges)
in case of not-normally distributed data. HOMA-IR, triglycerides and lipoprotein subfractions were
loge transformed to achieve approximately normal distributions. Between group differences in
variables were determined by T-tests for unpaired data and Chi-square tests where appropriate.
Univariate correlations were determined by Pearson correlation coefficients. Multivariable linear
regression analyses were carried out to disclose the independent relationships of RBP4, retinol and the
RBP4/retinol ratio with either T2DM or MetS. Additionally, multivariable linear regression analyses
were performed to disclose the independent associations with RBP4 and retinol with VLDL, LDL and
HDL subfraction characteristics, each in separate models. Two-sided p-values < 0.05 were considered
statistically significant.
3. Results
Forty-one (41) subjects with T2DM and 37 subjects without T2DM were included. Clinical
characteristics and biochemical data are presented in Table 1. Twenty-nine (29) of the diabetic patients
used glucose-lowering drugs (metformin and/or sulfonylurea). Antihypertensive drugs, particularly
angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists and diuretics,
alone or in combination were used by 19 T2DM subjects; none of the non-diabetic subjects were using
antihypertensive drugs. Three non-diabetic women were using estrogens. Other medications were
not taken.
As expected, T2DM subjects were classified with MetS more frequently, had higher blood
pressure, were more obese and had higher glucose and HbA1c levels and had higher HOMA-IR
when compared to non-diabetic controls (Table 1). In general, metabolic control was adequate in
the diabetic patients given an average HbA1c level of 50 mmol/mol. Total cholesterol, non-HDL
cholesterol, LDL cholesterol and apoB levels were not significantly different between diabetic and
non-diabetic individuals. Triglycerides were higher, whereas HDL cholesterol was lower in T2DM
subjects (Table 1). Plasma levels of RBP4, retinol and the RBP4/retinol ratio were not different between
diabetic and non-diabetic subjects (Table 1 and Figure 1A), also not after adjustment for age and sex
(RBP4, p = 0.63; retinol, p = 0.25; RBP4/retinol ratio, p = 0,19, respectively; data not shown). In contrast,
RBP4 and retinol levels were higher in subjects with MetS vs. subjects without MetS (Figure 1B; RBP4:
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41.38 ± 7.98 mg/L in subjects with MetS and 37.48 ± 8.48 mg/L in subjects without MetS, p = 0.041;
retinol: 2.37 ± 0.50 μmol/L in subjects with MetS vs. 2.14 ± 0.46 μmol/L in subjects without MetS,
p = 0.038). As a consequence, the RBP4/retinol ratio was not different between subjects with and
without MetS (17.61 ± 1.73 mg/μmol vs. 17.57 ± 1.91 mg/μmol, respectively, p = 0.78). The associations
of RBP4 and retinol with the presence of MetS remained close to significance after adjustment for age
and sex (retinol: β = 0.223, p = 0.052 and RBP4: β = 0.224, p = 0.051; data not shown). Additionally,
in age- and sex-adjusted multivariable linear regression analysis, RBP4 was independently associated
with elevated triglycerides (β = 0.348, p = 0.013), but not with the other individual MetS components (p
≥ 0.75 for each). Serum retinol levels were not associated with any of the MetS components (p > 0.40 for
each; data not shown). In univariate analysis, RBP4 and retinol were not significantly associated with
HOMA-IR (r = 0.088, p = 0.441 and r = 0.149, p = 0.19, respectively). Furthermore, RBP4, retinol and the
RBP4/retinol ratio were not significantly different between men and women (RBP4: 39.01 ± 8.40 mg/L
in men and 39.43 ± 8.53 mg/L in women, p = 0.83; retinol: 2.29 ± 0.46 μmol/L in men and 2.22 ± 0.51
μmol/L in women, p = 0.57; RBP4/retinol ratio: 17.10 ± 1.77 mg/μmol in men and 17.90 ± 1.80 mg/μmol
in women, p = 0.071).
Table 1. Clinical and laboratory characteristics in 41 subjects with Type 2 diabetes mellitus (T2DM) and
37 subjects without T2DM.
T2DM Subjects (n = 41) Non-Diabetic
Subjects (n = 37) p-Value
Age (years) 60 ± 10 52 ± 9 <0.001
Gender (men/women) 19/22 10/27 0.127
Metabolic syndrome (yes/no) 29/12 7/30 <0.001
Systolic blood pressure (mm Hg) 145 ± 20 129 ± 20 0.001
Diastolic blood pressure (mm Hg) 87 ± 9 81 ± 12 0.025
BMI (kg/m2) 29.0 ± 4.9 25.5 ± 4.1 0.001
Waist (cm) 100 ± 14 84 ± 13 <0.001
Glucose (mmol/L) 8.9 ± 2.3 5.6 ± 0.7 <0.001
HbA1c (mmol/mol) 50 ± 9 33 ± 3 <0.001
HOMA-IR (mU mmol/L2/22.5) 4.01 (2.94–6.99) 1.56 (1.13–2.03) <0.001
Total cholesterol (mmol/L) 5.53 ± 0.97 5.65 ± 0.98 0.578
Non-HDL cholesterol (mmol/L) 4.21 ± 1.05 4.06 ± 1.10 0.547
LDL cholesterol (mmol/L) 3.39 ± 0.88 3.46 ± 0.97 0.73
HDL cholesterol (mmol/L) 1.31 ± 0.39 1.59 ± 0.35 0.002
Triglycerides (mmol/L) 1.90 ± 1.60 1.34 ± 0.53 0.021
ApoB (g/L) 0.97 ± 0.24 0.91 ± 0.26 0.324
Apo A-1 (g/L) 1.37 ± 0.26 1.46 ± 0.21 0.080
RBP4 (mg/L) 40.13 ± 8.71 38.33 ± 8.11 0.349
Retinol (μmol/L) 2.33 ± 0.53 2.16 ± 0.43 0.129
RBP4/retinol ratio (mg/μmol) 17.38 ± 1.70 17.82 ± 1.94 0.290
Data are expressed in means ± SD, medians (interquartile range) or numbers. Abbreviations: Apo: apolipoprotein;
BMI: body mass index; HOMA-IR: homeostasis model assessment of insulin resistance; HbA1c: glycated hemoglobin;
HDL: high density lipoproteins; LDL: low density lipoproteins; RBP4: retinol binding protein 4. Differences between
subjects with and without T2DM were determined by T-tests (using loge transformed values in case of not-normally
distributed data) and Chi-square tests where appropriate. LDL cholesterol was calculated in 39 T2DM subjects and
in 36 non-diabetic subjects.
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Figure 1. (A) Plasma retinol binding protein 4 (RBP4) and retinol in 41 subjects with and 37 subjects
without Type 2 diabetes mellitus; (B) Plasma retinol binding protein 4 (RBP4) and retinol in 36 subjects
with and 42 without the metabolic syndrome (MetS). Data are expressed in box and whiskers plots
with mean and minimum to maximum values. All data points are shown.
Lipoprotein subfractions were quantified in 36 T2DM subjects and 27 non-diabetic subjects
(Table 2). T2DM patients had more large-sized VLDL particles, more LDL particles, more small-sized
LDL particles and more small-sized HDL particles, but less large- and medium-sized HDL particles.
Table 2. Lipoprotein subfraction characteristics in 36 subjects with Type 2 diabetes mellitus (T2DM)
and 27 subjects without T2DM.
T2DM Subjects (n = 36) Non-Diabetic Subjects
(n = 27) p-Value
Total VLDL (nmol/L) 68.9 (48.6–82.1) 58.7 (51.4–86.7) 0.56
Large VLDL (nmol/L) 6.8 (2.8–9.9) 2.9 (2.3–4.7) 0.035
Medium VLDL (nmol/L) 23.0 (15.8–40.6) 24.8 (12.5–38.2) 0.45
Small VLDL (nmol/L) 29.9 (20.2–42.9) 32.2 (21.1–44.3) 0.51
Total LDL (nmol/L) 1257 (1022–1540) 981 (856–1284) 0.004
IDL (nmol/L) 170 (118–234) 188 (140–257) 0.14
Large LDL (nmol/L) 509 (345–612) 469 (435–597) 0.57
Small LDL (nmol/L) 586 (400–850) 338 (149–442) 0.003
Total HDL (μmol/L) 32.9 (29.3–37.9) 33.8 (32.0–36.1) 0.75
Large HDL (μmol/L) 5.0 (2.6–6.6) 6.7 (4.6–9.9) 0.021
Medium HDL (μmol/L) 10.1 (8.3–14.4) 12.8 (11.5–16.1) 0.007
Small HDL (μmol/L) 17.7 (14.6–20.9) 14.3 (10.1–16.30 0.006
Data are expressed in medians (interquartile ranges). Abbreviations: VLDL: very low density lipoproteins; LDL low
density lipoproteins; IDL: intermediate density lipoproteins; HDL: high density lipoproteins. Differences between
subjects with and without T2DM were determined by T-tests using loge transformed values.
In univariate regression analysis, RBP4 was strongly correlated with retinol in all subjects
combined, and this relationship did not vary according to diabetes status (Table 3A–C). Plasma retinol
and RBP4 levels strongly correlated in all subjects combined (r = 0.881, p < 0.001), as well as in T2DM
subjects (r = 0.900, p < 0.001) and non-diabetic subjects separately (r = 0.859, p < 0.001) (Figure 2).
In all subjects combined, as well as in T2DM subjects and non-diabetic subjects separately, RBP4 and
retinol were unrelated to age, blood pressure, obesity measures and glycemic control, except for a
positive correlation of RBP4 with age in non-diabetic subjects. Notably, both RBP4 and retinol were
positively correlated with total cholesterol, non-HDL cholesterol, LDL cholesterol, triglycerides and
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apoB levels with essentially similar relationships in T2DM subjects and non-diabetic subjects separately
(Table 3A–C).
Table 3. Univariate relationships of retinol binding protein 4 (RBP4) and retinol with clinical and
laboratory variables in 78 subjects (A), 41 subjects with Type 2 diabetes mellitus (T2DM) (B) and 37
subjects without T2DM (C).




Systolic blood pressure 0.151 0.133





Total cholesterol 0.435 *** 0.399 ***
Non-HDL cholesterol 0.463 *** 0.421 ***
LDL cholesterol 0.384 *** 0.368 ***
HDL cholesterol −0.186 −0.163
Triglycerides 0.391 *** 0.313 **






Systolic blood pressure 0.022 0.026





Total cholesterol 0.376 * 0.321 *
Non-HDL cholesterol 0.425 ** 0.340 *
LDL cholesterol 0.315 * 0.271
HDL cholesterol −0.212 −0.122
Triglycerides 0.415 ** 0.293
ApoB 0.394 * 0.262
ApoA-I −0.150 −0.091
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Table 3. Cont.




Age 0.381 * 0.258
Systolic blood pressure 0.235 0.140





Total cholesterol 0.528 *** 0.555 ***
Non-HDL cholesterol 0.500 *** 0.526 ***
LDL cholesterol 0.514 *** 0.463 **
HDL cholesterol −0.090 −0.096
Triglycerides 0.416 * 0.332 *
ApoB 0.489 *** 0.494 ***
ApoA-I 0.184 0.146
Pearson correlation coefficients are shown. Triglycerides are loge transformed. Abbreviations: BMI: body mass
index; HbA1c: glycated hemoglobin; LDL: low density lipoproteins; HDL: high density lipoproteins. * p < 0.05; ** p
≤ 0.01; *** p ≤ 0.001.
Figure 2. Correlation of total plasma retinol with retinol binding protein 4 (RBP4) in 41 subjects with
and 37 without type 2 diabetes mellitus. All subjects: r = 0.881, p < 0.001; diabetic subjects: r = 0.900, p
< 0.001; non-diabetic subjects: r = 0.859, p < 0.001.
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With respect to lipoprotein subfractions, we observed positive univariate correlations of RBP4
and retinol with VLDL-P, large and medium VLDL, LDL-P, small LDL and small HDL, but inverse
correlations with large HDL (Table 4A–C). Again, these relationships were mostly similar in T2DM
subjects and non-diabetic subjects separately, although for HDL subfractions these relationships
appeared to be stronger in non-diabetic subjects. In addition, large VLDL (r = 0.537, p < 0.001), small
LDL (r = 0.476, p < 0.001) and large HDL (r = −0.403, p = 0.001) were correlated with HOMA-IR
in all subjects combined. Comparable relationships were found in T2DM and non-diabetic subjects
separately (data not shown).
Table 4. Univariate relationships of retinol binding protein 4 (RBP4) and retinol with lipoprotein
subfractions in 63 subjects; (A): all subjects; (B): 36 subjects with Type 2 diabetes mellitus (T2DM) and
(C): 27 subjects without T2DM.
All Subjects (A) (n = 63) RBP4 Retinol
Total VLDL 0.452 *** 0.381 **
Large VLDL 0.433 *** 0.341 **
Medium VLDL 0.293* 0.248 *
Small VLDL 0.178 0.187
Total LDL 0.398 *** 0.340 **
IDL –0.053 –0.098
Large LDL –0.007 0.118
Small LDL 0.423 *** 0.353 **
Total HDL 0.136 0.126
Large HDL –0.243 –0.258 *
Medium HDL –0.056 –0.010
Small HDL 0.317 * 0.290 *
T2DM Subjects (B) (n = 36) RBP4 Retinol
Total VLDP 0.423 * 0.322
Large VLDL 0.401 * 0.262
Medium VLDL 0.238 0.168
Small VLDL 0.160 0.176
Total LDL 0.255 0.191
IDL –0.227 –0.233
Large LDL –0.079 0.082
Small LDL 0.351 * 0.266
Total HDL 0.016 0.010
Large HDL –0.170 –0.190
Medium HDL –0.004 0.064
Small HDL 0.019 0.002
Non-Diabetic Subjects (C) (n = 27) RBP4 Retinol
Total VLDP 0.487 ** 0.472 *
Large VLDL 0.433 * 0.385 *
Medium VLDL 0.344 0.333
Small VLDL 0.270 0.293
Total LDL 0.529 ** 0.442 *
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Table 4. Cont.
All Subjects (A) (n = 63) RBP4 Retinol
IDL 0.309 0.257
Large LDL 0.223 0.301
Small LDL 0.467 * 0.366
Total HDL 0.478 * 0.502 **
Large HDL –0.287 –0.254
Medium HDL –0.027 0.051
Small HDL 0.523 ** 0.476 *
Pearson correlation coefficients are shown. All lipoprotein subfractions are loge transformed. Abbreviations: VLDL:
very low density lipoproteins; LDL: low density lipoproteins; IDL: intermediate density lipoproteins; HDL: high
density lipoproteins. * p < 0.05; ** p ≤ 0.01; *** p ≤ 0.001.
We next performed multivariable linear regression analysis to disclose the extent to which RBP4
and retinol were independently related to VLDL, LDL and HDL subfractions (Table 5). In age-, sex-
and diabetes status-adjusted analysis, RBP4 and retinol were independently related to large VLDL
and small LDL (Table 5, models A and B). RBP4 and retinol were also independently and inversely
associated with large HDL (Table 5, models A and B). When these analyses were additionally adjusted
for the use of metformin, sulfonylurea and antihypertensive medication, the positive relationships
of large VLDL with RBP4 (β = 0.494, p < 0.001) and retinol (β = 0.373, p = 0.003), of small LDL with
RBP4 (β = 0.511, p < 0.001) and with retinol (β = 0.376, p = 0.009), and the inverse relationship of
large HDL with RBP4 (β = −0.416, p = 0.011) and retinol (β = −0.343, p = 0.039) remained statistically
significant. Remarkably, when retinol was added as an independent variable to the model of RBP4 with
VLDL subfractions (Table 5, model A), the relationship of RBP4 with large VLDL remained significant
(β = 0.173, p = 0.022). Conversely, when RBP4 was added as independent variable in the model of
retinol with VLDL subfractions (Table 5, model B), the relation of retinol with large VLDL was lost
(β = −0.091, p = 0.28).
Given the correlation of plasma RBP4 levels with certain subfractions, we also assessed whether
RBP4 may actually physically interact with such lipoprotein particles. Lipoprotein particles, as well as
soluble proteins, were separated by FPLC from freshly-obtained (non-frozen) plasma of non-diabetic
individuals and fractions were analyzed for cholesterol, triglycerides, protein and RBP4 concentrations.
A representative FPLC profile is shown in Figure 3. RBP4 remained undetectable in the VLDL enriched
samples (B1–B9), while very high levels were detected in the fractions with soluble proteins (C2–C10).
Some overlap of RBP4 was detected with HDL-containing samples (B10–C2), but RBP4 was absent in
the peak fraction of HDL (C1), indicating that the overlap is due to co-elution rather than a physical
interaction between RBP4 and HDL. From these experiments, it is concluded that while plasma
levels of RBP4 strongly correlate with certain lipoproteins particles; this occurs in the absence of a
physical interaction.
Table 5. Multivariable regression analyses showing independent relationships of retinol binding
protein 4 (RBP4) and retinol with very low density lipoprotein (VLDL) subfractions (A), low density
lipoprotein (LDL) subfractions (B) and high density lipoprotein (HDL) subfractions (C) in 63 subjects
(36 subjects with and 27 subjects without Type 2 diabetes mellitus).
A VLDL Subfractions Model A Model B
β p-Value β p-Value
Age 0.305 0.027 0.226 0.12
Sex (men vs. women) –0.072 0.57 0.018 0.89
T2DM –0.079 0.60 0.017 0.92
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B LDL Subfractions Model A Model B
β p-Value β p-Value
Large VLDL 0.444 0.005 0.324 0.046
Medium VLDL 0.044 0.770 0.032 0.84
Small VLDL 0.183 0.13 0.206 0.105
Age 0.306 0.035 0.195 0.19
Sex (men vs. women) –0.180 0.19 –0.099 0.48
T2DM 0.157 0.33 –0.030 0.86
IDL –0.150 0.24 –0.138 0.30
Large LDL 0.106 0.39 0.221 0.090
Small LDL 0.539 <0.001 0.440 0.003
B HDL Subfractions Model A Model B
β p-value β p-value
Age 0.309 0.044 0.257 0.095
Sex (men vs. women) –0.180 0.26 0.006 0.97
T2DM –0.073 0.65 –0.008 0.96
Large HDL –0.336 0.034 –0.323 0.043
Medium HDL 0.145 0.38 0.302 0.073
Small HDL 0.262 0.076 0.254 0.086
β: standardized regression coefficient. All lipoprotein subfractions are loge transformed. IDL: intermediate density
lipoproteins; Models A: RBP4 as dependent variable; Models B: retinol as dependent variable.
 
Figure 3. Total protein, retinol binding protein 4 (RBP4), cholesterol and triglyceride concentrations in
fast protein liquid chromatography (FPLC) fractions from plasma of a representative control subject.
The location of peak fractions of very low density lipoprotein (VLDL), low density lipoprotein (LDL)
and high density lipoprotein (HDL) particles, as well as of the soluble proteins are indicated.
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4. Discussion
This study confirms and extends previous findings [6,7,12,13,16,17], showing that plasma RBP4 is
positively correlated with total cholesterol, non-HDL cholesterol, LDL cholesterol, triglycerides and
apoB in subjects with and without T2DM. The main novel finding is that the plasma concentration
of RBP4 is positively correlated with total VLDL and LDL particles, which appeared to be due
to relationships with large VLDL and small LDL particles. The univariate correlations did not
differ in diabetic and non-diabetic subjects. In multivariable linear regression analysis adjusted for
age, sex, diabetes status and the use of glucose lowering and antihypertensive medication, it was
demonstrated that RBP4 was independently related to large VLDL particles, as well as to small LDL
particles. The current study thus suggests that the positive relationship of RBP4 with (triglyceride-rich)
apoB-containing lipoproteins is attributable to associations with large VLDL and small LDL particles.
Notably, no physical interaction appeared to exist between RBP4 and lipoprotein particles.
In our study, plasma RBP4 levels were not elevated in T2DM subjects, in agreement with earlier
studies [12,13], but in contrast to other reports [5,9–11]. In addition, we did not observe a significant
correlation with insulin resistance as determined by HOMA-IR. However, we did find that RBP4 was
elevated in subjects classifying with MetS, which was attributable to its association with triglycerides.
In comparison, Ingelsson et al. also observed RBP4 elevations in MetS and demonstrated incrementally
higher RBP4 levels with an increasing number of MetS components [15]. Of note, while retinol was
found to be elevated in the subjects categorized with MetS as well, there was no significant relationship
with individual MetS components, and we observed no abnormalities in the RBP4/retinol ratio in
T2DM or MetS. In fact, there was a close correlation of retinol with RBP4 as anticipated [14], which
appeared to be linear over the full range of RBP4 concentrations observed. Taken together, these
findings support the notion that elevated levels of circulating RBP4, rather than retinol, represent the
primary abnormality in MetS.
RBP4 levels were predominantly associated with large VLDL particles, as well as with small LDL
particles, the latter finding being consistent with earlier observations using conventional methods
for lipoprotein subfraction quantification [17]. Given the product-precursor relationships of small
LDL particles with large VLDL [18,32,33], it is conceivable that the relationships of RBP4 with these
specific VLDL and LDL subfractions are interdependent. We also observed an independent and
inverse relationship of RBP4 with large HDL particles. It is well established that HDL cholesterol
is inversely associated with large VLDL, consequent to the process of cholesteryl ester transfer [19].
It was recently shown that large VLDL particles determine an increased cholesteryl ester transfer
in T2DM [20], but it is unclear whether RBP4 could interfere with this process. Of further interest,
RBP4 was associated with large VLDL independent of retinol, but retinol was not associated with
large VLDL independent of RBP4. This suggests that circulating RBP4 rather than retinol is primarily
related to large VLDL particles. In addition, large VLDL and small LDL particle concentrations were
expectedly elevated in T2DM [18,20], again consistent with the concept that large VLDL and small LDL
particles are metabolically interrelated [33]. Since our study neither showed an effect of the diabetic
state on plasma RBP4 nor on retinol, we surmise that circulating levels of RBP4 and retinol do not to a
considerable extent explain the predominance of large VLDL and small LDL particles in this condition.
Furthermore, large VLDL and small LDL particles were correlated with HOMA-IR whereas RBP4
and retinol were not. Circulating RBP4 and VLDL particles largely originate from the liver, but their
hepatic production and secretion machineries appear not interconnected. Still, the correlation between
the circulating levels led us to determine whether a possible physical interaction between RBP4 and
VLDL and (small) LDL particles exists. FPLC was used to separate lipoprotein particles from soluble
proteins as a mild approach to retain protein-protein and protein-lipid interactions. Still, no co-elution
of RBP4 with VLDL was observed, providing no evidence that such physical interaction actually exists.
We, therefore, hypothesize that RBP4 could directly interfere with the metabolism of triglyceride-rich
apoB-containing lipoproteins. As a potential mechanism, it is of interest that RBP4 transcriptionally
enhances CD36 expression [26], a protein that impairs VLDL secretion from mouse liver in vivo [34].
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While the current study was primarily focused on RBP4, our findings with respect to retinol levels
are also relevant. Retinol is the circulating form of vitamin A that is locally (in tissues) converted to
retinoic acids (such as all-trans retinoic acid and 9-cis retinoic acid) that activate transcription factors
(Retinoic Acid Receptor (RAR) and Retinoic X Receptor (RXR)) [35,36]. Retinol and retinoic acids
simulate hepatic RBP4 secretion and enhance de novo lipogenesis in the liver [34]. In line, retinoic
acids also stimulate VLDL secretion in rats [37]. More recently, the enzyme 17-beta hydroxysteroid
dehydrogenase 13 (HSD17b13) with retinol dehydrogenase activity, was implicated in the pathogenesis
of non-alcoholic fatty liver disease [38]. Retinol may, therefore, play multiple roles in hepatic fat
accumulation and triglyceride metabolism, both directly and indirectly, by interacting with RBP4.
In view of the accumulating though sometimes controversial epidemiological evidence indicating
that RBP4 is associated with incident CVD [23,24,26,39,40], the present findings with regard to the
association of RBP4 with small LDL particles are likely to be clinically relevant. Small dense LDL
particles are prone to oxidative modification [17] and may predict incident CVD beyond conventional
lipid measures [41–43]. Moreover, smaller-sized LDL particles may be more electronegatively charged
and upregulate the lectin-like oxidized LDL receptor in vitro, a pro-atherogenic phenomenon [44].
Such particles are associated with the extent and severity of coronary artery atherosclerosis [45]. We,
therefore, propose that the relationship of RBP4 with small LDL particles could contribute to its alleged
pro-atherogenic potential.
Several methodological issues of the present study need consideration. Diabetic subjects using
insulin and lipid lowering were not allowed to participate, in order to obviate confounding due to
effects of insulin and lipid-lowering drugs on glucose and lipid metabolism. As a consequence, T2DM
subjects with rather mild hyperglycemia and dyslipidemia were preferentially included, which could
to some extent mask relationships of RBP4 with dysglycemia and could underestimate relationships of
RBP4 with (apo)lipoproteins and lipoprotein subfractions. Furthermore, we excluded subjects with
impaired glomerular filtration rate. This was done to minimize confounding with respect to circulating
RBP4 due to chronic kidney disease in view of the inverse relationship of RBP4 with glomerular
filtration rate [15]. Obviously, the cross-sectional design of our study precludes to establish cause-effect
relationships with certainty. Finally, we consider the present findings as preliminary in view of the
rather low numbers of diabetic and non-diabetic participants included.
5. Conclusions
Serum RBP4 levels are related to large VLDL and small LDL particles, but in the absence of
a physical interaction between RBP4 and the lipoprotein particles. Higher RBP4 may be part of a
proatherogenic plasma lipoprotein profile. However, it seems unlikely that alterations in circulating
RBP4 per se contribute significantly to the predominance of large VLDL and small LDL in the
diabetic state.
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Abstract: Background: Gut microbiota-related metabolites, trimethylamine-N-oxide (TMAO), choline,
and betaine, have been shown to be associated with cardiovascular disease (CVD) risk. Moreover,
lower plasma betaine concentrations have been reported in subjects with type 2 diabetes mellitus
(T2DM). However, few studies have explored the association of betaine with incident T2DM, especially
in the general population. The goals of this study were to evaluate the performance of a newly
developed betaine assay and to prospectively explore the potential clinical associations of betaine and
future risk of T2DM in a large population-based cohort. Methods: We developed a high-throughput,
nuclear magnetic resonance (NMR) spectroscopy procedure for acquiring spectra that allow for
the accurate quantification of plasma/serum betaine and TMAO. Assay performance for betaine
quantification was assessed and Cox proportional hazards regression was employed to evaluate
the association of betaine with incident T2DM in 4336 participants in the Prevention of Renal and
Vascular End-Stage Disease (PREVEND) study. Results: Betaine assay results were linear (y =
1.02X − 3.75) over a wide range of concentrations (26.0–1135 μM). The limit of blank (LOB), limit of
detection (LOD) and limit of quantitation (LOQ) were 6.4, 8.9, and 13.2 μM, respectively. Coefficients
of variation for intra- and inter-assay precision ranged from 1.5–4.3% and 2.5–5.5%, respectively.
Deming regression analysis of results produced by NMR and liquid chromatography coupled to
tandem mass spectrometry(LC-MS/MS) revealed an R2 value of 0.94 (Y = 1.08x – 1.89) and a small bias
for higher values by NMR. The reference interval, in a cohort of apparently healthy adult participants
(n = 501), was determined to be 23.8 to 74.7 μM (mean of 42.9 ± 12.6 μM). In the PREVEND study
(n = 4336, excluding subjects with T2DM at baseline), higher betaine was associated with older age
and lower body mass index, total cholesterol, triglycerides, and hsCRP. During a median follow-up of
7.3 (interquartile range (IQR), 5.9–7.7) years, 224 new T2DM cases were ascertained. Cox proportional
hazards regression models revealed that the highest tertile of betaine was associated with a lower
incidence of T2DM. Hazard ratio (HR) for the crude model was 0.61 (95% CI: 0.44–0.85, p = 0.004).
The association remained significant even after adjusting for multiple clinical covariates and T2DM
J. Clin. Med. 2019, 8, 1813; doi:10.3390/jcm8111813 www.mdpi.com/journal/jcm149
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risk factors, including fasting glucose. HR for the fully-adjusted model was 0.50 (95% CI: 0.32–0.80,
p = 0.003). Conclusions: The newly developed NMR-based betaine assay exhibits performance
characteristics that are consistent with usage in the clinical laboratory. Betaine levels may be useful
for assessing the risk of future T2DM.
Keywords: betaine; trimethylamine N-oxide related metabolites; nuclear magnetic resonance
spectroscopy; type 2 diabetes mellitus
1. Introduction
Betaine (N,N,N-trimethylglycine) is an osmoprotectant as well as a methyl donor in one-carbon
metabolism [1,2]. Betaine is required for remethylation of homocysteine to methionine, a precursor
of the universal methyl donor S-adenosylmethionine (SAM) [1,2]. By decreasing SAM availability,
betaine deficiency may decrease phosphatidylcholine synthesis, promote hepatic steatosis and modify
very low-density lipoprotein (VLDL) synthesis and secretion [3]. Betaine was shown to be inversely
associated with triglycerides (TG) and phospholipid transfer protein (PLTP) activity, further supporting
the notion that low betaine levels may alter liver fat accumulation and lipid/lipoprotein metabolism [4].
Lower plasma betaine concentrations have been reported in subjects with metabolic syndrome,
type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic
steatohepatitis (NASH) [3,5–8]. Moreover, betaine levels were associated with disease severity in
subjects with NAFLD, betaine levels being significantly lower in subjects with NASH compared to
subjects with hepatic steatosis [3]. Plasma betaine levels arise from both dietary intake and endogenous
synthesis from dietary choline [1,2,9]. Having a high-throughput assay to measure plasma/serum
betaine levels may be a way of gaining a better understanding of the role of betaine in hepatic and
metabolic diseases.
The gut microbe-derived metabolite TMAO has been shown to be an independent marker of
cardiovascular disease (CVD) and mortality with higher levels of TMAO correlating with higher
risk [10–22]. Betaine has also been reported to be associated with CVD. However, in contrast to TMAO,
low plasma betaine levels were associated with increased CVD risk in most studies [14,23–26]. In one
study, however, Lever et al. reported that low betaine levels were associated with CVD events in
patients without T2DM, whereas in contrast, elevated betaine levels were associated with CVD in
patients with T2DM [27]. In addition, it has been shown that the association of betaine with CVD risk
was attenuated by TMAO, suggesting that it is TMAO that drives the risk of future CVD [14]. In the
same cohort [14], it was also found that a modest but statistically significant correlation exists between
TMAO and betaine.
Besides the cross-sectional associations of betaine with metabolic diseases, as well as prospective
relationships of betaine with CVD events, prospective studies have shown that lower betaine levels
were associated with a higher risk of incident T2DM. In a study of Norwegian subjects with suspected
angina pectoris, plasma betaine levels were inversely associated with incident T2DM even after
adjusting for multiple clinical characteristics and risk factors [7]. In subjects enrolled in the Prevención
con Dieta Mediterránea (PREDIMED) trial, higher betaine levels were associated with a reduced risk of
future T2DM [28]. In the Diabetes Prevention Program (DPP), a program designed to study progression
to T2DM in subjects with elevated fasting plasma glucose (FPG) and impaired glucose tolerance, low
betaine levels were associated with T2DM onset [6]. Moreover, this association remained significant
even after adjusting for covariates such as age, sex, body mass index (BMI), hypertension, ethnicity,
and FPG [6]. Additionally, the DPP lifestyle intervention led to an increase in betaine levels, suggesting
that betaine may have utility in monitoring the effects of interventions designed to prevent progression
to T2DM [6]. However, no studies to date have explored the association of betaine with incident T2DM
in a general population-based cohort.
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The goals of this study were to evaluate the laboratory performance of the newly developed
nuclear magnetic resonance spectroscopy (NMR)-based betaine assay and to explore potential clinical
associations of betaine and incident T2DM in a large prospective population-based cohort.
2. Methods
2.1. NMR Data Acquisition and Betaine Quantification by Peak Deconvolution
Serum/plasma specimens were diluted with citrate/phosphate buffer (3:1 v/v) to lower the pH to
5.3 in order to separate the betaine and TMAO signals which overlap at physiological pH (Figure 1).
One-dimensional (1D) 1H-NMR spectra were recorded as previously described [4,29]. Briefly, the
Carr–Purcell–Meiboom–Gill (CPMG) acquisition technique was utilized to suppress resonances from
macromolecules (e.g., proteins and lipoproteins) along with Water suppression Enhanced through
T1 effects (WET) gradient sequence to attenuate the water signal. Spectra were acquired at 47 ◦C
(spectral width = 4496.4 Hz, relaxation delay between scans = 5 s, direct detection time = 1.2 s,
number of scans = 48) on a Vantera NMR clinical analyzer (LabCorp, Morrisville, NC) equipped with
400 MHz (9.4 T) Agilent spectrometer [29,30]. Betaine was quantified from the acquired spectra using
a proprietary deconvolution algorithm that resolved the betaine region into its spectral components
(Figure 1). The α-anomeric glucose signal is used as a reference to locate the betaine peak. The betaine
peak at 3.22 ppm, as well as the glucose peaks on either side, were mathematically modeled using
lognormal and Lorentzian peak shapes. A linear function was incorporated into the algorithm to
adequately model the baseline around these peaks. After subtracting the baseline, the lineshape
deconvolution was achieved by a bound-constrained non-linear least-squares fitting algorithm. The
derived betaine signal amplitudes were converted to μM units using a factor that was empirically
determined by plotting data from dialyzed serum samples spiked with known amounts of betaine and
relating the betaine signal area to the expected concentrations.
Figure 1. 1D 1H CPMG NMR spectrum of serum used for modeling the betaine peak. (A) Expansion of
the spectrum where the betaine region is extracted for lineshape deconvolution. (B) The experimental
(red) spectrum overlaid with a mathematical fit (black) from a composite of lognormal (pink) and
Lorentzian (green) lineshapes after subtraction of the baseline in the betaine region. ppm = parts per
million; CPMG, Carr–Purcell–Meiboom–Gill; NMR, nuclear magnetic resonance.
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2.2. Assay Performance Testing
All assay performance studies were conducted according to Clinical and Laboratory Standards
Institute (CLSI) guidelines. Dialyzed serum pools devoid of betaine were analyzed as blanks (five
pools, four replicates, three days). Serum pools containing low concentrations of betaine were tested to
determine the limits of detection (LOD) (five pools, four replicates, three days) and quantitation (LOQ)
(eight pools, four replicates, three days). The LOB, LOD, and LOQ were calculated as previously
described [30]. Within-run (n = 20 replicates) and within-laboratory (n = 80 replicates) imprecision
were determined using serum pools with low, intermediate and high betaine values. These values
were targeted around the 50th and 100th percentile of the reference interval, as well a high value
that had been observed in clinical samples. Mean concentrations and coefficients of variation (%CV)
were calculated for each pool. For the tube comparison, specimens were drawn from 21 donors into
three blood collection tube types: Serum LipoTubes (Greiner Bio-One, Monroe, NC, USA), K2EDTA
plasma tubes and plain red top serum tubes without gel barriers (BD Diagnostics, Durham, NC, USA).
Specimen tubes were processed as per the manufacturer’s recommendations. Results for EDTA plasma
and plain serum tubes were compared to results for the LipoTube by calculating the mean % bias
for all 21 samples. Linearity was evaluated by comparing known spiked concentrations of betaine
with expected concentrations tested in quadruplicates across the biological range from 25 to 1200 μM
(n = 13).
A method comparison study was performed to compare betaine quantification by NMR versus
mass spectrometry as per CLSI guidelines [31]. Serum specimens were obtained from multiple donors
and aliquots were frozen at −80◦C until the time of analysis. The same frozen serum samples (n = 24)
were analyzed via NMR at LabCorp and in parallel by stable isotope dilution, high-performance
liquid chromatography with online electrospray ionization tandem mass spectrometry (LC-MS/MS)
at the Cleveland Clinic. Samples analyzed via the LC-MS/MS method were injected at a flow rate
of 0.8 ml/min to a 4.6 × 250 mm, 5 μm Luna silica column interfaced with an AB SCIEX 5000 triple
quadrupole mass spectrometer using d9-(trimethyl)-labeled internal standards [32]. Details of the
method for the LC-MS/MS assay have been previously described [10,32,33]. Samples for the method
comparison study spanned the reported reference interval for betaine [1].
To confirm the previously reported reference interval for betaine [1], two studies were evaluated.
For the first study, normal, apparently healthy (n = 501) men and women aged 18 to 80 were recruited
at LipoScience (now LabCorp, Morrisville, NC, USA). Informed consent was obtained from all donors
whose samples were analyzed and the study protocol was approved by a local Institutional Review
Board. Non-fasting serum specimens collected in LipoTubes and tested by NMR as described above.
Detailed descriptions of this study have been previously described [29,30]. The second study entailed
reanalyzing the digitally stored NMR spectra, from previously tested fasting EDTA plasma samples
from the Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study (n = 5621), using the
newly developed proprietary betaine assay software (LabCorp, Morrisville, NC, USA) [29]. Quantiles
for sample results from both studies were determined, and the reference intervals were estimated at
the 2.5th and 97.5th percentiles. Pearson’s correlation coefficients were determined, and no statistically
significant correlation was found between betaine and TMAO in either the normal healthy population
study that was used for the reference interval determination (r = 0.065, p = 0.149) or the PREVEND
study (r = -0.01, p = 0.508).
2.3. Cross-sectional and Prospective Analyses in Participants in the Prevention of Renal and Vascular
End-Stage Disease (PREVEND) Study
Details of the PREVEND study design and recruitment have been described before [34]. Briefly,
the PREVEND study is a Dutch cohort of predominantly Caucasian men and women drawn from the
general population of the city of Groningen in the northern part of the Netherlands. After exclusion
of subjects with insulin-treated diabetes and pregnant women, subjects with a urinary albumin
concentration ≥10 mg/L were invited to participate (n = 7768), 6000 accepted. In addition, a random
152
J. Clin. Med. 2019, 8, 1813
sample of 2592 individuals with a urinary albumin concentration <10 mg/L was included. During
the years 1997–1998, 8592 subjects aged 28–75 years completed the baseline survey. The baseline
for the current study was the second screening which took place between 2001 and 2003 (n = 6892).
Individuals who were diagnosed with T2DM or were missing data for diabetes at baseline or follow-up,
as well as those missing NMR at baseline or follow-up, were excluded, leaving 4336 subjects for the
present cross-sectional and prospective analyses. The follow-up period (period between baseline
and date of T2DM diagnosis) was determined to be 7.3 (IQR, 5.9–7.7) years for this analysis. T2DM
was ascertained if one or more of the following criteria were met: 1) FPG ≥7.0 mmol/L (126 mg/dL),
2) random sample plasma glucose ≥11.1 mmol/L (200 mg/dL), 3) self-report of a physician diagnosis
of T2DM, and 4) initiation of glucose-lowering medication use, retrieved from a central pharmacy
registry [35]. These criteria are consistent with current guidelines for the diagnosis of T2DM [36].
Calculations of BMI, as well as determinations of blood pressure, smoking status, alcohol intake,
hypertension and estimated glomerular filtration rate (eGFR), have been described previously [37].
At the second screening, venous blood was obtained after an overnight fast. EDTA plasma samples
were prepared and stored at −80 ◦C until testing occurred. Total cholesterol was measured on a
Beckman Coulter®AU680 analyzer, and high-density lipoprotein cholesterol (HDL-C) and triglycerides
(TG) were measured on an Olympus AU400 analyzer (Beckman Coulter, Brea, CA, USA) [38]. FPG
was measured by dry chemistry (Eastman Kodak, Rochester, NY, USA) and C-reactive protein (CRP)
was measured by nephelometry with a threshold of 0.18 mg/L (BNII, Dade Behring). Betaine results
were obtained as described above. This study was carried out in accordance with The Code of Ethics
of the World Medical Association (Declaration of Helsinki), cleared by an Institutional Review Board
and all donors signed consent forms.
2.4. Statistical Analyses
Statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA), Analyze-it
v3.90.1 (Analyze-it Software, Ltd., Leeds, UK) or IBM Statistics SPSS v23.0 (IBM Inc., Chicago, IL, USA).
For the analytical validation studies, linear regression analyses were performed. Deming regression
analysis and Bland–Altman plots were used to evaluate the correlation between the results obtained on
the two platforms for the method comparison study. Reference intervals were compared by assessing
the means using the Wilcoxon Rank Sum and Mann–Whitney tests and the distributions using the
Kruskal-Wallis test. For the epidemiological studies, data are expressed in mean ± SD (or SEM for
figures) when normally distributed, median (interquartile range) for skewed distribution and number
and percentages in case of categorical data. Differences between the tertiles of betaine were tested by
ANOVA or Kruskal Wallis for continuous variables and with χ2- test for categorical variables. Pearson’s
correlation coefficients were used to evaluate any potential relation between betaine and TMAO.
Crude and multivariable Cox proportional hazards regression analyses were performed to estimate
the effect of betaine on T2DM in a crude analysis as well as analyses adjusted for age and sex (model 1).
Further adjustments were then made for eGFR (model 2), BMI and smoking status (model 3), ethnicity,
FPG, total cholesterol, HDL-C, TG, CRP, and use of lipid-lowering drugs (model 4). In continuous Cox
proportional hazards regression models, betaine was log-base 2 transformed to allow for the expression
of the hazard ratios (HRs) per doubling of betaine. Additionally, betaine was used as a categorical
variable for analyses by tertiles. Data were presented as HRs and 95% CI confidence intervals (CIs).
Potential effect modification was evaluated by age, sex, and eGFR. Potential effect modifiers were
tested by entering both main effects and the cross-product term in Cox regression analyses. When effect
modification was observed, we proceeded with stratified analyses. For the sensitivity analyses, we
performed crude and multivariable Cox proportional hazards regression analyses excluding subjects
with previous CVD, use of lipid-lowering drugs, microalbuminuria and eGFR <60 mL/min/1.73 m2 at
baseline. Two-sided p-values <0.05 were considered statistically significant for all reported analyses.
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2.5. Ethic Approval and Consent to Participate
This study was carried out in accordance with The Code of Ethics of the World Medical Association
(Declaration of Helsinki), cleared by an Institutional Review Board and all donors signed consent forms.
3. Results
The NMR signals from betaine and TMAO overlap in the Carr-Purcell-Meiboom-Gill (CPMG)
collected spectrum of serum at physiological pH [29]. Hence, an assay was developed that reduces the
pH of the sample to 5.3. The betaine peak is not affected by the change in pH, however, the TMAO peak
is shifted downfield in the NMR spectrum which allows for accurate quantification of both betaine and
TMAO separately [29] (Figure 1). In order to assess its clinical usefulness, the analytical performance of
the NMR-based betaine assay was evaluated. The LOB, LOD, and LOQ were determined to be 6.4, 8.9,
and 13.2 μM, respectively, with the LOQ being below the previously reported normal reference interval
for betaine [1]. The coefficients of variation for intra-assay and inter-assay precision were 1.5–4.3% and
2.5–5.5%, respectively (Table 1). A tube comparison study revealed no significant differences between
results from serum collected in LipoTubes vs. results from serum collected in plain red top tubes (mean
% bias = −1.9) or EDTA plasma (mean % bias = 4.1). Linearity was demonstrated between 26.0 and
1135 μM, well above the upper limit of the normal reference interval [1], with a correlation coefficient
(R2) of 1.00 and a linear equation of Y = 1.02x − 3.75 (Figure 2A). Based on these data, the reportable
range for the NMR-based betaine assay was determined to be 13.2–1135 μM.
 
Figure 2. Linearity and method comparison data for the betaine assay. (A) Results of linearity study
(n = 13), (B) Deming regression comparison between LC-MS/MS and NMR measured betaine in serum
samples (n = 24), (C) Bland–Altman plot (n = 24). The limits of agreement (LoA) are depicted as dotted
blue lines, and the 0% bias is a solid black line.
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Mean 45.2 97.2 205.9
SD 2.5 4.0 5.2
CV (%) 5.5 4.1 2.5
Within-run b
Mean 44.1 95.6 205.6
SD 1.9 3.1 3.1
CV (%) 4.3 3.2 1.5
Abbreviations: CV, coefficients of variation; SD, standard deviation; a Based on CLSI EP5-A2 tested using three
controls, two runs per day in duplicate for 20 days (total n = 80); b Based on one run of 20 tests.
A method comparison study was performed to compare the quantification of betaine by NMR
versus LC-MS/MS. Deming regression analysis of betaine results from both platforms produced an R2
value of 0.94 (Y = 1.08x – 1.89) (Figure 2B). The Bland–Altman plot revealed that there was a small but
systematic bias for higher values produced by the NMR assay compared to results from the LC-MS/MS
assay (Figure 2C). The normal reference interval for betaine was confirmed in two populations, a
cohort of apparently healthy volunteers and the full set of PREVEND cohort participants (Table 2). The
distributions were similar between the two study populations, and the reference intervals were similar
to those previously reported [1]. The distributions for men and women in the cohort of apparently
healthy volunteers were not statistically different, and neither were the means. Therefore, there were no
significant between-gender differences in the distribution of results or the reference intervals, although
the results tended to be somewhat lower in women compared to men, as previously noted [1].







Female (n = 292)
Normal Healthy
Adult Volunteers




0th <13.2 a <13.2 a 24.6 13.3
2.5th 23.8 22.0 28.5 21.0
25.0th 34.1 32.4 37.3 30.8
50.0th 41.0 39.1 44.6 36.8
75.0th 49.5 46.9 52.4 43.8
97.5th 74.7 74.4 75.3 63.0
100th 104.1 101.6 104.1 190.7
Mean (SD) 42.9 (12.6) 40.7 (12.4) 46.0 (12.2) 38.1 (11.2)
Abbreviations: SD, standard deviation. a Lower bound of the reportable range is limited by the LOQ of this assay.
Of the 6892 PREVEND participants that completed the second round of screening, 4336 subjects
were included in this study. Subjects were excluded if they were missing NMR data, if they were
missing information regarding T2DM diagnosis at baseline or follow-up, or if they were diagnosed
with T2DM at baseline. Baseline clinical and laboratory characteristics for the entire cohort as well as
according to tertiles of betaine are shown in Table 3. Subjects with higher betaine levels were older,
more likely to be men and less likely to be Caucasian. Subjects with higher betaine levels also had
lower BMI, were more likely to be non-smokers and less likely to have high diastolic blood pressure.
Subjects in the highest tertile of betaine had lower, total cholesterol, TG and C-reactive protein (CRP).
They were more likely to be on lipid-lowering medications.
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Table 3. Baseline characteristics of the 4336 subjects of the Prevention of Renal and Vascular End-Stage
Disease (PREVEND) study of the overall population and according to tertiles of betaine.
Overall Tertiles of betaine p-Value
T1 T2 T3
Participants, n 4336 1445 1446 1445
Betaine, μM 36.9 (31.0–44.0) 28.7 (25.3–31.0) 36.9 (35.1–38.8) 47.3 (44.0–52.6)
Participants, n 4236 1398 1418 1420
TMAO, μM 4.6 ± 5.9 4.6 ± 5.1 4.7 ± 6.3 4.6 ± 6.4
General characteristics
Age, years 52.6 ± 11.5 51.3 ± 10.9 52.8 ± 11.4 53.7 ± 12.1 <0.001
Male sex, n (%) 2159 (49.8) 456 (31.6) 750 (51.9) 953 (66.0) <0.001
Ethnicity, Caucasian, n (%) 4164 (96.0) 1403 (97.1) 1400 (96.8) 1361 (94.2) 0.001
BMI, kg/m2 26.4 ± 4.2 26.7 ± 4.3 26.6 ± 4.2 26.0 ± 4.1 <0.001
Smoking status, n (%) 0.008
Never 1286 (29.7) 420 (29.1) 424 (29.3) 442 (30.6)
Former 1828 (42.2) 574 (39.7) 639 (44.2) 615 (42.6)
Current 1165 (26.9) 438 (30.3) 358 (24.8) 369 (25.5)
Alcohol consumption, never, n (%) 1004 (23.2) 329 (22.8) 351 (24.3) 324 (22.4) 0.26
eGFR, mL/min/1.73m2 93.5 ± 16.3 94.5 ± 15.9 93.1 ± 16.7 93.0 ± 16.3 0.02
Hypertension, n (%) 1280 (29.5) 406 (28.1) 443 (30.6) 431 (29.8) 0.33
Hypercholesterolemia, n (%) 1235 (28.5) 468 (32.4) 390 (27.0) 377 (26.1) <0.001
Parental history of CKD, n (%) 20 (0.5) 8 (0.6) 7 (0.5) 5 (0.3) 0.70
Circulation
SBP, mmHg 124.8 ± 18.1 123.9 ± 17.8 125.4 ± 18.2 125.1 ± 18.3 0.06
DBP, mmHg 73.0 ± 9.0 72.5 ± 9.1 73.4 ± 8.8 72.3 ± 9.0 0.02
Laboratory parameters
Total cholesterol, mmol/L 5.4 ± 1.0 5.6 ± 1.1 5.4 ± 1.0 5.2 ± 1.0 <0.001
HDL cholesterol, mmol/L 1.3 ± 0.3 1.2 ± 0.3 1.3 ± 0.3 1.2 ± 0.3 <0.001
Triglycerides, mmol/L 1.1 (0.8–1.6) 1.2 (0.8–1.7) 1.1 (0.8–1.6) 1.0 (0.8–1.5) 0.005
Fasting glucose, mmol/L 4.7 (4.4–5.2) 4.7 (4.4–5.2) 4.7 (4.4–5.2) 4.7 (4.4–5.2) 0.34
C-reactive protein, mg/L 1.2 (0.6–2.8) 1.4 (0.6–3.0) 1.2 (0.5–2.6) 1.1 (0.5–2.8) 0.005
Medication
Antihypertensive drugs, n (%) 716 (16.5) 221 (15.3) 239 (16.5) 256 (17.7) 0.12
Lipid lowering drug use, n (%) 304 (7.0) 62 (4.3) 94 (6.5) 148 (10.2) <0.001
Data are represented as mean ± SD, median (interquartile range) or n (%). Differences were tested by ANOVA
or Kruskal Wallis for continuous variables and with χ2- test for categorical variables. The eGFR is based
on the creatinine–cystatin C equation. Abbreviations: BMI, body mass index; eGFR, estimated glomerular
filtration rate; CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL,
high-density lipoproteins.
After a median (interquartile range) follow up period of 7.3 (IQR, 5.9–7.7) years, 224 new T2DM
cases were ascertained. Cox proportional hazards regression models revealed that the highest tertile
of betaine was associated with a lower incidence of T2DM. Hazard ratio (HR) for the crude model
was 0.61 (95% CI: 0.44–0.85, p = 0.004) (Table 4). The association remained largely unchanged after
adjustment for multiple clinical covariates and T2DM risk factors, including age, sex, eGFR, BMI,
smoking status, ethnicity, FPG, total cholesterol, HDL-C, TG, CRP, and use of lipid-lowering drugs.
In the fully adjusted model, the HR for the upper vs. the lower tertile was 0.50 (95% CI: 0.32–0.80,
p = 0.004). When the association of betaine with T2DM development was assessed as a continuous
variable, the same trend was observed albeit the association of betaine with incident T2DM did not
reach statistical significance in the fully adjusted model.
We observed that the association of betaine with T2DM was modified by sex (Pinteraction = 0.01),
but not by age (Pinteraction = 0.93) or eGFR (Pinteraction = 0.38). Betaine as continuous variable was
inversely associated with incident T2DM in men (HR: 0.44, 95% CI: 0.24–0.80, p = 0.007), but not in
women (HR: 0.97, 95% CI: 0.55–1.71, p = 0.93), after adjustment for age, eGFR, BMI, smoking status,
ethnicity, FPG, total cholesterol, HDL-C, TG, CRP, and use of lipid-lowering drugs (Table 5).
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HR (95% CI) p HR (95% CI) p HR (95% CI) p
Diabetes, no. of events (%) 224 (5.2%) 93 (6.4%) 74 (5.1%) 57 (3.9%)
Crude 0.79 (0.59–1.05) 0.10 1.00 (ref) 0.78 (0.57–1.05) 0.10 0.61 (0.44–0.85) 0.004
Model 1 0.60 (0.46–0.79) <0.001 1.00 (ref) 0.64 (0.47–0.88) 0.005 0.45 (0.32–0.64) <0.001
Model 2 0.59 (0.45–0.78) <0.001 1.00 (ref) 0.61 (0.45–0.84) 0.002 0.42 (0.29–0.59) <0.001
Model 3 0.63 (0.47–0.85) 0.002 1.00 (ref) 0.68 (0.50–0.94) 0.02 0.47 (0.33–0.66) <0.001
Model 4 0.69 (0.46–1.02) 0.06 1.00 (ref) 0.65 (0.43–0.96) 0.03 0.50 (0.32–0.80) 0.004
Abbreviations: eGFR, estimated glomerular filtration rate; T2DM, type 2 diabetes mellitus. Association between
betaine and development of diabetes in 4336 (224 cases) subjects of the Prevention of Renal and Vascular End-Stage
Disease (PREVEND) study as a continuous variable (2log-transformed) and according to tertiles (T1-T3). Hazard
ratios and 95% confidence intervals were derived from Cox proportional hazards regression models. The eGFR is
based on creatinine–cystatin C equation; Model 1: Adjustment for age and sex; Model 2: Model 1+ adjustment
for eGFR; Model 3: Model 2 + adjustment for body mass index and smoking; Model 4: Model 3 + adjustment for
ethnicity, fasting glucose, total cholesterol, high-density lipoprotein cholesterol, triglycerides, C-reactive protein,
and use of lipid-lowering drugs.
Table 5. Sex-stratified analyses of the association of betaine as a continuous variable and according to





HR (95% CI) p HR (95% CI) p HR (95% CI) p
Men
Diabetes, no. of events (%) 139 (6.4%) 54 (2.5%) 46 (2.1%) 39 (1.8%)
Crude 0.41 (0.26–0.64) <0.001 1.00 (ref) 0.49 (0.33–0.73) <0.001 0.34 (0.22–0.51) <0.001
Model 1 0.40 (0.26–0.62) <0.001 1.00 (ref) 0.49 (0.33–0.72) <0.001 0.32 (0.21–0.49) <0.001
Model 2 0.41 (0.26–0.65) <0.001 1.00 (ref) 0.46 (0.31–0.69) <0.001 0.32 (0.21–0.48) <0.001
Model 3 0.56 (0.35–0.90) 0.02 1.00 (ref) 0.54 (0.36–0.82) 0.003 0.43 (0.28–0.65) <0.001
Model 4 0.44 (0.24–0.80) 0.007 1.00 (ref) 0.43 (0.25–0.74) 0.003 0.36 (0.20–0.65) 0.001
Women
Diabetes, no. of events (%) 85 (3.9%) 39 (1.8%) 28 (1.3%) 18 (0.8%)
Crude 0.96 (0.59–1.53) 0.85 1.00 (ref) 1.01 (0.62–1.63) 0.98 0.95 (0.54–1.66) 0.86
Model 1 0.81 (0.52–1.27) 0.35 1.00 (ref) 0.89 (0.55–1.45) 0.65 0.83 (0.47–1.45) 0.51
Model 2 0.74 (0.48–1.15) 0.18 1.00 (ref) 0.86 (0.53–1.41) 0.56 0.67 (0.37–1.22) 0.19
Model 3 0.73 (0.47–1.15) 0.18 1.00 (ref) 0.96 (0.58–1.56) 0.85 0.62 (0.33–1.15) 0.13
Model 4 0.97 (0.55–1.71) 0.93 1.00 (ref) 1.02 (0.56–1.89) 0.94 0.74 (0.35–1.60) 0.45
Abbreviations: eGFR, estimated glomerular filtration rate; T2DM, type 2 diabetes mellitus. Association between
betaine and development of diabetes in 2159 men (139 cases) and 2177 women (85 cases) of the Prevention of Renal
and Vascular End-Stage Disease (PREVEND) study as a continuous variable (2log-transformed) and according to
tertiles (T1-T3). Hazard ratios and 95% confidence intervals were derived from Cox proportional hazards regression
models. The eGFR is based on creatinine–cystatin C equation; Model 1: Adjustment for age; Model 2: Model
1+ adjustment for eGFR; Model 3: Model 2 + adjustment for body mass index and smoking; Model 4: Model
3 + adjustment for ethnicity, fasting glucose, total cholesterol, high-density lipoprotein cholesterol, triglycerides,
C-reactive protein, and use of lipid-lowering drugs.
To ensure the results would be similar if the analyses were conducted in subjects at a lower
risk of CVD, a sensitivity analysis was performed excluding subjects with previous CVD, use of
lipid-lowering drugs, microalbuminuria and eGFR <60 mL/min/1.73 m2 at baseline (n = 2810 subjects
with 112 cases of T2DM ascertained) (Table 6). Cox proportional hazards regression models revealed
that the highest tertile of betaine was associated with a lower incidence of T2DM. HR for the crude
model was 0.58 (95% CI: 0.36–0.93, p = 0.03). The association remained significant after adjustment
for multiple clinical covariates and T2DM risk factors, including age, sex, eGFR, BMI, and smoking
status. Only the fully-adjusted model, with additional cumulative adjustment for ethnicity, FPG, total
cholesterol, HDL-C, TG, and CRP, lost statistical significance (0.57 95% CI: 0.32–1.04, p = 0.07).
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Table 6. Sensitivity analysis of the association of betaine as a continuous variable and according to
tertiles with development of T2DM, excluding subjects with previous CVD history, microalbuminuria,





HR (95% CI) p HR (95% CI) p HR (95% CI) p
Diabetes, no. of events (%) 112 (4.0%) 48 (4.9%) 39 (4.2%) 25 (2.8%)
Crude 0.75 (0.51–1.10) 0.14 1.00 (ref) 0.84 (0.55–1.28) 0.41 0.58 (0.36–0.93) 0.03
Model 1 0.57 (0.41–0.81) 0.002 1.00 (ref) 0.69 (0.45–1.05) 0.09 0.41 (0.25–0.67) <0.001
Model 2 0.59 (0.40–0.80) 0.001 1.00 (ref) 0.69 (0.45–1.05) 0.08 0.41 (0.25–0.67) <0.001
Model 3 0.62 (0.42–0.93) 0.02 1.00 (ref) 0.75 (0.49–1.15) 0.19 0.50 (0.31–0.82) 0.006
Model 4 0.69 (0.43–1.10) 0.12 1.00 (ref) 0.89 (0.55–1.46) 0.65 0.57 (0.32–1.04) 0.07
Abbreviations: CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; T2DM, type 2 diabetes
mellitus. Association between betaine and development of diabetes in 2810 (112 cases) subjects of the Prevention
of Renal and Vascular End-Stage Disease (PREVEND) study as a continuous variable (2log-transformed) and
according to tertiles (T1-T3). Hazard ratios and 95% confidence intervals were derived from Cox proportional
hazards regression models. The eGFR is based on creatinine–cystatin C equation; Model 1: Adjustment for age and
sex; Model 2: Model 1+ adjustment for Egfr; Model 3: Model 2 + adjustment for body mass index and smoking;
Model 4: Model 3 + adjustment for ethnicity, fasting glucose, total cholesterol, high-density lipoprotein cholesterol,
triglycerides, and C-reactive protein.
4. Discussion
Several chromatographic, chemical, and mass spectrometry (MS)-based techniques for
quantification of betaine have been reported [10,32,33,39,40]. With the advent of the Vantera clinical
analyzer, an automated high-throughput NMR spectrometer, NMR-based assays are now available in
the diagnostic laboratory for clinical use [29,30,41–44]. Hence, an NMR-based assay that quantifies
plasma/serum TMAO and betaine was developed for the diagnostic laboratory [4,21,29]. While the
NMR signals for TMAO and betaine align in NMR spectra acquired at physiological pH, this assay
uses a buffer with a lower pH that separates the two metabolites, allowing for their simultaneous
quantification [29]. Analytical validation of the NMR-based betaine assay revealed that it has
performance characteristics that are robust enough for use as a diagnostic or prognostic test in the
clinical laboratory.
The major finding of this study, however, is that lower circulating levels of betaine are associated
with future development of T2DM in a large population-based cohort. Lower betaine levels were
associated with increased risk of developing T2DM even after adjusting for clinical characteristics as
well as typical risk factors for T2DM such as BMI, lipids, and FPG. Previously, lower betaine levels were
reported to be associated with incident T2DM development in subjects across a spectrum of risks for
CVD, such as in Norwegian subjects with suspected angina pectoris, as well as in primary prevention
individuals enrolled in the PREDIMED dietary intervention trial [7,28]. In addition, betaine was
associated with future diabetes in the DPP, a program designed to study progression to, and possibly
prevention of, T2DM in subjects at high risk of T2DM [6]. Moreover, the prospective association of low
betaine levels with future T2DM in DPP remained significant after adjusting for risk factors such as
age, sex, BMI, hypertension, ethnicity and FPG [6]. Furthermore, the DPP lifestyle intervention led to
an increase in betaine, raising the hypothesis that betaine may have utility in monitoring the effects of
interventions designed to prevent progression to T2DM [6].
Betaine is required for remethylation of homocysteine to methionine, a precursor of the
universal methyl donor SAM [1,2]. By decreasing SAM availability, betaine deficiency may decrease
phosphatidylcholine synthesis, promote hepatic steatosis, and modify VLDL synthesis and secretion [3].
Betaine was shown to be inversely associated with TG and PLTP activity, further supporting the
notion that low betaine levels may alter liver fat accumulation and lipid/lipoprotein metabolism [4].
Furthermore, lower plasma betaine concentrations have been reported in subjects with metabolic
syndrome, T2DM, NAFLD, and/or NASH, supporting the association of low levels of betaine with
diseases that are associated with liver fat accumulation [3,5–8]. Moreover, betaine levels were associated
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with disease severity in subjects with NAFLD, betaine levels being significantly lower in subjects with
NASH compared to subjects with hepatic steatosis [3]. These observations support the findings of this
study, that lower betaine levels may be a good predictor of future T2DM.
Given that betaine has been described as being a precursor to TMAO, it seems counterintuitive
that lower betaine levels would coincide with higher TMAO levels and vice versa. However, we did not
find a statistically significant correlation between TMAO and betaine in the normal healthy population
we used for our reference interval study or in the PREVEND study. This may be attributed to the fact
that there are other precursors for TMAO such as carnitine [11], choline, phosphatidylcholine [10], and
trimethyllysine [45] that can give rise to TMAO via trimethylamine. In addition, choline is oxidized to
betaine [27] in humans, and betaine can be shunted for multiple metabolic functions [1,2] Therefore,
there may not be a clear relationship between TMAO and betaine, especially in normal, healthy
populations such as the ones analyzed in this study.
Subjects with cardiometabolic diseases such as T2DM and non-alcoholic fatty liver disease
(NAFLD) exhibit altered gut microbiome, and have higher levels of TMAO and lower levels of betaine
compared to healthy subjects [3,5–8,20,25,46,47]. Betaine, the gut-microbiome generated metabolite
TMAO, and dietary metabolites such as choline and L-carnitine, may help determine if a subject’s gut
microbiome is altered (gut dysbiosis), and identify individuals who may benefit from intensive dietary
or lifestyle intervention in order to reduce the progression to more severe metabolic disease such as
T2DM. Further studies are needed to confirm this to be the case.
There are several strengths and limitations in the current study. A strength of this study is that
it includes a large number of participants in the general population, whereas previously published
studies reported associations of betaine with incident T2DM in subjects who may have been at risk
of CVD or T2DM. In addition, the PREVEND study has a large number of participants with a large
age range, which could be considered a strength. Notably, the PREVEND study was designed to
study the impact of albuminuria on renal and CVD outcomes. Hence, the PREVEND subjects were
preferentially recruited based on an initially elevated urinary albumin concentration. However, a
sensitivity analysis excluding subjects with microalbuminuria and compromised renal function showed
an essentially similar association of betaine with future risk of T2DM. Furthermore, the majority of the
PREVEND participants were of Caucasian descent, and study results may not be applicable to subjects
of non-white ethnicities.
5. Conclusions
The newly developed NMR-based betaine assay exhibits excellent performance characteristics.
We found that lower circulating betaine was associated with increased risk of developing T2DM in
a large population-based cohort even after adjusting for clinical covariates and T2DM risk factors.
Potential clinical applications may include assessing the risk of future T2DM.
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Abstract: Atherothrombosis is the principal underlying cause of cardiovascular disease (CVD).
Microvesicles (MV) are small blebs originated by an outward budding at the cell plasma membranes,
which are released in normal conditions. However, MV release is increased in pathophysiologic
conditions such as CVD. Low density lipoprotein (LDL) and MV contribute to atherothrombosis
onset and progression by promoting inflammation and leukocyte recruitment to injured endothelium,
as well as by increasing thrombosis and plaque vulnerability. Moreover, (oxidized)LDL induces MV
release and vice-versa, perpetuating endothelium injury leading to CVD progression. Therefore,
MV and lipoproteins exhibit common features, which should be considered in the interpretation of
their respective roles in the pathophysiology of CVD. Understanding the pathways implicated in this
process will aid in developing novel therapeutic approaches against atherothrombosis.
Keywords: microvesicles; inflammation; lipoproteins; LDL cholesterol; microparticles; cardiovascular
disease; platelets; endothelial cells; leukocytes; atherothrombosis
1. Introduction
Atherothrombosis is the principal underlying cause of cardiovascular disease (CVD).
Atherosclerosis is caused by lipid accumulation associated with endothelial dysfunction and chronic
low-grade inflammation and oxidative stress. Innate immunity cells and vascular smooth muscle cells
respond to these perturbations by initiating interactions and gene programs that contribute to vascular
dysfunction and atherosclerotic plaque formation. Advanced atherosclerotic plaques, with a lipid-rich
atheroma, show inward remodeling encroaching in the arterial lumen, which decrease blood flow,
thus leading to tissue ischemia. Eventually, atherosclerotic plaques can rupture and provoke thrombus
formation that may occlude the lumen interrupting oxygen supply [1].
High plasma concentrations of low density lipoprotein (LDL) cholesterol induce atherosclerosis,
while decreasing LDL cholesterol levels associates with a reduced incidence of major CV events [2].
In fact, the life-long exposure of an artery to LDL cholesterol remains a principal determinant
of atherosclerotic progression [3]. Recently, enhanced perivascular adipose tissue mass and local
inflammation has been associated with increased atherosclerotic plaque burden [4], and immunity
cells and inflammation have a causal role in atherosclerosis progression by modulating the resident
cells in the artery wall [3].
Microvesicles (MV) derived from blood and vascular cells seem also being able to participate in
the initiation, progression and complications of atherothrombosis by a direct and a paracrine regulation
of target cells. Therefore, this review is aimed at summarizing the crosstalk between lipoproteins,
inflammation, and microvesicles in the pathophysiology of atherothrombosis.
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2. Atherosclerosis: Lipids and Inflammation
Atherosclerosis is considered a lipid-initiated, chronic and progressive inflammatory systemic
disease of large and medium arteries and characterized by inflammatory and immune responses
contributing to the onset and evolution of the disease and to plaque instability and rupture. It is
triggered by the presence of elevated levels of cholesterol in the vessel wall. On the other hand,
high density lipoprotein (HDL) particles, when functionally capable, can exert the opposite effect by
removing cholesterol from the circulation through the induction of reverse cholesterol transport, by
protecting LDL and other proteins from oxidative damage [5], and by inhibiting monocyte production
of inflammatory cytokines [6,7] and monocyte differentiation [8]. However, alterations in the HDL
structure and function can render dysfunctional HDL particles that may exert deleterious effects in the
CV system [9,10]. Inflammation plays a pivotal role in atherosclerotic plaque formation and instability
by promoting endothelial cell activation, endothelial dysfunction, loss of integrity and lipid deposition
in the intima and by impairing endothelial-repairing capacity [11].
The involvement of inflammation besides LDL in atherosclerosis has been recently proven in
the proof-of-concept CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) trial,
showing that interleukin 1β inhibition resulted in a 15% reduction in cardiovascular events [12].
Supporting these findings, it has been recently observed that interleukin 6 trans-signaling increases
the risk of cardiovascular events [13]. Interleukin 1β/ interleukin 6 signaling is activated by
the nucleotide-binding leucine-rich repeat-containing pyrine receptor 3 (NLRP3) inflammasome
platform [14]. However, (minimally modified) LDL activates the inflammasome [15–17], in its turn
activating the Interleukin 1β/ interleukin 6 signaling pathway, and thus hampering the dissection of
the separate roles of lipids and inflammation in atherosclerosis progression.
Atherosclerosis initiates with increases in endothelial permeability to circulating LDL and
its accumulation in the intima. Activated endothelial cells then release cytokines, chemokines,
and adhesion molecules attracting circulating leukocytes, and more specifically monocytes, into the
atherosclerotic lesion, inducing the differentiation of monocytes into proinflammatory macrophages
and finally foam cells [18]. Although the primary origin of foam cells in atherosclerotic lesions are
leukocytes [19], smooth muscle cells have been shown to differentiate to foam cells [20]. The rupture of
the atherosclerotic plaque is the most common trigger of thrombosis, leading to an infarction.
Therefore, atherosclerosis is driven by LDL and inflammation mediated by immune cells, leading
to thrombosis and a major CV event. In this process, MV act as a paracrine complementary system
ensuing atherothrombosis as will be further discussed.
3. Microvesicles
MV belong to the family of extracellular vesicles. Extracellular vesicles are literally defined by
the International Society for Extracellular Vesicles as “the generic term for particles naturally released
from the cell that are delimited by a lipid bilayer and cannot replicate, i.e. do not contain a functional
nucleus” [21]. MV are medium/large extracellular vesicles (0.1–1 μm) originated by an outward
budding at the plasma membrane from almost all cell types [21–24], and their release is increased when
activated, injured or undergoing apoptosis. The biogenesis of MV requires a structured rearrangement
of the plasma membrane which provokes physical bending of the membrane and restructuring of
the underlying actin cytoskeleton, inducing membrane budding, exposure of phosphatidylserine (PS)
from the inner leaflet to the cell surface and formation of membrane blebs. However, MV biogenesis
also occurs even if membrane lipid asymmetry is maintained [25]. Given their biogenesis, they contain
bioactive molecules from their parental cells, and lipids are essential components of MV. Cholesterol is
a structural component of the plasma membrane, which regulates cell functionality and subcellular
compartmentalization, and is a precursor or cofactor for several signaling molecules/pathways. In fact,
MV are enriched in cholesterol compared to plasma membranes [26,27], and cholesterol mediates their
formation and release, ensures membrane stability, and it is necessary for their uptake by target cells.
Although MV are known to carry biomolecules such as proteins, RNAs and even DNA, their complete
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molecular fingerprint is largely unexplored [28], probably because the molecular composition of MV is
largely influenced by the stimulus originating them [29,30].
Once released from the cell, MV reach target cells and transfer their molecular cargo, triggering
functional responses and phenotypic changes affecting cell functionality, both at the local and systemic
environments. The net effect of MV in target cells involves signaling at multiple levels including
their interaction with cell surface receptors, and transference of genetic material, metabolites and
cytosolic enzymes.
Although the current review is focused in the lipid-mediated role of MV in the pathogenesis of
atherothrombosis, it is worth mentioning that there are smaller extracellular vesicles sized ≤150 nm
called exosomes, formed by the fusion of intracellular multivesicular bodies with the plasma
membrane [23]. Exosomes are rich in biomolecules such as protein, mRNA and non-coding RNA such
as miRNA, and have also emerged as both regulators and biomarkers of CVD progression [31]. For
further information please refer to reviews [32–37].
4. Role of Microvesicles in Atherosclerosis
As previously mentioned, MV are released from all cell types, including platelets, endothelial
cells, smooth muscle cells, leukocytes and erythrocytes. Therefore, MV are released in the bloodstream
affecting local and distal vulnerable zones.
MV are involved in CVD progression by supporting cellular cross-talk leading to vascular
inflammation and dysfunction, leukocyte adhesion and tissue remodeling, thus creating an
inflammatory and prothrombotic milieu. In parallel to LDL, MV accumulate and promote the
progression of atherosclerotic plaques [38]. Given the externalization of PS during their biogenesis, and,
in some cases, tissue factor on their surfaces, MV are potent inducers of coagulation [39], and within
the atherosclerotic plaque, retained MV account for the procoagulant activity of the lipid core. MV
are the main reservoir of tissue factor activity, thus MV increase plaque vulnerability by promoting
coagulation after erosion or rupture of the atherosclerotic plaque. In fact, MV exposing PS in their
surface enhance clot propagation, cause apoptosis of nearby cells, and modulate gene expression via
a variety of pathways [25], for instance, by transferring monomeric C-reactive protein (CRP) to the
cell surface and generating pro-inflammatory signals [40]. Endothelial release of MV is associated to
increased cytokine production, and in its turn, increased cytokine production increases MV release.
In fact, it has been observed that pharmacological attenuation of inflammation induces a decreased
shedding of endothelial-derived MV [41]. Monocyte-derived MV increase endothelial thrombogenicity
and apoptosis in vitro by increasing endothelial tissue factor expression, also by the adherence of
tissue factor derived from MV to the endothelial cell membrane, by decreasing levels of tissue
factor pathway inhibitor (TFPI) and thrombomodulin, and by disrupting endothelial integrity [42].
In addition, MV can transfer cluster of differentiation 40 ligand (CD40L) which binds to monocyte
CD40 triggering the activation of tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6)
downstream signaling, activating in its turn nuclear factor (NF)-kB, thus inducing monocyte release of
inflammatory mediators [43]. Besides their prothrombotic activity [44], platelet-derived MV enhance
the expression of adhesion molecules and trigger the production of interleukins and TNF-α [45].
In addition, platelet MV recruit activated platelets to the endothelial injury area and can also activate
platelets; and platelet-derived MV also contribute to atherogeneis by inducing smooth muscle cell
proliferation [46]. Finally, it has been shown that erythrocytes can induce the vulnerability and rupture
of plaques in a dose-dependant manner [47]. This effect has been proposed to be indirectly mediated
by erythrocyte MV by activating the endothelium, attracting leukocytes and platelets, and enhancing
the whole inflammatory pathway [46], although scarce research has been done in this direction.
Therefore, MV contribute to atherothrombosis progression by indirectly elevating the thrombotic
risk through the induction of an inflammatory response and directly activating platelets and
coagulation. Although up to 200-fold elevated concentrations of MV have been found at the local
area of atherosclerotic plaques compared to plasma circulating levels [48], circulating MV from CVD
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patients [49] and healthy subjects [44] have shown significant prothrombotic activity per se, a role that
should not be underestimated in atherothrombotic progression.
Crosstalk between Lipoproteins and MV
Recent findings pinpoint some similarities between MV and lipoproteins: both MV and HDL and
LDL contain and transfer miRNA to target cells [50,51]; MV extracts have been shown to carry ApoE,
ApoB, ApoC-II, among others; and the size and density of small- and middle-sized MV closely overlap
with lipoproteins, as can be observed in Figure 1. As a matter of fact, some isolation techniques result
in co-purification of MV and lipoprotein particles [22,23,52].
Figure 1. Particle size of lipoproteins and microvesicles. HDL, high density lipoprotein; LDL, low
density lipoprotein; IDL, intermediate density lipoprotein; VLDL, very low density lipoprotein; and
MV, microvesicles.
Given this size overlap, it is of extreme importance that blood extraction for MV isolation and
characterization is being performed in fasting conditions. Depletion of lipoproteins for MV analyses and
vice-versa should be carefully considered in biomarker and functional studies. However, the half-life
of lipoproteins and MV differs significantly. In physiological conditions, remnant chylomicrons, LDL
and HDL, are readily metabolized and stored as intracellular lipid droplets in the liver and adipose
tissue. Oppositely, MV rapidly accumulate in resident macrophages of the liver, lungs, and spleen [53].
During atherosclerosis progression, oxidized lipoproteins accumulate in macrophages and other
subendothelial cells of the vascular wall provoking an inflammatory response and the progression
of the plaque formation. The contribution of circulating (not local) MV in atherothrombosis needs
further research.
As previously mentioned and summarized in Figure 2, monocyte-derived macrophages accumulate
cholesterol modified within the arterial wall during atherogenesis [54]. In its turn, cholesterol
accumulation in macrophages and foam cells enhance AV+ and tissue factor+MV release [55], potentially
contributing to the prothrombotic state in hypercholesterolemia [56], and to the prothrombotic core of
the lipid-rich vulnerable plaque [57].
166
J. Clin. Med. 2019, 8, 2059
Figure 2. Lipid and microvesicle crosstalk contributing to atherosclerosis progression.
It is known that oxidized low-density lipoprotein (oxLDL) activates platelets [58–60], thus inducing
a prothrombotic state [39]. In addition, oxLDL induces the cellular release of MV [33,39]. In fact, total,
AV+ and CD41a+ MV release was shown increased after challenging platelets with oxLDL (but not
native LDL) [61], and this effect was comparable to that of ADP. However, Nielsen et al. [62] observed
that in vitro incubation of platelets with oxLDL (or native LDL as well) did not significantly stimulate
CD41+ and CD41+/CD36+ MV release, suggesting that MV release induced by oxLDL may not be
mediated by the interaction with CD36 on platelets.
It has been shown that oxLDL, in a time- and dose-dependent manner, promotes the in vitro release
of endothelial MV rich in intercellular adhesion molecule 1 (ICAM-1) [63], which can be transferred
from MV to endothelial cells increasing monocyte adhesion to endothelial cells [64], further propagating
the atheroprone effects of oxLDL even in its absence. Moreover, enrichment of THP-1 monocytic
cells with unsterilized cholesterol resulted in increased MV production [65], and these MV induced
extensive leukocyte rolling and adherence to the endothelium. In the presence of oxLDL, high shear
stress-induced platelet-derived MV were able to activate THP-1 monocytes and induce them to generate
tissue factor-rich MV in vitro [66].
Elevated concentrations of circulating autoantibodies for oxLDL, a surrogate biomarker for LDL
oxidation in vivo, have been associated with increased levels of platelet- and monocyte-derived
circulating MV in acute coronary syndrome patients [66]. As previously stated, oxLDL induces
the cellular release of tissue factor-exposing MV, promoting coagulation and thrombosis, and also
disseminating the inflammatory response [39]. Although surface molecules of parental cells are
transferred to MV, the interactions between of oxLDL and MV are not entirely elucidated and the
consequent effects still remain unknown.
In addition to oxidized LDL, aggregated LDL but not native LDL increases tissue factor-loaded
MV from smooth muscle cells [67]. In their turn, oxidized MV have been shown to stimulate monocyte
adhesion to endothelial cells through oxidized membrane phospholipids, thus also contributing to
atherosclerosis progression [65,68,69].
Given the heterogenic composition of MV, they may have cardioprotective functions as well. As
recently reviewed, some MV carry antioxidant enzymes, conferring antioxidant activity at MV under
specific stimuli [70]. In its turn, MV have also been shown to both stimulate or inhibit angiogenesis
by several mechanisms of action, again depending on the cellular origin and molecular composition
derived from the trigger or condition originating their release [71].
5. Role of Microvesicles in Dyslipidemia
The pathophysiological link between postprandial hypertriglyceridemia, inflammation and
endothelial injury may be provoked by an excessive retention of lipoproteins in the extracellular
matrix and increased uptake by macrophages, thus initiating the atherogenic process. A large body
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of evidence indicates a direct relationship between postprandial hypertriglyceridemia and CVD
risk [72,73]. Postprandial dyslipidemia, independently of the caloric intake or the postprandial
state itself, is associated with increased endothelial-derived CD31+/CD42− [74], and total circulating
MV levels in healthy subjects [75], and to increased platelet-derived MV in men with different CV
risk burden [76], in parallel to increased markers of oxidative stress such as oxLDL and impaired
flow-mediated dilation [75]. The effects of postprandial hypertriglyceridemia on MV release in subjects
with metabolic dysregulation are quite unexplored and deserve further research, as the reported results
are controversial. Type 2 diabetic patients, who show exacerbated postprandial dyslipidemia, show
around 3.5 fold increased concentration of endothelial-derived CD144 circulating MV after a meal [77].
However, patients with carotid atherosclerosis show a similar postprandial elevation of circulating
platelet-derived MV, despite having higher postprandial hypertriglyceridemia than control subjects
free of atherosclerosis [78].
Patients with hypercholesterolemia show higher levels of monocyte- and platelet-derived MV
than healthy subjects [79–81]. Familial hypercholesterolemia (FH) is an autosomal dominant genetic
disorder associated with elevated LDL cholesterol levels and deposition in tendons (xanthomas),
and premature heart disease [82]. MV have been associated with atherosclerosis progression
and with a higher risk of atherothrombosis in FH patients. In fact, elevated concentrations of
total, endothelial cell-derived, erythrocyte-derived, monocyte-derived, tissue factor-loaded MV [83],
and platelet-derived MV [84], have been found in FH patients compared to healthy controls [85],
and identify subclinical atherosclerosis [80]. In addition, circulating CD36+ MV derived from
endothelial cells and monocytes were significantly higher in FH patients compared to healthy
controls [85], and monocyte-derived circulating MV in FH patients directly correlated with oxLDL
plasma concentrations [79]. Moreover, these patients showed increased concentrations of circulating
MV derived from leukocytes, and lymphocyte-derived CD3+/CD45+ circulating MV have been shown
elevated in FH patients with lipid-rich atherosclerotic plaques [86]. In addition, platelet- (CD41a+/AV+,
CD31+/AV+, CD41a+/CD31+/AV+), granulocyte- (CD66+/AV+), neutrophil- (CD11b+/CD66+/AV+),
and endothelial cell-derived (CD62E+/AV+/−) circulating MV discriminate and map coronary
atherosclerotic plaque and calcification [84], and leukocyte- and activated platelet-derived circulating
MV predict a major cardiovascular event in these patients three years before it takes place [87].
In FH patients, plasma apheresis reduces circulating MV concentration, mainly platelet-derived
MV AV+ [88].
Pharmacological Treatment of Dyslipidemia and Circulating MV
Given the crosstalk between lipids and MV, as discussed in a previous section, it appears
plausible that lipid lowering therapy may elicit a pleiotropic effect by (partially) inhibiting MV release,
contributing to explain their beneficial effects in atherothrombotic complications. We have observed
that statins reduce MV shedding from platelets, endothelial cells and leukocytes carrying markers
of cell activation [89], and this effect was found to be accumulative throughout years of treatment.
Other researchers have also observed that statins decrease MV release from several cell origins [90–92],
and modify their molecular fingerprint by decreasing their cargo of cell activation markers [93,94].
In stroke patients with hyperlipidemia, simvastatin treatment for 6 months reduced the percentage of
CD61+ platelet-derived MV to similar levels to those of age- and sex-matched controls [95].
However, some authors did not observe such effect of statins [96,97], and, as discussed in the 2019
ESC/EAS Guidelines for the management of dyslipidemias, the clinical relevance of the pleiotropic
effects of statins remains clinically unproven [98], and thus may be object of future research.
6. Conclusions and Future Perspectives
The studies summarized in this review evidence that MV are settled in the tandem lipids
inflammation, contributing to the progression of atherothrombosis leading to a major CV event.
Despite a huge body of research towards the understanding of the exact contribution of MV in this
168
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process, several questions remain unanswered, such as the specific interaction of MV with native and
modified LDL, the molecular fingerprint of MV, how do they qualitatively (by which pathways) and
quantitatively (in what amounts) contribute in the presentation of major CV events, and if they can be
considered real candidates as drug delivery vectors in the clinical setting. Given the central role of
MV in systemic inflammation and endothelial injury within the pathophysiology of atherothrombosis,
their link with lipids and lipoproteins are of particular interest. Understanding the pathways implicated
in this process will aid in developing novel therapeutic approaches against early atherosclerosis. In this
setting, MV and lipoproteins exhibit common features, which should be considered in the interpretation
of their respective roles in the pathophysiology of CVD.
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Abstract: High-density lipoproteins (HDL) exert anti-atherosclerotic effects via reverse cholesterol
transport, yet this salutary property is impaired in the setting of inflammation. GlycA, a novel
integrated glycosylation marker of five acute phase reactants, is linked to cardiovascular (CV) events.
We assessed the hypothesis that GlycA is associated with measures of impaired HDL function and that
dysfunctional HDL may contribute to the association between GlycA and incident CV events. Baseline
measurements of HDL cholesterol (HDL-C), HDL particle concentration (HDL-P), apoliprotein A1
(Apo A1), cholesterol efflux capacity, GlycA and high-sensitivity C-reactive protein (hs-CRP) were
obtained from the Dallas Heart Study, a multi-ethnic cohort of 2643 adults (median 43 years old; 56%
women, 50% black) without cardiovascular disease (CVD). GlycA was derived from nuclear magnetic
resonance imaging. Participants were followed for first nonfatal MI, nonfatal stroke, coronary
revascularization, or CV death over a median of 12.4 years (n = 197). The correlation between GlycA
and hs-CRP was 0.58 (p < 0.0001). In multivariate models with HDL-C, GlycA was directly associated
with HDL-P and Apo A1 and inversely associated with cholesterol efflux (standardized beta estimates:
0.08, 0.29, -0.06, respectively; all p ≤ 0.0004) GlycA was directly associated with incident CV events
(adjusted hazard ratio (HR) for Q4 vs. Q1: 3.33, 95% confidence interval (CI) 1.99, 5.57). Adjustment
for cholesterol efflux mildly attenuated this association (HR for Q4 vs. Q1: 3.00, 95% CI 1.75 to 5.13).
In a multi-ethnic cohort, worsening inflammation, as reflected by higher GlycA levels, is associated
with higher HDL-P and lower cholesterol efflux. Impaired cholesterol efflux likely explains some of
the association between GlycA and incident CV events. Further studies are warranted to investigate
the impact of inflammation on HDL function and CV disease.
Keywords: HDL; lipids; inflammation; atherosclerotic cardiovascular disease (ASCVD); cardiovascular
events; GlycA
1. Introduction
Although low high-density lipoprotein cholesterol (HDL-C) is considered an atherosclerotic
cardiovascular disease (ASCVD) risk factor, contemporary epidemiological studies suggest that HDL
particle concentration and HDL function better reflect HDL metabolism, and are better predictors
of ASCVD [1–4]. In particular, cholesterol efflux capacity (CEC) as a measure of reverse cholesterol
transport has been shown to inversely associate with prevalent and incident ASCVD in both low-risk
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and high-risk cohorts, independent of HDL-C and HDL particle concentration (HDL-P) [5]. Similarly,
HDL particle concentration is also inversely associated with ASCVD, independent of HDL-C [2].
Chronic inflammation accelerates atherosclerosis, presumably in part by modifying HDL and
its ability to promote reverse cholesterol transport [6–9]. GlycA is a circulating biomarker that
reflects inflammation via glycosylated acute phase reactants and is directly associated with incident
ASCVD [10–15]. GlycA predicts cardiovascular mortality, but the association was attenuated after
adjustment for cardiovascular risk factors. Further, a recent meta-analysis also reported that GlycA is
significantly associated with all-cause mortality [16].
GlycA is measured through nuclear magnetic resonance assay reflecting the mobile glycan
residues from N-acetyl methyl group attachments added in the inflammatory setting. GlycA is
modestly correlated with high-sensitivity C-reactive protein (hs-CRP) [12,17]. The most prominent
contributions to the GlycA signal are alpha1-antitrypsin, haptoglobin, alpha1-antichymotrypsin,
alpha1-acid glycoprotein, and transferrin [17]. These proteins are all associated with HDL in multiple
studies, except transferrin [18–20]. In the setting of inflammation, protein glycan structures undergo
modification, which can result in association with different receptors and changes in function [21,22].
For example, the protein composition of HDL differs in those with cardiovascular disease compared
to those without cardiovascular disease [23]. hs-CRP is associated with impaired HDL cholesterol
efflux [24]. Whether dysfunctional HDL is associated with this aggregated inflammatory biomarker,
GlycA, is unknown. Furthermore, though inflammation and dysfunctional HDL have been linked in
preclinical investigations, it remains unknown whether dysfunctional HDL explains part of the link
between inflammation and ASCVD in humans.
We assessed the hypothesis that GlycA is associated with impaired HDL function measures and
that the association between GlycA and incident cardiovascular (CV) events is partially explained by
dysfunctional HDL. We tested this hypothesis in the multiethnic, population-based Dallas Heart Study
(DHS) by investigating cross-sectional associations between GlycA with multiple HDL parameters and
longitudinal associations with incident ASCVD events.
2. Experimental Section
2.1. Study Design
The Dallas Heart Study is a multiethnic, population-based cohort of Dallas County residents aged
30 to 65 years [25]. There was intentional oversampling of black persons in the DHS, to comprise 50%
of the cohort. Persons with a history of cardiovascular disease (self-reported history of myocardial
infarction, stroke, heart failure, arterial revascularization, or arrhythmia), chronic kidney disease stage
V or self-reported dialysis were excluded from the study, as well as individuals without values of GlycA.
The final study sample included 2643 individuals. This research was approved by the UT Southwestern
Medical Center Institutional Review, and all participants provided informed written consent.
2.2. Assessment of HDL Parameters and GlycA
Participant blood collected in a fasting state at baseline through venipuncture was placed in
ethylenediamine tetraacetic acid (EDTA) tubes and stored at four degrees Celsius for less than 4 h.
Then, blood samples were centrifuged, and plasma was removed and stored at −70 degrees Celsius.
Traditional lipids were measured through previously described methods [25]. Cholesterol efflux
capacity was measured through the efflux of fluorescence-labeled cholesterol (boron dipyrromethene
difluoride reagent, BODIPY) from J774 macrophages to apolipoprotein B depleted plasma [5].
Apolipoprotein A1 (Apo A1), HDL particle concentration and size, and GlycA were measured
by nuclear magnetic resonance (NMR) spectroscopy (LabCorp, Inc.; formerly LipoScience, Raleigh,
SC, USA). GlycA is measured through detection of glycosylation of N-acetyl methyl groups of
specific serum proteins (predominately alpha1-acid glycoprotein, haptoglobin, alpha1-antitrypsin,
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alpha1-antichymotrypsin and transferrin) by NMR to calculate the concentration of GlycA in
micromol/L [11].
2.3. Clinical End Points
The primary end point of the study was incident atherosclerotic cardiovascular disease (ASCVD),
including first nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or CV death
over a median of 12.4 years (n = 197). A secondary end point, total cardiovascular disease (CVD),
includes ASCVD and hospitalization for congestive heart failure, atrial fibrillation, or peripheral
artery disease. Death from cardiovascular causes was defined by codes I00 to I99 in the International
Classification of Diseases, 10th Revision, from the National Death Index. Nonfatal cardiovascular events
data were obtained from the annual detailed surveying of subjects and hospitalization admissions
were tracked quarterly through the Dallas-Fort Worth Hospital Council Data Initiative database.
All end points were adjudicated by two cardiologists who were blinded to all exposure variables.
The vital status of participants was reviewed through 31 December 2013 [26].
2.4. Statistical Analysis
GlycA was the main exposure variable and was assessed for relationships with demographics and
risk factors as both a continuous variable (Spearman correlation coefficients) and as a categorical variable
across increasing quartiles (Jonckheere–Terpstra Test). Multivariable linear regression models adjusted
for age, sex, race/ethnicity, current smoking, hypertension, body mass index (BMI), waist circumference,
diabetes, homeostatic model assessment of insulin resistance (HOMA-IR), non-HDL cholesterol,
triglycerides, anti-hypertensive medications, and hs-CRP were used to assess the cross-sectional
association between HDL parameters and GlycA levels.
The hazard associated with baseline GlycA and incident ASCVD (the primary end point)
and total CVD (secondary end point) was estimated using Cox proportional hazards models.
Multivariable models included age, sex, race/ethnicity, smoking status, systolic blood pressure,
BMI, waist circumference, diabetes, HOMA-IR, non-HDL-C, triglycerides and statins. The variance
inflation factor between BMI and waist circumference is four, which does not suggest collinearity.
hs-CRP and HDL parameters (HDL-C, HDL-P, ApoA1, and cholesterol efflux) were serially added to
these models.
Two-sided P values of 0.05 or less were considered statistically significant. The statistical analysis
was performed with SAS software version 9.4 (SAS, Raleigh, NC, USA).
3. Results
3.1. Demographics
The mean age of study participants was 44, with 56% women and 50% blacks. GlycA was normally
distributed within the DHS (Figure 1).
The median value of GlycA in DHS was 327 μmol/L (interquartile range 291 μmol/L to 369 μmol/L),
with higher levels in women vs. men (p < 0.0001; Table 1) and significant differences by race/ethnicity
(p < 0.0001, Table 1).
Table 1. GlycA levels by gender and race/ethnicity in the Dallas Heart Study.
Category Mean +/− Standard Deviation
Overall (n = 2643) 332 +/− 62
Men (n = 1152) 318 +/− 60
Women (n = 1491) 344 +/− 60
White (n = 1305) 337 +/− 64
Black (n = 865) 327 +/− 60
Hispanic (n = 417) 332 +/− 59
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Figure 1. GlycA Distribution in DHS.
3.2. Univariate Correlations with GlycA
Increasing quartiles of GlycA were directly associated with age, systolic blood pressure, BMI, waist
circumference, diabetes, non-HDL-C, triglycerides, and hs-CRP (Table 2). GlycA was not associated
with HDL-C but was associated with increasing HDL-P. There was an inverse trend but no statistical
association with cholesterol efflux (p = 0.06).























Age (years) 42 (9.4) 44 (9.7) 44 (9.6) 45 (9.8) <0.0001
Systolic Blood Pressure (mmHg) 120 (16.2) 122 (17.4) 125 (18.2) 128 (19.7) <0.0001
BMI (kg/m2) 27 (5.5) 29 (5.7) 30 (7.1) 32 (8.0) <0.0001
Waist Circumference (cm) 93 (15.0) 98 (14.8) 100 (17.0) 104 (16.6) <0.0001
HOMA-IR 3.2 (4.1) 3.6 (3.1) 4.6 (4.8) 5.1 (4.5) <0.0001
Non-HDL (mg/dL) 127 (39.1) 130 (39.0) 132 (39.9) 136 (41.8) 0.001
Triglycerides (mg/dL) 84 (59, 123) 91 (69, 136) 104 (72, 153) 111 (78, 162) <0.0001
hs-CRP (mg/L) 1.9 (2.0) 3.4 (3.8) 5.2 (4.8) 9.5 (6.7) <0.0001
HDL-C (mg/dL) 49.9 (14.6) 49.6 (14.3) 50.3 (13.9) 50.2 (15.9) 0.7600
HDL-P (μmol/L) 32.5 (5.5) 33.0 (6.1) 33.4 (5.8) 34.3 (7.5) <0.0001
Cholesterol Efflux (normalized to pool) 1.06 (0.33) 1.01 (0.30) 1.03 (0.33) 1.02 (0.30) 0.06
Apo A1 (μmol/L) 122.1 (27.0) 125.4 (28.2) 128.2 (28.0) 132.3 (32.4) <0.0001
BMI = body mass index, HOMA-IR = homeostatic model assessment of insulin resistance, non-HDL = non-high-density
lipoprotein, hs-CRP = high-sensitivity C-reactive protein, HDL-C = high-density lipoprotein cholesterol,
HDL-P = high-density lipoprotein particle concentration, Apo A1 = apolipoprotein A1. Jonckheere–Terpstra test
reported for two-sided p-value. All values reported as mean (standard deviation), except for triglycerides, which are
reported as median (interquartile range).
Analyzed continuously in unadjusted univariate correlation analyses, GlycA was moderately
correlated with hs-CRP in those (Spearman r = 0.58; p < 0.0001). These correlations were qualitatively
higher in women vs. men (Spearman r = 0.59 for women, p < 0.0001; Spearman r = 0.50 for men,
p < 0.0001) and highest in whites (Spearman r = 0.61; p < 0.0001).
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Unadjusted associations between continuous GlycA and HDL parameters varied across parameters
and by sex and ethnicity (Supplemental Table S1). GlycA correlated inversely with HDL-C (Spearman
r = −0.11, p < 0.001) and directly with HDL-P (Spearman r = 0.14, p < 0.001) in women but not in men.
GlycA did not correlate with efflux within any sex or ethnicity (Spearman r = −0.05–0.02, p = 0.07–0.74).
3.3. Understanding Variation in GlycA
GlycA was modeled as an outcome in adjusted linear regression models that included age,
sex, race/ethnicity, current smoking, systolic blood pressure, BMI, waist circumference, diabetes,
HOMA-IR, non-HDL-C, triglyceride, and antihypertensive medication. hs-CRP was added serially to
this model to assess its additional contribution to variation in GlycA. Factors directly associated with
GlycA included age, women, Hispanic race/ethnicity, current smoking, systolic blood pressure, BMI,
waist circumference, triglycerides, and hs-CRP (all p < 0.05). The cardiovascular risk factor model
explained 17% of the variation in GlycA, increasing to 36% of the variation when hs-CRP was included.
HDL parameters were then individually entered into separate multivariable models, and HDL-C
was included in all models. GlycA was directly associated with HDL-P and Apo A1 and inversely
associated with cholesterol efflux (Table 3). Analysis of HDL subfractions revealed significant
associations with medium and large HDL particles but not small HDL particles.
Table 3. Association of GlycA with HDL Parameters.
Variable Standardized Estimate p-Value
HDL-P 0.08 <0.0001
Apo A1 0.29 <0.0001
Cholesterol Efflux −0.06 0.0004
HDL Medium 0.10 <0.0001
HDL Large −0.07 0.02
Each row is a separate linear regression model for GlycA adjusted for age, sex, race/ethnicity, current smoking, systolic
blood pressure, body mass index, waist circumference, diabetes, homeostatic model assessment of insulin resistance,
high-density lipoprotein cholesterol (HDL-C), non-HDL-C, antihypertensive medication, and high-sensitivity
C-reactive protein. The association displayed is for the independent addition of a single HDL parameter to this
model. Only statistically significant HDL parameters are included. HDL-P = high-density lipoprotein particle
concentration; Apo A1 = apolipoprotein A1.
There was a significant interaction between HDL-P and gender with respect to GlycA
(p for interaction < 0.001). HDL-P was associated with GlycA among women (standardized estimate
0.18, p < 0.0001) but not among men (p = ns) (Supplemental Table S2). Medium and small HDL-P were
both associated with GlycA in men and women (all p < 0.01).
3.4. GlycA, HDL Parameters, and Incident Cardiovascular Events
Over a median of 12.4 years, there were 197 first ASCVD events. Increasing GlycA concentration
was directly associated with ASCVD events in adjusted models (hazard ratio (HR) Q4 vs. Q1: 3.33,
95% confidence interval (CI) 1.99, 5.57). Further adjustment for cholesterol efflux mildly attenuated
this association (HR for Q4 vs. Q1: 3.00, 95% CI 1.75 to 5.13, Figure 2). Similar attenuation was seen
when analyzing GlycA and cholesterol efflux as continuous variables (Supplemental Table S3).
Increasing quartiles of GlycA remained directly associated with ASCVD in models adjusted for
HDL-P (HR for GlycA, Q4 vs. Q1: 3.46, 95% CI 2.06 to 5.84) or HDL-C (HR for GlycA, Q4 vs. Q1:
3.31, 95% CI 1.98 to 5.55). In contrast to the modest attenuation with addition of efflux, there was no
attenuation with adjustment for HDL-P (HR for HDL-P, Q4 vs. Q1: 0.61, 95% CI 0.41 to 0.90).
Over a median of 12.4 years, there were 239 total CVD events. In models adjusted for risk factors,
GlycA remained directly associated with total CV events (HR for Q4 vs. Q1: 2.70, 95% CI 1.76, 4.14).
Again, further adjustment for cholesterol efflux mildly attenuated this association (HR for Q4 vs.
Q1: 2.37, 95% CI 1.52, 3.70); however, cholesterol efflux remained inversely associated with total CVD
when adjusted for risk factors and GlycA (HR for Q4 vs. Q1: 0.69, 95% CI 0.48, 0.98).
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Figure 2. Hazard Ratios of Quartiles of GlycA (Q4 vs. Q1) derived from Cox Proportional Hazards
Models adjusted for age, sex, race/ethnicity, diabetes, current smoking, systolic blood pressure,
antihypertensive medications, non-high-density lipoprotein, body mass index, statin. Cholesterol
efflux was serially added to the models.
4. Discussion
In a large, low-risk, multi-ethnic cohort, we found that GlycA as an integrated measure of
inflammation associates with several HDL parameters, and impaired cholesterol efflux explains some
of the relationship of GlycA with CV events. We noted gender-specific associations between GlycA
and metabolic and lipid parameters and a modest correlation with hs-CRP.
Unlike most circulating markers, which reflect single enzymes, proteins, lipids, etc., GlycA is
a unique cardiometabolic marker as it directly reflects concentrations of five glycosylated acute phase
reactants—alpha1-antitrypsin, haptoglobin, alpha1-antichymotrypsin, alpha1-acid glycoprotein, and
transferrin [17]. Prior reports suggest that this NMR-derived marker of inflammation robustly correlates
with a variety of CV phenotypes (cardiovascular disease, coronary artery disease, cardiovascular
mortality, and total death), including the risk of incident CV events [10–15]. However, the relationships
with cardiometabolic processes underlying these risk associations have not been fully explored.
Inflammation has been linked to disordered lipid metabolism, especially dysfunctional HDL.
In particular, both acute and chronic inflammation can alter the HDL proteome and impair cholesterol
transport, anti-oxidant, and other atheroprotective functions [6–9]. However, most of these observations
have occurred at the preclinical level or on a limited basis among humans. Moreover, although CRP is
an established generalized marker of inflammation, GlycA is distinct from CRP in that it represents
multiple glycosylated proteins in response to cardiometabolic stress and perhaps is a unique reflection
of the intersection between inflammation and altered protein structure and function. This is supported
by the moderate but not high correlation between hs-CRP and GlycA seen in our study and previous
studies. Thus, we were keenly interested in the relationship between GlycA and parameters of HDL
particle composition and function.
Beyond HDL’s cholesterol load (HDL-C), total HDL particle number is a robust marker of
ASCVD and outperforms HDL-C in predicting ASCVD risk [1–4]. In addition, Apo AI is the most
abundant protein on HDL and associated with the majority of HDL’s atheroprotective functions. Unlike
Apolipoprotein B-containing particles, which have a 1:1 ratio of Apolipoprotein B to particle number,
the number of Apo AIs varies per HDL particle (2–4), resulting in only a moderate correlation between
HDL particle number and Apo AI concentration [27]. Therefore, both measures of HDL particles offer
complementary information on cardiometabolic risk. Lastly, the ability of HDL to promote reverse
cholesterol transport is considered its most important atheroprotective function, and cholesterol
efflux capacity has been the most studied aspect of this process in human epidemiologic studies,
demonstrating links to prevalent and incident ASCVD [5].
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The Dallas Heart Study is a population-based low risk cohort balanced by gender and enriched
for African Americans, offering the opportunity to explore both gender- and race/ethnicity-specific
correlates of GlycA. We discovered that several cardiometabolic risk factors including adiposity, blood
pressure, and dyslipidemia are associated with higher GlycA levels. Intriguingly, several of these
associations, in particular measures of adiposity, were enhanced and most prevalent among women,
and either weak or non-existent among men. With respect to markers of HDL metabolism, GlycA was
most strongly and directly associated with particle-related parameters (HDL-P and Apo AI) rather
than cholesterol content. These relationships were most evident in non-African Americans but also
varied by gender. Lastly, GlycA appeared to be inversely related to large HDL, mostly among women,
mirroring the associations with adiposity.
Thus, GlycA appears to be associated with altered lipid metabolism, especially among women,
and is most strongly linked to increased HDL particle number and Apo AI levels, with a trend toward
smaller HDL particles. Perhaps the glycosylation of acute phase reactants reflects a milieu in which
HDL particles are also modified with increased shedding of apolipoproteins and lipid-poor particles.
Accounting for these relationships with HDL particle number and Apo AI levels, there emerged a modest
inverse association between GlycA and cholesterol efflux, suggesting that on a per particle basis,
increased glycosylation and inflammation is linked to impaired HDL function at a population level.
Having demonstrated a modest but significant link between inflammation, as reflected by GlycA
and HDL metabolism, we then determined to what extent this link may explain the association
between GlycA and CV events. We found a modest effect of cholesterol efflux on GlycA’s relationship
with incident CV events. These findings at a population level suggest that dysfunctional HDL likely
contributes to the pathways linking inflammation and CVD.
In summary, despite the independent associations of GlycA, HDL particle number, and cholesterol
efflux with CV risk, markers of HDL metabolism were only modestly associated with GlycA, and
cholesterol efflux was the only marker to mildly explain the link between GlycA and CV risk. Future
studies may help to clarify the role of inflammation and dysfunctional HDL in CV risk by assessing
higher risk cohorts with chronic CV disease and/or those undergoing acute illnesses such as acute
coronary syndromes.
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Abstract: A higher sodium intake is conceivably associated with insulin resistant conditions like
obesity, but associations of non-alcoholic fatty liver disease (NAFLD) with a higher sodium intake
determined by 24 hours (24 h) urine collections are still unclear. Dietary sodium intake was measured
by sodium excretion in two complete consecutive 24 h urine collections in 6132 participants of the
Prevention of Renal and Vascular End-Stage Disease (PREVEND) cohort. Fatty Liver Index (FLI)
≥60 and Hepatic Steatosis Index (HSI) >36 were used as proxies of suspected NAFLD. 1936 (31.6%)
participants had an FLI ≥60, coinciding with the increased prevalence of type 2 diabetes (T2D),
metabolic syndrome, hypertension and history of cardiovascular disease. Sodium intake was higher
in participants with an FLI ≥60 (163.63 ± 61.81 mmol/24 h vs. 136.76 ± 50.90 mmol/24 h, p < 0.001),
with increasing incidence in ascending quartile categories of sodium intake (p < 0.001). Multivariably,
an FLI ≥60 was positively associated with a higher sodium intake when taking account for T2D, a
positive cardiovascular history, hypertension, alcohol intake, smoking and medication use (odds
ratio (OR) 1.54, 95% confidence interval (CI) 1.44–1.64, p < 0.001). Additional adjustment for the
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) diminished this association (OR
1.30, 95% CI 1.21–1.41, p < 0.001). HSI >36 showed similar results. Associations remained essentially
unaltered after adjustment for body surface area or waist/hip ratio. In conclusion, suspected NAFLD
is a feature of higher sodium intake. Insulin resistance-related processes may contribute to the
association of NAFLD with sodium intake.
Keywords: non-alcoholic fatty liver; sodium intake; insulin resistance; fatty liver index; hepatic
steatosis index; HOMA-IR
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence
of excessive alcohol use, and is emerging as the most common cause of chronic liver disease [1,2].
The spectrum of NAFLD ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis
and eventually cirrhosis [1,3]. NAFLD coincides with obesity and insulin resistance, and is seen as
the liver manifestation of the metabolic syndrome (MetS) [4]. NAFLD may in itself also increase the
risk for the development of MetS and type 2 diabetes mellitus (T2D) [5,6]. NAFLD predisposes to
plasma lipoprotein abnormalities, including elevations in apolipoprotein B-containing lipoproteins,
J. Clin. Med. 2019, 8, 2157; doi:10.3390/jcm8122157 www.mdpi.com/journal/jcm184
J. Clin. Med. 2019, 8, 2157
as evidenced by elevations in very low-density lipoproteins (VLDL) and consequently in higher
triglycerides, increased levels of low density lipoprotein (LDL) cholesterol, as well as in decreased
levels of high density lipoprotein (HDL) cholesterol [2,7,8], which predisposes to atherosclerotic
cardiovascular disease (CVD) [9]. The pathophysiological mechanisms underlying the development of
NAFLD are not fully clarified, but multifactorial contributors including environmental factors (diet),
central obesity, insulin resistance, alterations in gut microbiota and genetic factors are likely to play an
important role [10].
In recent years, individual sodium intake is presumably increased, with the majority of extra
sodium coming from diets filled-up with highly processed foods, particularly convenience foods [11].
High sodium intake is related to various metabolic disorders, such as obesity, insulin resistance, T2D,
MetS, hypertension and CVD [11–14]. In turn, high sodium intake may also deleteriously influence
metabolic diseases and is associated with expanding body fat and a diminished fat free mass [13,15].
Given increasingly documented associations of sodium intake with obesity [13,16,17], it is plausible to
postulate that high sodium intake coincides with NAFLD and could even play a role in its pathogenesis.
So far such a relationship has only been explored in two studies [14,18]. In these Asian studies,
sodium intake was either estimated by dietary recall questionnaires [18] or by estimation from spot
urine specimens [14]. Both studies found a positive relationship of NAFLD with estimated sodium
intake [14,18]. However, the preferred method for assessing dietary salt intake is by measurement of
sodium excretion in multiple 24 hour (24 h) urine collections, with other estimates being considered
to be less accurate [19]. Thus, large-scale studies on the association of NAFLD with sodium intake
measured by using multiple 24 h urine collections are still lacking.
Therefore, we initiated the present study to interrogate the impact of high sodium intake, assessed
by using multiple 24 h urine collections, on NAFLD. We carried out a cross-sectional analysis among
6132 participants of in the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) cohort
study, comprising a large and well-characterized population from the North of The Netherlands.
2. Materials and Methods
2.1. Study Design and Population
This study was performed among participants of the Prevention of REnal and Vascular ENd-stage
Disease (PREVEND) cohort study, a large prospective general population-based study that started
in 1997 [20,21]. The PREVEND study was approved by the Medical Ethics Committee of the
University Medical Center Groningen and is performed in accordance with Declaration of Helsinki
guidelines [20,21]. Written informed consent was obtained from all participants. PREVEND was
initiated to investigate cardiovascular and renal disease with a focus on albuminuria. All inhabitants
(28 to 75 years old) of Groningen, the Netherlands were sent a questionnaire on demographics and
cardiovascular morbidity, and were asked to supply urine specimens. Pregnant women, type 1 diabetic
subjects and T2D subjects using insulin were excluded from participation. Participants with an urinary
albumin concentration ≥10 mg/L were invited to our clinic together with randomly selected subjects
with an urinary albumin concentration <10 mg/L. The initial study population of the PREVEND study
comprised 8592 subjects who completed the total study screening program.
For the present study, we used data of participants who completed the second screening round
in the PREVEND study (2001–2003; n = 6893), in which 24 h urine collections are available [22,23].
We excluded all subjects with missing values on urinary sodium excretion and subjects in which
clinical and biochemical variables required to calculate the Fatty Liver Index (FLI), a proxy of NAFLD,
were not available, leaving 6132 participants (Figure 1).
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Figure 1. Flowchart of the study population.
2.2. Measurements and Definitions
Procedures at examination, measurements and definitions in the PREVEND study are reported in
detail previously [20–24]. Body mass index (BMI) was calculated as weight (kg) divided by height
squared (meter). Body surface area (BSA) was calculated as the square root of height (cm) multiplied
by weight (kg) divided by 3600. Waist circumference was measured as the smallest girth between rib
cage and iliac crest [20]. The waist/hip ratio was determined as the waist circumference divided by
the largest girth between waist and thigh. Blood pressure was assessed in a standardized fashion
on the right arm in supine position, every minute for 10 min, with an automatic Dinamap XL Model
9300 series device. The mean of the last 2 recordings was used [23]. Lipid lowering drugs and
other medications were not stopped prior to the clinical evaluation and blood sample collection.
T2D was defined as a fasting glucose ≥7.0 mmol/L, a random glucose ≥11.1 mmol/L, self-report of a
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physician diagnosis or the use of glucose lowering drugs. Daily alcohol consumption was recorded
with one alcoholic drink being assumed to contain 10 grams of alcohol. Smoking was categorized into
current and never/former smokers. A positive cardiovascular history included: hospitalization for
myocardial ischemia, obstructive coronary artery disease or revascularization procedures. Information
on medication use was combined with information from a pharmacy-dispensing registry, which has
complete information on drug usage of >95% of subjects in the PREVEND study [20,21].
Participants collected two consecutive 24 h urine specimens after thorough oral and written
instruction. They were asked to avoid heavy exercise during the urine collection and instructed to
postpone the urine collection in case of a urinary tract infection, menstruation or fever [22,23]. Urinary
sodium concentration (in mmol/L) was multiplied by the urine volume in liters per 24 h to obtain a
value in mmol/24 h. Results of two consecutive 24 h urine collections were averaged for analyses.
Estimated glomerular filtration rate (eGFR) was calculated applying the combined creatinine cystatin
C-based Chronic Kidney Disease Epidemiology Collaboration equation [25].
For the diagnosis of suspected NAFLD, we used the algorithm of the Fatty Liver Index (FLI) [26].
The FLI was calculated according to the following formula [26]:
[e (0.953 × loge (triglycerides + 0.139 × BMI + 0.718 × loge (GGT) + 0.053 ×waist
circumference − 15.745)/[1 + e (0.953 × loge (triglycerides) + 0.139 × BMI + 0.718 ×
loge (GGT) + 0.053 ×waist circumference − 15.745)] × 100
(1)
where GGT is gamma-glutamyltransferase.
The optimal cut-off value for the FLI is documented to be 60 with an accuracy of 84%, a sensitivity
of 61% and a specificity of 86% for detecting suspected NAFLD as determined by ultrasonography [26].
Therefore, FLI ≥60 was used as proxy of NAFLD. The FLI is currently considered as one of the
best-validated steatosis scores for larger scale screening studies [27]. Alternatively, we used the Hepatic
Steatosis Index (HSI) [28]. The HSI is defined as follows:
HSI = 8 × ALT/AST ratio + BMI (+2, if diabetes; +2, if female) (2)
where ALT is alanine aminotransferase and AST is aspartate aminotransferase.
The cut-off value of the HSI for detecting suspected NAFLD is 36 [28]. In these equations, BMI
is expressed in kg/m2, triglycerides are expressed in mmol/L, and GGT, ALT and AST are expressed
in U/L.
The MetS was defined according to the revised National Cholesterol Education Program Adult
Treatment Panel (NCEP-ATP) III criteria [29]. Participants were categorized with MetS when at least
three out of five of the following criteria were present: waist circumference >102 cm for men and
>88 cm for women; plasma triglycerides ≥1.7 mmol/L; HDL cholesterol <1.0 mmol/L for men and
<1.3 mmol/L for women; hypertension (blood pressure ≥130/85 mm Hg or the use of antihypertensive
medication); hyperglycemia (fasting glucose ≥5.6 mmol/L or the use of glucose lowering drugs).
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was calculated by:
Fasting plasma insulin (mU/L) × fasting plasma glucose (mmol/L)/22.5 (3)
2.3. Laboratory Methods
Laboratory methods are reported as described in detail previously [20–24]. Venous blood samples
were drawn after an overnight fast while participants had rested for 15 min. Heparinized plasma and
serum samples were obtained by centrifugation at 1400× g for 15 min at 4 ◦C. Plasma and serum samples
were stored at −80 ◦C until analysis. Glucose was measured directly after blood collection. Plasma
total cholesterol, triglycerides and HDL cholesterol were measured as previously described [20,21,24].
Non-HDL cholesterol was calculated as the difference between total cholesterol and HDL cholesterol.
LDL cholesterol was calculated by the Friedewald formula if triglycerides were <4.5 mmol/L [30].
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Serum ALT and AST were measured using the standardized kinetic method with pyridoxal phosphate
activation (Roche Modular P; Roche Diagnostics, Mannheim, Germany). Serum GGT was assayed
by an enzymatic colorimetric method (Roche Modular P, Roche Diagnostics, Mannheim, Germany).
Standardization of ALT, AST and GGT was performed according to International Federation of
Clinical Chemistry guidelines [31–33]. High sensitivity C-reactive protein (hsCRP) was assayed by
nephelometry. Serum creatinine was measured by an enzymatic method on a Roche Modular P
analyzer (Roche Diagnostics, Mannheim, Germany). Serum cystatin C was measured by Gentian
Cystatin C Immunoassay (Gentian AS, Moss, Norway) on a Modular analyzer (Roche Diagnostics,
Indianapolis, IN, USA).
Urine samples collected at home were stored cold (4 ◦C) for a maximum of 4 days. After
handing in the urine collections, specimens were stored at −20 ◦C. Urinary sodium was measured by
indirect potentiometry with a MEGA clinical chemistry analyzer (Merck & Co., Inc., Kenilworth, NJ,
USA). Urinary albumin excretion (UAE) was measured by nephelometry (Dade Behring Diagnostic,
Marburg, Germany).
2.4. Statistical Analysis
IBM SPSS software (IBM Corp, version 23.0, Armonk, NY, USA) was used for data analysis.
Results are expressed as mean ± standard deviation (SD), median with interquartile range (IQR) or as
numbers (percentages). Normality of distribution was assessed and checked for skewness. HOMA-IR
was loge-transformed for analysis to achieve an approximately normal distribution. Between group
differences in variables were determined by unpaired T-tests or ANOVA (Analysis of Variance) test for
normally distributed variables, Mann–Whitney U or Kruskal–Wallis test for non-normally distributed
variables or by Chi-square tests for categorical variables where appropriate. Multivariable binary
regression analyses were carried out to disclose the independent associations of urinary sodium
excretion with an elevated FLI and HSI when taking account of clinical covariates and laboratory
parameters. In multivariable analyses, urinary sodium excretion was expressed per 1 SD increment.




The study population consisted of 6132 subjects of whom 1936 (31.6%) were categorized with
a FLI ≥60, as proxy of NAFLD. Table 1 shows the clinical characteristics and laboratory data of the
participants according to FLI categorization. Subjects with a FLI ≥60 were older and more likely
to be men (men 66.2% vs. women 33.8%), to be classified with MetS, T2D as well as hypertension
and had a positive cardiovascular history more frequently. Consequently, subjects with FLI ≥60
used antihypertensive medication and glucose and lipid lowering drugs more frequently. BMI, BSA,
waist circumference, waist/hip ratio, glucose, insulin, HOMA-IR, liver function tests, total cholesterol,
non-HDL cholesterol, LDL cholesterol, triglycerides and creatinine were significantly higher in subjects
with FLI ≥60, but eGFR and HDL cholesterol were lower. Sodium intake, determined by averaged 24 h
urine sodium excretion was higher in participants with an FLI ≥60 (Table 1, 163.63 ± 61.81 mmol/24 h
vs. 136.76 ± 50.90 mmol/24 h, p < 0.001).
Baseline characteristics categorized according to quartile categories of sodium intake are shown
in Table 2. Suspected NAFLD, with either an FLI ≥60 or HSI >36 were both significantly higher in each
ascending quartile category of urinary sodium excretion (p < 0.001). As the urinary sodium excretion
increased, participants were more likely to be male, to be classified with MetS, T2D, had a higher
BMI, BSA, waist circumference, waist/hip ratio and higher levels of glucose, insulin and HOMA-IR
(all p < 0.001). Of note, hypertension and history of CVD were not significantly different between
urinary sodium excretion quartiles.
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Table 1. Baseline characteristics including averaged 24 h urinary sodium excretion (two collections) in
4196 subjects with a Fatty Liver Index (FLI) < 60 and 1936 subjects with an FLI ≥ 60.
FLI < 60, n = 4196
(68.4%)
FLI ≥ 60, n = 1936
(31.6%)
p Value
Age (years), mean ± SD 52.2 ± 12.0 57.2 ± 11.4 <0.001
Sex <0.001
Men, n (%) 1750 (41.7) 1282 (66.2)
Women, n (%) 2446 (58.3) 654 (33.8)
MetS, n (%) 372 (8.9) 1193 (61.7) <0.001
Type 2 diabetes mellitus, n (%) 130 (3.1) 256 (13.2) <0.001
History of cardiovascular disease, n (%) 192 (4.6) 194 (10.0) <0.001
Hypertension, n (%) 1014 (24.2) 1050 (54.3) <0.001
Current smokers, n (%) 1184 (28.2) 513 (26.5) 0.162
Alcohol ≥ 10 g/day, n (%) 139 (3.3) 117 (6.1) <0.001
Antihypertensive medication, n (%) 613 (14.6) 703 (36.3) <0.001
Glucose lowering drugs, n (%) 73 (1.7) 152 (7.9) <0.001
Lipid lowering drugs, n (%) 273 (6.5) 307 (15.9) <0.001
Systolic blood pressure (mm Hg), mean ± SD 121 ± 17 135 ± 18 <0.001
Diastolic blood pressure (mm Hg), mean ± SD 71 ± 9 77 ± 9 <0.001
BMI (kg/m2), mean ± SD 24.8 ± 2.9 30.9 ± 4.1 <0.001
BSA (m2), mean ± SD 1.87 ± 0.17 2.12 ± 0.18 <0.001
Waist circumference (cm), mean ± SD 86.0 ± 9.2 105.0 ± 9.2 <0.001
Waist/hip ratio, mean ± SD 0.87 ± 0.07 0.96 ± 0.07 <0.001
Glucose (mmol/L), mean ± SD 4.80 ± 0.86 5.48 ± 1.41 <0.001
Insulin (mU/L), median (IQR) 6.80 (5.1–9.3) 13.00 (9.5–19.0) <0.001
HOMA-IR (mU mmol/L2/22.5), median (IQR) 0.36 (0.04–0.70) 1.10 (0.73–1.53) <0.001
hsCRP (mg/L), median (IQR) 1.02 (0.49–2.32) 2.44 (1.23–4.47) <0.001
ALT (U/L), median (IQR) 15 (12–20) 23 (17–32) <0.001
AST (U/L), median (IQR) 22 (19–25) 25 (21–29) <0.001
ALP (U/L), mean ± SD 65 ± 19 76 ± 23 <0.001
GGT (U/L), median (IQR) 19 (14–27) 40 (28–61) <0.001
Total cholesterol (mmol/L), mean ± SD 5.32 ± 1.01 5.67 ± 1.06 <0.001
Non-HDL cholesterol (mmol/L), mean ± SD 3.98 ± 0.99 4.57 ± 1.02 <0.001
LDL cholesterol (mmol/L), mean ± SD 3.51 ± 0.92 3.74 ± 0.94 <0.001
HDL cholesterol (mmol/L), mean ± SD 1.34 ± 0.31 1.10 ± 0.24 <0.001
Triglycerides (mmol/L), median (IQR) 0.95 (0.72–1.26) 1.67 (1.28–2.20) <0.001
Serum creatinine (umol/L), mean ± SD 82.92 ± 22.42 89.56 ± 19.23 <0.001
eGFR (mL/min/1.73 m2), mean ± SD 93.8 ± 16.4 86.5 ± 17.8 <0.001
Averaged 24 h urine excretion values
Sodium excretion (mmol/24 h), mean ± SD 136.76 ± 50.90 163.63 ± 61.81 <0.001
UAE (mg/24 h), median (IQR) 7.44 (5.65–11.21) 10.04 (6.69–18.81) <0.001
Data are given in number with percentages (%), mean ± standard deviation (SD) for normally distributed data or
median with interquartile ranges (IQR) for non-normally distributed data. HOMA-IR was loge transformed for
analyses. LDL cholesterol was calculated by the Friedewald formula if triglycerides were <4.5 mmol/L in 6028
subjects. Abbreviations: 24 h, twenty-four hours; ALP, alkaline phosphatase; ALT, aminotransferase; AST, aspartate
aminotransferase; BMI, body mass index; BSA, body surface area; FLI, Fatty Liver Index; eGFR, estimated glomerular
filtration rate; GGT, gamma-glutamyltransferase; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance;
HDL, high density lipoproteins; hsCRP, high sensitivity C-reactive protein; LDL, low density lipoproteins; MetS,
metabolic syndrome; T2D, type 2 diabetes mellitus; UAE, urinary albumin excretion.
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Table 2. Baseline characteristics of the study population according to quartile categories of averaged 24
h urinary sodium excretion (two collections) in 6132 subjects.
24 h Urinary Sodium Excretion p Value
Quartile 1 Quartile 2 Quartile 3 Quartile 4
N (%) 1533 (25.0) 1532 (25.0) 1532 (25.0) 1533 (25.0)
24 h Sodium excretion (mmol/day), mean ± SD 82.14 ± 18.02 122.92 ± 9.79 155.83 ± 10.08 220.06 ± 42.67 <0.001
Suspected NAFLD
FLI ≥ 60, n (%) 329 (21.5) 386 (25.2) 505 (33.0) 715 (46.6) <0.001
HSI > 36, n (%) 324 (21.1) 355 (23.2) 445 (29.0) 608 (39.7) <0.001
Age (years), mean ± SD 54.9 ± 12.6 54.1 ± 12.1 53.0 ± 12.0 52.1 ± 11.3 <0.001
Sex <0.001
Men, n (%) 466 (30.4) 632 (41.3) 822 (53.7) 1.112 (72.5)
Women, n (%) 1067 (69.6) 900 (58.7) 710 (46.3) 421 (27.5)
MetS, n (%) 333 (21.7) 344 (22.5) 375 (24.5) 512 (33.4) <0.001
Type 2 diabetes mellitus, n (%) 82 (5.3) 89 (5.8) 98 (6.4) 117 (7.6) 0.007
History of cardiovascular disease, n (%) 96 (6.3) 90 (5.9) 100 (6.5) 100 (6.5) 0.605
Hypertension, n (%) 506 (33.0) 491 (32.1) 517 (33.7) 550 (35.9) 0.057
Current smokers, n (%) 493 (32.2) 427 (27.9) 385 (25.1) 391 (25.5) <0.001
Alcohol ≥ 10 g/day, n (%) 66 (4.3) 65 (4.3) 52 (3.4) 73 (4.8) 0.810
Antihypertensive medication, n (%) 342 (22.3) 317 (20.7) 327 (21.3) 330 (21.5) 0.718
Glucose lowering drugs, n (%) 49 (3.2) 49 (3.2) 56 (3.7) 71 (4.6) 0.027
Lipid lowering drugs, n (%) 152 (9.9) 146 (9.5) 136 (8.9) 146 (9.5) 0.585
Systolic blood pressure (mm Hg), mean ± SD 124 ± 19 125 ± 20 125 ± 18 128 ± 17 <0.001
Diastolic blood pressure (mm Hg), mean ± SD 71 ± 9 73 ± 9 73 ± 9 74 ± 9 <0.001
BMI (kg/m2), mean ± SD 25.7 ± 4.1 26.1 ± 4.0 26.6 ± 4.3 28.1 ± 4.5 <0.001
BSA (m2), mean ± SD 1.86 ± 0.19 1.91 ± 0.19 1.97 ± 0.19 2.07 ± 0.20 <0.001
Waist circumference (cm), mean ± SD 87.9 ± 11.8 89.7 ± 11.9 91.8 ± 12.0 97.3 ± 12.9 <0.001
Waist/hip ratio, mean ± SD 0.87 ± 0.08 0.88 ± 0.08 0.90 ± 0.08 0.93 ± 0.08 <0.001
Glucose (mmol/L), mean ± SD 4.94 ± 1.07 4.96 ± 1.09 4.98 ± 1.11 5.12 ± 1.08 <0.001
Insulin (mU/L), median (IQR) 7.50 (5.3–10.9) 7.60 (5.5–11.0) 8.10 (5.8–11.8) 9.50 (6.6–14.3) <0.001
HOMA-IR (mU mmol/L2/22.5), median (IQR) 0.49 (0.11–0.91) 0.46 (0.12–0.90) 0.53 (0.15–0.97) 0.72 (0.32–1.20) <0.001
hsCRP (mg/L), median (IQR) 1.37 (0.65–3.07) 1.35 (0.58–3.09) 1.33 (0.61–2.87) 1.31 (0.63–3.08) 0.036
ALT (U/L), median (IQR) 15 (12–21) 16 (12–22) 17 (13–25) 20 (14–28) <0.001
AST (U/L), median (IQR) 22 (19–26) 22 (19–26) 23 (20–26) 23 (20–27) <0.001
ALP (U/L), mean ± SD 69 ± 21 69 ± 23 66 ± 18 69 ± 19 0.089
GGT (U/L), median (IQR) 21 (14–34) 21 (14–33) 23 (16–37) 27 (18–43) <0.001
Total cholesterol (mmol/L), mean ± SD 5.45 ± 1.05 5.39 ± 1.03 5.37 ± 1.03 5.46 ± 1.04 0.372
Non-HDL cholesterol (mmol/L), mean ± SD 4.14 ± 1.04 4.11 ± 1.02 4.10 ± 1.04 4.26 ± 1.03 <0.001
LDL cholesterol (mmol/L), mean ± SD 3.59 ± 0.94 3.55 ± 0.92 3.54 ± 0.92 3.63 ± 0.94 0.079
HDL cholesterol (mmol/L), mean ± SD 1.31 ± 0.32 1.29 ± 0.32 1.27 ± 0.31 1.20 ± 0.29 <0.001
Triglycerides (mmol/L), median (IQR) 1.08 (0.79–1.45) 1.06 (0.75–1.55) 1.05 (0.80–1.54) 1.22 (0.86–1.75) <0.001
Serum creatinine (umol/L), mean ± SD 82.77 ± 24.48 83.48 ± 17.41 85.78 ± 26.83 87.67 ± 15.93 <0.001
eGFR (ml/min/1.73 m2), mean ± SD 89.0 ± 17.1 91.0 ± 17.1 92.7 ± 17.3 94.2 ± 16.7 <0.001





p-values represent p for trend. Data are given in number with percentages (%), mean ± standard deviation (SD) for
normally distributed data or median with interquartile ranges (IQR) for non-normally distributed data. HOMA-IR
was loge transformed for analyses. LDL cholesterol was calculated by the Friedewald formula if triglycerides
were <4.5 mmol/L (6028 subjects). Abbreviations: 24 h, twenty-four hours; ALP, alkaline phosphatase; ALT,
aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BSA, body surface area; eGFR, estimated
glomerular filtration rate; FLI, Fatty Liver Index; GGT, gamma-glutamyltransferase; HOMA-IR, Homeostasis Model
Assessment of Insulin Resistance; HDL, high density lipoproteins; hsCRP, high sensitivity C-reactive protein; HSI,
Hepatic Steatosis Index; LDL, low density lipoproteins; MetS, metabolic syndrome; T2D, type 2 diabetes mellitus;
UAE, urinary albumin excretion.
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3.2. Independent Associations of Suspected NAFLD with Sodium Intake
Multivariable binary regression analyses were subsequently performed in order to establish the
independent associations of suspected NAFLD with urinary sodium excretion (Tables 3 and 4). In age-
and sex-adjusted analysis, FLI ≥60 was positively associated with an increased sodium excretion
(expressed per 1 SD increment) (Table 3, Model 1, odds ratio (OR) 1.54, 95% confidence interval (CI)
1.45–1.64, p < 0.001). This positive association was also demonstrated after additional adjustment for
presence of T2D, a positive history of CVD, hypertension, alcohol intake (≥10 and <10 g/day) and
current smoking (Table 3, Model 2, OR 1.51, 95% CI 1.42–1.61, p < 0.001), and for eGFR, UAE, use of
antihypertensive medication and glucose and lipid lowering drugs (Table 3, Model 3, OR 1.54, 95% CI
1.44–1.64, p < 0.001). Finally, after additional adjustment for HOMA-IR the association of FLI ≥ 60 with
urinary sodium excretion was attenuated but remained present (Table 3, Model 4, OR 1.30, 95% CI
1.21–1.41, p < 0.001). In alternative analyses with an HSI >36 instead of FLI ≥60 (Table 4), essentially
similar positive associations of HSI >36 with urinary sodium excretion were found (Table 4, Model
1–4). When the multivariably adjusted models (Tables 3 and 4) were further adjusted for BSA, as a
measure of body size, the positive association of increased sodium excretion remained present both
with respect to an FLI ≥60 (OR 1.13, 95% CI 1.05–1.21, p < 0.001) and to an HSI >36 (OR 1.21, 95% CI
1.13–1.31, p < 0.001). Furthermore, when these models were further adjusted for waist/hip ratio as a
measure of body fat distribution, the positive associations of increased sodium excretion remained
present both with respect to a FLI ≥60 (OR 1.25, 95% CI 1.15–1.36, p < 0.001) and to an HSI > 36 (OR
1.37, 95% CI 1.27–1.48, p < 0.001).
The positive association of FLI ≥60 with urinary sodium excretion was present in women and
men separately (Table S1). Likewise, the association of HSI >36 with urinary sodium excretion was
present in both women and men (Table S2). However, neither the association of FLI ≥60 nor of HSI >36
was different between sexes (fully adjusted model including age; p interaction = 0.396 for FLI ≥ 60 and
p interaction = 0.298 for HSI >36, respectively).
Sensitivity analyses in 3221 participants (Tables S3 and S4), after exclusion of subjects with
alcohol intake ≥10 g/day, a positive history of CVD, presence of hypertension, impaired eGFR
(<60 mL/min/1.73 m2), elevated UAE (>30 mg/24 h), use of antihypertensive medication, glucose
lowering drugs and lipid lowering drugs, also showed positive associations of FLI ≥ 60 with urinary
sodium excretion after adjustment for age, sex, T2D and current smoking (Table S3, Models 1 and 2).
After additional adjustment for HOMA-IR, the association of FLI ≥ 60 with urinary sodium excretion
was again attenuated but remained significant (Table S3, Model 3). Similar sensitivity analyses with
HSI > 36 iterated these findings (Table S4).
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4. Discussion
In this large-scale, cross-sectional study in a predominantly Caucasian population we have
demonstrated, to the best of our knowledge, for the first time a positive association of higher sodium
intake, determined by two consecutive 24 h urinary sodium excretions, with suspected NAFLD. In our
study we used an elevated FLI [26], and in alternative analyses an elevated HSI [28] as proxies of
NAFLD, in keeping with international recommendations to use biomarkers to categorize subjects with
suspected NAFLD in large-scale studies [27]. In multivariable regression analyses, accounting for
various clinical variables, including BSA, as a measure of body size, eGFR and UAE, suspected NAFLD
remained independently associated with a higher sodium intake. Interestingly, both for FLI and HSI,
this association was attenuated after further adjustment for HOMA-IR. Taken together, the present
study demonstrates that suspected NAFLD is positively associated with sodium intake. Furthermore,
our current findings conceivably suggest that insulin resistance may represent a metabolic intermediate
in explaining the relationship of higher sodium intake with NAFLD.
Two earlier cross-sectional studies have investigated the association of sodium intake with
NAFLD [14,18]. Huh et al. described that Korean subjects recruited from the general population
(Korea National Health and Nutrition Examination Surveys study) with suspected NAFLD had higher
urinary sodium spot concentration values [14]. Choi et al. observed that higher sodium intake
was associated with a greater prevalence of NAFLD among young and middle-aged asymptomatic
Korean adults participating in a hospital-based cohort study. In this report, sodium intake was
estimated by dietary recall questionnaires [18]. Very recently, perceived sodium intake determined
by questionnaire was found to predict NAFLD development among Chinese people [34]. Our
present results corroborate these previous studies. However, these surveys were performed in Asian
populations with different dietary habits and sodium intake compared to Europeans [14,18], and used
less reliable methods to estimate sodium intake compared to multiple 24 h urinary sodium excretion
measurements [19]. The International Consortium for Quality Research on Dietary Sodium/Salt (TRUE)
(with representative experts in hypertension, nutrition, statistics and dietary sodium) recommends that
for a correct estimation of 24 h dietary sodium consumption, multiple complete 24 h urine samples are
preferred to take account of short-term variations in dietary intake [19]. The hospital-based cohort could
introduce another potential draw-back of the findings by Choi et al., which may limit extrapolation of
their findings to the general population [18]. Hence, to date our study is the first study assessing the
association of suspected NAFLD with high sodium intake, as determined by multiple 24 h urinary
sodium excretion levels. Second, the current repost is the first to describe the positive association of
high sodium intake in NAFLD in a predominantly Caucasian population.
The presently documented sodium intake amounted to 164 mmol/24 h and 137 mmol/24 h in
subjects with and without an elevated FLI, respectively. In comparison, the World Health Organization
currently recommends a salt intake of 5 grams per day, corresponding to 86 mmol of sodium per day [35],
which is evidently lower than that documented in the present report. However, this recommendation
was published later than the documentation of urinary sodium excretion used for the present report.
In view of higher sodium intake in obese individuals [13,16,17], and the impact of obesity on NAFLD
development [1], the here reported association of NAFLD with urinary sodium excretion is not
unexpected. Furthermore, it has been suggested that the relationship of sodium intake with obesity is
more pronounced in women [36], as presently documented for suspected NAFLD. While excessive
sodium intake and its relation with obesity is to an important extent due to consumption of highly
processed foods and increased total calorie intake [11,13,15], it should be noted that high sodium intake
could directly impact on obesity development even independent from energy intake [37,38]. Chronic salt
overload promotes adipocyte hypertrophy in rats [39,40]. Furthermore, increased leptin concentrations
have been described in animal studies in response to high sodium intake [39]. Indeed, high sodium
induces lipogenesis and inflammatory adipocytokine secretion in adipocytes, which may provide a
possible mechanism for inflammatory adipogenesis in sodium-linked obesity [41], and in turn may also
play a role in accelerated NAFLD development [42]. On the other hand, in experimental animal models,
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the inhibition of the renin-angiotensin-aldosterone system reduces the activation of stellate and Kupffer
cells and reduces oxidative stress possibly leading to the improvement of NAFLD [43]. Furthermore,
higher sodium intake is likely to downregulate the renin-angiotensin-aldosterone system [44], whereas
low dietary sodium as well as exogenous angiotensin II suppress plasma adiponectin [45], an adipokine
which has been proposed to protect against NAFLD development [46]. Thus, it seems unlikely that
renin-angiotensin-aldosterone system-mediated effects are directly involved in the association of
NAFLD with higher sodium intake.
Remarkably in our study, the association of a higher sodium intake and NAFLD was attenuated
after adjusting for HOMA-IR, raising the possibility that insulin resistance may play a role in explaining
the association of NAFLD with higher sodium intake. In rats, a high-salt diet may promote insulin
resistance [47]. In humans, insulin resistance was independently and positively associated with a
higher sodium intake [48,49]. The results of our cross-sectional study are in agreement with the
hypothesis that a higher sodium intake, possibly via an effect on insulin resistance, promotes the
development of NAFLD. Of further note, the association of an elevated FLI and HSI with a higher
sodium intake remained present after adjustment for the BSA, and alternatively the waist/hip ratio.
This would suggest that this association is at least in part independent of body size and body fat
distribution, a potentially relevant finding in view of the reported relation of sodium consumption
with adiposity [13,16,17]. Obviously, further research is needed to delineate the responsible pathogenic
mechanisms more precisely.
The relationship of high sodium intake with cardiometabolic diseases is well established [11,36,50].
It is also evident that a higher sodium intake increases systemic blood pressure [44]. Interestingly,
high blood pressure may also independently contribute to the development of NAFLD, even in the
absence of obesity and MetS [51]. In turn, a bi-directional effect has been proposed where NAFLD
represents an important risk factor for the development of hypertension, possibly involving insulin
resistance [51]. From a clinical perspective our study supports the contention that it is important to
take sodium intake into account when evaluating the adverse impact of NAFLD on the incidence of
cardiovascular disease, hypertension and diabetes [6,9,52].
Our study has several strengths. Our sample size of over 6000 individuals enabled robust
calculations on effect sizes and sufficiently powered subgroup and multivariable adjusted analyses.
Additionally, the PREVEND population is well characterized, with extensive and standardized
measurements [20,21]. On the other hand, a number of limitations and methodological aspects also
need to be discerned. First, its cross-sectional design does not allow cause-effect relationships to be
established with certainty, nor can we exclude the possibility of reversed causation. Second, an elevated
FLI was chosen as a proxy of suspected NAFLD. Notably, the FLI and HSI do not translate in an absolute
measure of hepatic fat accumulation. Thus over- and underestimation of suspected NAFLD could have
occurred. Nonetheless, the FLI is considered to have sufficient accuracy for NAFLD assessment, and
its current use is in line with international guidelines to apply biomarker scores in order to characterize
NAFLD in larger-sized cohorts [26,27]. Moreover, the positive association of suspected NAFLD with
sodium intake was confirmed using the HSI as an alternative algorithm for NAFLD categorization [28].
Performing liver ultrasound or liver biopsy for the diagnosis of NAFLD, was not feasible in the
PREVEND cohort study. Third, we could not differentiate between simple hepatic steatosis and hepatic
fibrosis; therefore, no relationship of hepatic fibrosis with sodium intake could be established. Fourth,
to preclude collinearity with the FLI and/or HSI in the statistical analyses, variables making part of the
equations (i.e., BMI and waist circumference) were not included in multivariable analyses. Instead
we used BSA and waist/hip ratio in subsidiary analyses. Fifth, since alcohol intake and medical
history were based on self-administered questionnaires, some misreporting by individuals cannot be
excluded. However, considering the large number of subjects, this limitation is unlikely to have major
effects on the interpretation of our results. Furthermore, the proportion of subjects using alcohol in
excess of 30 gram per day in the PREVEND cohort is rather low, i.e., about 5.2% [53]. We adjusted
for alcohol consumption and the association of an elevated FLI with sodium intake remained present
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in sensitivity analyses in which we excluded subjects with alcoholic intake ≥10 g/day. Furthermore,
the PREVEND cohort is possibly enriched with people with micro-albuminuria. For this reason, we
adjusted for eGFR and UAE in multivariable regression analysis and carried out a sensitivity analysis
excluding subjects with impaired eGFR and elevated UAE. Reassuringly these analyses yielded similar
positive and independent associations of suspected NAFLD with high sodium intake. Finally, no
detailed information of diet composition is available in the PREVEND study. For this reason, we
cannot exclude a contribution of unmeasured changes in diet components that are associated with a
higher sodium intake in prevalent NAFLD, and the relationship of higher urinary sodium excretion
and suspected NAFLD.
In conclusion, this study shows that suspected NAFLD is featured by a higher sodium intake.
It seems conceivably that insulin resistance-related processes may explain in part the association of
NAFLD with sodium intake.
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Abstract: Both environmental and genetic factors contribute to relative species abundance and
metabolic characteristics of the intestinal microbiota. The intestinal microbiota and accompanying
microbial metabolites differ substantially in those who are obese or have other metabolic disorders.
Accumulating evidence from germ-free mice and antibiotic-treated animal models suggests that
altered intestinal gut microbiota contributes significantly to metabolic disorders involving impaired
glucose and lipid metabolism. This review will summarize recent findings on potential mechanisms
by which the microbiota affects intestinal lipid and lipoprotein metabolism including microbiota
dependent changes in bile acid metabolism which affects bile acid signaling by bile acid receptors
FXR and TGR5. Microbiota changes also involve altered short chain fatty acid signaling and influence
enteroendocrine cell function including GLP-1/GLP-2-producing L-cells which regulate postprandial
lipid metabolism.
Keywords: gut microbiota; lipoprotein metabolism; metabolic disorder
1. Introduction
The gastrointestinal microbiota represents the largest population of microbial community in the
human body. This community contains more than 100 trillion microbial cells inhabiting in the small
and large intestine which is estimated to be comparable to the total number of cells in the human
body [1]. Additionally, approximately 3.3 million gut microbial genes are detected, which is 150-fold
more genes than found in the human genome [2]. Earlier studies have suggested that gut microbiota
are involved in several (patho-)physiological processes, including the metabolism of certain nutritional
and drug compounds, the development of host immunity, intestinal inflammatory states, and colon
cancer development [3–5]. Due to the advance of genomic techniques, gut microbiota studies and
findings have dramatically expanded in the past decade [6,7]. The two commonly used approaches,
16S or 18S ribosomal RNA (rRNA) sequencing and metagenomic sequencing, have been frequently
employed in the microbiota characterization studies. The former approach can detect phylogenetic
profiling of microbiota, while the later analyzes all the community DNA within the samples. Moreover,
metatranscriptomics or metaproteomics provide transcriptional or protein information for functional
studies [8,9]. Although the gut microbiota is composed of more than 1000 species of bacteria, a set of
core microbiota harbor in healthy human individuals [8]. Most of the core bacteria belong to five phyla
(Firmicutes, Proteobacteria, Bacteriodetes, Actinobacteria, and Veerrucomicrobia) in humans [10].
The composition and stability of human microbiota exhibit various changes at different stages
of life. The first intestinal bacterial colonization occurs during birth, and the infant gut microbiota
could be affected by the mode of newborn delivery, the type of feeding, and other factors (e.g., host
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genetics, antibiotics, prescribed drugs, probiotic and prebiotics supplementation) [11,12]. At three to
five years of age, children start to harbor microbiota that are comparable to the ones in adults. After
childhood, the gut microbiota become quite stable, although long-term changes can occur in response
to the changes in diet and lifestyle, the usage of antibiotics and probiotics, infection, and surgery [13].
The dysbiosis of microbiota has been linked with several human metabolic diseases, such as obesity,
diabetes, and nonalcoholic fatty liver disease (NAFLD) [14–18]. In this review, we will present the
available evidence implicating gut microbiota in the regulation of lipid and lipoprotein metabolism
and potential mechanisms underlying this regulation (Figure 1).
Figure 1. Mechanisms of the role of microbiota in host lipoprotein metabolism. The intestine and liver
are two major organs involved in lipid and lipoprotein metabolism. In the intestine, BA emulsify fat into
smaller fat particles which allows lipases to breakdown triglycerides into fatty acids. Fatty acids can
then be absorbed and be used as substrates for CM assembly. CM production contributes to postprandial
TG levels. Microbiota within intestine generates SCFA, secondary BA and LPS. SCFA and FA can
activate receptors on enteroendocrine L-cells to release GLP-1/GLP-2 which regulate postprandial CM
production. SCFA and BA are absorbed and enter the portal circulation. In the liver, SCFA can act as
substrates for de novo lipogenesis and contribute to VLDL production. BA can activate FXR and TGR5
signaling pathways to regulate VLDL assembly. VLDL and its products IDL and LDL contribute to
fasting TG levels. BA, bile acids; CM, chylomicron; FXR, farnesoid X receptor; FA, fatty acids; GLP-1/2,
Glucagon-like peptide 1/2; IDL, intermediate density lipoprotein; LPS, lipopolysaccharide; LDL, low
density lipoprotein; SCFA, short-chain fatty acid; TGR5, G-protein-coupled bile acid receptor; TG,
triglyceride; VLDL, very low density lipoproteins.
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Role of Microbiota in Metabolic Disorders
Metabolic syndrome is a group of interlinked disorders that includes hypertension, insulin
resistance, visceral obesity, low high-density lipoprotein (HDL) cholesterol, and elevated
triglycerides [19]. Numerous clinical studies have shown that metabolic syndrome is associated
with increased risk of cardiovascular disease and type 2 diabetes [20]. Emerging studies from the
last 15 years have implicated gut microbiota as a pathogenic factor affecting many components of the
metabolic syndrome. Backhed and colleagues were the first to report a striking difference in body fat
content observed between germ-free (GF) mice and conventionally raised mice with the latter having
40% higher body fat content [21]. These observations promoted many future studies exploring the
role of gut microbiota in metabolic health. In exploration of the relative abundance of microbial taxa,
the gut of obese mice was found to have a 50% reduction in the abundance of Bacteroidetes along
with a proportional increase in Firmicutes [22]. Interestingly, patients with obesity also have a similar
alteration in the relative proportion of Bacteroidetes and Firmucutes and this was shown to improve
with a low-calorie diet [23].
Alterations in the gut microbiome from high-fat diet (HFD) feeding result in an increased
proportion of lipopolysaccharide (LPS)-containing microbiota in the gut which has been linked to
increased glycemia and insulinemia [24]. While earlier studies have determined differences in relative
abundance of microbial taxa present in the gut of obese mice versus lean mice, recent studies have
focused on particular microbial species and their metabolites that mediate the observed effects. For
example, imidazole propionate is identified as a microbially produced histidine-derived metabolite
that is higher in subjects with type 2 diabetes and was associated with impaired glucose tolerance and
insulin signaling when administered to mice [25]. More recently, the tryptophan-derived microbial
metabolite indole was found to upregulate the expression of miR-181 in white adipocytes leading to
improvements in body weight gain, glucose tolerance, and insulin sensitivity [26]. While changes in gut
microbiota occur due to HFD feeding, it is also important to consider that diets high in fat are typically
lower in fiber compared to chow controls, which could also contribute to these phenotypes [27].
There is also evidence of microbiota dependent protection from metabolic disorders. A study
reported that transfer of feces from healthy individuals to individuals with metabolic syndrome via a
duodenal catheter alters the fecal microbiota of recipients and is associated with improvements in insulin
sensitivity [28]. Studies in mice have revealed specific species to be beneficial for improving metabolic
disorders: for example, Akkermansia muciniphila treatment has the ability to improve diet-induced
obesity, fasting glycemia, and adipose tissue metabolism [29]. While these studies provide insight
for the development of therapies that target human gut microbiota for treatment of obesity and its
associated metabolic disorders, the intricate process of how specific specifies of bacteria and their
metabolites regulate energy metabolism remain unclear.
2. Regulation of Lipoprotein Metabolism by the Gut Microbiome
2.1. Introduction of Lipoprotein
Dietary lipid contributes to around 35% of daily energy resource in humans [30,31]. As lipids
are insoluble in water, the human digestive organs have developed a complex system of digestive
and absorptive processes by transporting lipids in the form of lipoproteins. Lipoprotein particles are
synthesized in the liver and intestine and are composed of lipids (such as phospholipids, cholesterol
and triglycerides) and apolipoproteins [31]. Based on size and density, lipoproteins are classified into 5
classes: chylomicron (CM), very low density lipoproteins (VLDL), intermediate density lipoprotein
(IDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) particles [32]. Each class
of lipoprotein has a specific function in lipid metabolism. CM, as the largest lipoprotein particle,
transports dietary triglycerides and cholesterol from the intestine to peripheral tissues, while VLDL are
synthetized in the liver to export triglycerides. VLDL particles contain apolipoprotein B 100 (ApoB100)
as the main structural apolipoprotein and CM contain ApoB48, a truncated form of ApoB100. Both
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VLDL and CM are assembled by the microsomal triglyceride transfer protein (MTP) which incorporates
lipids into ApoB. LDL particles are the catabolic products of VLDL, while HDL is involved in reverse
transport of cholesterol back to the liver [32]. Any deficiency during the lipid digestion process and
lipoprotein synthesis cycle could result in dyslipidemia, a key factor in the pathogenesis of metabolic
disorders (such as obesity, diabetes, and NAFLD) [33–36].
The intestine is not only the site for lipid digestion and absorption, but also serves as the major
home for microbiota. Gut microbiota has the ability to modulate dietary lipid composition, digestion,
and absorption, potentially altering intestinal lipoprotein formation. Abnormal levels of lipoproteins
have been observed in GF mice and antibiotic-treated mice. GF mice are found to be resistant to
develop an obesity phenotype under HFD feeding [37], partly due to the deficiencies in lipid digestion,
absorption, and transport [38]. Recent studies have demonstrated that GF mice exhibit decreased
plasma triglyceride and LDL compared to control mice, and this alteration was associated with
decreased intestinal absorption and hormone peptide secretion [38]. Furthermore, supplementation
of specific strain bacteria (e.g., Lactobacillus rhamnosus gg) to conventionally reared mice resulted in
body weight gain, increased levels of LDL and cholesterol, and the altered expression of several genes
involved in lipid transport [38]. Another study has shown that GF mice have significantly lower levels
of fasting triglycerides and VLDL production when compared to conventionally reared mice [37]. To
date, there are few systematic analyses of the association between the microbiome composition and
lipid profiles in human and animal studies, which will be discussed as follows.
2.2. The Association between the Gut Microbiome and Lipid Profile
An early study by Carr et al. showed that supplementation of grain sorghum lipid extract (GSL)
significantly improved the HDL/non-HDL cholesterol equilibrium in the Syrian hamster model [39]. A
follow-up study by Martinez et al. characterized the interplay among diet, gut microbial ecology, and
host metabolism [40]. Using 16S rRNA sequencing, Martinez et al. demonstrated that the abundance of
Bifidobacteria, which was significantly increased under GSL-supplemented diet feeding, was positively
associated with plasma HDL cholesterol levels, while the abundance of Coriobacteriaceae, decreased
under GSL diet feeding, was positively associated with non-HDL plasma cholesterol levels [40].
In humans, Cotillard et al. analyzed the intestinal bacterial genes in 49 obese or overweight
individuals by high-throughput sequencing technology [41]. Two groups of humans with high
bacterial gene count (HGC) and low bacterial gene count (LGC) were defined in this study. The LGC
group exhibited significantly higher frequency of insulin resistance and higher levels of fasting serum
triglycerides, as well as higher LDL cholesterol, when compared to the HGC group [41]. Another
human study reported by Le Chatelier et al. performed quantitative metagenomics with fecal DNA
extracted from 169 obese individuals and 123 nonobese control individuals. They found that the LGC
group was associated with elevated serum leptin, triglycerides and free fatty acids (FFA), decreased
serum adiponectin, and decreased levels of HDL-cholesterol [42].
Fu et al. studied the largest correlation cohort to date, for which fecal samples were collected
and the lipid profile determined in 893 participants [43]. Based on α diversity analysis, microbiota
operational taxonomic unit (OTU) richness was negatively correlated with body mass index (BMI) and
triglycerides, but positively correlated with HDL, while there was no significant correlation between
microbial richness and LDL or total cholesterol levels. Furthermore, several microbes were correlated
with lipid levels or BMI. For instance, the family of Clostridiaceae/Lachnospiracease was specifically
associated with LDL but not with BMI and other lipoproteins; the genus of Eggerthella was associated
with increased triglyceride and decreased HDL levels, while the Butyricimonas was strongly associated
with decreased triglyceride levels [43].
In addition, a study of 30 hypercholesterolemia individuals and 27 healthy controls reported
differences in commensal bacterial profiles between hypercholesterolemic subjects and controls [44]. In
this study, Rebolledo et al. analyzed the fasting whole blood lipid profile and bacterial community
profiles by denaturing gradient gel electrophoresis. As expected, hypercholesterolemia subjects
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had higher levels of serum total cholesterol, triglycerides, and LDL-cholesterol than controls, while
they harbored a lower richness and diversity of gut microbiota, thus proposing a potential role of
the gut microbiota in the development of hypercholesterolemia [44]. Karlsson et al. performed
the metagenomic sequencing with fecal samples collected from 145 European women with normal,
impaired, or diabetic glucose control, and reported a negative correlation between serum triglycerides
and Clostridum, and a positive correlation between HDL and Clostridium [45].
Recently, a lifestyle intervention study was performed with a low-saturated-fat and reduced-energy
intake diet in 1065 metabolic syndrome patients and healthy subjects [46]. The metabolic syndrome
patients had at least three of the following factors: central obesity (waist circumference ≥80 cm
in women and ≥90 cm in men), fasting blood glucose ≥ 5.50 mmol/L, triglyceride concentration ≥
1.65 mmol/L, low levels of HDL cholesterol (<1.00 mmol/L in men and <1.25 mmol/L in women),
and systolic and/or diastolic blood pressure ≥ 130/85 mm Hg. Positive association between the body
mass index and the gut microbiota dysbiosis, and negative association between insulin resistance and
HDL-C concentration were found in metabolic syndrome patients. A short period (15 days) of diet
intervention decreased the level of serum triglycerides, while the longer-term (75 days) intervention led
to a significant reduction in VLDL, CM, LDL, small HDL particle, and improved glucose tolerance in
44.8% of metabolic syndrome patients. Moreover, the lifestyle intervention ameliorated gut dysbiosis,
resulting in a reduction in the P/ B ratio and an increase in the abundance of Akkermansia muciniphila
and Faecalibacterium prausnitzii [46].
2.3. Evidence from Other Studies
Atherosclerosis-prone apolipoprotein E-deficient (ApoE-/-) mice exhibit delayed lipoprotein
clearance and consequently develop dyslipoproteinemia [47]. Antibiotic (i.e., ampicillin) treatment was
found to transiently improve glucose tolerance, lower plasma LDL and VLDL cholesterol levels, and
reduce aortic atherosclerotic lesion area in Apo E-/- mice, suggesting that alteration of gut microbiota
can attenuate dyslipoprotienemia in this model [48]. Additionally, a few studies have reported that gut
microbiota could regulate the production of apolipoproteins and MTP [49,50]. Sato et al. found that
rats receiving four days of antibiotics (streptomycin and penicillin) had reduced lymphatic transport
of triglycerides and phospholipids, and decreased levels of mucosal apolipoproteins B, A-I, and
A-IV, suggesting that gut microbiome promotes lipid absorption, probably by regulating intestinal
production of apolipoproteins and secretion of CM [51]. Jin et al. also reported that six weeks of
antibiotic (penicillin G (Pen G) and erythromycin (Ery)) treatment in mice resulted in increased hepatic
lipid accumulation and higher circulating triglyceride levels and expression of key genes involved in
FFA synthesis, triglyceride synthesis, and transport including MTP. [49].
A recent study in hamsters suggested that soybean sterols could alleviate HFD-diet-associated
liver pathology and abnormal cholesterol metabolism by altering both host gene expression
and gut microbiota composition [52]. Specifically, compared to the HFD vehicle group, the
supplementation of soybean sterols significantly reduced the levels of triglycerides, total cholesterol, and
non-HDL-cholesterol, increased the expression of cholesterol absorption/sterol excretion-related genes
(e.g., NPC1L1, ABCG5, and ABCG8), and decreased the expression of cholesterol biosynthesis-related
genes (e.g., SREBP2 and LDL-R). The addition of soybean sterols significantly increased the abundance
of Lactobacillus, Oscillospira, and Akkermansia, and also the levels of all six short-chain fatty acids in
the fecal content. In addition, a few studies have shown plant sterol esters could decrease plasma
LDL cholesterol levels in humans [53–55]. A follow-up study revealed the link between gut bacteria
and the cholesterol-lowering ability of plant sterol esters [56]. In this study, 13 healthy people with
elevated plasma LDL cholesterol were administered with Stearate-enriched plant sterol esters for
four weeks. This supplementation resulted in microbiota population change according to 16s rRNA
pyrosequencing, and also correlated significantly to changes in serum cholesterol concentrations [56].
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3. Mechanisms of the Role of Microbiota in Host Lipid Metabolism
3.1. Bile Acids
Bile acids are the major functional component of bile, which are synthesized in the liver and
stored in the gall bladder, and further released in the intestine. One of the major functional roles of bile
acids is to emulsify dietary fat [57]. However, bile acids are also known to act as important signaling
molecules involved in metabolic pathways (i.e., glucose and lipid metabolism) [58] via interacting
with various host bile acid receptors, such as nuclear receptors farnesoid-X-receptor (FXR) and cell
membrane receptor Takeda G protein-coupled receptor 5 (TGR5) [58].
Based on recent studies of microbiota depletion or GF animal models, gut microbiota was found
to be a key player in the regulation of lipid metabolism via bile acid receptor signaling. Many studies
have shown that the remarkable change in gut microbiota induced by antibiotics treatment correlates
with decreased intestinal FXR signaling as well as modified bile acid composition [59–62]. When
comparing GF and conventionally raised mice, dramatically different composition of the bile acid
pool and expression profile of genes involved in bile acid synthesis, conjugation, and reabsorption
were observed [62]. Kuno et al. found a five-day antibiotics (vancomycin and polymyxin B) treatment
decreased amounts of secondary bile acid-producing bacteria in feces and reduced the levels of
secondary bile acid [lithocholic acid (LCA) and deoxycholic acid (DCA)] [63]. Another hamster study
reported that four weeks of an antibiotics cocktail alleviated HFD-induced hepatic steatosis and glucose
intolerance, which correlated with the modulation of gut microbiota, bile acids, and FXR signaling [64].
However, Reijnders et al. reported that a seven-day antibiotic (amoxicillin or vancomycin) treatment
did not have any clinical impact on host metabolism in obese humans, although changes in microbiota,
short-chain fatty acids levels, and bile acid levels were observed [65].
Bile acids are originally produced from cholesterol in hepatocytes as conjugated and primary
bile acid (cholic acid (CA) and chenodeoxycholic acid (CDCA)). Specific enzymes (i.e., bile salt
hydrolase (BSH), bile acid-inducible (BAI) enzymes) deconjugate and dehydroxylate these primary
bile acids to generate unconjugated and secondary bile acids (lithocholic acid (LCA), deoxycholic acid
(DCA)) [57]. Recent studies have shown that gut microbiota control the homeostasis of bile acids, thus
impacting various host pathophysiological processes [58,66]. BSH, which was discovered in 1995, is
one of the well-known bacterial bile acid deconjugating enzymes [67,68]. BSH has been detected in
various commensal gut microbial species belonging to both gram-positive and gram-negative bacteria,
including Lactobacillus, Bifidobacterium, Enterococcus, Clostridium spp, and Bacteroides spp. A functional
metagenomics study revealed that functional BSH is abundantly present in the gut and enriched in the
human gut microbiome [69].
In addition, it has been proposed that there is bidirectional interaction between gut microbiota
and host bile acid profiles. Changes of the gut microbiota could alter the expression level of BSH and
subsequently result in changes of bile acid pool, as evidenced by antibiotics treatment or GF animal
studies [62,70]. In addition, bile acids are known to be toxic to bacteria and affect the growth rate of
certain bacteria. In vivo studies suggest that bile acids alter microbiota composition and are associated
with host metabolic changes. Islam et al. found that supplementation of primary bile acid (i.e., cholic
acid) in the diet could alter plylum-level composition of gut microbiota, and similar changes were found
in HFD studies [71]. In another study, GF and conventional mice were fed with different diets (control
diet, control diet plus primary bile acid CA, and CDCA and HFD) for eight weeks [72]. Enhanced fat
mass accumulation and metabolic changes were observed in conventional mice, but not in GF mice.
Besides the impaired glucose metabolism, elevated amounts of hepatic triglycerides, cholesteryl esters,
and monounsaturated fatty acids were shown in the bile acids treatment group [72]. Additionally, a
shift of gut microbiota communities were found in bile acids-fed mice, including increased abundance
of Desulfovibrionaceae, Clostridium lactatifermentans, and Flintibacter butyricus, and decreased abundance
of Lachnospiraceae [72]. Moreover, according to metatranscriptomic analysis, changes of genes involved
in lipid and amino acid metabolism were observed in this study [72]. In addition, the bile acid profiles
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and microbiota were found to be altered in certain disease conditions, such as obesity and type 2
diabetes (T2D), which also indicates a link between bile acid and gut microbiota [66].
Role of Bile Acid Signaling through FXR and TGR5
Recent studies have revealed that alteration of gut microbiota could not only affect the bile acid
pool, but also influence the bile acid receptor signaling (i.e., FXR and TGR5). FXR is a nuclear receptor
which is expressed in the liver, stomach, duodenum, jejunum, ileum, colon, white adipose tissues,
kidney, gall bladder, heart, kidney, and adrenal cortex adrenal gland [73]. Bile acids act as ligands to
bind and activate FXR, with CDCA and its conjugated forms being the most potent natural agonists
(CDCA >LCA >DCA >CA) [74]. FXR has been reported to be involved in glucose homeostasis,
energy expenditure, and lipid metabolism. Watanabe et al. has shown that CA could prevent hepatic
triglyceride accumulation, decrease VLDL secretion, and lower serum triglyceride in a type 2 diabetes
mouse model of hypertriglyceridemia [75]. Furthermore, the protective effects were due to an increase
in short heterodimer partner (SHP) following FXR activation, resulting in a subsequent reduction
of hepatic sterol regulatory element binding protein-1c (SREBP-1c) expression and other lipogenic
genes [75]. An earlier study has shown that CDCA could activate FXR signaling and lead to decreased
expression of MTP and apoB, thereby lowering lipoprotein production in HepG2 cell culture [76].
Using Syrian golden hamsters, Bilz et al. have also shown that activation of FXR by CDCA in a
high-fructose diet could reduce VLDL triglycerides, VLDL, and IDL/LDL cholesterol levels, mainly
by decreasing de novo lipogenesis and hepatic secretion of triglyceride-rich lipoproteins [77]. FXR
stimulatory bacteria strains that were selected based on a luciferase assay with the FXR reporter were
able to improve HFD-induced obesity phenotype in mice [78]. Controversial results were, however,
reported from the study on human non-alcoholic fatty liver disease, showing that decreased activation
of liver FXR was found in these patients and associated with increased expression of liver X receptor,
SREBP-1c, and hepatic steatosis [79]. However, another study showed FXR signaling was activated
in obese human intestines, and intestine-selective FXR inhibitor improved obesity and metabolic
syndrome in HFD-induced obese mice [80].
TGR5 is a transmembrane G-protein-coupled receptor and widely expressed among various
tissues, including gallbladder, small intestine, colon, liver, brain, skeletal muscle, heart, and the enteric
nervous system. Bile acids can bind to TGR5 and act as potent agonists (with rank of LCA> DCA
>CDCA> CA) [81]. Similar to FXR, TGR5 activity can regulate glucose and lipid homeostasis. Several
in vivo studies in mice have suggested that TGR5 activation by synthetic agonists could improve
insulin and glucose tolerance as well as liver and pancreatic function [82], decrease plasma triglycerides
and LDL-cholesterol [83], and ameliorate hepatic steatosis [84]. However, controversial results have
been reported with a TGR5 KO mice model, as TGR5 KO female mice gained much more body weight
and accumulated more fat mass under HFD feeding, while TGR5 knockout male mice did not show
significant difference in body weight gain or fat mass accumulation when compared to the wild-type
control [85]. Another study reported that TGR5 KO mice have decreased fasting-induced hepatic
lipid accumulation, an increased hepatic fatty acid oxidation rate, and decreased hepatic fatty acid
uptake [86].
Additionally, activation of FXR and/or TGR5 was reported to increase glucagon-like peptide-1
(GLP-1) secretion, a hormone peptide which contributes to maintaining the metabolic homeostasis.
Pathak et al. has shown that both FXR and TGR5 agonists could increase glucose-induced GLP-1
secretion [87]. In addition, activation of TGR5 increased intracellular cAMP, which further enhanced
GLP-1 secretion [82]. Additionally, a TGR5 agonist was able to induce GLP-1 secretion in human
studies [88], while glucose-induced GLP-1 secretion was reduced in FXR or TGR5 KO mice compared
to control mice [89]. The role of GLP-1 in lipid and lipoprotein metabolism will be discussed below.
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3.2. Short Chain Fatty Acids (SCFAs)
SCFAs are the fermentation products of non-digestible carbohydrates by gut microbiota. Gut
microbiota have enzymes that the host lacks to break down these carbohydrates. The undigested
dietary fibers as well as proteins that “escape” digestion and absorption are sequentially fermented in
the small and large intestines by gut bacteria [90]. SCFAs can be divided into five groups: formic acid
(C1), acetic acid (C2), propionic acid (C3), butyric acid (C4), and valeric acid (C5). The majority of gut
SCFAs are acetate, propionate, and butyrate, which constitute more than 95% of the SCFA content [91].
After production, SCFA can be absorbed in the cecum, colon, and rectum, and then enter the mesenteric
vein, drain into the portal vein, and finally into circulation [92]. After entering the circulation, SCFA
can affect the metabolism of several peripheral tissues, including liver, adipose tissue, and skeletal
muscle [93]. The advent of advanced genomic sequencing approaches has yielded great progress
in identifying the bacteria responsible for SCFA production. Among the three major gut SCFAs,
propionate and butyrate production are detected within a few conserved and substrate specific bacteria,
while acetate production are widely distributed among bacterial groups. For butyrate production, a
small number of gut bacteria, including Faecalibacterium prausnitzii, Eubacterium rectale, Eubacterium
hallii, and Ruminococcus bromii are the major responsible strains [94]. Additionally, a few studies
studying specific dietary ingredients have associated SCFA production with certain bacterial species.
For instance, resistant starch greatly contributed to butyrate production in the colon predominantly
by Ruminococcus bromii [95], while mucin was fermented into propionate mainly by Akkermansia
municiphilla [96].
SCFAs play key roles in various physiological processes, such as regulation of energy intake,
energy harvesting, glucose metabolism, lipid metabolism, adipogenesis, and immune responses,
as well as pathophysiology of obesity and related metabolic disorders. Both animal and human
studies support the relationship between the gut microbiota, SCFA, and metabolic disorders (i.e.,
obesity, T2D, NAFLD). Obese mice and humans show a changed ratio of Firmicutes to Bacteroidetes
and increased fecal concentration of SCFA [97–100]. The obese phenotype of Toll like receptor 5 KO
mice were also associated with gut dysbiosis and enhanced cecal SCFA production [101]. In humans,
the butyrate-producing bacteria have been associated with the beneficial metabolic effects of the fecal
transplantation from lean donors to obese patients [28], while a lower capacity to ferment complex
carbohydrates was found in the microbiota of obesity patients compared to lean controls [102]. In
the liver, acetate and butyrate are the major substrates for de novo lipogenesis, as well as substrates
in cholesterolgenesis, while propionate appears to be an effective inhibitor of both processes [103].
Under physiological conditions, SCFAs such as acetate and propionate were found to inhibit adipose
tissue lipolysis [104], resulting in reduced FFA flux from the adipose tissue to liver, but an opposite
phenotype was observed in fatty liver disease. A previous human study also reported that propionate
supplementation in the diet was able to prevent body weight gain and liver fat accumulation in NAFLD
patients [105].
Many studies have suggested that SCFA are related to the release of gut-derived satiety hormones,
in particular GLP-1 and peptide YY (PYY). Based on in vitro studies using intestinal cell lines from
both rodents and humans, SCFAs can stimulate the secretion of PYY and GLP-1 from L-cells, which
were dependent on the SCFA receptors GPR41 and GPR43 [106–110]. Furthermore, evidence from
in vivo studies has shown that carbohydrate feeding (i.e., oligofructose, inulin, and resistant starch)
can increase PYY and GLP-1 secretion in rodents [111–113]. Moreover, human studies with either
supplementation of SCFA or fermentable polysaccharides (i.e., oligofructose) have shown that weight
loss, improved hepatic lipid content, and glucose metabolism were associated with enhanced PYY
and GLP-1 release and secretion [105,114–116]. However, it warrants further studies to investigate
the effects of physiologically relevant SCFA mixtures on the secretion of GLP-1 and PYY and their
metabolic consequences in humans.
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3.3. Enteroendocrine Cell Regulation of Hormone Secretion
The intestine harbors specialized cells called enteroendocrine cells that secrete hormones in
response to nutrients and microbial metabolites. In turn, these gut hormones can regulate nutrient
metabolism and feeding behavior [117]. Classification of enteroendocrine cells was originally based on
expression of one or two hormones, however, transcriptional profiling has determined that these cells
can express multiple hormones, making them less distinct than previously recognized [118]. There is
accumulating evidence that microbiota can regulate enteroendocrine cell development and function.
Intestinal enteroendocrine cells like absorptive enterocytes have an apical membrane facing the gut
lumen which allows for interaction with microbes and their metabolites.
3.3.1. Microbial Regulation of Enteroendocrine L-Cells
Two gut hormones discovered by our lab as being important regulators of intestinal lipid
metabolism are GLP-1 and GLP-2, co-secreted in equimolar amounts by enteroendocrine L-cells.
Microbiota-derived products such as SCFAs have been shown to stimulate GLP-1 secretion via activation
of the G-protein-coupled receptor FFAR2. Microbiota can also influence the L-cell transcriptome. Using
transgenic GLU-Venus mice driving expression of yellow fluorescent protein under the proglucagon
promoter, Arora et al. found that genes related to vesicle organization and synaptic vesicle cycle
such as synaptophysin, synaptotgamins, Rab, and SNAP proteins were downregulated in L-cells
from conventionally raised GLU-Venus mice compared to GF GLU-Venus mice, suggesting GF mice
have enhanced hormone secretion [119]. They also observed that L-cells from conventionally raised
GLU-Venus mice have upregulated expression of nutrient sensing receptors and downregulated
expression of the bile acid receptor TGR5 compared to GF GLU-Venus mice [119]. Studies over the
past few years have revealed the link between gut microbiota and GLP-1 signaling. Evidence has
shown a higher plasma GLP-1 level observed in GF mice and antibiotic treated animals compared to
controls [38,120]. Importantly, activation of TGR5 has been shown to increase GLP-1 secretion, and
enhanced TGR5 expression in GF mice could contribute to elevated GLP-1 levels found in GF mice [121].
A few studies have also shown that prebiotics administration results in increased level of GLP-1 in
the circulation of rats and humans [111,114,122]. Additionally, the beneficial effects of prebiotics in
diabetes and obesity models were dependent on a functional GLP-1, as the protective effects were
not observed in GLP-1R KO mice [123]. The fermentation products of gut microbiota, such as SCFAs
and bile acids, may underline the mechanisms for the crosstalk between microbiota and GLP-1 since
microbiota metabolites are involved in stimulating the secretion of certain gut peptide hormones,
including PYY, GLP-1, and GLP-2. SCFAs are able to bind to and activate selected G-protein-coupled
receptors in different tissues to regulate peptide hormone secretion (e.g., activation of GPR41 and 43
to release GLP-1 secretion) [106–110]. Thus, microbiota and their metabolites have the capacity to
regulate enteroendocrine L-cell function leading to altered hormone release. The roles of GLP-1 and
GLP-2 in regulating lipoprotein metabolism will be discussed below.
GLP-1
As an incretin hormone, GLP-1 is well known to induce insulin secretion and subsequently
decrease the circulating glucose levels [124,125]. However, GLP-1 also regulates appetite, body
weight loss, and lipid metabolism [126–128]. In addition to decreasing adipose lipolysis [129], GLP-1
is involved in regulation of intestinal and liver lipid/lipoprotein metabolism [128]. The role of
GLP-1 in modulating intestinal lipoprotein production has been extensively studied in both animal
models as well as humans [130]. Administration of GLP-1 receptor agonist exendin-4 or dipeptidyl
peptidase 4 (DPP-4; as a GLP-1 degradation enzyme) inhibitor in hamsters both significantly reduce
intestinal lipoprotein production and plasma triglycerides and cholesterol within the triglyceride-rich
lipoprotein fraction [130]. Conversely, blocking GLP-1 receptor signaling by infusion of the GLP-1
receptor antagonist exendin 9-39 or using GLP-1 receptor knockout mice enhanced apoB48-containing
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lipoprotein secretion [130]. Similar effects were shown in a rat model, while administration of native
GLP-1 decreased intestinal fat absorption and production of apoB and apoAIV [131]. Administration
of DDP-4 inhibitor in T2D patients exhibited benefit effects on postprandial levels of triglycerides
(TG), apoB48, CM triglycerides [132] and hepatic triglycerides [133,134]. Antidiabetic drug exenatide
(53% GLP-1 homology) reduced postprandial triglycerides and apoB48 in T2D patients [135]. Overall,
GLP-1 activity has been shown to exert very beneficial effects on lipid and lipoprotein homeostasis.
GLP-2
Alongside GLP-1, its sister peptide GLP-2 is co-secreted from L-cells upon luminal lipid
sensing [136]. GLP-2 plays an important role in increasing the absorption of carbohydrates and amino
acids from the intestinal lumen by increasing nutrient transporter expression [137–139]. Although
secreted in equimolar amounts, these hormones have opposing roles in regulation of postprandial
lipids. In a hamster model and in healthy humans, GLP-2 was found to raise postprandial CM
production and plasma triglycerides [140,141]. A GLP-2 mediated increase in CM production in
hamsters was associated with increased apical expression of the fatty acid translocase CD36 which is
involved in fatty acid uptake [142]. Interestingly, coadministration of GLP-1 and GLP-2 for 30 minutes
in hamsters results in a GLP-2 dominant effect and an increase in CM secretion [143]. Similarly, in an
insulin resistant model, the stimulatory actions of GLP-2 appear to override the inhibitory effects of
GLP-1 [143]. Considering that the half-life of GLP-2 is longer than GLP-1, increasing L-cell hormone
secretion may result in a GLP-2 dominant effect, leading to excess accumulation of atherogenic CM
particles. Thus, microbial regulation of enteroendocrine L-cells can have profound implications for
lipoprotein metabolism.
3.3.2. Microbial Regulation of Enterochromaffin Cells
Microbial regulation has also been observed for other enteroendocrine cells. Indigenous
spore-forming microbes from colons of specific pathogen free (SPF) mice were found to increase colonic
and blood serotonin levels and these spore forming microbes were associated with a particular set of
metabolites that positively correlated with serotonin levels [144]. In line with this, mice inoculated with
spore-forming Clostridium ramosum have an increased number of serotonin-producing cells known
as enterochromaffin cells [145]. This was shown to occur through increases in transcription factors
regulating enterochromaffin cell development. As a result, mice inoculated with C. ramosum had
higher levels of serotonin and gained more weight on a HFD. This is consistent with emerging studies
proposing a role for gut-derived serotonin in obesity [146–148]. Interestingly, gut-derived serotonin
has been shown to positively regulate liver lipid metabolism [149–151]. Using tryptophan hydroxylase
1 knockout mice which lack the enzyme for synthesizing serotonin in the gut, Choi et al. found that
these mice are protected from HFD-induced fatty liver [149]. Under HFD feeding, these mice showed
decreased expression of genes involved in lipogenesis but no differences in apoB or MTP expression.
This would suggest that that serotonin does not affect VLDL secretion, however no experiments
besides gene expression were done to directly measure VLDL secretion in this model. Considering the
close proximity of enterochromaffin cells to absorptive enterocytes, it is possible that serotonin could
modulate aspects of intestinal lipid metabolism. Studies with C. ramosum found that colonization
by this serotonin-enhancing bacterium increased expression of lipid transporters such as CD36 and
FATP4 in the colon [145]. Furthermore, serotonin treatment of Caco-2 cells also increased CD36 and
FATP4 protein levels [145]. Given that the colon is generally not a major site of lipid absorption, the
significance of these findings in serotonin-mediated lipid absorption are unclear, however the role of
serotonin in small intestine lipid absorption and metabolism remains to be elucidated.
3.4. Gut Barrier Function
Barrier function at the intestinal mucosal interface enables absorption of water and essential
nutrients, but also protects against ingested or endogenous toxins. The intestinal epithelial layer
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consists of absorptive enterocytes, goblet cells, enteroendocrine cells, tuft cells, and Paneth cells.
Substances can pass through this barrier via a transcellular route involving selective transporters
or simple diffusion. Alternatively, they can pass through in the space between epithelial cells, a
process known as paracellular diffusion. Some residing bacteria produce LPS which activate Toll-like
receptor 4 (TLR4) [152]. LPS is restricted within the gut lumen, however, when intestinal barrier
function is weakened, LPS can enter the blood circulation and trigger systemic inflammation [24].
Lebrun et al. have demonstrated that when gut barrier function is compromised as is with dextran
sodium sulfate treatment or via ischemia/reperfusion in mice, LPS stimulates a rapid and robust rise
in GLP-1 [153]. The authors attributed these findings to mechanisms involving enhanced LPS access
to TLR4 receptors located on GLP-1-secreting enteroendocrine cells when gut barrier function was
altered. Thus, gut barrier function can have important implications for enteroendocrine cell responses
to microbial metabolites.
Additionally, LPS can be internalized by enterocytes through a transcellular route involving a
TLR4-dependant mechanism and can be incorporated into CM [154]. LPS absorption from the gut
was found to be associated with fat absorption since plasma LPS concentrations increased by 50%
after ingestion of a high-fat meal [155]. While increased LPS into the circulation via enhanced gut
permeability is known to be associated with systemic inflammation [24], the role of LPS contained
within CM is unknown. In states of insulin resistance, postprandial overproduction of CM particles
is observed and leads to an increase in atherogenic CM remnant particles [156–159]. Interestingly,
long-chain triglyceride ingestion in mice led to an increase in plasma LPS which was mainly associated
with the CM remnant fraction [154]. LPS contained within CM remnants could contribute to their
proatherogenic nature since elevated concentrations of circulating LPS correlate well with an increased
atherosclerosis risk [160]. LPS injection accelerates plaque formation in both mice and rabbits [161,162]
and apoE-/- mice with a genetic deletion of the LPS receptor TLR4 have significantly reduced plaque
formation [163,164]. Whether LPS alone or LPS associated with CM remnants is responsible for these
observations remains unknown.
3.5. Other Microbiota Metabolites
Gut microbiota are known to provide a small proportion of amino acids to host by de novo
sythesis. Hoyles et al. reported a positive association of hepatic steatosis with gut microbial amino
acid metabolism based on the study of 56 morbidly obese, weight-stable, nondiabetic women [165].
Interestingly, animo acid phenylacetate (PAA) was strongly correlated with steatosis, which was found
to be mainly produced by bacteroides spp in humans. Both fecal microbiota transplants and chronic
phenylacetate treatment revealed that phenylacetate induced liver steatosis. Serum PAA may thus be a
useful biomarker and a potential therapeutic target for treatment of hepatic steatosis [166].
4. Concluding Remarks
A key role for gut microbiota in modulating metabolic health is now widely acknowledged,
but the underlying mechanisms are not clearly understood. Of particular interest are the links
between dietary nutrients, intestinal flora, and the regulation of carbohydrate and lipid metabolism.
Although modulation of lipid and lipoprotein homeostasis by gut microbiota is largely unexplored,
emerging evidence suggest important roles in regulation of dietary fat absorption and postprandial
lipid metabolism. Evidence also suggests a potential role in regulating hepatic lipid accumulation and
development of hepatic steatosis. These potential links appear to be mediated by microbiota-mediated
regulation of intestinal enteroendocrine system and secretion of specific gut peptides. Complex
interactions between bacterial populations in the gut and the intricate network of enteric neurons as
well as gut immune system are also likely to play important roles in modulating nutrient metabolism
and metabolic health. However, no direct experimental evidence currently exists, and new research
efforts are needed to explore these links and elucidate the underlying mechanisms.
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Abstract: Decreased circulating levels of free thiols (R-SH, sulfhydryl groups) reflect enhanced
oxidative stress, which plays an important role in the pathogenesis of cardiometabolic diseases.
Since hyperglycemia causes oxidative stress, we questioned whether plasma free thiols are altered
in patients with type 2 diabetes mellitus (T2DM) without cardiovascular disease or renal function
impairment. We also determined their relationship with elevated triglycerides and very low
density lipoproteins (VLDL), a central feature of diabetic dyslipidemia. Fasting plasma free thiols
(colorimetric method), lipoproteins, VLDL (nuclear magnetic resonance spectrometry), free fatty
acids (FFA), phospholipid transfer protein (PLTP) activity and adiponectin were measured in 79 adult
non-smoking T2DM subjects (HbA1c 51 ± 8 mmol/mol, no use of insulin or lipid lowering drugs),
and in 89 non-smoking subjects without T2DM. Plasma free thiols were univariately correlated with
glucose (r = 0.196, p < 0.05), but were not decreased in T2DM subjects versus non-diabetic subjects
(p = 0.31). Free thiols were higher in subjects with (663 ± 84 μmol/L) versus subjects without elevated
triglycerides (619 ± 91 μmol/L; p = 0.002). Age- and sex-adjusted multivariable linear regression
analysis demonstrated that plasma triglycerides were positively and independently associated with
free thiols (β = 0.215, p = 0.004), FFA (β = 0.168, p = 0.029) and PLTP activity (β = 0.228, p = 0.002),
inversely with adiponectin (β = −0.308, p < 0.001) but not with glucose (β = 0.052, p = 0.51). Notably,
the positive association of free thiols with (elevated) triglycerides appeared to be particularly evident
in men. Additionally, large VLDL were independently associated with free thiols (β = 0.188, p = 0.029).
In conclusion, circulating free thiols are not decreased in this cohort of non-smoking and generally
well-controlled T2DM subjects. Paradoxically, higher triglycerides and more large VLDL particles are
likely associated with higher plasma levels of thiols, reflecting lower systemic oxidative stress.
Keywords: adiponectin; free thiols; nuclear magnetic resonance spectroscopy; phospholipid transfer
protein activity; triglycerides; type 2 diabetes mellitus; large very low density lipoproteins
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1. Introduction
Reactive oxygen species (ROS) play essential roles in cell signalling and homeostasis [1,2].
Enhanced oxidative stress results from an imbalance between ROS production and antioxidant defence,
and is prominently involved in the pathogenesis of cardiometabolic disorders including diabetes
mellitus and atherosclerotic cardiovascular disease (CVD) [3]. Yet, current information with respect to
the extent to which systemic oxidative stress is enhanced in the diabetic state is still limited. It has
been well established that systemic ROS are increased under chronic hyperglycemic circumstances
leading to progression of beta-cell deterioration, insulin resistance and atherosclerosis [4]. Remarkably
however, it is not well known whether systemic oxidative stress is already enhanced in patients
with type 2 diabetes mellitus (T2DM) free of clinically manifest CVD, chronic kidney disease (CKD)
and albuminuria.
Thiols are organic compounds that are characterised by the presence of a sulfhydryl (R-SH) moiety [5].
R-SH groups are readily oxidised by ROS and other reactive species. The plasma concentration of free
thiols has been proposed to mirror systemic or local ROS production in such a way that a decline
in circulating free thiols indicates an enhanced oxidative tone [6,7]. In line with this supposition,
decreased plasma levels of free thiols have been observed among persons with CVD as compared to
healthy subjects [8,9]. In stable heart failure patients, higher levels of serum free thiols were associated
with favourable disease outcomes [7]. In hemodialyis patients, free thiols tend to be decreased in
the context of coinciding non-alcoholic fatty liver disease [10]. Furthermore, among renal transplant
recipients higher free thiols concentrations were associated with a beneficial cardiovascular risk profile
and a better patient and graft survival [11]. Recently, we demonstrated that in T2DM patients treated
in primary care with high circulating free thiols concentrations were associated with lower HbA1c
levels and less microvascular complications [12].
Elevated triglycerides, which are mainly carried by plasma very low density lipoproteins (VLDL),
are a central hallmark of diabetic dyslipidemia [13–15]. Despite intense study, the pathogenesis of
altered (hepatic) VLDL metabolism in the diabetic state has still not been fully elucidated. Among other
mechanisms, enhanced free fatty acid (FFA) and glucose availability contribute to increased hepatic VLDL
production in the context of T2DM [13,16,17]. Notably, the secretory control of VLDL particles by the liver
is a complex process, governed by endoplasmic reticulum (ER)/proteasome-associated degradation, post
ER pre-secretory proteolysis and receptor-mediated degradation, i.e., re-uptake mediated via low density
lipoprotein (LDL) receptors and proteoglycan abundancy [18–21]. Of particular note, in vitro studies
have revealed that intra-hepatic degradation of VLDL particles via post ER pre-secretory proteolysis
is triggered by intracellular ROS, coinciding with an enhanced oxidant tone [18,21,22]. Given the role
of the liver in the metabolism of fatty acids, glucose and other substrates it is not surprising that the
liver is crucially involved in generating ROS [23]. Additionally, since the plasma pool of free thiols is
mainly associated with albumin, it is conceivably that the liver contributes at least in part to systemic
ROS status. Combined, these findings make it plausible to hypothesise that systemic ROS status is linked
to triglyceride metabolism.
The present study was initiated, firstly, to discern the extent to which plasma levels of free thiols,
as a proxy of systemic ROS status, are altered in T2DM subjects without clinically manifest CVD disease
and preserved renal function. Secondly, we aimed to determine associations of plasma triglycerides
and VLDL particle characteristics with free thiols, thereby testing a hitherto unexplored relationship of
elevated triglycerides and systemic ROS.
2. Experimental Section
2.1. Subjects and Clinical Measurements
The study was performed at the University Medical Center Groningen (Groningen, the Netherlands)
and was approved by the local medical ethics committee (METC2002/174c). Caucasian participants of
European descent (aged >18 years) were recruited by advertisement. Written informed consent was
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obtained from all participants. T2DM had been diagnosed by primary care physicians using guidelines
from the Dutch College of General Practitioners (fasting plasma glucose≥7.0 mmol/L and/or non-fasting
plasma glucose≥11.1 mmol/L). Only T2DM patients who were treated with diet alone or in combination
with metformin and/or sulfonylurea were allowed to participate. T2DM subjects using insulin or other
glucose lowering medication were excluded. Further exclusion criteria were clinically manifest CVD,
renal insufficiency (estimated glomerular filtration rate (e-GFR) <60 mL/min/1.73 m2 and⁄or urinary
albumin >20 mg/L). e-GFR was calculated based on the serum creatinine-based Chronic Kidney Disease
Epidemiology Collaboration equation [24]. Subjects with liver disease (serum transaminase levels >2
times above the upper reference limit), pregnant women and subjects who were using lipid lowering
drugs were also excluded. Subjects who used other medications (except for oral contraceptives),
current smokers and subjects who used >3 alcoholic drinks daily were additionally excluded. Subjects
using anti-hypertensive medication were allowed to participate. Physical examination did not reveal
pulmonary or cardiac abnormalities. BMI (kg/m2) was calculated as weight (kg) divided by height (m)
squared. Waist circumference was measured as the smallest circumference between rib cage and iliac
crest. Blood pressure was measured after 15 min of rest at the left arm using a sphygmomanometer.
The participants were evaluated between 08.00 and 10.00 h after an overnight fast.
The metabolic syndrome (MetS) was defined according to NCEP-ATP III criteria [25]. Three or more
of the following criteria were required for categorization of subjects with MetS: waist circumference >
102 cm for men and > 88 cm for women; hypertension (blood pressure ≥130/85 mmHg or the use of
antihypertensive drugs); fasting plasma triglycerides ≥1.70 mmol/L; HDL cholesterol <1.00 mmol/L
for men and <1.30 mmol/L for women; fasting glucose ≥5.60 mmol/L. Insulin sensitivity was estimated
by homeostasis model assessment of insulin resistance (HOMA-IR) applying the following equation:
fasting plasma insulin (mU/L) × glucose (mmol/L)/22.5 [26].
2.2. Laboratory Measurements
EDTA-anticoagulated plasma samples were stored at −80 ◦C until analysis, except for plasma
glucose and glycated hemoglobin (HbA1c) levels which were measured shortly after blood collection.
Glucose was measured on an APEC glucose analyser (APEC Inc., Danvers, MA, USA).
High sensitivity C-reactive protein (hs-CRP) was measured by nephelometry with a threshold of 0.18
mg/L (BNII, Dade Behring). Glycated hemoglobin (HbA1c) was measured by high performance liquid
chromatography (Bio-Rad, Veenendaal, The Netherlands). Plasma total cholesterol and triglycerides were
assayed by routine enzymatic methods (Roche/Hitachi cat nos 11,876,023 and 11,875,540, respectively;
Roche Diagnostics GmBH, Mannheim, Germany). HDL cholesterol was measured with a homogeneous
enzymatic colorimetric test (Roche/Hitachi, cat no 04,713,214; Roche Diagnostics GmbH, Mannheim,
Germany). LDL cholesterol was calculated by the Friedewald formula if plasma triglycerides were
<4.5 mmol/L. Apolipoprotein B (apo B) was measured by immunoturbidimetry (Roche/Cobas Integra
Tina-quant, cat. Number 03032574, respectively; Roche Diagnostics, Roche Diagnostics GmBH, Mannheim,
Germany). Plasma free fatty acids (FFA) were measured with a kit from Wako Diagnostics (HR Series
NEFA-HR (2), Wako Chemicals GmbH, Neuss, Germany).
VLDL particle concentrations and VLDL subfractions were measured by nuclear magnetic
resonance (NMR) spectroscopy with the LP3 algorithm (LabCorp, Morrisville, North Carolina,
USA) [27,28]. VLDL particle classes and subfractions were quantified from the amplitudes of their
spectroscopically distinct lipid methyl group NMR signals. The diameter range estimate for VLDL
(including chylomicrons if present) was >60 nm to 29 nm, The VLDL particle concentration (VLDL-P)
was calculated as the weighted average of the respective lipoprotein subclasses. The intra-assay
coefficient of variation (CV) for VLDL-P amounts to 11.0%.
Plasma PLTP activity was assayed with a phospholipid vesicles-HDL system, using (14C)-labelled
dipalmitoyl phosphatidylcholine as described [29,30]. Briefly, plasma samples (1 μL) were incubated
with (14C)-phosphatidylcholine-labelled phosphatidylcholine vesicles and excess pooled normal HDL
for 45 min. at 37 ◦C. The method is specific for PLTP activity. Plasma PLTP activity levels vary linearly
222
J. Clin. Med. 2020, 9, 49
with the amount of plasma added to the incubation system. PLTP activity was related to the activity
in human reference pool plasma and was expressed in arbitrary units (AU; 100 AU corresponds to
13.6 μmol phosphatidylcholine transferred per mL per h). The intra-assay CV of PLTP activity was 5%.
Insulin was assayed by microparticle enzyme immunoassay (AxSYM insulin assay: Abbott
Laboratories, Abbott Park, IL, USA). Total adiponectin was measured by enzyme-linked immunosorbent
assay (Linco Research Inc., St. Charles, MO, USA, cat no EZHADP-61k). The provided by this assay
are strongly correlated with results obtained by enzyme-linked immunoassay measurement [31].
Plasma free thiols were assayed as described with minor modifications [32,33]. After thawing,
samples were four-fold diluted using 0.1 M Tris buffer (pH 8.2). Background absorption was measured
at 412 nm using the Varioskan microplate reader (ThermoScientific, Breda, the Netherlands), together
with a reference measurement at 630 nm. Subsequently, 20 μL 1.9 mM 5,5′-dithio-bis (2-nitrobenzoic
acid) (DTNB, Ellman’s Reagent, CAS no. 69-78-3, Sigma Aldrich Corporation, St. Louis, MO, USA)
was added to the samples in 0.1 M phosphate buffer (pH 7.0). After an incubation time of 20 min
at room temperature, absorbance was measured again. Final serum free thiol concentrations were
established by parallel measurement of an L-cysteine (CAS no. 52-90-4, Fluka Biochemika, Buchs,
Switzerland) calibration curve (range from 15.6 μM to 1000 μM) in 0.1 M Tris/10 mM EDTA (pH 8.2).
The intra-assay CV of free thiols amount to 6%.
2.3. Statistical Analysis
SPSS (IBM SPSS Statistics for Windows, Version 23.0. IBM Corp. Armonk, NY, USA) was used for
data analysis. The distributions of all variables were examined using histograms and Q-Q plots. Data
are expressed as mean (with standard deviation (SD)) or median (with interquartile range (IQR)) for
normally distributed and non-normally distributed data, respectively. Nominal data are presented as
n (with percentage (%)). Non-parametrically distributed data were loge transformed for statistical
analysis. Between-group differences in continuous variables were determined by unpaired T-tests.
Between-group differences in dichotomous variables were determined by χ2-analysis. Univariate
relationships were assessed using Pearson correlation coefficients. Multivariable linear regression
analysis was applied to disclose the independent contribution of variables. A p-value <0.05 (two-sided)
was used to indicate statistical significance.
3. Results
3.1. Study Population
The study population comprised 79 T2DM subjects and 89 non-diabetic subjects (Table 1).
Median diabetes duration was 5 (interquartile range (IQR) 4–6.5) years. Fourteen T2DM subjects used
metformin and 11 used sulfonylurea alone, whereas these drugs were used combined in 24 patients.
No other glucose lowering drugs were taken. The other T2DM subjects were given lifestyle advice
only. Anti-hypertensive medication (mostly angiotensin-converting enzyme inhibitors, angiotensin II
receptor antagonists and diuretics, alone or in combination) were taken by 33 T2DM subjects and by
none of the non-diabetic subjects (p < 0.001). Estrogens were used by two pre- and two postmenopausal
non-diabetic women. Other medications were not used.
As shown in Table 1, T2DM subjects were on average 4 years older than the non-diabetic subjects,
were more obese, had higher blood pressure, fasting plasma glucose and HbA1c levels, were more
insulin resistant and categorised with MetS more frequently. Sex distribution was not different between
the groups. e-GFR was similar in the groups.
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Table 1. Clinical and laboratory characteristics in 79 subjects with Type 2 diabetes mellitus (T2DM) and






Age (years) 59 ± 9 55 ± 9 0.011
Sex (men/women) 49/30 49/40 0.45
Metabolic syndrome (yes/no) 54/25 21/68 <0.001
Systolic blood pressure (mm Hg) 144 ± 20 131 ± 19 <0.001
Diastolic blood pressure (mm Hg) 87 ± 9 83 ± 11 0.007
BMI (kg/m2) 28.6 ± 4.8 25.9 ± 3.9 <0.001
Waist (cm) 100 ±13 89 ± 9 <0.001
Glucose (mmol/L) 8.9 ± 2.3 5.6 ± 0.7 <0.001
HbA1c (mmol/mol) 51 ± 8 39 ± 5 <0.001
Insulin (mU/L) 10.8 (7.2,15.3) 6.5 (4.7,8.6) <0.001
HOMA-IR (mU mmol/L2/22.5) 3.96 (2.37,6.64) 1.57 (1.09,2.29) <0.001
e-GFR (mL./min/1.73 m2) 91 ± 13 87 ± 14 0.12
Total cholesterol (mmol/L) 5.38 ± 0.96 5.74 ± 0.99 0.022
Non-HDL cholesterol (mmol/L) 4.12 ± 1.04 4.25 ± 1.06 0.44
LDL cholesterol (mmol/L) 3.27 ± 0.85 3.53 ± 0.89 0.06
HDL cholesterol (mmol/L) 1.26 ± 0.38 1.49 ± 0.40 <0.001
Triglycerides (mmol/L) 1.70 (1.17,2.30) 1.31 (0.89,1.95) 0.034
ApoB (g/L) 0.95 ± 0.23 0.96 ± 0.23 0.55
VLDL-P (nmol/L) 69.5 (46.2,88.7) 61.8 (51.6,101.6) 0.83
Large VLDL (nmol/L) 7.1 (2.7,11.1) 3.5 (2.0,9.4) 0.019
Medium VLDL (nmol/L) 28.9 (14.9,41.3) 25.3 (13.2,44.8) 0.86
Small VLDL (nmol/L) 27.7 (16.8,43.9) 33.9 (21.2,44.5) 0.076
FFA (mmol/L)) 0.35 ± 0.12 0.30 ± 0.12 0.001
PLTP activity (AU) 104 ± 11 94 ± 10 <0.001
Adiponectin (mg/L) 14.3 (10.7,26.3) 20.1 (14.9,43.0) <0.001
Free Thiols (μmol/L) 645 ± 102 630 ± 78 0.31
Data are expressed in means ± SD, medians (interquartile range) or numbers. Abbreviations: ApoB: apolipoprotein
b; BMI: body mass index; e-GFR: estimated glomerular filtration rate; FFA: free fatty acids; HbA1c: glycated
hemoglobin; HDL: high density lipoproteins; LDL: low density lipoproteins; PLTP: phospholipid transfer protein;
VLDL: very low density lipoproteins: VLDL-P: very low density particle concentration. Differences between
subjects with and without T2DM were determined by T-tests (using loge transformed values in case of not-normally
distributed data) and by χ2 tests, where appropriate. VLDL particle concentrations and VLDL subfractions were
measured in 66 subjects with diabetes and in 56 subjects without diabetes. LDL cholesterol was calculated by the
Friedewald formula in 75 T2DM subjects and in 87 non-diabetic subjects.
3.2. Comparison of Laboratory Variables between Subject Categories
Plasma total cholesterol was lower in T2DM subjects, which was due to lower HDL cholesterol.
Triglycerides were higher in T2DM subjects but non-HDL cholesterol, LDL cholesterol and apolipoprotein
b (ApoB) levels were not different between the groups. The total VLDL particle concentration was not
different between the groups, but large VLDL particles were increased, whereas small VLDL particles
tended to be decreased in T2DM subjects. Plasma FFA and PLTP activity were elevated, whereas
adiponectin was decreased in T2DM subjects (Table 1).
In all subjects combined, plasma free thiol concentrations were higher in men (n= 98, 655± 87μmol/L)
than in women (n = 70, 614 ± 91 μmol/L, p = 0.003). Free thiols were not different between T2DM and
non-diabetic subjects (Table 1), and were not significantly related to diabetes duration (r = −0.136,
p = 0.23). Free thiols were also not different in T2DM subjects compared to non-diabetic subjects after
exclusion of T2DM subjects using glucose lowering medication (n = 20, 600 ± 109 μmol/L, p = 0.14),
antihypertensive medication (n = 44, 652 ± 110 μmol/L, p = 0.21) or both classes of drugs (n = 15,
598 ± 117μmol/L, p = 0.17). Likewise, free thiols were also not different between subjects with MetS
(n = 75, 643 ± 89 μmol/L) and without MetS (n = 93, 633 ± 92 μmol/L, p = 0.49). Free thiols were
not different in subjects with elevated glucose (p = 0.39), enlarged waist circumference (p = 0.44) or
elevated blood pressure (p = 0.29) compared to subjects who did not fulfil these MetS criteria (data not
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shown). Notably, free thiols were higher in subjects with elevated triglycerides (n = 71, 663 ± 84 μmol/L,
p = 0.002) or with low HDL cholesterol (n = 45, 661 ± 84 μmol/L, p = 0.042) compared to subjects who
did not fulfil these MetS criteria (triglyceride criterion: 619 ± 91 μmol/L; HDL cholesterol criterion
(629 ± 92 μmol/L).
3.3. Univariate Correlations
In all subjects combined, univariate analysis showed that plasma free thiols were inversely
correlated with age, HDL cholesterol, FFA and adiponectin, and positively with glucose, e-GFR,
non-HDL cholesterol, triglycerides, VLDL particle concentration and large-and medium-sized VLDL
particles (Table 2, panel A). Comparable correlations were observed in T2DM subjects separately
(Table 2, panel B and panel C). The univariate correlations of plasma free thiols with triglycerides and
with large VLDL particles are shown in Figure 1, panel A and panel B, respectively. In non-diabetic
subjects, free thiols were correlated positively with total cholesterol, non-HDL cholesterol, triglycerides
and ApoB, and inversely with FFA and adiponectin (Table 2, panel C). Neither in all subjects combined
nor in T2DM subjects and non-diabetic subjects separately were free thiols correlated with blood
pressure, BMI, waist circumference and PLTP activity (Table 2, panel A, B and C). In addition, in all
subjects combined, PLTP activity was correlated positively with triglycerides (r = 0.325, p < 0.001) and
FFA (r = 0.162, p = 0.036; data not shown). Similar correlations of PLTP activity with triglycerides were
found in T2DM subjects and non-diabetic subjects separately (data not shown).
Table 2. Univariate relationships of plasma free thiols with clinical and laboratory variables in all
subjects combined (n = 168, panel A), Type 2 diabetic (T2DM) subjects (n = 79, panel B) and in
non-diabetic subjects (n = 89, panel C).
(A) All Subjects
(n = 168) Free Thiols
(B) T2DM Subjects
(n = 79) Free Thiols
(C) Non-Diabetic Subjects
(n = 89) Free Thiols
Age −0.183 * −0.297 ** −0.098
Systolic blood pressure −0.053 −0.074 −0.093
Diastolic blood pressure 0.031 0.145 −0.119
BMI 0.059 −0.012 0.108
Waist 0.131 0.057 0.172
Glucose 0.196 * 0.262 * 0.012
HbA1c 0.151 0.186 −0.013
Insulin 0.095 0.022 0.131
HOMA-IR 0.141 0.106 0.132
e-GFR 0.213 ** 0.271 * 0.144
Total cholesterol 0.084 −0.057 0.281 **
Non-HDL cholesterol 0.168 * 0.056 0.314 **
LDL cholesterol 0.034 −0.148 0.247 *
HDL cholesterol −0.232 ** −0.302 ** −0.137
Triglycerides 0.285 *** 0.290 ** 0.260 *
ApoB 0.129 0.063 0.349 ***
VLDL-P 0.204 * 0.247 * 0.138
Large VLDL 0.266 ** 0.333 ** 0.129
Medium VLDL 0.234 ** 0.333 ** 0.081
Small VLDL −0.013 0.007 −0.020
FFA −0.187 * −0.210 −0.224 *
PLTP activity 0.034 −0.096 0.133
Adiponectin −0.261 *** −0.259 * −0.247 *
Pearson correlation coefficients are shown. Non-parametrically distributed data are loge transformed. * p < 0.05;
** p≤ 0.01: *** p≤ 0.001. Abbreviations: ApoB: apolipoprotein B; BMI: body mass index; e-GFR: estimated glomerular
filtration rate; FFA: free fatty acids: HbA1c: glycated hemoglobin; HDL: high density lipoproteins; LDL: low density
lipoproteins; PLTP: phospholipid transfer protein; VLDL: very low density lipoproteins; VLDL-P: very low density
particle concentration. VLDL particle concentrations and VLDL subfractions were measured in 66 subjects with
diabetes and in 56 subjects without diabetes. LDL cholesterol was calculated by the Friedewald formula in 75 T2DM
subjects and in 87 non-diabetic subjects.
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Figure 1. Univariate correlations of plasma free thiols with plasma triglycerides (panel A; 79 type 2
diabetic subjects and 89 subjects without diabetes) and with very large very low density lipoprotein
(VLDL) (panel B; 66 type 2 diabetic subjects and 58 subjects without diabetes). Legend: closed symbols
represent subjects without diabetes; open symbols represent subjects with type 2 diabetes. The log
transformed data (i.e., triglyceride and large very low density lipoproteins) were used. The back
transformed measures are shown on the Y-axis. Pearson correlation coefficients: free thiols with
triglycerides; all subjects, r = 0.285, p < 0.001; Type 2 diabetic subjects, r = 0.290, p = 0.01; subjects
without diabetes, r = 0.260, p = 0.014. Free thiols with large VLDL: all subjects, r = 0.266, p = 0.003;
Type 2 diabetic subjects, r = 0.333, p = 0.006; subjects without diabetes, r = 0.138, p = 0.31.
In all men combined (n= 98), plasma free thiols were inversely correlated with age and adiponectin,
and positively with HOMA-IR, e-GFR, triglycerides, VLDL particle concentration and large VLDL
particles (Table S1). In all women combined (n = 70), plasma free thiols were not significantly correlated
with any of the variables listed in Table 2 (Table S1).
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3.4. Multivariable Linear Regression Analyses
Multivariable linear regression analyses were first carried out to disclose the association of free
thiols with the diabetic state when taking account of age and sex. In this analysis, free thiols were not
significantly related to the presence of T2DM after adjustment for age and sex (p = 0.159; data not
shown). Next, we examined the extent to which plasma free thiol concentrations were independently
associated with the individual MetS components. This analysis showed that free thiols were positively
associated with elevated triglycerides but not with other MetS components (Table 3). Furthermore, free
thiols were positively associated with male sex (Table 3). In an additional analysis, now also including
e-GFR, there was no independent association of free thiols with e-GFR (β = 0.122, p = 0.20), while the
relationship with elevated triglycerides remained significant (β = 0.209, p = 0.011). In a sex-stratified
analysis, plasma free thiols were positively associated with elevated triglycerides in men (Table S2).
In women, plasma free thiols were not significantly related to any of the individual MetS components
(Table S2).
Table 3. Multivariable linear regression analysis demonstrating independent associations of plasma
free thiols with age, sex and individual metabolic syndrome components in 168 subjects (79 Type 2
diabetic subjects and 89 non-diabetic subjects).
β p-Value
Age −0.205 0.011
Sex (men versus women) 0.213 0.005
Elevated glucose 0.074 0.35
Elevated blood pressure −0.069 0.40
Enlarged waist 0.021 0.80
Elevated triglycerides 0.200 0.015
Low HDL cholesterol 0.060 0.47
Abbreviations: β: standardised regression coefficient; HDL: high density lipoproteins.
Given the association between triglycerides and free thiols, we next determined whether this
relationship remained when taking account of the diabetic state instead of the MetS criterion of
elevated plasma glucose. In this analysis, plasma triglycerides were positively associated with free
thiols (β = 0.271, p < 0.001) after adjustment for age (β = 0.01, p = 0.89), sex (β = 0.001, p = 0.97) and
the presence of diabetes (β = 0.245, p = 0.059). Subsequently, we tested whether other variables
that were univariately related to plasma triglycerides or free thiols including PLTP activity, FFA and
adiponectin (Table 2). Plasma glucose was also included in these models in view of its univariate
correlation with free thiols. In this multivariable model, with plasma triglycerides as dependent variable,
plasma triglycerides were positively and independently associated with free thiols, FFA and PLTP
activity, and inversely with adiponectin but not with glucose (Table 4). These associations remained
significant after further adjustment for the use of sulfonylurea, metformin and antihypertensive drugs
(data not shown). Similar associations of plasma triglycerides with free thiols, FFA, PLTP activity
and adiponectin were found with HbA1c or the presence of T2DM instead of plasma glucose (data
not shown).
In sex-stratified analysis, it was found that plasma triglycerides were positively associated
with free thiols, FFA, PLTP activity and inversely with adiponectin in men (Table S3). In women,
plasma triglycerides were positively associated with PLTP activity and tended to be inversely associated
with adiponectin, but the association with free thiols was not significant (Table S3).
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Table 4. Multivariable linear regression analysis demonstrating independent associations of plasma
triglycerides with age, sex, free thiols, free fatty acids, phospholipid transfer protein activity and
adiponectin and glucose in 168 subjects (79 Type 2 diabetic subjects and 89 non-diabetic subjects).
β p-Value
Age −0.044 0.55
Sex (men versus women) 0.016 0.84
Free thiols 0.215 0.004
FFA 0.168 0.029
PLTP activity 0.228 0.002
Adiponectin −0.308 <0.001
Glucose 0.052 0.51
Triglycerides and adiponectin are loge transformed. Abbreviations: β: standardised regression coefficient; FFA: free
fatty acids: PLTP phospholipid transfer protein.
Finally, we determined the association of free thiols with VLDL subfractions. Large-sized VLDL
particles were positively and independently associated with free thiols and FFA, and inversely with
adiponectin (Table 5, panel A). Medium-sized VLDL particles tended to be associated positively with
free thiols and were inversely associated with adiponectin (Table 5, panel B). Small-sized VLDL particles
were not independently associated with any of these variables (Table 5, panel C). In sex-stratified
analyses, the independent association of large VLDL particles with plasma free thiols did not reach
statistical significance in men (β = 0.184, p = 0.14) or in women (β = 0.188, p = 0.14; data not shown).
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4. Discussion
In this cohort of non-smoking and in general appropriately controlled T2DM subjects, we report
that circulating levels of free thiols are still maintained. In the current study, we excluded T2DM
subjects who smoked, those with clinically manifest CVD or impaired renal function as well as subjects
using insulin or lipid lowering medication. Therefore, the present findings suggest that decreased free
thiol concentrations, as a proxy of enhanced systemic oxidative stress, are unlikely to represent an early
feature of relatively moderate chronic hyperglycemia. Second, we report here for the first time that
plasma triglycerides and in particular large VLDL particles are positively and independently related to
free thiols in multivariable linear regression analysis in which we accounted for age, sex, glucose (or
alternatively the presence of diabetes), FFA, PLTP activity and adiponectin. Notably, the association of
free thiols with triglycerides appeared to be particularly evident in men. We consider this novel and
seemingly surprising finding to agree with the hypothesis that systemic ROS status may impact on
triglyceride metabolism. As a mechanism, we postulate that this association may at least in part be
attributable to an effect of hepatic ROS to inhibit VLDL release in the bloodstream.
To underscore the lack of effect of the presence of T2DM on plasma free thiol concentrations
as observed in the present study, we also carried out sensitivity analyses after exclusion of T2DM
subjects using any glucose lowering medication, antihypertensive medication or both classes of drugs.
Again, it was found that plasma free thiols were not decreased in the cohort of T2DM subjects studied.
Our results can be compared with another study on thiols in T2DM by Pasaoglu et al. [34]. In a
small study among 40 T2DM subjects (20 newly diagnosed and 20 treated using oral blood glucose
lowering therapy only) and 20 non-diabetic subjects they demonstrated lower plasma total thiol levels
among persons with T2DM as compared to control subjects (605 ± 36 versus 665 ± 60 μmol/L) [34].
Since a negative correlation between HbA1c and thiols has been reported [12], it should be taken
into account that T2DM subjects in their study were poorly regulated with an average HbA1c of
74 ± 30 mmol/mol and of 78 mmol/mol, in newly diagnosed and medically treated T2DM subjects,
respectively. Recently, we measured free thiols in a population of 929 T2DM outpatients treated in
primary care [12]. In this cohort, we found significant multivariable associations between free thiols
and the presence of macrovascular complications, age, BMI, diastolic blood pressure, HbA1c (all
inverse associations), male sex, diabetes duration and use of platelet aggregation inhibitors (all positive
associations). In addition, there was (modest) additional value for free thiols for risk prediction of
long-term complications. In agreement with these and previous results, we observed in the current
study that free thiols declined with ageing and were higher in men than in women [11,12], whereas we
also confirmed a positive relationship with e-GFR at least in univariate regression analysis [11].
Data concerning the relationship of ROS status and circulating free thiols in particular on fasting
plasma triglycerides in humans is scarce. In the aforementioned study amongst primary care treated
T2DM patients, there was no association between plasma free thiols and triglyceride concentrations
in multivariable analysis [12]. It should be noted, however, that in this population, samples were
non-fasting and 80% of the patients used cholesterol-lowering medication. Amongst persons with type
1 diabetes, no association between plasma free thiols and triglycerides was present [35]. Interestingly,
in mice receiving a high-saturated fat diet, the intake of the anti-oxidative ‘thiol donor’ n-acetyl cysteine
decreased plasma triglyceride concentrations possibly by lowering the activity and mRNA of malic
enzyme, fatty acid synthase and 3-hydroxy-3-methylglutaryl coenzyme A reductase [36,37].
In the present study, we assessed the relationship of plasma free thiols with triglycerides not only
when taking account of FFA and glucose, which are well-known substrates of hepatic triglyceride
synthesis [13,16], but also of PLTP activity and adiponectin. We found that plasma triglycerides as well
as large VLDL particles were associated with FFA levels in agreement with the contention that FFA
provide an important source for hepatic VLDL synthesis [13,17,38]. Although hepatic overproduction of
large VLDL particles, a central feature of diabetic dyslipidemia, has been proposed to be to an important
extent driven by hyperglycemia [16], plasma triglycerides were not independently associated with
glucose, which we ascribe to the modestly elevated fasting glucose levels in the current T2DM cohort.
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Importantly, studies in mice with genetic Pltp deficiency have revealed that PLTP is able to
promote the hepatic secretion of apoB-containing lipoproteins [39], effect which was subsequently
found to be attributable to the ability of PLTP to regulate ROS-dependent intracellular degradation
of newly assembled VLDL [40,41]. In humans, plasma PLTP activity has repeatedly been shown
to be associated with plasma triglyceride metabolism [42–45]. Moreover, genetic variation in Pltp
associates with lipid traits including triglycerides [46]. Plasma triglycerides were indeed positively
associated with PLTP activity in the current study. Of note, this relationship was independent from its
positive association with plasma free thiols. In establishing the association of plasma triglycerides
with free thiols, we also accounted for plasma adiponectin in multivariable regression analysis.
Adiponectin may stimulate hepatic fatty acid oxidation and ameliorate the development of hepatic
steatosis [47]. In line, we previously reported an inverse relationship of plasma adiponectin with alanine
aminotransferase [48]. Importantly, adiponectin has been implicated in preventing mitochondrial
dysfunction, and hence, may inhibit ROS production in vitro, possibly by promoting uncoupling
protein 2 expression [47]. Of note, we observed an inverse univariate relationship of plasma free thiols
with adiponectin, thereby providing a rationale to adjust for plasma levels of this adipokine when
evaluating the association of plasma triglycerides with free thiols. Still, plasma triglycerides as well as
large VLDL particles remained associated with plasma free thiols when considering adiponectin in
multivariable linear regression analysis. Taken together, our current study provides support for the
hypothesis that ROS status may influence triglyceride metabolism even independent of plasma glucose,
FFA, PLTP activity and adiponectin. However, since plasma free thiols were not different between the
currently studied T2DM and non-diabetic subjects, it seems unlikely that alterations in ROS status
explain to a considerable extent why plasma triglycerides and large VLDL particle concentrations
are increased in T2DM. Additionally, the mechanisms responsible for apparent sex-differences in the
association of free thiols with triglycerides are not yet clear. Plasma free thiols are higher in men than
in women as confirmed in the current study [11,12]. Additionally, fasting plasma triglycerides may
also be higher in men (as derived from [49]). Among other explanations it seems, therefore, plausible
that there is less between subject variation in free thiols and triglycerides in women compared to men,
which could to some extent blunt the strength of the correlation between free thiols and triglycerides
in women.
Our findings are relevant from a diagnostic perspective. In transplant patients and heart failure
patients the systemic redox status may have predictive power for outcome [7,11]. In recent work
we also showed that the systemic level of free thiols is a better reflection of disease activity in
inflammatory bowel disease than faecal calprotectin, the classical marker [50]. However, free thiols
are also receptive to therapeutic modulation, and can therefore be considered a potential therapeutic
target for therapy [51,52]. In clinical trials, a cysteine derivative N-Acetylcysteine directly reduces
disulfide bonds and act thereby as a glutathione (GSH) precursor [52]. Although promising, therapeutic
results are inconsistent and these compounds may be effective in selected patients with low free
thiol concentrations.
Several other methodological aspects of our study need to be discussed. First, we carried
out a cross-sectional study. For this reason, cause-effect relationships cannot be established with
certainty, nor can we exclude the possibility of reversed causation. Hence, we cannot exclude that
alterations in triglyceride metabolism could affect the balance between ROS production and antioxidant
defence. In this vein, a scenario is also possible whereby increased hepatic substrate availability
leads to enhanced β-oxidation which in turn affects hepatic ROS production. Second, the sample
size of the current study was rather limited, possibly masking relatively modest associations between
variables of interest. Third, only diabetic subjects who did not use lipid lowering medication were
allowed to participate, thereby avoiding confounding due to effects of statins on triglycerides and
PLTP activity [53,54]. As a consequence, it is likely that T2DM subjects with mild dyslipidemia
were preferentially included. Fourth, only non-smokers participated. This exclusion criterion was
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implemented in order to avoid effects of smoking on systemic ROS [55]. Moreover, cigarette smoking
affects lipid metabolism, including elevations in PLTP activity [56].
5. Conclusions
Plasma free thiols, which mirror the redox status, are still maintained in generally adequately
controlled non-smoking T2DM subjects, without clinically manifest cardiovascular disease or chronic
kidney disease indicating limited organ and cell damage. Higher fasting plasma triglycerides and
increased large VLDL particles concentrations are inversely associated with free thiols, raising the
possibility that enhanced oxidative stress could be paradoxically implicated in less severe dyslipidemia.
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